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1.0 Contextual Statement 
 
As a veterinary histologist at Tasmania’s Animal Health Laboratory, Department of Primary 
Industries, Parks, Water and Environment (DPIPWE), I am positioned to respond to any emerging 
biosecurity risk. It was incomprehensible in 2002 to foresee how sectioning and staining the first 
of an extraordinary number of Tasmanian devil tumours would influence my professional life as a 
medical scientist. Tasmanian devil numbers plummeted and the likelihood of losing Tasmania’s 
iconic marsupial to ‘Devil Facial Tumour Disease’ (DFTD) became clearly evident. Research into the 
aetiology of the transmissible cancer became paramount. I was a co-author on two initial papers 
by Richmond Loh et al. (1, 2) describing the immunohistochemistry and pathology of DFTD 
followed by a broader paper by Stephen Pyecroft et al. (3) integrating the histopathology, 
cytogenetics and epidemiology of this unusual transmissible tumour. Our immunohistochemical 
research continued to investigate tissue specific markers that define DFTD and its transmissible 
nature. I dovetailed my research at the Animal Health Laboratory through graduate research at 
the University of Tasmania where I secured two research grants offered by ‘Save the Tasmanian 
Devil Program’ (STDP), funding crucial to advancing our research findings. During my candidature, I 
have tested and validated over 150 commercially available anti-human antibodies on Tasmanian 
devil (marsupial) tissues, unfortunately sequence homology was not always one hundred percent 
with approximately half failing to recognise marsupial protein sequences.  
DFTD is a clonally evolved tumour of Schwann cell origin (4) affecting Tasmanian devils 
(Sarcophilus harrisii) and is transferred by biting. This thesis presents my research as two major 
chapters. Firstly, a very comprehensive immunohistochemical approach investigating neural crest 
derived Schwann cell and melanocyte associated markers. These findings are novel and will 
contribute significantly to the understanding of the pathobiology of this unusual tumour. I have 




Devil Facial Tumour 1 (DFT1) Immunophenotype Reveals a Progenitor-Like Cell with Schwann 
cell, Melanocyte and Self-Renewal Characteristics. 
In addition to gene and protein expression by DFTD, I wanted my immunohistochemical research 
findings to be applied in a practical way. I identified ERBB3 as a biomarker that can be utilised in 
both the early detection of DFTD and the identification of potential therapeutic regimes that could 
be applied therapeutically to wild Tasmanian devils to eradicate this disfiguring and terminal 
disease. This article was published in 2017 (chapter 2) ahead of the main body of my research 
(chapter 1) to expedite modes of DFT1 treatment, prevention and eradication which is a high 
priority of the STDP. 
 
ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial 
tumour 1 (DFT1). 
 
In summary, my research has comprehensively redefined the immunophenotype of DFTD, 
expressing novel proteins not available in the current literature. I show divergent origins of DFTD, 
a progenitor like cell with Schwann cell and melanocyte lineages, self-renewal characteristics that 
contributes to MHC down regulation and therefore enhanced transmissibility. I describe for the 
first time the histomorphology of the 5 strains of DFTD and extensively immunohistochemically 
stain these strains to determine any variation present. My findings are drafted for imminent 
manuscript submission. From my research, I published the first description of the expression of 
ERBB3 by DFTD and its possible early detection and possible therapeutic approach. I also first 
reported the expression of ERBB3 in cutaneous lymphoma in Tasmanian devils.  It is reassuring 
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that two subsequent publications, like ourselves, found ERBB3 to be important in DFTD 
tumourigenesis (5, 6).  
As unbelievable as it seems researching a transmissible tumour in Tasmanian devils, it would be 
inconceivable to think I would be involved in a second transmissible tumour however, this is 
exactly what has happened. At DPIPWE I was involved in the Histology and immunohistochemistry 
of this newly described Tasmanian devil tumour. During my candidature I collaborated with fellow 
Tasmanian devil researchers Ruth Pye et al. (7) and Max Stammnitz et al. (8) through STDP by 
providing histological and immunohistochemical components of the research defining this second 
devil facial tumour. Our research findings have therefore renamed the original DFTD as DFT1, with 
the newly described tumour named DFT2, its intention to avoid confusion in the literature. My 
contribution to DFT2 is outlined in chapter 3 of my thesis. My future directions are to publish 
unfinished immunohistochemical work completed during my candidature and continue 
researching DFT1 and DFT2 by collaboration with Tasmanian devil researchers as well as continue 
histological and immunohistochemical support at the Animal Health Laboratory, DPIPWE. 
 
Dane Hayes 
PhD candidate,  
University of Tasmania,  
School of Health Sciences, 
Launceston. 
 
Medical Scientist, Cytotechnologist CT (ASC),  
Animal Health Laboratory 






2.0 Introduction: Tasmanian Devil Facial Tumour Disease 
(DFTD/DFT1) and the discovery of a second Transmissible Devil 
Facial Tumour (DFT2) 
 
2.1 The Emergence of Devil Facial Tumour Disease (DFTD) 
 
The Tasmanian devil (Sarcophilus harrisii) belongs to the Dasyuridae family, it is a 
carnivorous marsupial that is extinct on mainland Australia, now found only on the island of 
Tasmania. Superficial dermal cutaneous lesions of wild Tasmanian devils can be found commonly in 
the form of skin sores (9) and neoplasia (10). Multiple spontaneous neoplasms in captive 
Tasmanian devils have been recorded, including squamous cell carcinoma of the lip and gingiva, 
dermal lymphosarcoma (11), trichoepithelioma, papilloma and keratoacanthoma (12) and a single 
devil with multiple unrelated tumours involving internal organs in combination with skin (13), 
suggestive of potential metastasis. Similar observations were made while reviewing Dasyurid 
archival material at the Australian Registry of Wildlife Health (14) and recently, two captive female 
devils with pruritus and dermatitis were diagnosed with cutaneous T-cell lymphoma (15). None of 
the recorded neoplastic superficial lesions found in captive or wild Tasmanian devils appeared to 
mimic the newly described firm, flattened centrally ulcerated soft tissue lesions of DFTD affected 
Tasmanian devils (1). 
The first evidence of DFTD in wild populations occurred in 1996 when several Tasmanian devils 
with facial lesions were photographed by Christo Baars in the north east of the state; however, a 
tissue diagnosis was not obtained until 2001 (16). Review of Tasmanian devil archival slides 
submitted to the Animal Health Laboratory, DPIPWE, revealed a single case in 1997 that was 
consistent with DFTD (1, 17) indicating that this tumour had been present in Tasmania for at least 
5 years prior to tissue diagnosis. An emerging disease was finally recognised in 2003 (17) because 
of the prevalence of DFTD during the previous two to three years. The disease had spread from 
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the north east of the state both south and westward with high mortality rates of up to 90% in 
some areas leaving very few animals over twelve months old. Thus, a transmissible viral aetiology 
was suspected such as those induced by cancer-causing retroviruses similar to feline leukaemia 
virus or Koala retrovirus. Speculation was that a viral agent directly transferred from animal to 
animal by biting while engaged in fighting results in the tumours, which arise at the site of 
inoculation, typically affecting the mouth and facial areas. However, extensive testing by the 
Australian Animal Health Laboratory, CSIRO by cell culture and electron microscopy (unpublished 
data, DH, Alex Hyatt, AAHL, CSIRO) has not isolated a viral agent (3).  
Histologically, the ‘facial tumours’ consist of round cells with a high nuclear to cytoplasmic ratio 
but are not limited to the face as the neoplastic lesions metastasise to local draining lymph nodes 
and bone marrow. The breakthrough report came from Pearse et al. proposing that DFTD is 
transmitted by allograft, an infectious cell line, transferring cells of friable tumours from devil to 
devil through biting (18). The karyotype of a normal devil consists of fourteen chromosomes 
including XX or XY chromosomes however; the Karyotype of DFTD contains only thirteen 
chromosomes and is grossly abnormal. Both chromosomes two, one chromosome six, both sex 
chromosomes are missing, deletion of the long arm of chromosome one and four unidentified 
marker chromosomes are also present. Characterisation was further determined by G-banding by 
Pearse et al. (18) and has subsequently been reassessed in 2012 by Deakin et al. (19) using 
chromosome painting highlighting minor chromosome misidentification (see Genomic 
Investigation of the Tasmanian devil and DFTD below for details). 
The interesting fact was that all eleven tumours studied (early, late and metastasis) had 
exactly the same complex abnormal karyotype, all with no apparent intermediate stages between 
normal and tumour chromosomes present,  suggesting that a single breakpoint was unlikely. 
Further support for the allograft theory was the absence of both sex chromosomes regardless of 
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the sex of the affected devils and the discovery of a pericentric inverted chromosome 5 in one 
devil that was not reflected in its tumour karyotype, being present only in cultures of its normal 
tissues, a result that was unexpected.  
 
2.3 Initial Pathology and Immunohistochemistry of DFTD 
 
A comprehensive study of the pathology of DFTD by Loh et al. in 2006 (1) revealed tumours 
tended to be located on the face, lips and oral mucosa. Most tumours were well circumscribed, 
firm soft tissue masses, flattened and centrally ulcerated and exudative. The cut surface was pale, 
and visible fibrous septae gave the tumour a multinodular appearance, sometimes the tumours 
were necrotic centrally. Almost equal numbers of male and female devils with DFTD were 
examined suggesting neither sex was favoured for transmission and devils with DFTD were greater 
than two years of age suggesting younger devils perhaps avoid confrontation. 
Histopathology revealed all tumours examined were microscopically similar originating in the 
dermis or submucosa of the oral tissues. The cells were pleomorphic round cells with single 
nucleus without nucleoli, high nuclear to cytoplasmic ratio, little eosinophilic cytoplasm with often 
indistinct cell borders forming bundles, cords, packets, palisades, nests or sheets depending on the 
tumour, forming vascularised nodular aggregates that were minimally infiltrative. Metastasis was 
apparent in sixty-five percent of cases with regional lymph nodes involved as well as distant 
organs including lungs, heart, kidney, spleen, mammary, adrenal, pituitary, rib and ovary. Electron 
microscopy revealed few specialised organelles but occasional ribosome-lamellar complexes, 
secretory granules, myelin bodies and desmosome like structures were recorded. Together, the 
comparable histopathology and electron microscopy observations suggest that DFTD is derived 
from a single cell type.  
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In addition to the pathology of DFTD above, Loh et al. 2006 also comprehensively described the 
immunohistochemical features of DFTD by the application of antibodies commonly used to 
differentiate tumours of unknown origin. These antibodies would detect any differentiating 
features associated with DFTD in order to classify this very unusual transmissible tumour (2). No 
immunoreactivity for CD16, CD57 and CD3 was evident indicating that the tumour does not 
originate from the myeloid/lymphoid lineages and therefore initial histological classification of 
DFTD being a possible lymphosarcoma would appear unlikely. It was noticed that very few 
lymphocytes infiltrate the tumour perhaps suggesting support for the allograft theory. No 
reactivity for Von Willebrand Factor excludes the possibility of an endothelial cell derived tumour. 
No reactivity to pan-Cytokeratin AE1/AE3 and epithelial membrane antigen (EMA) also excludes 
epithelial carcinomas. No reactivity to smooth muscle antigen (SMA) and desmin excludes a 
muscle origin. No reactivity to glial fibrillary acidic protein (GFAP) would exclude glial origins. The 
immuno-positive staining for S100 protein, vimentin (VIM), Melan-A (MLANA), neuron specific 
enolase (ENO2), chromogranin A (CHGA) and synaptophysin (SYN) would suggest neural crest 
derived tumour including sarcoma, melanoma and undifferentiated neuroendocrine tumour. 
Because DFTD is non-pigmented, an amelanotic melanoma was excluded on the basis that no pre-
melanosomes or melanosomes were identified during electron microscopical examination and 
histochemical staining such as Masson Fontana were also negative. In conclusion, the 
immunohistochemical expression of neuroendocrine markers CHGA, SYN, ENO2, mesenchymal 
marker VIM and neural crest marker S100 indicated that DFTD is of neuroectodermal origin.  
The next exciting research chapter published by Murchison et al. in 2010 (4) used large scale 
genetic analysis including microsatellite genotyping, mitochondrial genome analysis and deep 
sequencing of the DFTD and microRNAs that revealed the clonal transmissible DFTD was of 
Schwann cell origin. The genetic analysis revealed that nine of twenty genes validated were 
actually involved in the myelination pathway and the cells responsible for myelination are central 
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nervous system oligodendrocytes and peripheral nervous system Schwann cells. Myelin surrounds 
nerve axons providing the necessary insulation for nerve impulse conduction. Key genes identified 
by transcriptome analysis identified as structural components of myelin included myelin protein 
zero (MPZ), peripheral myelin protein 22 (PMP22), myelin basic protein (MBP) and specifically the 
peripheral nervous system myelin protein periaxin (PRX). Protein expression was also documented 
for PMP22, MPZ, MBP and PRX with immunohistochemical expression confirmed for PMP22, MBP 
and PRX. PRX was expressed in all DFTD samples and therefore it was proposed that PRX be used 
as a marker for DFTD. Additionally several genes involved in transcription of myelination were also 
identified such as SRY-box 2 (SOX2), SRY-box 10 (SOX10), c-JUN (JUN) and POU Class 3 Homebox 1 
(POU3F1) and neural crest markers nerve growth factor (NGFR) and intermediate filament nestin 
(NES). This research reinforces previous research that DFTD is of neural crest origin but provides 
the genetic and expressional evidence that the Schwann cell is likely to be the origin of DFTDs. The 
significance of neuroendocrine markers expression is yet to be elucidated and I will discuss this 
further in chapter one of this thesis. 
A paper by Tovar et al. in 2012 stemming from Murchison et al. 2010 further examines Schwann 
cell and neural crest markers and demonstrates once again the positive immunohistochemical 
staining of PRX, PMP22, MBP, NGFR, NES and S100. This study showed reduced EN02 and no CHGA 
staining which is in contrast to the original studies by Loh et al. (2); however, the antibodies used 
in this research were different. For example, the ENO2 used by Tovar et al (20) was a different 
mouse clone and CHGA was a mouse monoclonal, whereas Loh et al. (2) employed a rabbit 
polyclonal. I have also noticed that monoclonal CHGA and SYN do not stain DFTD however; the 
converse applies when using polyclonal antibodies thus indicating that different antigens are 
targeted, specific sequences in the case of the monoclonal and a variety of antigens for the 
polyclonal (DH, unpublished observation).  It was noted on immunohistochemistry that MBP had 
cross reactivity with epithelium and connective tissue, which may indicate that the monoclonal 
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antibody used may be less specific as only two out of twenty samples showed immuno-reactivity. I 
further examine MBP in detail in chapter one of my thesis to further determine this myelin 
structural protein. This research demonstrates overwhelming evidence that PRX is an excellent 
diagnostic marker for DFTD and this has proven to be the case over the ensuing years as I employ 
PRX as a diagnostic marker in the routine laboratory (DH, personal observation).  
 
2.4 Investigation of the Immune system of the Tasmanian devil 
 
The Tasmanian devils immune system has come under considerable investigation in attempt to 
ascertain possible deficiencies that would allow transmission of an allograft. Very few CD3 positive 
T-cell lymphocytes are seen infiltrating the tumour (2) thus, immune surveillance failure must be 
considered contributory to tumour dispersal. Early examination of Tasmanian devil immune 
system by Woods et al. (21) and Kreiss et al. (22, 23) demonstrated similar characteristic as 
placental mammals with an expected range of white blood cells including neutrophils, 
lymphocytes, monocytes, basophils and eosinophils present in peripheral blood smears. Thymic 
tissues was found in juveniles and subadults, splenic architecture displayed typical red and white 
pulp with B-cells located in the white pulp and T-cells located near arterioles. Lymph nodes also 
displayed a typical arrangement of B-cell follicles located in the cortex and T-cell areas in the 
paracortex. B-cell areas appeared activated and there were numerous plasma cells noted in the 
spleen and lymph nodes of devils with DFTD. When the immune system was challenged with T-cell 
mitogens such as phytohemagglutanin and concanavalin-A and T- and B-cell mitogen pokeweed 
mitogen, all induced lymphocyte proliferation but there is a diversity of responses among the 
devils tested. The subcutaneous injection of horse red blood cells into male and female Tasmanian 
devils produced a strong antibody response demonstrating an appropriate humoral response. The 
observed phagocytosis of bacteria by neutrophils showed the innate immune system is functional. 
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These experiments demonstrate that the Tasmanian devil is certainly capable of stimulating 
lymphocyte proliferation and therefore infer that the Tasmanian devil’s immune system is 
completely competent. Interestingly, when mixed lymphocyte reactions were performed 
measuring the allogenic T-cell response, no proliferation of lymphocytes occurred raising the 
possibility that lack of diversity at the major histocompatibility complex (MHC) may contribute to 
the allograft not being recognised as ‘non-self’ by the host’s immune system. 
Kreiss et al. (24) immunohistochemically examined Tasmanian devil lymph nodes employing CD3 
(T-cell), CD79b (B-cell) and HLA-DR (MHC-II antigen presenting cells – dendritic, macrophage, 
lymphocytes -B-cell, activated T-cell) to reveal the outer cortex rich in lymphoid follicles containing 
CD79b (mantle zone) and HLA-DR (germinal centre) positive cells whereas, CD3 positive cells were 
located within the inner cortex. The architecture and specific cell identity reported here further 
support that the Tasmanian devil immune system has the necessary components of an adaptive 
immune system and adequate response. Kreiss et al. (25) demonstrated that despite little or no 
MHC-I and -II mismatches, all five allograft skin grafts were rejected, most within as little as 
fourteen days. A mixed lymphocyte reaction was performed again employing devils from the skin 
graft experiment. These devils were from different geographical locations with some proliferation 
occurring, noticeably between eastern and western Tasmanian devils, indicating some allelic 
differences between them.  Evaluation of cytotoxicity responses was performed by Brown et al. 
(26) finding that Tasmanian devils elicited either very little cytotoxic response or none at all to the 
injection of irradiated DFTD cells with montanide adjuvant whereas injected human K562 cells 
(erythroleukaemia) did develop a cytotoxic response. Antibody dependent cell-mediated 
cytotoxicity occurred within four hours, less time than is needed than cytotoxic T-cell response of 
at least 18 hours, upon exclusion of monocytes, neutrophils and T-cells would indicate the 
presence of Natural Killer cells are the likely effector cells responding to the xenogenic tumour 
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cells. Natural killer receptors (natural killer complex - NKC and leukocyte receptor complex - LRC) 
have been identified in the genome of the Tasmanian devil (27), with six assumed NKC genes 
located on chromosome five and forty-three open reading frame LRCs located on chromosome 
three. 
Howson et al. (28) further classifies subpopulations of T-cell (CD4 and CD8) and B-cells (IgG and 
IgM) by the production of specific Tasmanian devil monoclonal antibodies against CD4, CD8, IgG 
and IgM. Dendritic cells are also identified by antibodies MHC-II, CD1a and CD83, in addition to 
classic antibodies CD3, CD79b and MHC-II. Immunohistochemical expression of these markers 
showed no B-cell markers within DFTD; however, CD3, CD4 and CD8 were present in all tumour 
samples with CD8 easily identified in the stroma, although CD4 was not always present. 
Intratumourally all eight samples stained for CD3 and CD8 but only three stained for CD4. Within 
and surrounding DFTD, MHC-II stained antigen presenting cells (presumed macrophages) and 
dendritic cells staining with CD1a were observed surrounding the tumour but not within the 
tumour. However, no CD83 positivity for activated dendritic cells was seen. The surprising finding 
was that the majority of T-cells within the tumour were CD8 and not CD4 as expected.  
Why is it that Tasmanian devils less than one year of age do not succumb to DFTD? An explanation 
was offered by Cheng et al. (29) who found that as devils develop and reach puberty (sub adults) 
there is a noticeable alteration in immune system. Abundance of lymphocytes decreased at 
puberty for both male and female devils thus an increased neutrophil-lymphocyte ratio occurs 
negatively affecting the balance between innate and adaptive immunity. Additionally a lower 
interferon (IFN)-γ-interleukin 4 (IL4) ratio occurs where the IFN-γ/T-helper 1 (Th1) cells, such as 
cytotoxic and NK T-cells are inhibited by IL4 forcing differentiation of T-cells toward Th2 cells, or a 
humoral response. A murine xenograft model for DFT1 reported by Kreiss (30) showed 
conclusively that tumours grown in laboratory mice mimicked transmissible DFT1. Inoculation of 
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DFT1 Cell cultures into 17 non-obese diabetic/severe combined immunodeficiency (NOD/SCID) 
mice resulted in all mice developing tumours (x-DFT1). In addition, 7 NOD/SCID mice were 
inoculated with viable cultures from x-DFT1, a second passage, with all mice once again producing 
tumours. This suggests self-renewal characteristics and I discuss this in depth in chapter 1 of my 
thesis. All x-DFT1 tumours appeared histologically identical to the original DFT1 and the x-DFT1 
karyotype was essentially similar to the pseudodiploid clone although an increase in the near 
triploid clone was observed. Neither immune competent BALB/c mice nor non-viable freeze/thaw 
tumour cells produced tumours and the tumours were all PRX positive. 
 
2.5 Experimental immunisation procedures and immunotherapy 
 
Kreiss et al. (31) showed evidence of humoral and cytotoxic immune responses when Tasmanian 
devils were immunised by killed DFTD cells. Two devils were immunised with DFTD strain two 
inactivated by freeze/thaw containing montanide adjuvant, two devils were immunised with DFTD 
strain three inactivated by sonication containing montanide and CpG 1668 adjuvant and four 
devils were immunised with DFTD strain 3 cells inactivated by irradiation containing montanide 
and CpG 1668 or CpG 1585 adjuvant. One devil that received freeze/thaw cells did produce 
antibodies, both devils that received sonicated cells produced antibodies and cytotoxic responses 
and all four devils receiving irradiated cells developed cytotoxic responses with three of those 
devils producing antibodies. Previous irradiated DFTD cells that were used to immunise devils did 
not produce antibodies or cytotoxic responses (26) may be explained perhaps by genetic diversity 
among Tasmanian devils however, this research uses CpG adjuvant which acts via Toll like receptor 
nine (TLR9) activating innate immune cells circumventing immune ignorance. Two of the above 
eight Tasmanian devils were challenged with live DFTD strain 3 cells; those that received 
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freeze/thaw containing montanide adjuvant, one devil produced tumour, but the second devil 
only produced tumour (strain 3) when challenged a second time. Interestingly, this particular devil 
also had an antibody response and thus may provide evidence that immunisation did provide 
some protection. Because these devils developed tumours, it was deemed unethical to challenge 
the other six devils. Evidence of immune recognition occurring in wild Tasmanian devils had been 
disappointing until a large survey conducted by Pye et al. (32) showed a limited, but positive 
response. This research encompassed fifty-two wild Tasmanian devils; serum was collected over a 
7-year period with forty-five of those devils comprising multiple collections. The sera was tested 
for IgG antibodies to DFTD MHC-I negative cells, and DFTD MHC-I positive cells interferon γ (IFN-γ) 
exposed which can also be stained for β2 microglobulin (B2M), a component of the MHC I 
molecule. Of the 52 wild Tasmanian devils, forty six did not produce detectable IgG antibodies to 
DFTD regardless of MHC-I status, however the remaining six devils had detectable levels of IgG 
against MHC I DFTD positive cells, but not MHC-I DFTD negative cells. These six devils were DFTD 
free when initially sampled but developed DFTD during the study therefore, anti-DFTD antibodies 
were detected as clinical signs progressed. Remarkably four of the six devils actually exhibited 
tumour regression. Previously it has been shown experimentally that captive Tasmanian devils 
immunised with killed DFTD cells can elicit an immune response (31) but this study demonstrates 
that naturally occurring immunity also occurs in a small number of individuals. The potential for 
wild Tasmanian devils to be immunised against DFTD was approached comprehensively by Tovar 
et al. (33) who experimented with four different immunisation and booster protocols that 
included heat treated, freeze/thawed, sonicated and irradiated DFTD cells. Protocols that involved 
treatment of these DFTD cells with a number of molecules including IFN-γ, Trichostatin A, TD2-Ga 
(histone deacetylase inhibitor) or TD3-Ty (upregulates MHC-I). Vaccines also utilised a number of 
adjuvants including ISCOMATRIXTM, PolyIC and CpG. Devils immunised with sonicated and IFN-γ 
treated DFTD cells together with multiple adjuvants ISCOMATRIXTM, PolyIC and CpG appeared to 
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produce IgG antibodies to both DFTD MHC-I positive and DFTD MHC-I negative cells. One devil 
failed to produce DFTD and two other devils exhibited delayed onset of DFTD, suggesting some 
immune protection against DFTD occurs. Pye et al. (34) are currently monitoring two different 
vaccination strategy trials involving the wild release of vaccinated Tasmanian devils at two sites: a 
northern location at Narawntapu National Park and the northeastern location of Stoney Head. 
Narawntapu National Park released devils vaccine consisted of sonicated and irradiated DFTD 
MHC-I positive cells with adjuvants ISCOMATRIXTM, PolyIC and CpG as outlined above (33). Stony 
Head released devils vaccine consisted of sonicated and irradiated DFTD MHC-I positive cells with 
adjuvants ISCOMATRIXTM, PolyICLC (Histonol®) and imiquimod. This protocol change was 
implemented following experimentation (35) finding these adjuvants induced a more rapid 
antibody response that was sustained longer and was also able to shorten this vaccine protocol 
which is quite practical when confronted with wild animal recapture. At the conclusion of both 
trials, seventeen of nineteen Narawntapu and all thirty-three Stoney Head devils had 
seroconverted following immunisation of DFTD. Five months after the primary course the Stoney 
Head devils had higher overall antibody levels than the Narawntapu devils despite receiving only 
two immunisations compared to up to four immunisations received by the Narawntapu devils. 
This trial is ongoing and we eagerly await the degree of success that immunisation against DFTD 
offers. 
 
2.6 Major Histocompatibility Complex in the Tasmanian devil 
 
The first characterisation of Tasmanian devil MHC genes was reported by Siddle et al. (36), 
describing six unique class II β-chain sequences from at least three loci (marsupial class II DA 
family), thirteen unique class I sequences from at least seven loci. MHC consists of multiple genes 
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encoding for molecules that recognise foreign antigens and evoke adaptive immunity through 
interaction with T-cells, providing resistance and recognising self from non-self. MHC contains 
class I molecules consisting of two chains; α- and β2 microglobulin and Class II molecules also 
consist of two chains, α- and β-. Siddle et al. (37) found that DFTD cells expressed both MHC class I 
and class II genes, but because the class I sequences show little variation it was suggested that 
transmission of DFTD without recognition by the immune system may be a result of low MHC 
diversity. Additionally, MHC class II, usually expressed by haematopoietic cells such as 
macrophages and monocytes, was also expressed by DFTD. Comprehensive screening of MHC 
class I α1 by Siddle et al. (38) revealed twenty five different MHC types (types A-V and type 1) with 
some differences noted between the eastern and western populations of Tasmanian devils where 
ten of the twenty five types were found only in western devils. Class I sequences can be divided 
into group I and group II where eighty percent of the range of devils contained both, as did DFTD 
cells leaving twenty percent of individuals that had a restricted MHC range. The difference in 
individual sequence variants (0-6 group I, 0-4 group II) was found to be allelic copy number 
variation, thus the MHC diversity is low in Tasmanian devils. Subsequent testing using MHC linked 
microsatellite markers found that there was no variation in copy number of alleles (39, 40). It was 
also suggested that a genetic sweep might have occurred affecting class I genes resulting in 
similarity in allelic content and gene copy number of eastern devils. Importantly, most Tasmanian 
devils studied had MHC types similar to those of DFTD although some do not. It is these restricted 
MHC types that could potentially offer immune response to DFTD.  A comprehensive study of MHC 
class II genes by Cheng et al. (41) also revealed that genetic diversity is low. Marsupials typically 
have two classical MHC class II gene families designated as DA; a single α chain gene – Saha-DAA 
and three DA β chain genes Saha-DAB1, 2 and 3) and DB which so far has only revealed a 
pseudogene DBB. In the Tasmanian devil population studied (60), the DA-α chain is invariable and 
the β chain genes show restricted polymorphism. It would appear that Tasmanian devil has only a 
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functional MHC class II DA family whereas the DB genes are likely to be lost in its genome. This 
study illustrates low diversity of MHC class II, likely attributed to genetic drift on the island as well 
as founder effects after population bottlenecks. The above studies by Siddle et al. and Cheng et al. 
together show reduced MHC I and II diversity in Tasmanian devils. Using bacterial artificial 
chromosome (BAC) libraries Cheng at al. (42) describes further MHC class I and class II regions of 
the Tasmania devil based on BAC contigs. A total of five class I genes were identified and named 
Saha-UA, UB, UC, UD and UK and a total of four class II genes all belonging to the DA gene family; 
Saha DAA, Saha-DAB1, DAB2 and DAB3. A deletion was found in Saha-UA and was found to be 
present in fifty four percent of tested northwest devils but none in the south, and variation with 
east and central Tasmanian populations. Recent investigations by Siddle et al. (43) has shown that 
surface MHC class I are not expressed on the surface of DFTD cells due to down regulation of 
genes such as B2M, TAP1, TAP2 (Transporter 1 or 2, ATP binding cassette SUB-family B member) 
and MHC class II DM beta, (DMB) associated with this pathway. Production of two devil specific 
antibodies; a monoclonal antibody against class I heavy chain employed in western blot analysis 
and polyclonal antibody against B2M employed Immunohistochemically, enables cellular 
expression of MHC class I. Very little class I was detected on western blots and no B2M was 
detected on DFTD cell culture cells. If DFTD cells were treated with Trichostatin A or recombinant 
devil IFN-γ down regulated B2M, TAP1, TAP2 were also shown to be restored suggesting that 
these genes are structurally sound and gene suppression is related to acetylation state of histones. 






2.7 Genomic Investigation of the Tasmanian devil and DFTD 
 
Whole genome analysis by Miller et al. (44) was performed on two four-year-old Tasmanian devils 
(one female, one male) and their DFTDs from northern and southern Tasmanian geographic 
locations. The genome was found to be 3.3 gigabase pairs. Their analysis revealed that their 
tumours were not from the host however, it was estimated that the tumours may contain thirty 
percent of nuclear DNA and fifteen percent of mitochondrial DNA could be from the host devil. 
Because DFTD is transmissible then the diploid genome of both the original and present host and 
tumour as well somatic mutations of the tumour have to be taken into account when analysing 
DFTD. Murchison et al. (45) assembled the genome of a female Tasmanian devil using Phusion2 
pipeline, estimated at 2.89 and 3.17 gigabase pairs using both sequencing and flow cytometry. 
Chromosome homology of the Tasmanian devil was compared to that of the opossum and genes 
were identified using Ensembl genome annotation pipeline. As previously reported neither sex 
chromosomes are identifiable in the DFTD karyotype, therefore the gender of the founder devil is 
unknown. Murchison et al. searched for the Y chromosome (SRY gene) which was amplified in a 
male devil but not in the female as expected; however, this is not amplified in DFTD. The X 
chromosome was searched for using reverse chromosome painting experiments and copy number 
analysis and it was determined that there were approximately two copies present, likely to be 
homologous pairs rather than recent duplicates. This suggests that the original DFTD founder devil 
was a female. It was also found that geographically distant DFTD subclones are acquiring new 
variations in karyotype, DNA sequences and genomic copy number indicating ongoing somatic 
change but despite this, DFTD is a relatively stable lineage and the transmissible cancer is most 
likely not due to genomic instability. Demonstration of evolutionary changes in DFTD by Pearse et 
al. (46) documents at least four novel chromosomal variants (strains), from two hundred and sixty 
nine diseased devils at different sites around Tasmania, from 2004-2011. Strain one is the simplest 
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karyotype, the original karyotype reported by Pearse et al. (18) in 2004 from Bronte Park. Strain 
two was first observed in 2005 and within its karyotype is a fifth marker which appears to be a 
duplication of the p-arm of marker one. Strain three was detected in 2005 and found exclusively 
on Forestier Peninsula in southeast Tasmania. A variant of strain three was recorded containing an 
interstitial inversion in the q-arm of the non-deleted chromosome three. Strain four was recorded 
in 2006 but only found in five devils from Freycinet Peninsula and is similar to strain two but has 
additional chromosome rearrangements including; interstitial deletion of the p-arm of 
chromosome five, translocation involving chromosome six and of marker two and variable number 
of double minute chromosomes (DM). 
Karyotype examination of DFTD samples from between 1996 (disease emergence) prior to testing 
in 2004 were not available. No intermediate karyotype between the normal devil and strain one 
has been detected. It is possible that strain two was the original transmissible tumour type 
whereby strain one is derived from strain two with the loss of marker five or, strain two could 
have derived from strain one by a single chromosomal rearrangement by duplication of the short 
arm of marker one. Examination of karyotypes revealed both diploid and tetraploid cells of strain 
one since 2004 but in 2006, animals with only tetraploid strains one and two have been identified. 
Low frequency strain four may represent a more aggressive strain because it is fast growing in 
vitro and the presence of DM indicated instability, thus host death would occur more rapidly 
reducing transmission rates. Pearse et al. (46) noticed that more complex chromosomal 
rearrangements do occur in advanced primary tumours and metastasis alongside the four strains 
described. These rearrangements have not been seen in any two devils from the same population 
and therefore it is unlikely that these evolved tumours are transmissible. 
Deakin et al. (19) combined chromosome painting and gene mapping (BAC clones) to determine 
the complex chromosomal rearrangements of 105 genes, including three strains of DFTD. This 
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analysis identified chromosome mismatches when comparing the previously reported karyotype 
by Pearce et al. (18). The Deakin et al. karyotype shows both chromosome one are absent and 
both chromosome two are present, both chromosome six and one chromosome five are present 
(Originally, the Pearse et al. karyotype had both chromosome twos missing, both chromosome 
ones present and chromosome fives were present with one chromosome six absent). Additionally, 
Deakin et al. found that the p-arm of one homologue of chromosome two contained translocated 
regions from chromosome one and the X chromosome and one of homologue of chromosome six 
had a translocated region from the X chromosome. Comparison of Tasmanian devil, opossum and 
wallaby show there is considerable rearrangement within some gene blocks by multiple inversions 
with the most conserved among marsupials being the long arm of chromosome three. This makes 
construction of a virtual map difficult and more genes would be required but sufficient to predict 
the gene content of each chromosome. The DFTD karyotype is remarkably stable in-vivo with only 
minor cytogenetic strain differences, stability after multiple passages with no progressive 
chromosomal rearrangements detected in-vitro is also apparent. Tumour evolution, as 
represented by strains one to three in this study, can be identified by G-banding but chromosome 
painting allows much more precise characterisation. Chromosome painting of DFTD strain one 
revealed that the marker chromosome M1 was predominantly made up of chromosome one and a 
small portion of the X chromosome. M2 was predominantly chromosome five and a small 
proportion of chromosome one and X chromosome. M3 was predominantly chromosome one and 
a small proportion of X chromosome and finally M4 consisted entirely of chromosome five. Gene 
mapping revealed only subtle differences between strains such as the presence of M5 containing 
one gene from chromosome one and one from the X chromosome present in strains two and 
three. The list of all the genes that were identified in relation to the strains is beyond the scope of 
this review but is available in detail (19). It is noteworthy that my research in chapter two of my 
thesis does assess over 40 genes and their expression in each of the strains of DFTD, contributing 
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additional information on gene expression in DFTD strains. In conclusion, this research maps 
chromosome restructuring and gene rearrangements comprising DFTD and suggest that the 
founder devil was female. It is also suggested by Deakin et al. (19) that the original tumourigenesis 
was triggered by chromothripsis, a shattering of the chromosomes, and in the case of DFTD 
restructuring has elicited a stable, transmissible, clonal tumour.  
Taylor et al. (5) employed the BAC library and fluorescent in situ hybridisation (FISH) to map 
candidate genes commonly associated with peripheral nerve sheath tumours and cancers in 
general. Current data was overlayed with previous mapping to provide a visual comprehensive 
gene mapping of chromosome one showing the relocation of genes to markers M1, M2 and M3. 
Two genes associated with Schwann cell tumours are epithelial growth factor receptor (EGFR, or 
ERBB1) and insulin like growth factor binding protein 1 (IGFBP1), which are located on devil 
chromosome 1 but located on DFTD markers M1q and M3q are involved in driving of 
tumourigenesis. Genes of interest associated with malignancy that were not located on 
chromosome one was ERBB3 (also from the epithelial growth factor family/HER3) and TP53, a 
tumour suppressor. ERBB3, normally located on chromosome five, is located differently in DFTD 
appearing on 4p with a copy gain located on marker chromosome M4q. My research had 
previously identified ERBB3 at an expression level as well as detecting it in the serum of devils, 
thus promoted ERBB3 as both an early biomarker of DFTD as well as a possible therapeutic target 
(47). This is covered in detail in chapter two of my thesis. TP53 is located on devil chromosome 
four and for the most part remained unchanged in DFTD but one sample did show an increased 
copy number with translocation to DFTD markers M1p and M5p. This gene is important in 
regulating cell cycle and preventing genomic mutations. TP53 along with IGF2R (insulin like growth 
factor receptor two) and nerve growth factor (NGF) both located on chromosome four were also 
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highlighted as potential gene candidates and these genes are discussed in more detail in chapter 
one of my thesis.  
It is well established that DFTD is a clonal tumour being transmitted from one host to the next, 
exposing the tumour to different genetic backgrounds and tumour microenvironments therefore, 
the role of epigenetics was explored by Ujvari et al. (48). Epigenetic processes are heritable 
changes not caused by DNA sequence changes but involve DNA methylation, the addition of a 
methyl group to cytosine at the five-carbon position, essential to gene expression. This research 
investigated the DNA methyltranferases (DNMT) responsible for methylation and Methyl-CpG 
binding domain (MBD) proteins responsible for demethylation to ascertain DNA methylation 
regulation. DFTD had a higher number of methylation sites (amplified fragment length 
polymorphism sites) when compared to non-peripheral nervous tissue (liver, heart, kidney, brain) 
but a similar number of methylation sites when compared to peripheral nervous tissue (sciatic 
nerve). The mean number of hemimethylated sites were significantly higher in DFTD samples 
when compared to sciatic nerve and other tissues. These results suggest that DFTD has active 
demethylation occurring, possibly through increased MBD2 and MBD4 genes, thus despite being 
genetically stable DFTD is evolving through epigenetic modifications, although no significant 
differences were seen between DFTD strains. Ingles et al. (49) employed immunoflourescent 
staining using 5-methylcytosine antibody to assess methylation status of chromosomes. All DFTD 
chromosomes, including rearranged marker chromosomes displayed strong telomeric methylation 
but little interstitial. What was interesting was that the rearranged chromosomes had restored 
telomeric methylation despite their initial loss. Ingles et al. documented in detail the 
immunofluorescent characteristics of the DFTD chromosomes, for example, the short arm of M1 
was hypermethylated, M4 was the most hypermethylated being on both telomeric ends and M5, 
present on all strains except strain 1, was intensely hypermethylated particularly the short arm. In 
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conclusion, no changes in DNA methylation was observed in DFTD over time with the fluorescent 
method used, contrary to Ujvari (48) but this could be attributed to hemimethylated sites rather 
than fully methylated or the semiquantitative immunofluorescent method used by Ingles et al. 
In addition to epigenetic responses of DFTD, Ujvari (50) also provides evidence that an 
anthropogenic selection has occurred at Forestier Peninsula, a selective sweep in fact. It has been 
suggested that the active removal of diseased individuals at this site increases DFTD response and 
evolution with increased tetraploid tumours, thus selection of a slower growing tumour. 
Ujvari et al. (51) found that DFTD has short telomeres and the copy number has increased over 
time in the tumour but no difference has been noted between geographical locations or strains. 
Telomerase is greatly upregulated in DFTD and this prevents cells entering replicative senescence 
with telomere elongation kept in check by the shelterin complex, perhaps offering genetic stability 
and increased proliferation. The characteristic short telomeres of DFTD were also reported by 
Bender et al. (52), who also found telomere dimorphism was not present in DFTD tumour cells. 
Genetic assessment of 433 tissue samples from devils within the northwest and western 
Tasmanian region was performed between 2000-2006, while taking founder devils into the captive 
breeding program, over an area of approximately 250,000 km2 area. Storfer et al. (53) used 
microsatellite analysis finding that genetic structure was present and populations appeared to 
consist of two or three clusters within the study area south, northeast and northwest. Another 
study using ten microsatellite loci to investigate genetic diversity in areas affected by DFTD 
compared to those areas not affected during 1999 and 2006-2007 was analysed by Bruniche-Olsen 
et al. (54). Results indicated that since the onset of DFTD no decline in diversity was evident, 
perhaps due to the short duration of population decline or because of low variability in the 
microsatellite loci there is insufficient statistical power to detect short-term loss of genetic 
29 
 
diversity.  There was stable genetic structuring in geographic locations and DFTD mediated 
changes in gene flow following DFTD spread. 
Ensuring that the Tasmanian devil insurance populations are genetically as diverse as possible is 
difficult when employing microsatellite markers because distinguishing closely related individuals 
is difficult. Wright et al. (55) has used single nucleotide polymorphisms (SNPs) which has benefits 
over other genotyping methods because it is better able to assess familial relationships among 
devils, particularly offspring. This enables an accurate pedigree, breeding recommendations, 
continued monitoring of genetic diversity of Tasmanian devils, the reduction of inbreeding and 
increased success when insurance population devils are reintroduced back into the wild. Morris et 
al. (56) employed SNPs to examine 167 genes immune related genes including interferon, 
chemokine, cytokine and natural killer T-cell receptor families. Their findings were that genetic 
diversity at functional loci is seriously low however, some diversity remains such as MHC, which is 
crucial to disease resistance. Hendricks et al. (57) employed restriction site associated DNA 
sequencing (RAD) to identify and genotype SNPs from thirty-eight geographic locations around 
Tasmania. They found limited genetic diversity, largely agreeing with previous data above, 
grouping north-western populations and central plateau and east coast populations as the two 
major clusters. It was noted that there were also sites intermediate to the two clusters above, 
those being central-west and Macquarie Harbour (Macquarie Heads) also previously identified by 
Brunichen et al. (58) as well as broad scale geographic structure within the two major regions. This 
methodology makes available data for future management of insurance populations whereby 
individuals from the intermediate zones, central-west and Central Plateau can be considered 





2.8 Tasmanian devil populations: Impact and insurance population strategies 
 
In 2006, a decade after the first description of tumours characteristic of DFTD, Hawkins et 
al. (16) reported that approximately fifty one percent of Tasmania had been infiltrated with 
histologically confirmed DFTD from forty one geographic sites. The numbers of devils affected at 
each site varied with up to eighty three percent of trapped adults affected and in addition, 
spotlight sightings also declined simultaneously by eighty percent, indicating population decline. It 
was reported by Lachish et al. (59) that an increase in DFTD affected subadults (1-2 year’s old) was 
occurring which will have an adverse effect on the number of devils reaching adulthood (>2 year’s 
old). The mark-recapture trapping program found wild populations of the Tasmanian devil have 
been significantly reduced in Tasmania where the possibility of extinction either locally within 10-
15 years or completely within 25-35 years (60) was predicted at the time.  
The disease has impacted on the life history of the Tasmanian devil. Normally, the 
marsupial will begin seasonal breeding at age two having annual litters until age five and death at 
age six. Jones et al. (61) found in disease ravished populations, females were only able to survive 
one breeding season and may not survive to rear the litter and that precocial breeding in one-year 
olds was on the increase. This documents that wild populations of Tasmanian devils were adapting 
to the disease impacts by early reproduction however, what genetic effects or resistance it has on 
the population remains to be seen. In 2009 McCallum et al. (62) found that disease levels were 
persistently high at fifty percent in two to three year old devils despite population density declined 
up to ninety percent in these areas. This data is inconsistent with density dependent transmission 
of DFTD, rather transmission is independent of density but dependent on frequency reaffirming 
that extinction of this iconic marsupial is a real possibility. One particular site monitored by 
Hamede et al. (63) at West Pencil Pine found that when compared to other devil populations 
(Freycinet, Fentonbury, and Forestier) the West Pencil Pines population continued to have a range 
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of ages (> 3 year olds) and a contrasting less than twenty percent of one to two year old breeding 
females. Hamede et al. (63) reported that DFTD was tetraploid in this area and that these tumours 
may be less proliferative or perhaps this population engage in aggressive biting behaviour less 
often. Further to this Hamede et al. (64) found that at West Pencil Pine devils with fewer bites 
were more likely to develop DFTD suggesting dominant devils may be inoculated by biting affected 
subordinate devils with DFTD. Further to this, Wells et al. (65) found that those devils with the 
greatest reproductive value, often the socially dominant devils, are most affected by DFTD when 
compared to non-infected individuals. This finding would suggest that infection of DFTD selectively 
removes the fittest devils from the population and this would have long term implications to both 
genetic diversity and social structure of surviving Tasmanian devils.  As reported above, West 
Pencil Pine had reduced prevalence of DFTD during the first five years of the disease outbreak with 
a tetraploid strain predominating. Hamede et al. (66) reported increased disease prevalence rates 
at his site when the tetraploid lineage was replaced with a diploid lineage where causative 
mechanisms include spread from adjacent populations, virulence of tumour ploidy, transmission 
rates and genetic differences. As of 2017 Lazenby et al. (67) reported that the disease now covers 
eighty percent of Tasmania, a thirty percent increase since reported in 2006 by Hawkins et al. (16), 
with a similar degree of decline in spotlight sightings (eighty three percent) and population 
densities (seventy seven percent) in affected locations. Fentonbury was the only location where a 
slight population increase was recorded and investigations here are ongoing. Recently Grueber et 
al. (68) reported in a landscape level analysis of field data publications, that indeed devils were 
significantly younger in DFTD affected sites. The females in these sites were also more likely to 
demonstrate evidence of breeding than those devils in sites unaffected by DFTD, where this could 
not be attributed to body condition or age difference. In a spatially explicit metapopulation model 
study, Siska et al. (69) predicted that the long term persistence of both DFTD and its host, the 
Tasmanian devil, but the population size would be approximately nine percent of the original 
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healthy population size that was previously enjoyed in Tasmania prior to the emergence of DFTD. 
This study highlights that this considerable reduction in population density has already altered the 
usual age structure of wild Tasmanian devils. Compounded by loss of genetic diversity in an 
environment where loss of habitat and road kill are continuing pressures, further endeavours in 
conservation of this iconic species are required. The timeframe of the pre-clinical stage of DFTD 
remains largely undetermined with observations ranging from 2-13 months (16, 32, 62, 64, 70) but 
as little as 1 month has been recorded (DH, manuscript in preparation, laboratory records 
DPIPWE). In a quest to discover a pre-clinical marker for DFTD, Hayes et al. (47) identified ERBB3 
as the first potential serum biomarker for DFTD. My research found that serum ERBB3 was 
elevated in devils with advanced DFTD when compared to healthy non-infected devils and 
therefore the possibility to use ERBB3 as a screening method is proposed. ERBB3 is now 
recognised as a therapeutic target and therefore the potential exists to consider modes of 
administration in addition to existing whole cell vaccination such as ERBB3 monoclonal antibody, 
peptide or xenogeneic vaccines including checkpoint inhibitors. A combinatorial 
immunotherapeutic approach will enhance cytotoxic destruction, provide long-term immunity 
from DFT1 and therefore eradicate this transmissible tumour from the wild. Additionally, elevated 
serum ERBB3 levels was also detected in Tasmanian devils with cutaneous lymphoma (15), a T-cell 
lymphoma affecting older devils whose appearance is not confused with DFTD. In depth analysis of 
ERBB3 as an early serum biomarker, immunohistochemical expression and therapeutic 
applications are discussed in chapter two of my thesis. 
In an attempt to suppress the spread of DFTD, selective culling of DFTD affected devils was 
performed at Forestier Peninsula during extensive trapping (four hundred and forty eight devils) 
and recording expeditions 2004-2008. A control population at Freycinet Peninsula (six hundred 
and thirty three devils), was exposed to the same rigorous trapping regime as Forestier Peninsula 
but devils with DFTD were not removed from the population. Lachish et al. (71) compared the two 
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populations finding that selective culling was ineffective and did not slow the rate of disease 
progression or reduced the population-level impacts, put simply, the trial really only culled those 
individuals that would die of the disease naturally in the wild. Population modelling by Beeton et 
al. (72) also came to the same conclusion as Lachish et al. (71) that managing DFTD through 
selective culling did not appear to be a practicable approach to managing DFTD in the wild. Two 
studies used chemotherapeutic approaches to establish possible treatment modalities employed 
vincristine (73) and doxorubicin and carboplatin (74) trials none of which DFTD responded to, 
therefore chemotherapy would not be an effective form of treatment for wild Tasmanian devils.  
 
Given the precipitous population decline in wild Tasmanian devils and dire forecast of 2007, 
strategies to retain wild populations of devils began in earnest. Jones et al. (75) in 2007 suggested 
the establishment of an ‘ark’ or ‘insurance’ population, consisting of both captive and wild-living 
populations isolated from DFTD as a priority for the conservation management of the Tasmanian 
devil. Possible methods of maintaining a disease free insurance population include zoos, wildlife 
parks, fostering orphaned young from diseased mothers, fenced in enclosures and free ranging 
island populations. Modelling wildlife disease has its challenges when compared to human or 
livestock disease situations, no one strategy appears superior to the other, modelling may 
therefore need a number of different approaches (76). The main focus of the initiation of 
insurance populations in 2006 was simply to save the Tasmanian devil from extinction with local 
and national wildlife parks, free-range enclosures and Maria Island. Hogg et al. (77) reports that 
the success of this breeding program has realised its goal by reaching a carrying capacity of 600 
devils retaining ninety nine percent of founding gene diversity. Hogg et al. also highlights that 
there was no influence on pairing success in regards to zoo or wild-born origins but wild-born 
females produced more joeys per female and downward trend in the number of joeys from 
captive females between respective generations in captivity. This has modified intake of founder 
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devils for insurance populations because of the better understanding of genetic providence and 
birth origin, for example accepting orphaned female devils (77). A recent report by Rogers et al. 
(78) followed up on twenty eight captive raised devils (nineteen from intensive captive 
management and nine from free range enclosures [twenty two hectares]) found ninety six percent 
of the devils had survived the first year following release onto Maria Island. The research also 
found that irrespective of captive management, the devils gained weight and intensive captive 
management does not diminish their instinctive behaviour of scavenging and hunting, showing 
captive bred devils, regardless of management, can be released successfully onto offshore islands 
as a viable conservation strategy. A second study of fourteen of the translocated devils to Maria 
Island by Thalman et al. (79) concurred with the above report by Rogers et al. (78). They were able 
to show that the devils frequented agricultural and urban habitats avoiding wet eucalypt forests. 
One devil died not from malnutrition but misadventure such as fighting or collapse of a wombat 
burrow where the body was recovered. Pedigree modelling on the Maria Island population by 
McLennan et al. (80) predicted genetic diversity of ninety-five percent for another two years and 
would drop to seventy seven percent after forty years. If however ten new founder female devils 
were introduced every three years this would preserve the ninety-five percent gene diversity until 
2056. Forestier Peninsula has been subject to removal of DFTD since 2012 and declared disease 
free towards the end of 2015 whereupon a devil proof fence was erected across the 800m isthmus 
connecting the peninsula to mainland Tasmania. Here thirty five captive bred adult devils free of 
DFTD were reintroduced to Forestier Peninsula in November 2015 and ten captive bred juveniles 
were reintroduced in February of 2016 forming part of the Tasmanian devil insurance population 
(81). While captive breeding is crucial to survival of the Tasmanian devil, Grueber et al. (82) noted 
that nineteen of the fifty devils included in their study of reintroduced captive bred devils into 
Forestier Peninsula and Narawntapu National Park, were victims of vehicular road kill suggesting 
captive bred devils may be naïve to such post-release risks. 
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Together, there is a strong collaborative approach to saving the Tasmanian devil by integrating 
multidisciplinary laboratory based research within a conservation management framework 
devised by the Save the Tasmanian Devil Program (STDP) (83). This cooperative approach has 
witnessed great advancement in understanding the nature and origins of DFTD by identifying both 
genetic and expressional proteins, molecular markers for genetic diversity in founder populations 
and vaccine development in wild Tasmanian devils. Paramount to STDP is conservation 
management and the complete success of insurance populations of intensive, free-range 
enclosure or Island relocation, all of which are triumphantly at capacity, providing individuals 
suitable for relocation to decimated devil populations within Tasmania. 
 
2.9 DFT2: A second transmissible Tasmanian devil facial tumour 
 
The comprehensive sixteen-year overview above focuses solely on research and conservation 
management directed at DFTD. Unfortunately, for the Tasmanian devil a second transmissible 
tumour has been identified in this species, now termed Devil Facial Tumour 2 (DFT2), seemingly 
restricted to the Channel Peninsula south of Hobart. A comprehensive overview of DFT2 and my 
collaboration is provided in chapter three of my thesis but briefly outlined below for completion of 
devil Facial Tumour literature review. 
 
Pye et al. (7) identified five cases from twelve in the Channel Peninsula as non-classical DFTD, 
despite the external appearance of facial tumours indistinguishable to DFTD. It was noted that the 
histomorphology was not consistent with typical pleomorphic small round cells forming distinct 
bundles, cords or packets of DFTD (1) in contrast, these cases had pleomorphic sheets containing 
amorphic, stellate and fusiform cell types with the distinct bundles, cords or packets characteristic 
of DFTD noticeably absent. Periaxin Immunohistochemical staining was performed which is 
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expressed by DFTD but was negative on two unusual facial tumours. As previously discussed, the 
distinctive DFTD karyotype has both chromosome two homologs absent, one of the chromosome 
5 homolog absent, both X sex chromosomes absent and the presence of four abnormal marker 
chromosomes. In contrast to DFTDs karyotype, the unusual tumours karyotype has additional 
material on chromosomes one, two and four, a deletion involving chromosome 5 and monosomy 
for chromosome six. Both X and Y sex chromosomes were present. Of greatest significance was 
that all five tumours had the identical complex karyotype and therefore conceivable that they 
were derived from a single clone and for this reason we named the tumour DFT2, a second 
transmissible devil facial tumour. Previous investigations using fluorescent insitu hybridization had 
identified two X chromosome copies in DFT1 ((19, 45) and further examination by Pye et al. (7) of 
10 X chromosome variants all mapping to the X chromosome only, confirms that DFT1 carries two 
homologous X chromosomes and the tumour probably arose from a female devil originally. 
Because the DFT2 karyotype is completely different to DFT1 and carries a Y chromosome 
indicating the origin of DFT2 was from a male devil, and DFT2 is negative for Periaxin, together the 
evidence supports that a single clonal origin of DFT1 and DFT2 is discordant. This discovery of DFT2 
certainly provides some insight into the vulnerabilities of the Tasmanian devil given this is the 
second transmissible tumour in the species within twenty-two years, with DFT2 appearing as 
recently as 2014. We further investigated and reported by Stammitz et al. (8) the functional and 
genetic characteristics of DFT1 and DFT2 in an attempt to elucidate any commonalities between 
the two transmissible tumours. Our panel of IHC showed similar characteristics with both DFT1 
and DFT2, both being positive for S100, ENO2 and VIM and negative for SMA and CK. As previously 
reported, DFT1 is strongly positive for PRX (20) which is routinely used for a diagnostic marker; 
however, in contrast to DFT1, DFT2 is negative for PRX, providing an expressional distinction. 
Genotyping DFT1 and DFT2 at 320 nuclear polymorphic loci, and compared to previous data (84) 
found that DFT1 arose geographically in the North East of Tasmania Mt William area however, 
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DFT2 arose in the south east Channel Peninsula area. Essentially, DFT1 and DFT2 appear to have 
emerged independently at separate locations. Interestingly, because DFT2 contains a Y 
chromosome it was noticed that of the now eleven DFT2 tumours identified  (85) nine of these 
tumour were grafted into male hosts, one a female host and the other female host the Y 
chromosome was not detected. It remains to be seen if female devil hosts provide some type of 
immunological resistance to DFT2. In wrapping up our research we screened a number of drugs for 
potential therapeutic agents. It was found that both DFT1 and DFT2 were sensitive to receptor 
tyrosine kinases (RTK), particular DFT1s sensitivity to ERBB2 mediated Afatinib which is reassuring 
as our ERBB3 studies suggested a number of regimes that included the dimer ERBB2/ERBB3. DFT2 
had sensitivity to Axitinib, which is active against PDGFR and KIT, both of which are discussed in 
depth in chapter 1 of my thesis. In a recent publication Caldwell et al. (86) found that DFT2 
expresses B2M as well as classical and non-classical MHC class I heavy chains, which is contrary to 
DFT1 which has lost expression of MHC class I molecules. Results showed that expression of MHC 
class I alleles varied on DFT2 tumours with the highest expression of classic MHC-I allele also found 
present within host devils. This research by Caldwell et al. (86) suggests that loss of MHC is not 
necessary for tumour transmission because of varied expression however, subclones may be 
selected upon transmission if they have downregulated MHC as the tumour encounters different 
devils immune systems. It is predicted that DFT2 is likely to be losing MHC antigens already and 
this could lead to widespread transmission throughout the remaining fragile wild populations of 
Tasmanian devils, on the back of the decimation caused by DFT1. Evidence would suggest that the 
Tasmanian devil may well be prone to transmissible cancers, increasing the urgency of biomarkers 













3.1 Standard Histology and Immunohistochemistry chapters 1-3. 
Devil Facial Tumour 1 (DFT1) Immunophenotype Reveals a Progenitor-Like Cell with Schwann cell, 
Melanocyte and Self-renewal Characteristics (Chapter 1). 
ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial 
tumour 1 (DFT1) (Chapter 2). 
DFT1 and DFT2 histology and immunohistochemistry (Chapter 3) 
A second transmissible cancer in Tasmanian devils 
The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils 
 
 
3.2  Standard Histology 
Tasmanian Devil tissues were fixed in 10% Neutral Buffered Formaldehyde (Confix, ACFC, 
Australian Biostain, Traralgon, Victoria, Australia) for 24 hours and selected tissues were cassetted 
and processed overnight using a standard 15 hour overnight procedure in the TP1050 tissue 
processor (Leica Microsystems, Wetzlar, Germany). Tissues were orientated on the EG1160 (Leica), 
embedded in paraffin wax (Surgipath Paraplast, 39601006, Leica), sectioned at 3 microns using 
Leica RM2245 microtome, adhered to microscope slides (Menzel Glaser, Braunschweig, Germany) 
and dried for 20 minutes at 60OC. Sections were deparaffinised, rehydrated and stained using Jung 
autostainer XL (Leica) for Haematoxylin (Harris’ Haematoxylin, AHHNA, Australian Biostain) and 
Eosin, dehydrated cleared and mounted in CV Mount (Leica, 046430011). 
 
3.3  Standard Immunohistochemistry 
 
Archival Tasmanian devil tissues and tumours were sectioned at 3 microns, floated onto 
Superfrost plus slides (Menzel Glaser) and subjected to standard deparaffinisation and rehydration 
techniques using an automated stainer (Leica). Antigen retrieval in tissue sections was conducted 
in citrate buffer at pH 6.0 (Reveal Decloaker, Biocare Medical, California, USA) at 1200C for 8 
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minutes using a Pascal pressure chamber (Dako, Glostrup, Denmark) then cooled to 20oC. 
Endogenous peroxidase activity was quenched using 3% hydrogen peroxide (Ajax Finechem, 
Sydney, Australia, 260) in methanol (Ajax, 723) for 30 minutes. Detection of primary antibodies 
was achieved using Mach1 Universal HRP-Polymer detection kit (Biocare Medical, California, USA, 
M1U539GL10). Protein block (Background Sniper BS966L10) was applied for 20 minutes prior to 
application of primary antibodies. Primary antibodies were applied to both devil tumour and 
normal devil control tissues at room temperature for 30 minutes. Negative control was omission 
of primary antibody with buffer substitution. Universal HRP-polymer was applied for 30 minutes 
(MRH538L10) followed by 1 drop of Betazoid DAB Chromogen 3,3’- Diaminobenzidine (BDB900G) 
in 1ml of substrate buffer (DB900) applied for 4 minutes. Tris buffered saline (Biocare Medical, 
TWB945) was used to rinse between all steps. Slides were rinsed, stained with Carazzi’s 
Haematoxylin for 5 minutes, washed for 3 minutes in tap water, dehydrated, cleared and mounted 
in CV mount. Sections were viewed under light microscopy using Olympus BX41 (Olympus 
corporation, Tokyo, Japan) and selected areas were photographed using an Olympus digital 
camera (DP20). 
 
3.4  Immunohistochemical detection systems 
 
There are many choices of immunohistochemical kits available on the market today. One of the 
most common older technologies utilized is the Avidin-Biotin Complex or the “ABC” methodology 
(figure 1). This relies on two major components; avidin, a large glycoprotein extracted from egg 
white that has four high affinity binding sites to Biotin which is the second major component, a 
low molecular weight vitamin. Biotin conjugated enzyme (peroxidase) and Avidin are allowed to 
react together to form a complex, this is then added to the tissue section which has a secondary 
biotinylated antibody attached. The biotinylated antibody binds to the ABC complex forming a 
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larger complex to which the chromogen (DAB) is added in order to reacted with the enzyme 
resulting in a brown colour change (87).  
 
 
Figure 1: Diagrammatic representation of the ABC method of detection.  
Diagram reference: Ramos-Vara et al.(87) 
 
I previously used the ABC method but more recently substituted this method with the LSAB 
method. The LSAB method is similar but substitutes Avidin with Streptavidin (from the bacterium 
Streptomyces avidinii). This reduces the higher non-specific background staining caused by Avidin 
cross-reacting with lectins. An additional problem with both methods is that endogenous biotin 
(such as in liver or kidney tissue) can also contribute to background staining, making interpretation 
problematic. One such method that avoids both Avidin and Biotin non-specific staining is to use 
systems that employ polymer-based technology such as the Biocare micropolymer technology 
(Figure 2), which I utilised for my thesis. This method is able to increase the number of enzyme 
linked polymers adhered to antibody, is more compact than the ‘ABC’ complex, thus offering less 




Figure 2: Avidin Biotin free enzyme linked micropolymer technology.  
Diagram reference: Biocare https://biocare.net/wp-content/uploads/MACH103.pdf 
 
 
3.5  Antigen (Epitope) retrieval  
 
Formaldehyde is the preferred choice of histologists for fixing tissues as this small aldehyde 
infiltrates tissue and provides crosslinks between some amino acids and peptides. At a molecular 
level (figure 3) the formaldehyde reacts with hydrogen on the amino groups forming 
hydroxymethyl compound, crosslinks form and further reaction with hydrogen forms a methylene 
bridge. These crosslinks cause a conformational change (mainly tertiary and quaternary) in the 






Figure 3:Cross-linking induced by formaldehyde fixation at a molecular level.  
Diagram reference: Ramos-Vara et al. 2005 (87). 
 
 
In most cases, for the application of immunohistochemistry to formalin fixed paraffin embedded 
(FFPE) tissue sections, crosslinking caused by formaldehyde fixation must be reversed to “reveal” 
the antigens/epitopes (figure 4) for successful antibody adherence. This can be achieved by using 
either heat induced epitope retrieval (HIER) or enzyme induced epitope retrieval (EIER). HEIR 
involves the use of heat in various buffers and pH such as citrate pH 6.0 or EDTA pH 9.0 and is 
successfully achieved using a pressure cooker-like device (Figure 5), typically with programmable 
temperature and time for precise control over retrieval conditions. My experimentation found 
that epitope retrieval was best achieved using citrate pH 6.0, 8 minutes at 120 oC with relatively 
little background staining whereas higher pH buffers introduced some background or non-specific 
staining at this temperature. While pressure cookers are still currently in use in small laboratories 
or the research setting, they have largely been replaced by lower temperature longer time 
antigen/epitope retrieval technologies (e.g. routine human diagnostic high throughput 







Figure 4: Antigen retrieval reverses the conformational changes revealing antigen/epitopes. 
Diagram reference: Romos-Vara et al 2005.(87) 
 
 
Figure 5: Antigen retrieval Pascal pressure cooker.  
(Dako/Agilent https://www.agilent.com/) 
 
3.6  Monoclonal and polyclonal antibodies 
 
The targeting of marsupial cellular tissue antigens/epitopes by immunohistochemistry is a difficult 
task because virtually all commercial antibodies, whether monoclonal or polyclonal, are antibodies 
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produced using human immunogens. The host species for the polyclonal antibodies used in my 
research were rabbits, immunised with purified antigen, producing antibodies against this specific 
antigen. However, rabbit polyclonal antibodies have both advantages and disadvantages in their 
application. The advantage of a polyclonal antibody, providing the antisera is affinity purified, is it 
will contain a mixture of different antibodies directed at different epitopes present on a given 
protein immunogen. Essentially this does provide multiple epitope recognition, which can be 
particularly advantageous for non-human species. This feature is useful when identifying 
marsupial epitopes, where the marsupial-human amino acid sequence homology of the many 
antibodies present may range from fifty to one hundred percent. The disadvantage with the 
polyclonal antibody is that some of the antibodies may cross react with other cellular epitopes on 
non-target proteins. Thus, while polyclonal antibodies have higher affinity and wide reactivity they 
have lower specificity when compared to monoclonal antibodies (87). Monoclonal antibodies in 
contrast to polyclonal antibodies are most commonly produced in mouse, although rabbit 
monoclonal antibodies are becoming increasingly popular in the market place. Following 
immunisation of the mouse with purified antigen, antibody producing B-cells are harvested from 
the spleen and fused with mouse myeloma cells conferring immortality on the hybrid. Because B-
cells will produce a variety of antibodies, the hybridomas can be screened for specificity and 
selected on this basis. Generally, monoclonal antibodies are more specific with less non-specific 
staining than polyclonal antibodies although the possibility of cross-reaction with non-target 
epitopes can occur if the initial antigen used comprised a small amino acid sequence (87). The 
choice of using monoclonal or polyclonal antibodies for a given marsupial epitope depends 
primarily on whether the amino acid sequence of the antigen is known. The Tasmanian devil 
genome has been sequenced and is available at Ensembl gene browser (https://www.ensembl.org/) 
therefore, I was able to use the orthologue protein alignment tool for human and Tasmanian devil 
amino acid sequences for the given gene of interest and compare the homology of the two 
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sequences. Exact comparison is only possible when manufacturers provide the actual position of 
the amino acids or the actual amino acid sequence from which I could deduce the actual position 
within the gene. For example, if we compare human and Tasmanian devil orthologue sequences 
 
Figure 6: Orthologue protein alignment of nerve growth factor receptor (NGFR). 
Figure reference: Ensembl gene browser (https://www.ensembl.org/) 
 
of nerve growth factor receptor (NGFR) (figure 6) we can determine mismatch amino acid regions 
of the manufactures antigen to deduce the anti-human antibody with the most sequence 
homology to the Tasmanian devil sequence. In practice, if manufacturer-A’s antigen sequence is 
aa’s 1-38 and manufacturer-B’s antigen sequence is aa’s 88-120 we can see that both of the these 
illustrate amino acid mismatches with homology only at approximately fifty percent. However, if 
47 
 
manufacturer-C’s antigen sequence is aa’s 121-142 it has one hundred percent homology and 
therefore this antibody would be worthy of immunohistochemical evaluation. Some genes are 
conserved across species for example, proliferating cell nuclear antigen (PCNA) has one hundred 
percent homology (figure 7) and therefore any number of antibodies would be suitable. 
Figure 7: Orthologue protein alignment for proliferating cell nuclear factor (PCNA). 
Figure reference: Ensembl gene browser (https://www.ensembl.org/) 
 
When only polyclonal antibodies are available or perhaps only monoclonal with unknown 
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4.1  Abstract 
 
Devil Facial Tumour 1 (DFT1) is a clonally evolved tumour of Schwann cell origin affecting 
Tasmanian devils (Sarcophilus harrisii). Transferred by biting, it is now one of two transmissible 
neoplasms in this species. The orofacial regions of the Tasmanian devil are a rich source of 
peripheral nerves often injured during mastication or aggression between individuals, initiating a 
cascade of molecular signals transdifferentiating Schwann cells into Bungner Schwann cells, 
augmenting axonal repair within the wound microenvironment. We hypothesised that DFT1 may 
have originated from malignant transformation of the Bungner Schwann cell where, theoretically, 
the wound microenvironment, or niche, would provide the necessary trophic factors crucial to 
DFT1 transmission, survival and proliferation. Our extensive research explores 
immunohistochemical expression of common progenitor and developmental cell markers of the 
Schwann and Melanocyte lineages including self-renewal. Our results reveal DFT1 is a progenitor-
like cell with Schwann cell, melanocyte and self-renewing characteristics. 
 
4.2  Introduction 
 
4.2.1 Vertebrate Neural crest 
 
The neural crest (NC), is unique to the vertebrate embryo and advocated as the fourth germ layer 
(88) due to the diversity of cell types derived from the NC. Induction of the NC occurs at the neural 
plate border between the neural plate and the non-neural ectoderm where NC cells (NCCs) are 
specified and reside within the elevating neural folds and dorsal neural tube after its closure. 
Delamination, a process whereby partial or complete epithelium-to-mesenchymal transition (EMT) 
separates the NC from the surrounding neuroepithelial cells, now transitory and multipotent, 
migrates extensively throughout the developing embryo. Induction and migration phases are 
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highly dynamic and governed by the NC gene regulatory network (GRN) permitting NCCs 
interpretation of signals from the microenvironment, including other NCCs, navigation of 
embryonic pathways and their terminal differentiation depends on the axial level of the NCCs 
origin. The cranial NC (CNC) is the origin of ectomesenchymal cells of craniofacial skeleton, 
including bone, cartilage, connective tissue and most of the dental tissues. The trunk NC (TNC) is 
responsible for secretory cells of the adrenal (chromaffin) and thyroid (parafollicular) glands, form 
dorsal root ganglia (DRG) and autonomic nerves. The vagal NC contributes the enteric nervous 
system (ENS), cardiac mesenchyme and smooth muscle vasculature. NCCs from all axial levels 
differentiate into melanocytes and contribute to the peripheral nervous system (PNS) delivering 
sensory, sympathetic and parasympathetic neurons and glia to the developing embryo (above 
paragraph reviewed in (89-92)).  
4.2.2 Marsupial neural crest 
 
Studies on chick, mouse, rat and others provides extensive knowledge of vertebrate embryonic 
development.  Although closely aligned, differences in NC development between species exist 
(89). Marsupial (metatherian) young are born extremely immature or altricial when compared to 
eutherian (placental) newborns, following a short intrauterine gestation and even shorter period 
of organogenesis yielding minimal respiratory, urogenital, skin, digestive and cardiovascular 
function for extrauterine survival (93-95). The degree of development in marsupials is narrow but 
the Dasyurids, the group to which Tasmanian devils belong to, are at the extreme end and 
therefore classed as ultra-altricial with the newborn weighing 5-20mg. Despite its embryonic state, 
the marsupial neonate must have considerable functional independence enabling movement. The 
marsupial neonate exhibits advanced features essential for survival; including movement from the 
birth canal to the teat area or pouch, recognition of the nipple, attachment and suckling (reviewed 
in (95-97)). Studies on the grey short tailed opossum, Monodelphis domestica, show early 
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differentiation and migration of the neural crest is responsible for advanced development of 
craniofacial region giving rise to most of the bone, cartilage and connective tissues and patterning 
for musculature (96, 97) necessary for orofacial development. Relative advancement of the 
forelimb of the marsupial, including the Tasmanian devil (98, 99), and the neuromuscular junction 
of the western grey kangaroo, Macropus fuliginosus (100) are considered crucial to neonate 
movement, specifically, Tasmanian devil metacarpals are developed but phalanges have not yet 
differentiated (96). Relative to its body size, precocious development of the trigeminal sensory 
pathway in the eastern quoll, Dasyurus viverrinus, is evident, possibly augmenting somatosensory 
signals from the face (101). The olfactory system is thought to guide the neonate to the mothers 
pouch and while the tammar wallaby, Macropus eugenii, shows early nerve fibres it was deemed 
insufficient for reception (102) however, it was concluded that the olfactory systems was 
developed at birth because the neonate is directionally influenced by the mothers pouch odours 
(103). Innervation of the mystacial vibrissae follicles in the brush tail possum, Trichosurus 
vulpecula, reveal Merkel cell-neurite complexes as well as specialised Schwann cell (SC) processes 
at terminal nerves called Palisade, Bulbous and Compound endings (104). Merkel cells present in 
the northern native cat, Dasyurus hallucatus, and other marsupials are highly sensitive touch 
receptors, present around the oral region and fusion area on the lips would aid the neonate to 
sense attachment to the teat (105, 106). Melanocytes are seen in the dermis and epidermis of the 
brush tail possum as early as two days (107) and 10 days in the northern native cat (108). These 
comparative marsupial studies illustrate the relative shift in timing of development compared to 
eutherian vertebrates. Advancement of the neonate, particularly early neural crest differentiation, 
migration for craniofacial formation, forelimb development, neuronal and sensory networks 




4.2.3 Schwann cell linage 
 
The NC derived glial components of the PNS can be categorised into six cell types: (1) Satellite cells 
(STC) envelop neuronal cell bodies (soma) of the DRG and sympathetic and parasympathetic 
ganglia (109, 110) actively participate in the processing of sensory signals that enhances somatic 
activity (111). (2) Boundary cap cells (BCs) appear transiently at dorsal root entry zones (DREZ) and 
motor exit points (MEP) and function as gatekeepers between the motor neuron axons exiting the 
CNS and sensory afferent axons entering the central nervous system (CNS) (112). Additionally, BCs 
also contribute to populations of STC, Schwann cell precursors (SCPs), nociceptive neurons (113), 
thermoreceptive neurons (114), mature Schwann cells (115) and terminal glia of the skin (116). (3) 
Schwann cells are Integral to peripheral nerve development transitioning from neural crest stem 
cell (NCSC) to SCP, both phenotypes being migrating and proliferative. The SCP is dependent upon 
paracrine axonal signals to survive in order to generate immature Schwann cells (ISC). ISCs cease 
migration, develop autocrine survival signals and deposit basal lamina distinguishing themselves 
from the SCP. Just before birth and continuing postnatally, ISCs engage in radial sorting of late 
embryonic nerves segregating large diameter axons from those of smaller diameter.  ISCs that 
form a 1:1 relationship with large axons, now termed pro-myelinating Schwann cells, will exit the 
cell cycle and form myelinating Schwann cells (MSC). Remaining small diameter axons will not be 
myelinated; instead, they are ensheathed by non-myelinating Schwann cells (NMSC) forming 
Remak fibres/bundles (reviewed in (109, 117-119)).  
MSCs are renowned in the PNS but the less familiar NMSC are also integral to development and 
function of the PNS (120, 121) with the ability to form MSC (122). NMSC are harboured in diverse 
microenvironments to perform homeostatic functions in bone marrow (123, 124) or envelop the 
spiral ganglion neurons of the cochlea (125). Within NMSCs are the (4) Teloglia or Terminal Glia 
(TG) which are central to somatosensory innervation in the skin associated with mechanosensory 
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complexes such as lanceolate (126), Merkel, Ruffini, Pacinian and free nerve endings (127, 128), C-
fibres (129, 130), and Meissner corpuscles (131, 132). TG are also present as peri-islet Schwann 
cells in the pancreas (133) and peri-synaptic Schwan cells at the neuromuscular junction (134, 
135). (5) Enteric glia are also NMSC and are present throughout the ENS as mucosal or 
intramuscular enteric glia (136, 137). Lastly (6) Olfactory ensheathing cells (OEC) are specialized 
peripheral glia that share homology with Schwann cells (138) and are unique in that the OEC 
envelop from peripheral olfactory axons through to the olfactory bulb (139) located in the CNS. 
4.2.4 Melanocyte lineage 
 
NC derived pigment cells, or melanocytes, localise classically as cutaneous melanocytes in the skin 
epithelium and dermis or non-classically in non-cutaneous anatomical sites such as the eye (except 
retinal pigment epithelium), ear, heart, CNS meninges and adipose tissue (140, 141). Melanocytes 
have two distinct migratory pathways: At the trunk level, firstly, early delaminating NCCs proceed 
dorsoventrally between the neural tube and somites classically differentiating into neurons, glia 
and endoneurial fibroblasts (142, 143). Recent research has demonstrated that a subset of SCPs 
that lose contact with growing peripheral nerves, do not form glia and instead adopt a melanocyte 
fate (144) . Secondly, late migrating NCCs arise from the dorsal neural tube, accumulate in the 
‘migration staging area’, receive early specification allowing migration dorsolaterally between the 
superficial ectoderm and dermomyotome to eventually colonise the skin (reviewed in (142, 145)). 
In populating the skin, late dorsolateral migrating melanoblasts form the first wave of colonising 
melanocytes whereas the early migrating dorsoventral SCP derived melanoblasts will form the 
second wave of melanocytes (146). Recently, mouse cranial melanocytes have also been identified 
as arising from two populations; initially from nerve associated SCP and later from a nerve 




4.2.5 DFT1 Immunohistochemical study  
 
Our research documents for the first time the histomorphology and immunohistochemical 
expression of five strains of DFT1. We comprehensively employ 51 antibodies commonly used to 
discern neural crest derived Schwann cell and melanocyte lineages including growth, transcription 
and stem cell/self-renewal markers. We compare our immunohistochemical expression between 
strains and with previously published gene expression (4). Briefly, markers include; Schwann cell: 
MPZ, PRX, MBP, PMP22, PLP1, GFAP, GAP43 and MAG. Growth factors: NGFR, IGF2R, PDGFB and 
VEGF; Bungner Schwann cell: JUN, SHH and STAT3; Melanocyte markers: MITF, MLANA, TYR and 
PNL2; transcription factors: SOX10, SOX2, PAX3, TFAP2A and ERG2; and stem cell/self-renewal: 
EPCAM, CD44, PROM1, POU5F1 and NES. Immunohistochemical expression of myelin related 
proteins revealed a mixed SC phenotype consisting of precursor, immature, mature MSC and 
NMSC markers, characterising the various stages of Schwann cell development. The expression of 
JUN, SHH and STAT3 reveals the molecular signature of an activated repair program. The 
expression of growth factors IGFR2, BDNF and PDGFB indicate autocrine survival program 
activated by axonal loss. Essentially, melanocyte markers were negative for MLANA, TYR and MITF; 
however, unexpectedly, all cytogenetic strains expressed the melanocyte marker PNL2, suggesting 
that DFT1 is bipotent. Expression of NGFR, NES, SOX2, POU5F1, EPCAM, CD44, and PROM1 
indicates a neural crest like-stem cell with self-renewal characteristics. Together, the phenotype 











To provide excellent contrast against 3,3’-diaminobenzidine (DAB) stained primary antibodies 
PNL2, MLANA, TYR and MITF we used a modified 0.2 % Azure blue (Aldrich 86,105-7) pH 6.0 for 1 
minute, differentiate in 95% ethanol 10 minutes, dehydrate clear and mount in CV mount (148, 
149) turning brown melanin granules metachromatically green. We performed histochemical 
staining for melanin using well established histological methods; Schmorl’s stain (ferricyanide to 
ferrocyanide, Prussian blue reaction) and Masson Fontana stain (reduction of ammoniacal silver to 
metallic silver, Argentaffin reaction) (150). 
 
4.3.2 DFT1 morphology and immunohistochemical assessment  
 
DFT1 Primary tumours, three each from strains 1-5, listed in table 1, were assessed by 
Haematoxylin and Eosin staining and immunohistochemically stained with primary antibodies 
listed in table 2. Microscopically, 10 by 10 high power fields for each DFT1 tumour strain were 
assessed semi quantitatively for expression of each antibody and the numerical average expressed 
as a percentage. Intensity of staining was also recorded as follows; negative (0), weak (1/+), 
moderate (2/++) and strong (3/+++). We present both percent expression and the intensity 
gradient averages of immunohistochemical staining as heat maps. We generated heat maps to 
measure differences in strain protein expression, using GraphPad Prism version 7.04, GraphPad 




Table 1: Primary tumour Tasmanian devils. 












/ Tumour size 
(cm) 
S1 1 982009104719592 12/0820 4 F, 4.5 West pencil 
pine 
Left lateral 
Upper lip, 2.5cm 
S1 2 R00000000003005 12/1594 1 M, 3.2 Huon Valley Rostral Lower 
Jaw, 8x5x2cm 
S1 3 982000000122095 12/2095 2 F, 3.7 Upper Natone Right upper 
lip/nose, 5x5x2 
S1 16 982009104883696 10/1830 Adult M, 7.2 Narawntapu 
Latrobe 
Right face 4x4x3 
S1 17 982009106165902 10/2449 Adult F, 6.1 AHL Prospect Right cheek 
5x4x4 
S1 18 982009104350416 10/1829 Adult F, 5.4 Narawntapu 
Latrobe 
Left lower lip, 
8x8x3 
S2 4 982009104751722 11/2824 4 F, 5.7 Parrawe 
Waratah 
Right lateral 
lower jaw, 3x3x2 
S2 5 982009106037874 12/4333 3 M, 7.9 Takone 
Wynyard 
Right lateral 
lower jaw, 15x20 
S2 6 982000123129847 13/0854 3 M, N/A Takone 
Wynyard 
Left lower jaw, 
3x2x1 
S2 7 982000190559724 12/3207 2 F, 4.5 Kempton Right lower jaw 
incisor, 10x7x7 




S2 20 NC 10/0944 2 M, N/A Mole Creek Left face, 2x2 
S2 21 M00000PT101692 10/1692 Adult M, 5.3 Lake Leak Right face 1x2 




S3 9 982000123122487 12/2320 2 M, 6.0 Sorrell 
Dunalley 
Right cheek, very 
large. 
S3 10 982000123208272 12/3045 2 F, 5.5 Bangor 
Dunally 
Left cheek, 7x7x3 
S3 22 982009105195643 10/0129 2 M, 9.3 Bangor 
Dunally 




S3 23 982009104928037 10/2226 2 M, 9.1 Forestier 
Dunally 
Inside mouth top 
lip, 10x9x6 




S4 11 982009106218282 11/4115 2 F, 4.6 AHL Prospect Left upper lip, 
4x4x2 
S4 12 982009105830109 11/3426 1 F, 5.2 AHL Prospect Right cheek, 
2x2x2 
S4 25 NC 06/2179 3 F, N/A Freycinet 
Bicheno 
Lower lip 4x4 





S5 14 982009106144920 12/3084 2 F, 4.6 Takone 
Wynyard 
Face/Lip 2x2x1 
S5 15 982009106037874 12/1979 3 M, 10.7 Takone Yolla Right cheek 
0.5x0.5 
S5 26 982009100367728 06/3549 2 F, N/A Dunalley Right Lip, 6x6 
S5 27 NC 06/3519 1 F, N/A Dunalley Under chin 1x1 
S5 28 982009105193063 07/2895 2 M, N/A Dunalley Lip, 1x1x1 
Tasmanian devils 1-15 primary pilot study tumours. Devils 16-28 devils additional tumours. N/A = data not 
available. Adult = no age recorded but individual was an adult. NC = not microchipped. 
 
Table 2: Immunohistochemistry antibodies applied to DFT1 S1-5 tissues. 
 
Primary Antibody Gene 
Symbol 
Clone/Poly Host Manufacturer Product 
code 
Dilution 
Peripheral Myelin Protein 
22 





MAG Polyclonal Rabbit Thermo Fisher Scientific PA5-30087 1:50 
Myelin Basic Protein MBP 2H9 Mouse Genetex GTX60519 1:1500 
Proteolypid Protein 1, 
PLP/DM20 
PLP1    1:1000 
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Glial Fibrillary Acidic 
Protein  
GFAP Polyclonal  Rabbit                                                                                                                                             Biocare Medical CP040 1:100 
Myelin Protein Zero, P0 MPZ Polyclonal Rabbit Merck Millipore ABN363 1:2000 











RPSA EPR8469 Rabbit Abcam (Epitomics) ab133645 1:200 
Laminin  Rabbit Polyclonal Thermo Fisher 
Scientific 
RB-082-A0 1:50 
Gap Junction Protein 
Beta 1, CX32, Connexin 
32 
GJB1 Polyclonal Rabbit Merck 
(Sigma-Aldrich) 
HPA010663 1:15 
Nerve Growth Factor 
Receptor, p75NTR  ,CD271 
NGFR Polyclonal Rabbit Merck Millipore 07-476 1:150 
S100 Calcium Binding 
Protein B 
S100B Polyclonal Rabbit Agilent (Dako) Z0311 1:1200 
Vimentin VIM V9 Mouse Agilent (Dako) M0725 1:800 
Enolase 2, Neuron 
Specific Enolase, NSE 
ENO2 BBS/BC/VI-H14  
Mouse 
Agilent (Dako) M0873 1:200 
Insulin Like Growth 
Factor Receptor 2, 
M6PR 
IGF2R EPR6599 Rabbit Abcam (Epitomics) ab124767 1:300 
Platelet Derived Growth 
Factor Subunit Beta 
PDGFB Y92 Rabbit Abcam (Epitomics) ab32570 1:50 
Transforming Growth 
Factor Beta Receptor 2 
TGFBR2 Polyclonal Rabbit Abcam ab216483 1:250 
Vascular Endothelial 
Growth Factor Alpha, 
VEGF-A 
VEGFA EP1176Y Rabbit Abcam (Epitomics) ab52917 1:50 
Tyrosinase TYR T311 Mouse Agilent (Dako) M3623 1:50 
59 
 
Anti-Melanoma (PNL2)  PNL2 Mouse Thermo Fisher 
Scientific (Invitrogen) 
18-0485 1:100 







Kinase, C-KIT, CD117 





MITF C5+D5 Mouse Thermo Fisher 
Scientific (Invitrogen) 
18-0369 1:50 
Early Growth Response 
2, KROX20 
EGR2 Polyclonal Rabbit Abcam  ab43020 1:600 
SRY-box 2 SOX2 EPR3131 Rabbit Abcam (Epitomics) ab92494 1:50 
SRY-box 10 SOX10 EPR4007 Rabbit Abcam (Epitomics) ab155279 1:150 
Paired box 3 PAX3 Polyclonal Rabbit Abcam ab180754 1:600 
JUN Proto-oncogene AP-
1 TF Subunit, c-JUN 
JUN E254 Rabbit Abcam (Epitomics) ab32137 1:50 
Transcription Factor AP-
2 Alpha, AP-2 
TFAP2A EPR2688(2) 
Rabbit 
Abcam (Epitomics) ab108311 1:50 
Notch 1 NOTCH1 EP1238Y Rabbit Abcam (Epitomics) ab52627 1:50 
Catenin Beta 1, Beta 
Catenin 
CTNNB1 E247 Rabbit Abcam ab32572 1:50 
Signal Transducer and 
Activator of 
Transcription 3 
STAT3 9D8 Mouse Abcam ab1193652 1:2000 
Nestin NES Polyclonal Rabbit  Genetex  GTX37606 1:50 
Epithelial Cell Adhesion 
Molecule, EpCAM, 
CD326 
EPCAM EPR677(2) Rabbit Abcam (Epitomics) ab124825 1:150 
Prominin 1, CD133 PROM1 Polyclonal Rabbit St. Johns Laboratory STJ20168 1:2000 
CD44 Molecule CD44 Polyclonal Rabbit Abcam ab190926 1:50 
POU Class 5 Homebox 1, 
OCT4 
POU5F1 EPR2054 Rabbit Abcam ab109183 1:100 
60 
 
Sonic Hedgehog SHH Polyclonal Rabbit Biorbyt Orb146711 1:500 
Ubiquitin C-terminal 
Hydrolase L1, PGP9.5 



















Molecular Weight, CK 
 34βE12 Mouse Agilent (Dako)   1:50 
Brain Derived 
Neurotrophic Factor 
BDNF EPR1292 Rabbit Abcam (Epitomics) ab108319 1:2000 
Neurotrophic Receptor 
Tyrosine Kinase 2, TRKB 
NRTK2 EPR1294 Rabbit Abcam (Epitomics) ab134155 1:100 
Cytokeratin, CK  AE1/AE3 Mouse Agilent (Dako) M3515 1:100 
α-Smooth Muscle 
Antigen, SMA 
 1A4 Mouse Agilent (Dako)  M0851 1:200 
Muscle Specific Actin, 
MSA 





DEAD-Box Helicase 4, 
Vasa 
DDX4 Polyclonal Rabbit Merck 
(Sigma-Aldrich) 
HPA037664 1:500 
Y-Box Binding Protein 2 YBX2 Polyclonal Rabbit Merck 
(Sigma-Aldrich) 
HPA053904 1:200 







Proliferating cell nuclear 
antigen 








4.3.3 Statistical analysis 
 
To compare the significance of percent expression between the strains for each antibody I 
performed two way ANOVA, followed by standalone comparison using Fisher’s LSD test. The 
analysis was carried out using GraphPad Prism version 7.04, GraphPad Software, La Jolla California 
USA, www.graphpad.com. 
 
4.3.4 Comparative analysis of gene to protein expression of DFT1 strains 
 
Previously published DFT1 gene abundance data by Murchison et al. (4) in the supplementary 




Antibody percentage positive DFT1 cells in strains 1-5 cells are illustrated by heat map in figure 8 
and the antibody intensity of staining of DFT1 positive cells in strains 1-5 are illustrated by heat 
map in figure 9 with average antibody percent expression and intensity of strains 1-5 shown in 
table 3. The antibody percentage of DFT1 positive cells in strains 1-5 (protein expression) were 
tabulated against the gene abundance data from Murchison et al. (4) in table 4 for comparative 
analysis of Schwann cell and melanocyte lineages, growth factors, transcription factors and 










S1 S2 S3 S4 S5 
PMP22 95 90 75 95 95 
MAG 94 95 97 98 96 
MBP 0 0 0 0 0 
PLP1 88 87 90 90 91 
GFAP 49 42 28 52 65 
MPZ 22 31 51 48 50 
PRX 96 97 98 96 98 
GAP43 0 0 20 0 0 
LAMA2 89 92 95 95 93 
GJB1 85 87 90 89 86 
NGFR 96 95 94 98 97 
S100 50 56 51 39 35 
VIM 98 99 97 97 98 
NSE 90 89 85 91 95 
IGFR2 99 98 98 99 96 
PDGFB 93 70 85 82 85 
TGFBR2 95 98 98 95 95 
VEGFA 85 87 89 90 92 
TYR 0 0 0 0 0 
PNL2 8 47 12 96 10 
MLANA 0 0 0 0 0 
KIT 80 79 89 77 87 
MITF 0 0 0 0 0 
EGR2 80 78 50 68 91 
SOX2 90 84 83 50 36 
SOX10 86 80 86 86 83 
PAX3 82 80 85 80 80 
JUN 90 91 90 84 90 
TFAP2A 83 87 85 89 82 
NOTCH1 96 92 98 94 90 
CTNNB1 80 78 82 86 89 
STAT3 90 92 91 92 93 
NES 91 92 96 79 88 
EPCAM 94 96 95 96 97 
PROM1 82 81 90 81 80 
CD44 77 89 85 75 72 
POU5F1 90 90 90 90 85 
SHH 93 95 92 90 95 
UCHL1 73 85 78 45 75 
NF 0 0 0 0 0 
CALB2 0 0 0 0 0 
       
Legend 0 25 50 75 100 




Antibodies Intensity of Strain expression 
S1 S2 S3 S4 S5 
PMP22 M S M M S 
MAG S S M S S 
MBP N N N N N 
PLP1 W W W W W 
GFAP M M W W W 
MPZ W W W W W 
PRX S S S S S 
GAP43 N N  W N N 
RPSA S S S S S 
GJB1 W M M M W 
NGFR S S S S S 
S100 M M M M M 
VIM S S S S S 
NSE S S S S S 
IGFR2 S M M M M 
PDGFB M M S M M 
TGFBR2 M M M M M 
VEGFA S S M S S 
TYR N N N N N 
PNL2 W W W M W 
MLANA N N N N N 
KIT W M M W M 
MITF N N N N N 
EGR2 W W W W W 
SOX2 M M M M M 
SOX10 M M M M M 
PAX3 M S M M M 
JUN M M M M M 
TFAP2A M M M M M 
NOTCH1 W M W W W 
CTNNB1 S M M M S 
STAT3 S S S S S 
NES M M M W W 
EPCAM S S S S S 
PROM1 M M M W  M 
CD44 W W W W W 
POU5F1 S M M S S 
SHH M M M M M 
UCHL1 W M W W M 
NF N N N N N 
CALB2 N N N N N 
       
Legend N W M S  




Table 3: Antibody average percent and intensity of expression. 
Antibody 
Ave % 
(S1-S5) Strain Immunohistochemical Protein expression 
  PMP22 90 Moderate to strong cytoplasmic and membranous  
MAG 96 Moderate to strong cytoplasmic and membranous  
MBP 0 No expression was evident 
PLP1 87 Weak cytoplasmic and membranous  
GFAP 47 Weak to moderate cytoplasmic and membranous  
MPZ 40 Weak cytoplasmic and membranous  
PRX 97 Strong cytoplasmic, membranous, including nuclear  
GAP43 20 Weak cytoplasmic and membranous, strain 3 only. 
RPSA 93 RPSA strong cytoplasmic and membranous  
GJB1 87 Weak to moderate cytoplasmic  
NGFR 96 Strong cytoplasmic and membranous  
S100 46 Moderate cytoplasmic and nuclear  
VIM 99 Strong cytoplasmic and membranous  
ENO2 90 Strong cytoplasmic  
IGF2R 98 Moderate to strong cytoplasmic staining  
PDGFB 83 Strong cytoplasmic and membranous  
TGFBR2 96 Moderate cytoplasmic staining  
VEGFA 88 Moderate to strong cytoplasmic  
TYR 0 no expression was evident 
PNL2 43 Granular cytoplasmic staining  
MLANA 0 No expression was evident 
KIT 82 Weak to moderate cytoplasmic  
MITF 0 No expression was evident 
EGR2 73 Weak nuclear  
SOX2 60 Moderate nuclear  
SOX10 84 Moderate nuclear  
PAX3 81 Moderate to strong nuclear  
JUN 89 Moderate nuclear  
TFAP2A 85 Moderate nuclear  
NOTCH1 94 Weak to moderate cytoplasmic  
CTNNB1 83 Moderate to strong cytoplasmic and membranous  
STAT3 92 Strong nuclear and some cytoplasmic  
NES 89 Weak to moderate cytoplasmic  
EPCAM 96 Strong cytoplasmic  
PROM1 83 Weak to moderate cytoplasmic  
CD44 80 Weak membranous  
POU5F1 89 Moderate to strong nuclear  
SHH 93 Moderate cytoplasmic  
UCHL1 71 Weak to moderate cytoplasmic  
NEFL/H 0 No expression was evident 




Table 4: DFT1 gene abundance counts (cDNA) vs protein expression strains 1-5. 
Antibody Gene Strain Immunohistochemical Protein expression and percentage  
  PMP22 83 Moderate to strong cytoplasmic and membranous (S1 95%, S2 90%, S3 75%, S4 95%, S5 95%) 
MAG 8 Moderate to strong cytoplasmic and membranous (S1 94%, S2 95%, S3 97%, S4 98%, S5 96%) 
MBP 47 no staining was observed 
PLP1 67 Weak cytoplasmic and membranous (S1 88%, S2 87%, S3 90%, S4 90%, S5 91%) 
GFAP 1 Weak to moderate cytoplasmic and membranous (S1 49%, S2 42%, S3 28%, S4 52%, S5 65%) 
MPZ 283 Weak cytoplasmic and membranous (S1 22%, S2 31%, S3 51%, S4 48%, S5 50%) 
PRX 279 Strong cytoplasmic, membranous, including nuclear (S1 96%, S2 97%, S3 98%, S4 96%, S5 98%) 
GAP43 30 Weak cytoplasmic and membranous (S3 20 %) 
LAMA2 25 RPSA strong cytoplasmic and membranous (S1 89%, S2 92%, S3 95%, S4 95%, S5 93%) 
GJB1 1 Weak to moderate cytoplasmic (S1 85%, S2 87%, S3 90%, S4 89%, S5 86%) 
NGFR 34 Strong cytoplasmic and membranous (S1 96%, S2 95%, S3 94%, S4 98%, S5 97%) 
S100 N/A Moderate cytoplasmic and nuclear (S1 50%, S2 56%, S3 51%, S4 39%, S5 35%) 
VIM 303 Strong cytoplasmic and membranous (S1 98%, S2 99%, S3 97%, S4 97%, S5 98%) 
ENO2 0 Strong cytoplasmic (S1 90%, S2 89%, S3 85%, S4 91%, S5 95%) 
IGF2R 20 Moderate to strong cytoplasmic staining (S1 99%, S2 98%, S3 98%, S4 99%, S5 96%) 
PDGFB 7 Strong cytoplasmic and membranous (S1 93%, S2 70%, S3 85%, S4 82%, S5 85%) 
TGFBR2 13 Moderate cytoplasmic staining (S1 95%, S2 98%, S3 98%, S4 95%, S5 95%) 
VEGFA 25 Moderate to strong cytoplasmic (S1 %, S2 %, S3 %, S4 %, S5 %) 
TYR 0 no expression was evident 
PNL2 N/A Granular cytoplasmic staining (S1 8%, S2 47%, S3 12%, S4 96%, S5 10%) 
MLANA 6 no expression was evident 
KIT 19 Weak to moderate cytoplasmic (S1 80%, S2 79%, S3 89%, S4 77%, S5 87%) 
MITF 3 no expression was evident 
EGR2 9 Weak nuclear (S1 80%, S2 78%, S3 50%, S4 68%, S5 91%) 
SOX2 27 Moderate nuclear (S1 90%, S2 84%, S3 83%, S4 50%, S5 36%) 
SOX10 24 Moderate nuclear (S1 86%, S2 80%, S3 86%, S4 86%, S5 83%) 
PAX3 3 Moderate to strong nuclear (S1 82%, S2 80%, S3 85%, S4 80%, S5 80%) 
JUN 55 Moderate nuclear (S1 90%, S2 91%, S3 90%, S4 84%, S5 90%) 
TFAP2A 7 Moderate nuclear (S1 83%, S2 87%, S3 85%, S4 89%, S5 82%) 
NOTCH1 4 Weak to moderate cytoplasmic (S1 96%, S2 92%, S3 98%, S4 94%, S5 90%) 
CTNNB1 60 Moderate to strong cytoplasmic and membranous (S1 80%, S2 78%, S3 82%, S4 86%, S5 89%) 
STAT3 74 Strong nuclear and some cytoplasmic (S1 90%, S2 92%, S3 91%, S4 92%, S5 93%) 
NES N/A Weak to moderate cytoplasmic (S1 91%, S2 92%, S3 96%, S4 79%, S5 88%) 
EPCAM 8 Strong cytoplasmic (S1 94%, S2 96%, S3 95%, S4 96%, S5 97%) 
PROM1 3 Weak to moderate cytoplasmic (S1 82%, S2 81%, S3 90%, S4 81%, S5 80%) 
CD44 16 Weak membranous (S1 77%, S2 81%, S3 85%, S4 75%, S5 72%) 
POU5F1 N/A Moderate to strong nuclear (S1 90%, S2 90%, S3 90%, S4 90%, S5 85%) 
SHH 14 Moderate cytoplasmic (S1 93%, S2 95%, S3 92%, S4 90%, S5 95%) 
UCHL1 35 Weak to moderate cytoplasmic (S1 73%, S2 85%, S3 78%, S4 45%, S5 75%) 
NEFL 7 no expression was evident 
NEFLH 9 no expression was evident 
CALB2 2 no expression was evident 
N/A – Not available, S1-S5 = DFT1 Strains 1-5. Gene counts Murchison et al. 2010 
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4.4.1 DFT1 strains 1-5 histomorphology 
 
Karyotypic description of DFT1 revealed that there are at least four major chromosomally distinct 
strains (variations) (46) with a rare fifth strain (DH, personal communication Anne-Maree Pearce 
unpublished data, DPIPWE). Conversely, a comprehensive histological description of DFT1 strains 
1-5 have not been described until now. Representative photomicrographs of strain 1-5 are 
illustrated in figure 10. 
 
 
Figure 10: Histomorphology of DFT1 strains 1-5. 
Representative Haematoxylin and Eosin stained DFT1 Strain 1 A, Strain 2 B, Strain 3 C, Strain 4 D, Strain 5 E. 
and normal Schwann cells F. Black arrow shows larger calibre nerve myelinated by Schwann cell and red 
arrows show small calibre myelinated and unmyelinated nerves enveloped by Remak Schwann cells. All 







There is a densely cellular neoplasm effacing the dermis. The neoplasm consists of packets and 
cords of pleomorphic round to polygonal cells supported by fine fibrovascular stroma. These cells 
have indistinct cell borders, moderate eosinophilic cytoplasm and central oval nucleus, with fine 
stippled chromatin and prominent nucleolus or two nucleoli. There is a mitotic figure and low to 
moderate numbers of apoptotic cells. There is mild to moderate anisocytosis and anisokaryosis. 
Strain 2 
There is a densely cellular neoplasm effacing the dermis. The neoplasm consists of packets and 
cords of pleomorphic round to polygonal cells supported by fine fibrovascular stroma. These cells 
have indistinct cell borders, moderate amphiphilic cytoplasm and central oval nucleus, with fine 
stippled chromatin and prominent nucleolus or two nucleoli. There is a mitotic figure and low 
numbers of apoptotic cells. There is mild to moderate anisocytosis and anisokaryosis and mild 
nuclear moulding between low numbers of neighbouring cells. 
Strain 3 
There is a densely cellular neoplasm effacing the dermis.  The neoplasm consists of packets and 
cords of pleomorphic round to polygonal cells supported by fine fibrovascular stroma. These cells 
have indistinct cell borders, moderate eosinophilic cytoplasm and central oval nucleus, with fine 
stippled chromatin and prominent nucleolus. There are 1-2 mitoses per HPF and low numbers of 
apoptotic cells. There is very mild anisocytosis and anisokaryosis. 
Strain 4 
There is a densely cellular neoplasm effacing the normal dermis, leaving only remnant collagen 
fibres. The neoplasm consists of packets and cords of pleomorphic round to polygonal cells 
supported by fine fibrovascular stroma. These cells have indistinct cell borders, moderate 
eosinophilic cytoplasm and central oval nucleus, with coarse chromatin and prominent nucleolus. 
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There are 1-2 mitoses per HPF and low to moderate numbers of apoptotic cells. There is very mild 
anisocytosis and anisokaryosis. Low numbers of neighbouring cells display nuclear moulding. 
Strain 5 
There is a densely cellular neoplasm effacing the dermis. The neoplasm consists of packets and 
cords of pleomorphic round to polygonal cells supported by fine fibrovascular stroma. These cells 
have indistinct cell borders, moderate eosinophilic cytoplasm and central oval nucleus, with coarse 
chromatin and nucleolus (which is present in most cells but not prominent). There are low to 
moderate numbers of apoptotic cells. There is very mild anisocytosis and anisokaryosis. 
 
4.4.2 DFT1 histomorphology summary 
 
In summary, all strains share similar microscopic architecture, round to polygonal cells forming 
packets supported by fine fibrovascular stroma. The cellular details of each strain are also similar, 
with the polygonal to round cells having indistinct cell borders, moderate eosinophilic cytoplasm 
and single central oval nucleus with prominent nucleolus. There is similar mild cell variation both 
within and across strains in chromatin patterns (varying from finely stippled, coarse to reticular), 
degree of anisokaryosis, anisocytosis and numbers of mitotic figures per high power field. For 
these reasons, discriminating between strain types is not possible, based on these histological 













4.4.3 DFT1 strains 1-5 - Schwann cell lineage immunohistochemistry 
 
 
Figure 11. DFT1 strains 1-5 - Schwann cell lineage immunohistochemistry. 
Representative photomicrographs: PMP22 Strain 1 a, MBP Strain 1 b, MPZ Strain 1 c, MAG Strain 2 d, NGFR 
Strain 2 e, PRX Strain 2 f, GFAP Strain 3 g, PLP1 Strain 3 h, GAP43 Strain 3 i, RPSA Strain 4 j, GJB1 Strain 3 k, 
S100 Strain 2 l, VIM Strain 1 m, NOTCH1 Strain 2 n, CTNNB1 Strain 1o, SHH Strain 1 p. All micrographs are 







Figure 12: DFT1 strains 1-5 - Schwann cell lineage immunohistochemistry control tissue.  
PMP22 A peripheral nerve, MBP B peripheral nerve, MPZ C peripheral nerve, MAG D peripheral nerve, 
NGFR E peripheral nerve non-myelinating Schwann cells, PRX F peripheral nerve, GFAP G peripheral nerve 
non-myelinating Schwann cells, PLP1 H peripheral nerve, GAP43 I optic nerve positive and adjacent 
peripheral nerve, RPSA J peripheral nerve, GJB1 K peripheral nerve, S100 L peripheral nerve, VIM M 
peripheral nerve, NOTCH1 N testis, CTNNB1 O intestine, SHH P, testis. All controls are Tasmanian devil 
tissues. All micrographs are x40 magnification and scale bar represents 30 microns 
 
DFT1 strains 1-5 Schwann cell lineage immunohistochemical results documented in figures 8, 9 
and table 3 demonstrates that most Schwann cell markers had similar expression and intensity of 
staining between strains with some exceptions noted. PMP22 (moderate to strong cytoplasmic 
and membranous S1 95%, S2 90%, S3 75%, S4 95%, S5 95%) demonstrated only 75 percent of cells 
in strain 3 were positive compared to other strains averaging 94%. MBP was not detected in any of 
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the strains however, as shown in micrograph figure 11b, MBP is clearly detectible in normal 
peripheral nerve but is absent in surrounding tumour cells. MPZ (weak cytoplasmic and 
membranous S1 22%, S2 31%, S3 51%, S4 48%, S5 50%), GFAP (weak to moderate cytoplasmic and 
membranous S1 49%, S2 42%, S3 28%, S4 52%, S5 65%) and S100 (moderate cytoplasmic and 
nuclear S1 50%, S2 56%, S3 51%, S4 39%, S5 35%) all demonstrated some variation in strain 
expression. Interestingly GAP43 was only expressed in strain 3 and therefore suggests that GAP43 





Figure 13: DFT1 strains 1-5 - Schwann cell lineage immunohistochemistry Heat maps.  
Demonstration of percentage expression (0-100%) and intensity gradient of staining (0-3).  
 
As described above, the heat maps in figure 13 illustrate varied percent expression by PMP22, 
MPZ, GFAP, and S100. GAP43 illustrates expression in strain 3 only and MBP is not expressed by 




Figure 14: DFT1 strains 1-5 - Schwann cell lineage immunohistochemistry strain variation. 
Significance of percent expression between strains. 
 
We compared the percentage expression of each of DFT1 strains 1-5 for each antibody for any 
significant differences (figure 14) finding *p<0.05 = PMP22 strain 1 vs 3, 3 vs 4, 3 vs 5. MPZ 1 vs 4, 
2 vs 3. GFAP 1 vs 3, 2 vs 5, 3 vs 4. GAP43 1 vs 3, 2 vs 3, 3 vs 4 and 3 vs 5. S100 2 vs 5. **p<0.01 MPZ 
1 vs 3 and 1 vs 5. ***p<0.001 GFAP 3 VS 5. There was no significant difference between other 
strains. These differences were also reflected in the heat maps. 
 
Figure 15: DFT1 strains 1-5 - Schwann cell lineage immunohistochemistry comparative analysis. 




Comparative analysis of gene counts and protein expression of Schwann cell lineage was 
compared in table 4 and graphically represented in figure 15. Active genes PMP22, MBP, PLP1, 
MPZ, PRX, GAP43, LAMA2, NGFR, VIM, CTNNB1 and SHH have gene activity with corresponding 
protein expression except for MBP where protein expression is completely absent. Although MPZ 
gene activity is high, only 22%-50% of cells express MPZ weakly. GAP43 gene activity was 
expressed only in strain 3 suggesting this marker may indeed be specific for strain 3. Further, the 
Tasmanian devil tumour used by Murchison et al. (4) to obtain the gene abundance data was 
actually strain 3 tumour (DH, personal communication, Elizabeth Murchison) correlating the two 
results but this does not exclude other stains at this stage. Low activity genes MAG, GFAP, GJB1 
and NOTCH1 showed MAG, GJB1 and NOTCH1 was expressed in most cells with GFAP expression 


















4.4.4 DFT1 strains 1-5 - Schwann cell lineage growth factor immunohistochemistry 
 
 
Figure 16: DFT1 strains 1-5 Schwann cell lineage growth factor immunohistochemistry.  
Representative micrographs: PDGFB Strain 3 a, IGFR2 Strain 3 b, TGFBR2 Strain 1 c, VEGFA Strain 2 d. All 





Figure 17: DFT1 strains 1-5 Schwann cell lineage growth factor immunohistochemistry control 
tissue.  
PDGFB A intra tumoural blood vessel, IGFR2 B pancreatic islet, TGFBR2 C testis, VEGFA D kidney. All controls 
are Tasmanian devil tissues. All micrographs are x40 magnification and scale bar represents 30 microns. 
 
Assessment of the immunohistochemical staining of Schwann cell lineage growth factor markers 
represented in figures 8, 9 and table 3 show that most growth factors had similar expression and 
intensity of staining with one noted exception. PDGFB (Strong cytoplasmic and membranous (S1 
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93%, S2 70%, S3 85%, S4 82%, S5 85%) which demonstrated increased positivity in strain 1 
compared to other strains with strain 2 showing less positivity than the other strains. 
 
Figure 18: DFT1 strains 1-5 Schwann cell lineage growth factor immunohistochemistry heat 
maps.  
Demonstrating percentage expression (0-100%) and Heat map intensity gradient of staining (0-3).  
 
As described above in figure 18, the heat maps illustrate varied percent expression by PDGFB with 
some mild variation in staining intensity noticed. 
 
 
Figure 19: DFT1 strains 1-5 Schwann cell lineage growth factor immunohistochemistry strain 
variation.  




We compared the percentage expression of each of DFT1 strains 1-5 for each antibody for any 
significant differences (figure 19) finding *p<0.05 = PDGFRB strain 2 vs 3, 2 vs 5, 3 vs 5. **p<0.01 
PDGFRB 1 vs 2. This difference was also reflected in the heat maps of figure 18. There was no 
significant difference between other strains. 
 
Figure 20: DFT1 strains 1-5 Schwann cell lineage growth factor immunohistochemistry 
comparative analysis.  
Graphical representation of gene counts vs protein expression. 
 
Comparative analysis of gene counts and protein expression of Schwann cell lineage growth 
factors was compared in table 4 and graphically represented in figure 20. Active genes IGF2R, 
TGFBR2 and VEGFA have gene activity with corresponding protein expression. Gene activity for 
PDGFB was low but the majority of DFT1 cells expressed this protein. 
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4.4.5 DFT1 strains 1-5 Melanocyte lineage immunohistochemistry 
 
 
Figure 21: DFT1 strains 1-5 Melanocyte lineage immunohistochemistry. 
Representative micrographs. MITF Strain 1 a, Occasional MITF nuclear positivity Strain 5 b, TYR Strain 1 c, 
occasional TYR cytoplasmic staining Strain 3 d, MLANA Strain 5 e, occasional MLANA cytoplasmic staining 
Strain 3 f, PNL2 Strain 4 g, Schmorl’s stain Strain 4 h, Masson Fontana stain Strain 4 i, KIT Strain 3 j. All 







Figure 22: DFT1 strains 1-5 Melanocyte lineage immunohistochemistry control tissues. 
MITF A, TYR B, MLANA C, PNL2 D, Schmorl’s stain E, Masson Fontana stain F, KIT G. All controls are 
Tasmanian devil hair bulb tissues except for G which is intestinal mast cells. All micrographs are x40 
magnification and scale bar represents 30 microns 
 
DFT1 strains 1-5 melanocyte lineage immunohistochemical results documented in figures 8, 9 and 
table 3 demonstrates that Melanocyte lineage markers MITF, TYR and MLANA was not expressed 
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by DFT1 (figures 21a, c, e). However, on very intense screening of entire tumours very occasional 
isolated cells did show; MITF nuclear positivity figure 21b, TYR cytoplasmic staining figure 21d  and 
cytoplasmic MLANA staining figure 21f. PNL2 figure 21G, demonstrated varied granular 
cytoplasmic staining of cells (8 % strain 1, 47 % strain 2, 12 % strain 3, 96 % strain 4 and 10 % strain 
5). No expression was present for either the Schmorl’s stain or Masson Fontana stain for melanin, 






Figure 23: DFT1 strains 1-5 Melanocyte lineage immunohistochemistry heat maps.  
Heat map Demonstrating percentage expression (0-100%) and intensity gradient of staining (0-3). 
 
As described above in figure 23, the heat maps illustrate varied percent expression by PNL2 with 
some mild variation in staining intensity noticed. MITF, TYR and MLANA were essentially negative. 




Figure 24: DFT1 strains 1-5 Melanocyte lineage immunohistochemistry strain variation.  
Percentage expression significant difference between DFT1 strains 1-5. 
 
We compared the percentage expression of each of DFT1 strains 1-5 for each antibody for any 
significant differences (figure 24) finding **p<0.01 PNL2 1 vs 4, 3 vs 4, 4 vs 5. There was no 
significance difference between other strains. 
 
Figure 25: DFT1 strains 1-5 Melanocyte lineage immunohistochemistry comparative analysis.  




Comparative analysis of gene counts and protein expression of melanocyte lineage was compared 
in table 4 and graphically represented in figure 25 graphically. Activity was low or absent for genes 
TYR, MLANA and MITF with corresponding absence of cellular expression of these proteins in 




4.4.6 DFT1 strains 1-5 Schwann cell and Melanocyte lineage transcription factor 
immunohistochemistry 
 
Figure 26: DFT1 strains 1-5 Schwann cell and Melanocyte lineage transcription factors 
immunohistochemistry. 
Schwann cell and Melanocyte lineage transcription factor immunohistochemistry: SOX10 Strain 2 a. SOX2 
Strain 2 b. EGR2 Strain 2 c. PAX3 Strain 3 d. JUN Strain 1 e. TFAP2A Strain 4 f. All micrographs are x40 







Figure 27: DFT1 strains 1-5 Schwann cell and Melanocyte lineage transcription factor 
immunohistochemistry control tissues.  
Schwann cell and Melanocyte lineage transcription factor immunohistochemistry control tissues: SOX10 A. 
SOX2 B. EGR2 C, PAX3 D. JUN E. TFAP2A F. All controls are Tasmanian devil peripheral nerve tissues except 
for F, which is skin. All micrographs are x40 magnification and scale bar represents 30 microns.  
 
DFT1 strains 1-5 Schwann cell and melanocyte lineage immunohistochemical results documented 
in figures 8, 9 and table 3 demonstrates that most Schwann cell and transcription factor markers 
had similar expression and intensity of staining between strains with two exceptions, as noted. 
SOX2 (moderate nuclear S1 90%, S2 84%, S3 83%, S4 50%, S5 36%) and ERG2 (weak nuclear S1 







Figure 28: DFT1 strains 1-5 Schwann cell and Melanocyte lineage transcription factor 
immunohistochemistry Heat maps.  
Demonstrating percentage expression (0-100%) and intensity gradient of staining (0-3). 
 
As described above in figure 28 the heat maps illustrate varied percent expression by SOX2 and 
ERG2. There is some mild variation of staining intensity between strains noted. 
 
Figure 29: DFT1 strains 1-5 Schwann cell and Melanocyte lineage transcription factor 
immunohistochemistry strain variation.  
Percentage expression significant difference between strains. 
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We compared the percentage expression of each of DFT1 strains 1-5 for each antibody for any 
significant differences (figure 29) finding *p<0.05 = SOX2 strain 1 vs 4, 2 vs 5, 3 vs 5. ERG2 strain 3 
vs 4. **p<0.01 SOX2 strain 1 vs 5. Evident here by a lower percentage of staining cells of strain 3 
(50%) and strain 4 (34%). There was no significant difference between other strains. 
 
Figure 30: DFT1 strains 1-5 Schwann cell and Melanocyte lineage transcription factor 
immunohistochemistry comparative analysis.  
Gene counts and protein expression of Transcription factors 
 
Comparative analysis of gene counts and protein expression of Schwann cell and melanocyte 
lineage transcription factors (table 4) was compared graphically (figure 30). Active genes SOX10, 
SOX2 and JUN show gene activity with corresponding protein expression. Low activity genes EGR2, 













Figure 31: DFT1 strains 1-5 Stem cell and multipotency marker immunohistochemistry. 
Representative micrographs. ENO2 Strain 3 a. UCHL1 Strain 3 b. CALB2 Strain 4 c. Neurofilament protein 
(pan-NEFL, NEFM, NEFH) Strain 2 d. PROM1 Strain 3 e. CD44 Strain 4 f. STAT3 Strain 4 g. POU5F1 Strain 2 h. 






Figure 32: DFT1 strains 1-5 Stem cell and multipotency marker immunohistochemistry control 
tissues.  
ENO2 A peripheral nerve. UCHL1 peripheral nerve B. CALB2 intestine C. NF (H/M/L) peripheral nerve D. 
PROM1 E testis. CD44 F lymph node. STAT3 G testis. POU5F1 H testis. NES I testis, EPCAM J intestine. All 
controls are Tasmanian devil tissues. All micrographs are x40 magnification and scale bar represents 30 
microns. 
 
Assessment of the immunohistochemical staining of stem cell and multipotency 
immunohistochemistry markers represented in figures 8, 9 and table 3 show that most growth 
factors had similar expression and intensity of staining with two exceptions. UCHL1 (weak to 
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moderate cytoplasmic S1 73%, S2 85%, S3 78%, S4 45%, S5 75%) demonstrates some expression 
between strains, particularly strain 4, with only 45% of cells positive. CD44 (weak membranous S1 
77%, S2 81%, S3 85%, S4 75%, S5 72%) and NES (weak to moderate cytoplasmic (S1 91%, S2 92%, 
S3 96%, S4 79%, S5 88%) demonstrated minor expression between strains. CALB2 and NEFM/H 





Figure 33: DFT1 strains 1-5 Stem cell and multipotency marker immunohistochemistry heat 
maps.  
Percentage expression (0-100%) and heat map intensity gradient of staining (0-3).  
 
Figure 33, UCHL1 shows obvious variation between strains whereas CD44 and NES show minor 





Figure 34: DFT1 strains 1-5 Stem cell and multipotency marker immunohistochemistry strain 
variation.  




We compared the percentage expression of each of DFT1 strains 1-5 for each antibody for any 
significant differences (figure 34) finding *p<0.05 CD44 2 vs 5 and NES 3 vs 5, ***p<0.001 UCHL1 1 
v 4, 2 v 4, 3 v 4, 4 v 5. Evident here by a lower percentage of staining cells by strain 4 (45%). There 












Figure 35: DFT1 strains 1-5 Stem cell and multipotency marker immunohistochemistry 
comparative analysis.  
Gene counts and protein expression stem cell and multipotency markers. All micrographs are x40 
magnification and scale bar represents 30 microns. 
 
 
Comparative analysis of gene counts and protein expression of stem cell and multipotency markers 
(table 4) was compared graphically (figure 35). Active genes STAT3, CD44 and UCHL1 show 
corresponding protein expression. Low activity genes ENO2, EPCAM and PROM1 showed protein 
expression in most DFT1 cells, whereas low activity genes NEFL, NEFM and CALB2 were not 
expressed by DFT1.  
4.5 Discussion 
 
Phenotypically, DFT1 expresses both Schwann cell (precursor, immature, mature MSC and NMSC) 
and melanocyte marker PNL2, suggesting bipotency. The additional expression of Schwann cell 
autocrine survival factors and transdifferentiating Bungner Schwann cell (repair) markers typifies 
Schwann cell plasticity. The expression of markers of neural crest stem cells and self-renewal 
properties suggests DFT1 is a progenitor-like cell. Immunohistochemistry is able to regionalise 
expression of proteins providing information in addition to molecular gene and protein expression.  
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We compared Murchison’s et al. gene abundance data with our immunohistochemical analysis for 
concordance finding that most of the active genes were translated into proteins, such as PRX. 
Several genes with very little activity translated into proteins readily detected by 
immunohistochemistry, such as MAG. Of particular note was the active MBP gene, its protein was 
not detected, indicating a translation anomaly. GAP43 was the only protein specifically expressed 
by only one strain, DFT1 strain 3. Gene expression is complex and messenger RNA (mRNA) and the 
synthesised protein are not always correlated (151). Non-coding RNAs (ncRNAs) such as transfer 
RNA (tRNA) and ribosomal RNA (rRNA) are key to translation; however the importance of small 
ncRNAs (sncRNAs) such as short interfering RNAs (siRNAs), microRNAs (miRNAs) and long ncRNAs 
(lncRNAs) in the regulation of protein translation has received much attention (152). The highly 
rearranged chromosomes of DFT1 adds yet another level of complexity because the translocation 
of genes within the stable karyotype will effect gene expression (4, 5, 19, 45, 46). Even though 
direct comparison of gene and protein expression is extremely difficult given ncRNA modifications, 
histone modifications, transcription factor binding and three dimensional folding (153, 154) we 
discuss our results relevant to Schwann cell and melanocyte lineage. 
To encapsulate the diversity of these findings I will discuss DFT1 under the following headings;  
4.5.1 Schwann cell/melanocyte GRN,  
4.5.2 PNL2 antibody,  
4.5.3 Bipotent Schwann cell/melanocyte lineage, 
4.5.4 The Bungner (repair) Schwann cell,  
4.5.5 Neural crest stem cells, multipotency and self-renewal,  
4.5.6 Adult Skin and craniofacial stem cells, 
4.5.7 DFT1: clonal evolution, cancer stem cell and plasticity models. 
 
 
4.5.1 Schwann cell-melanocyte GRN and lineage markers  
 
The GRN governing the formation and differentiation of the NC including specification of the 
Schwann cell and melanocyte lineages is complex, often signalling and transcription factors 
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appearing reiteratively during development [reviewed in (155-158)]. Briefly, forkhead box D3 
(FOXD3) is expressed in most of the pre-migratory and migratory NC including neural and glial 
precursors but is down regulated in dorsolaterally migrating melanoblasts in aves (159-161) and 
mice (162) illustrating developmental segregation of the neural and melanocyte lineage (163, 
164). The dorsolateral migrating melanoblasts express endothelin receptor type B (EDNRB) and 
receptor tyrosine kinase KIT responsive to their ligands endothelin B and KITL ligand respectively. 
While not essential for initial specification EDNRB is required for migration and proliferation and 
KIT, which is expressed by DFT1, is required for survival, migration and proliferation (165). 
Similarly, ventrally migrating SCP derived melanocytes also downregulate FOXD3, detach from the 
nerves and migrate to the ectoderm to differentiate (166). The suppression of MITF by FOXD3 
prevents PAX3 from binding to the promoter in early stages until the downregulation of FOXD3 
initiates lineage bifurcation of the neural/glial and melanocyte lineages (161). The canonical 
Wingless-type MMTV integration site family (WNT)/beta- catenin (CTNNB1) signalling pathway is 
instrumental in both melanocyte (167-171) and Schwann cell development (172-175). We found 
DFT1 expressed moderate to strong CTNNB1 staining, both membranous and cytoplasmic, 
however no obvious nuclear staining was apparent suggesting that translocation of CTNNB1 from 
the cytosol to the nucleus is not occurring. Central to the canonical WNT signalling is the CTNNB1 
dependent pathway, however the canonical pathway now includes both WNT/TOR (mammalian 
target of rapamycin) and WNT/STOP (WNT dependent stabilisation of proteins), both of which are 
independent of CTNNB1. Both CTNNB1 dependent and independent pathways begin with WNT 
ligands binding to receptor Frizzled (FZD) and co-receptor low density lipoprotein related protein 
5/6 (LRP5/6) where CTNNB1 is stabilised and prevented from proteosomal degradation by the 
‘destruction complex’ as would be the case in the absence of WNT signals. The CTNNB1 dependent 
pathway allows CTNNB1 to accumulate in the cytoplasm prior to nuclear entry affecting 
transcription of downstream genes via the transcription factor 7/lymphoid enhancer binding 
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factor (TCF/LEF) transcription factor family. The CTNNB1 independent pathways differ after 
recruitment of the ‘destruction complex’ by upregulating mTOR which increases protein 
translation or the avoidance of ubiquitination of several other proteins, hence STOP, which peaks 
during mitosis. Non-canonical signalling does not involve CTNNB1 and transduces signals through 
FZD, ROR/RYK, G protein receptors to activate three main pathways; 1. WNT/planar cell polarity 
(PCP) also known as the WNT/c-Jun N-terminal kinase (JNK) 2. WNT/Ca2+ and 3. WNT/RTK 
(receptor tyrosine kinase) [reviewed in (176-179)]. In addition to CTNNB1 expression, DFT1 Gene 
expression reveals a number of receptors and proteins integral to WNT signalling including 
WNT3a, LRP6, R-spondin 3 (RSPO3), FZD2/3/8, LRP6 (4) often indicative of canonical signalling 
(180)  but expected nuclear staining was not present. This suggests a number of scenarios; 1. 
CTNNB1 is at levels below our detection system. 2. More likely, CTNNB1 independent signalling 
through WNT/mTOR or WNT/STOP or non-canonical signalling through WNT/PCP, WNT/ Ca2+ or 
WNT/RTK signalling pathways. We have previously shown that YAP1/TAZ signalling is active in 
DFT1 (8), these co-activators of the Hippo pathway are activated by WNT/STOP or WNT/RTK (178). 
Hippo signalling can regulate CTNNB1 because YAP1/TAZ can bind to CTNNB1 thus inhibiting 
translocation to the nucleus (181), a plausible mechanism for nuclear absence of CTNNB1 in DFT1. 
We previously identified expression of ERBB3 by DFT1 (47) which can be transphosphorylated by 
receptor tyrosine kinase like orphan receptor 1 (ROR1) and subsequent activation of YAP1 target 
genes (182), highlighting crosstalk between ERBB3 and Hippo-YAP1 pathways. Our current 
research has also identified JUN, part of the non-canonical WNT/PCP pathway and therefore active 
in DFT1; we discuss JUN further in Schwann cell repair. We have identified possible WNT signalling 
pathways active in DFT1 but further research is required to tease out the intricacies including cross 
talk with TGFβ, SHH, IGF and Notch involved in maintenance and proliferation of cancer stem cells 
(CSCs) (177, 183). 
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Early melanocyte marker gene MITF (isoform M, specific for melanocytes) is the master regulator 
of melanocyte development and differentiation (184-187). The transactivation of MITF involves at 
least transcription factors PAX3, SOX10, both expressed by DFT1, and cAMP responsive element 
binding protein 1 (CREB1), In addition to WNT/CTNNB1/LEF1, to regulate transcription genes 
driving melanogenesis. As indicated above, without CTNNB1 translocation to the nucleus, 
transcription of melanocyte genes may be impaired. These include enzymes TYR, tyrosinase 
related protein 2/dopachrome tautomerase (DCT) and tyrosinase related protein 1 (TYRP1); and 
melanosomal proteins premelanosome protein/Pmel17/HMB45/gp100 (PMEL) and MLANA (188, 
189). I found the clone used for PMEL was unsuccessful on devil tissue and therefore did not form 
part of the melanocyte panel, but this marker will be further examined in the future. TYR, MITF, 
MLANA were essentially negative although a very occasional positive cell was noticed during 
screening. This implies that the necessary melanocyte molecular machinery is present in DFT1. 
PNL2 was positive in all strains and we discuss its significance in detail below.  Neuregulin 1 
(NRG1)/Erb-B2 receptor tyrosine kinase 3 (ERBB3) signalling, while not essential for melanoblast 
formation, does suppress melanocyte differentiation and pigmentation, via depressed MITF, even 
in the presence of WNT3a, endothelin 3 (EDN3) and KIT ligand (steel factor, SCF/stem cell 
factor/KITLG) which strongly promote melanocyte differentiation (190). We first reported 
expression of ERBB3 by DFT1 (47) thus, ERBB3/NRG1 signalling is another possible mechanism for 
the suppression of MITF preventing differentiation. Critical to progression from SCP to MSC is the 
transition from reliance on nerve NRG1 to autocrine actors PDGF and IGF, Adameyko et al. found 
while both NRG1 and IGF1 led to cell survival, only IGF1 led to the development of MITF positive 
melanocytes indicating opposing effects of NRG1 and IGF1 on SC and melanocyte fate (144). DFT1s 
expression of IGFR2 and PDGFB suggests an autocrine survival network and its ERBB3 expression 
would be suppressive to melanocyte development, despite SOX1O and PAX3 expression. SOX2 was 
shown also to bind to MITF-m promoter repressing a melanocyte fate, and could reverse 
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melanocytes already specified, thus controls melanocyte differentiation from SCPs (147). The 
expression of SOX2 by DFT1 provides another regulatory pathway, in addition to NRG1, by which 
the melanocyte programs can be suppressed in the SCP. In Schwann cells, WNT/CTNNB1 is crucial 
in the lineage decision to become either MSC or NMSC during the process of radial sorting (191) 
which would be in keeping with DFT1s lack of nuclear expression. WNT/CTNNB1 signalling does 
not appear to promote the transformation of melanocytes from SCPs (192). SOX10, expressed by 
DFT1, is also required for glial fate, survival (193), developmental progression (194) and regulates 
the expression ERBB3 in NCCs and the developing SCs (195). Survival of SCPs is dependent on 
axonal paracrine signals from NRG1 and its receptor ERBB3 (117, 196), however, the 
transformation from SCP to immature SC induces secretion of a number of autocrine survival 
factor including IGF2, neurotrophin 3 (NT3) and PDGFB (109, 197). In addition to SOX10, a number 
of other transcription factors also regulate SC development, either positively towards myelination 
such as early growth response 2/KROX20 (ERG2) or the negative downregulation of myelination 
genes by SOX2, TFAP2A, JUN and PAX3 (109, 198). DFT1 expresses the transcription factors SOX2, 
TFAP2A and JUN that are responsible for the down regulation of myelination, further supported by 
the fact that DFT1 does not contain myelin (1) and reaffirmed by our results that DFT1 does not 
express MBP, a protein that is integral to myelin formation. NOTCH1 is essential for SCP transition 
to immature SC but equally NOTCH1, can also negatively regulate myelination (199), as NOTCH1 is 
expressed by DFT1 its role may therefore likely to be negative. The sequential differentiation from 
SCP to ISC to either MSC or NMSC is evident by differing marker expression of each cell type. 
Expression of the markers ERBB3, NGFR and SOX10 are common to NC, SCP and ISC with NGFR 
also expressed in NMSC. TFAP2A is expressed only in NC and SCPs. The expression of TFAP2A by 
DFT1 is very interesting as this indicates that DFT1 is in an undifferentiated state. Expression of 
MPZ, PMP22, PLP1, and GAP43 is common to SCP and ISC. As MPZ, PMP22 and PLP1 is expressed 
by DFT1 of particular importance is that MPZ and PMP22 are expressed at the early SCP and ISC 
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stages of development and not just in the mature myelinating phenotype. GFAP, S100 and the 
expression of laminin (forms basal lamina) first appears at the ISC stage. MSC continue to express 
MPZ, PMP22 and PLP1 with additional markers ERG2, MBP, MAG, PRX, GJB1 and S100. The NMSC 
expression includes markers GFAP, GAP43 and S100 in addition to NGFR (109, 117-119, 200). DFT1 
does express all these markers indicating phenotypes from all developmental stages of SC. DFT1s 
expression of laminin and their integrin and dystroglycan receptors (DH, manuscript in 
preparation, figure 36N and 36O) is in keeping with the characteristic SC transition from SCP to 
ISC. Laminin 2, the major SC laminin consists of α2, β1, γ1 laminins and these were active in DFT1 
transcriptome (β1 gene was not available) (4). We also tested the laminin marker RPSA, a non-
integrin 36/67-kDa laminin receptor which was also strongly expressed both membranous and 
cytoplasmically by DFT1. RPSA is associated with cancer promoting adhesion, migration, 
metastasis and less tumour differentiation (201, 202). While the SC laminin-integrin-dystroglycan 
binding is well documented in literature (203-205), the expression of RPSA by SCs was not at all 
evident and may represent another significant SC antigen requiring further research. The only 
marker that was not expressed by DFT1 was MBP, a protein integral to compact myelin. This may 
be explained by the expression of PAX3, also expressed by DFT1, which has been shown to 
suppress MBP transcription (206). PRX is also generally associated with a myelinating phenotype 
so why is it strongly expressed by DFT1?  The PRX gene encodes for two PRX isoforms, 147 KdA L-
PRX and 16 kDa S-PRX both of which contain PDZ domains in their N terminus but are localised 
differently in myelinating Schwann cells, L-PRX localised to the plasma membrane and S-PRX 
diffusely throughout the cytoplasm. PRX is also expressed in the nucleus embryonically and is 
redistributed to the plasma membrane and further upregulated postnatally during myelination. 
(207-210). This is interesting because DFT1 does express PRX in the nucleus, the cytoplasm and the 
plasma membrane. PRX was first demonstrated to be expressed by DFT1 in 2010 (4, 20), the 
primary antibody used in those studies and by ourselves is a polyclonal rabbit and therefore, the 
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actual antigen is unknown. It is possible that the antibody will detect both L-PRX and S-PRX if the 
antigen/s encompassed the PDZ domain. It has also been shown that L-PRX and S-PRX do interact 
through the PDZ domain, which may affect the shuttling of L-PRX between the cytoplasm and the 
nucleus (211). Parkinson et al. demonstrated that PRX could be activated in SCPs by EGR2 in the 
absence of other early activation signals but importantly, there was also an ERG2 independent 
activation of PRX and ERG2 may not be responsible for activating the gene during normal 
development (212). DFT1 does not produce myelin and expresses EGR2 weakly thus an ERG2 
independent activation may contribute some understanding as to why PRX expression is strongly 
expressed in DFT1. 
 
4.5.2 Anti-melanocyte antibody PNL2 
 
The monoclonal antibody PNL2, an anti-melanocyte antibody, has similar specificity but is a 
different antigen to MLANA and PMEL antibodies (213) having high specificity for melanocytes of 
the skin, oral mucosa and malignant melanoma. PNL2’s exact immunogen is unknown although its 
antigen is present on a recombinant protein corresponding to the C-terminal of the subtype 2 of 
human somatostatin receptor (SSTR2) and yet, the antibody is unreactive with SSTR2. Extensive 
testing revealed that PNL2 was sensitive to melanocytes but it also stained granulocytes, 
melanotic schwannoma and perivascular epithelioid cell tumour (PEComa) family including clear 
cell sugar carcinoma (CCST), angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM) (213). 
Interestingly, canine granulocytes are not stained by PNL2 (214, 215) and our results would 
indicate that Tasmanian devil granulocytes are also not stained by PNL2. It was suggested that 
PNL2 may cross react with a granulocyte epitope derived from a different gene than is recognised 
in melanocytes (216). Comparing DFT1 with cutaneous PECOMAs, DFT1 lacks MITF, and MLANA 
but expresses S100 and SOX10, two markers typically negative in PECOMA (217). Histochemically, 
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PECOMAs are often PAS positive for cytoplasmic glycogen whereas DFT1 has been shown to be 
negative for glycogen (1, 218) Somatostatin receptors are normally located on tissues of 
neuroendocrine origin and therefore it may not be surprising that malignant melanoma also 
expresses functional somatostatin receptors (219). In human studies, PNL2 has been compared 
with other melanocyte markers: PMEL, MLANA, TYR, MITF and S100, illustrating immunoreactivity 
of similar sensitivity (216, 220, 221) [reviewed in (222, 223). In veterinary pathology PNL2 staining 
of melanocytes and melanoma has been successfully applied to murine (224), porcine (225), 
equine (226), canine (214, 215, 227) and feline (228, 229) tissues with excellent sensitivity and 
specificity when compared to the melanocyte markers above. The data presented above illustrates 
PNL2s specificity for melanocytes and PECOMAs but how does this translate to DFT1? We know 
from electron microscopical studies that melanosome-like structures were not identified in DFT1 
(1) and the expression of melanocytic markers by PECOMAs is due to the presence of pre-
melanosomes (126). Our research suggests that PNL2 may be an early melanoblast antigen that is 
expressed before the pre-melanosomal stage and because MITF was negative in DFT1, suggests 
that activation of PNL2 may be independent of MITF. While not directly related to PNL2, Epstein et 
al. (230) found Tasmanian devils had evidence of a rapid evolutionary response to DFT1 and 
identified CD146 and a number of other genes as being from strongly selected genomic regions. As 
well as immune function, CD146 is a multifaceted molecule in functioning in foetal development, 
adhesion, angiogenesis, cancer and melanoma (231, 232). Interestingly, CD146, is also known as 
melanoma cell adhesion molecule (MCAM) and therefore I would be intrigued to determine if any 
relationship exists between PNL2 and MCAM, both being identified as melanoma antigens. In my 
future studies DFT1 would benefit also by the inclusion of other melanoma antigens such as PMEL 





4.5.3 The Bipotent Schwann cell/melanocyte progenitor 
 
While our research confirms DFT1 has a SC phenotype, the unforeseen expression of PNL2 would 
appear somewhat contrary; however, it is conceivable that DFT1 is, more specifically, a bipotent 
Schwann cell/melanocyte progenitor. Following early reports of the appearance of melanocytes 
from spinal ganglia cultures (233), it was suggested that the appearance of melanocytes could 
represent a change in cell fate (234). Because the culture of 5 day old chick embryo DRG and 
peripheral nerve explants produced melanocytes, it was proposed that a bipotent precursor cell 
having both myelino/melano genesis potential was responsible (235, 236). The use of 12-O-
tetradecanoylphorbol-18-acetate (TPA) on older chick embryo DRG as well as sympathetic ganglia 
and peripheral nerve was able to reverse developmental restriction of melanogenesis in peripheral 
nerve (237). The expression of melanoma-associated antigens on Schwann cells of traumatic 
neuroma and neurofibroma cell cultures reflects the common origins of SCs and melanocytes 
(238) and the identification of chick multipotent NCCs, differentiating into neurons, Schwann cells 
and melanocytes (239, 240) confirms such speculation. Clonal cultures of NC revealed a few 
melanocytes present in SC clones suggesting a bipotent precursor has survived after NC migration 
(241). TPA was shown to reverse the developmental restrictions trans-differentiating Schwann cell 
precursors into melanocytes and endogenous protein kinase C (PKC) activity may influence 
commitment of the bipotent Schwann cell/melanocyte progenitor to undergo melanogenesis (low 
PKC activity) or Schwann cell development (high PKC activity) (242). Basic fibroblast growth factor 
(bFGF) is also capable of reversing restriction of melanogenesis in early Schwann cell precursors 
(243) and the augmentation of  bFGF by TPA also transdifferentiates SCPs into melanocytes (243, 
244). The effects of retinoic acid testing on clonal cultures of cranial and trunk neural crest cells 
revealed that in addition to adrenergic and melanocyte differentiation, cultures also contained 
glial cells indicating pluripotency (245). EDN3 was found to promote proliferation and survival of 
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bipotent glial/melanocyte precursors including unipotent glial and melanocyte precursors. Avian 
embryonic epidermal melanocyte cultures exposed to EDN3 resulted in heterogeneous progeny 
consisting of melanocytes, cells expressing both melanocyte and glial markers and non-pigmented 
cells with only glial phenotype (246) showing reversal of the melanocyte program. EDN3 was 
shown to act not only on precursor cells but also on differentiated Schwann cells suggesting that it 
is able to reverse the differentiation program and induce melanogenesis (247). Purified glial cells 
responded to EDN3 enhancing survival and proliferation transitioning toward a melanocytic 
program, single cultures contained mixed progeny of glial, melanocyte and melanoblast cell types 
(248). In both CNC and TNC cultures, a repertoire from pluripotent glial (G) /neural (N) 
/melanocyte (M) /myofibroblast (F) to bipotent GM progenitor was evident, including self-renewal 
(249). As DFT1 expresses Schwann, melanocyte and self-renewal markers such as SOX2 and 
POU5F1 (discussed below) it implies that the DFT1 has activated a program reminiscent of early 
developmental stages. Experimental injury caused by cutting adult mouse sciatic nerve, 
particularly neurofibromatosis 1 (Nf1) mutant mice, induced pigmentation around the injury site. 
Further, nerve grafts from both wild type and Nf1 mice into albino adult mice resulted in 
pigmentation, thus both experiments show melanocytes are derived from adult peripheral nerve 
and can be attributed to glial cells retaining the ability to form pigment within the wound 
environment (250). Murine embryonic and neonatal KIT+/CD45- melanoblasts were shown to be 
multipotent giving rise to N, G and F in addition to M with self-renewal capability including GM 
type colonies (251). As with DFT1, the expression of KIT enhances survival, migration and 
proliferation but may be contributory to self-renewal also. Definitive evidence that the ventrally 
migrating SCP is the cellular origin of nerve derived melanocytes was confirmed by tracing 
experiments showing dermal and hair follicle melanocytes originated from SCPs associated with 
embryonic nerves innervating the skin in mice (144). Adameyko et al. also found by cutting the 
sciatic nerve, EGR2 positive pro-MSC and MSC retain the ability to form pigment at the site of 
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injury (144). NRG1/ERBB3 signalling appears critical to SC/melanocyte fate because in ERBB3 
deficient mice there is a significant increase in melanocytes despite a decrease in SCPs and 
additionally, cultures of DRG and SCP showed NRG1 to be suppressive to melanocyte 
differentiation (144). As DFT1 expresses ERBB3 (47), it is possible that there is a suppressive effect 
accounting for the negativity of most of the melanocyte markers. Similar findings were reported in 
zebrafish; pigment cell precursors are associated with peripheral nerves and ganglia in post-
embryonic development, additionally these precursors are absent in ERBB deficient mutants (252) 
and evidence of a stem cell population associated with DRG giving rise to ventromedial 
melanophores that migrate along nerves are also ERBB dependent (253) . Cultured human foreskin 
melanocytes dedifferentiated to Schwann-like cells that when transplanted into injured rat sciatic, 
behaved as Schwann cells closely associating with nerves and glia (254). Rare pigmentation in 
Schwann cell tumours is recognised in both melanotic schwannoma and pigmented neurofibroma 
(often associated with Nf1) which tend to be benign but have the potential to become malignant 
and are often positive for MLANA, TYR, PNL2 and PMEL (255, 256). In addition, neurofibroma 
associated with Nf1 have been shown to contain NES positive progenitors, as does DFT1, which 
may represent alteration in self-renewal program potentially contributing to tumourigenicity.  
Melanocytic differentiation can also be present in non-pigmented diffuse neurofibromas (257). In 
veterinary tumours, a canine pigmented diffuse neurofibroma has also been recorded (258). An 
epithelioid malignant peripheral nerve sheath (EMPNST) tumour expressed PMEL showing 
melanocytic differentiation (259) which could be confused with a malignant melanoma with 
MPNST features (260). Divergent differentiation can also be exhibited by malignant melanoma and 
benign melanocytic naevi whereby Schwannian differentiation (often termed neurotization) is a 
feature. This is often expressed in spindle cell desmoplasic malignant melanoma/neurotrophic 
melanoma (261, 262). The experimental evidence cited above indicates that NC multipotent, 
bipotent and particularly the SCP have the molecular machinery to differentiate and/or 
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dedifferentiate into glia or melanocyte phenotypes during normal development or in disease. 
Although DFT1 is non-pigmented, the expression of PNL2 and SC markers provides evidence that 
the tumour is at least a bipotent progenitor-like cell. 
4.5.4 The Bungner (Repair) Schwann cell 
 
When peripheral nerve injury occurs phenotypically mature SCs dedifferentiate reprogramming 
from myelination to a progenitor-like phenotype that will support nerve survival and regeneration. 
These repair SCs or bridging SCs termed Bungner SCs (BSC) form regeneration tracks called bands 
of Bungner which function to direct axon ends to their targets (263-265). Quiescent intact SCs 
distal to nerve injury (dSC) dedifferentiate and down regulate myelination genes including EGR2, 
MPZ, MBP, MAG and PRX and upregulate early SC genes including JUN, NGFR, SOX2, GFAP, PAX3 
and NCAM and simultaneously activating genes specifically related to repair including signal 
transducer and activator of transcription STAT3, SHH, glial derived neurotrophic factor (GDNF) and 
artemin. Our results show that DFT1 expresses STAT3, SHH, SOX2, NGFR, PAX3, GFAP and JUN, 
upregulated in the repair program with downregulation of EGR2, MPZ and MAG showing reduced 
expression, MBP was not expressed although PRX was still strongly expressed. The plasticity of 
MSC and NMSC (Remak), recapitulated by the BSC is often termed ‘dedifferentiation’ however, 
‘reprogramming’ or ‘transdifferentiation’ more correctly describes the two distinct phenotypic 
states (263, 264, 266-268). Clements et al. found that when the repair program is activated, 
dedifferentiation was not simply a reversal of the SC development program because a stem-like 
state is created (pluripotency factors SOX2, POU5F1 and NANOG) and BSCs reduced their repair 
potential but increased proliferation and differentiation toward mesenchymal characteristics. A 
stem-like state is reflected in DFT1 as the tumour expresses SOX2, POU5F1 and NES. Additionally, 
the mesenchymal cell marker VIM, highly expressed in embryonic development and upregulated 
during nerve degeneration (269), it is also strongly expressed by DFT1. This describes a distinct 
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molecular difference that exists between BSC and dSC populations (265). Both the myelinating and 
repair programs can be active in Schwann cells for 3 days until there is significant downregulation 
of MPZ and ERG2 (270). Transcription factors, JUN and STAT3 and SOX2 are instrumental in nerve 
repair although they play different roles. JUN functions as a negative regulator of myelination thus 
supresses this program however, JUN is also an activator of the repair program and subsequent 
Wallerian degeneration (198, 263, 271). In the developing SC, JUN is low or absent in SCPs, 
upregulated in ISC and downregulated in MSC although it is detected in many NMSCs (266). It 
appears the primary role of JUN in SCs is during injury as inactivation of JUN in embryonic SCs, 
development proceeds normally (272). STAT3 has a duel role, it is crucial to long term autocrine 
survival (IGF, NT3 and PDGFB) and importantly, responsible for the maintenance of the BSC 
phenotype (273). DFT1 expresses IGFR2, PDGF, BDNF (DH, BDNF and its ligand TRKC results not 
presented, see figure 30A-D) and NGFR illustrating an active autocrine survival program, although 
with no axonal contact this is not surprising. Inactivation of STAT3 causes abnormal morphology of 
BSC and their regeneration tracks and fails to sustain repair markers such as JUN, SHH and BDNF.  
In SC development, STAT3 is detectable from SCP to adult SCs but does not appear significant in SC 
development, so it appears like JUN, STAT3s primary role in SCs is restricted to post injury BSCs 
(273). STAT3 also has important functions in various stem cells; outlined in the next section below.  
SOX2 is expressed by ISC, as is JUN, and is normally downregulated for myelination to occur, SOX2 
is re-expressed in nerve injury and must once again be downregulated for re-myelination to occur 
during repair (268, 274). DFT1 expresses JUN, SOX2 and STAT3 all three transcription factors are 
re-expressed by SCs during nerve injury. Important to the repair program is the upregulation of a 
number of neurotrophic factors in addition to GDNF including BDNF, neurotrophin 3 (NT3), nerve 
growth factor (NGF), vascular endothelial growth factor (VEGF), NGFR, N- cadherin (CDH2), PDGFB 
and IGFR2 (197, 264, 266). This critical component of SC plasticity is demonstrated by DFT1s 
expression of IGF2, PDGFB, NGFR, and VEGFA. NRG1- III signalling is essential for myelination 
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however, during nerve regeneration SC derived secretion of NRG1- I and NRG1-II is prominent 
during the same time that axonal NRG1- III is lost (275-277). While SC derived NRG1-I and NRG1-II 
provides an autocrine loop their presence also has a negative regulatory effect on the myelination 
(278). Concomitant upregulation of the ERBB2/3 dimer upon nerve injury occurs (275, 276) where 
ERBB3 expression decreases one day after injury but Is strongly upregulated at day 7 post injury 
levels remaining elevated during regeneration (279, 280). I reported the expression of ERBB3 by 
DFT1 (47) and this would be in keeping with autocrine expression of NRG1 thus exerting a negative 
myelination signal. In addition, constitutive activation of NRG1/ERBB signalling has been 
associated with proliferation of neoplastic SCs in MPNST and neurofibromas (281) whereby 
sustained NRG1/ERBB expression may have occurred in DFT1 from nerve injury causing malignant 
transformation of a Bungner cell. Indeed, ERBB3 was also identified as a candidate gene for 
tumorigenesis in DFT1, where its mapping was rearranged with increased copy number (5) 
detected. MBP is also downregulated after injury and completely disappears during degenerating 
conditions (279), logically this could account for MBPs absence in DFT1. SHH, normally low or 
absent in ISCs, is controlled by JUN and is upregulated in SCs of injured nerves (263, 266, 271). SHH 
which is normally repressed in SCs by polcomb repressive complex 2 (PCR2), is also activated by 
demethylation of histone H3 lys27 (H3K27) upon nerve injury (282). SHH is also upregulated in 
damaged nerves facilitating nerve regeneration while its upregulation in SCs offers a 
neuroprotective effect as BDNF is also increased in cultured SCs (283, 284). VEGF has neurotrophic 
and mitogenic activity on both neurons and SCs enhancing survival, axonal outgrowth and 
proliferation of SCs (285). VEGF is upregulated in SCs secondary to nerve injury facilitating 
angiogenesis and oxygen delivery, macrophage recruitment for myelin degradation and axonal 
maintenance by SCs (286) similarly expressed by DFT1. Loss of contact between SCs and axons 
causes alteration to cytoskeletal antigens including upregulation of intermediate filaments VIM, 
GFAP, neurofilament (NEFM and NEFL) and laminin. VIM, otherwise normally restricted to the 
105 
 
outer ring of cytoplasm in MSCs; GFAP, normally only present in NMSC or immature myelinating 
SCs and laminin present on SCs from the ISC stage; all of whose activity intensifies maintaining SC 
alignment with neurotrophic molecules promoting axonal outgrowth (287). NEFM has been shown 
to be expressed in developing SCs and dedifferentiating Schwann cells during Wallerian 
degeneration along with VIM and both NEFL and NEFM mRNA are expressed during nerve repair 
(288, 289). DFT1 was essentially negative for neurofilament, although a very small focus showed 
occasional light cytoplasmic positivity (figure 36E), GFAP was expressed in approximately 50 
percent of cells; however VIM and laminin (DH, data not presented, figure 36N and 36O) were 
strongly expressed in most. Of note is that pigmentation can occur at the site of peripheral nerve 
injury and repair. We outlined above how experimental injury caused by cutting adult mouse 
sciatic nerve induced pigmentation around the injury site (250). Similarly, Adameyko et al. 
suggests that EGR2 may restrict differentiation of SCPs into melanocytes but they still retain the 
ability to form pigment when challenged by loss of nerve contact in the repair microenvironment 
(144). The expression of PNL2 would indicate that DTT1 does retain some melanocyte antigens 
that become evident during reprogramming during injury or malignancy. Additionally, Nf1 
deficient mouse SCs at the wound site formed neurofibromas indicating that the wound changes 
from a normally tumour suppressive microenvironment to tumour conducive one (290). TGFβ is 
expressed by MSC as well as NMSC including SCPs, embryonic SCs and satellite SCs (291) and in 
developing nerves, it appears to modulate two opposing SC programs; death and proliferation. In 
the SC, TGFβ can block myelination in favor of a NMSC phenotype (292, 293) but in MPZ/PMP22 
expressing multipotent progenitors TGFβ will produce mainly myofibroblasts or neurons 
depending on cell cluster size (294). TGFβ and NRG1 activate the JUN NH2-terminal kinase (JNK)-
JUN pathway in SCs necessary for apoptosis and proliferation. This can be suppressed by EGR2 
upon myelination and cell death can be impeded by NRG1 and autocrine factors (295, 296). As SCs 
align with growing nerves TGFBR2 acts as a mitogen for those SCs associating with axons in a 1:1 
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ratio and NRG1 but superfluous non-associated SCs will apoptose (297). Recently, nerve injury was 
shown to upregulate TGFBR2 in the BSC, reprograming the cell to an invasive mesenchymal like 
cell type, promoting directional migration and thus nerve regeneration. These changes also 
indicate that transdifferentiation and activation of the repair program is more closely associated 
with ESCs than their immediate progenitors of the neural crest as cellular plasticity may be 
influenced by injury causing malignant transformation (265). Our results show DFT1 expresses 
TGFBR2 in the setting of a SC transdifferentiation phenotype including strong expression of 
mesenchymal marker VIM.  Intriguingly, insights into cancer stem cells have revealed that the 
reprogramming of somatic cells may be contributory to some cancers (298), more specifically, 
concurrent induction of the Schwann cell repair program caused by cancer invasion of nerves 
guides cancer cells towards SCs where axonal guidance is a defining feature of BSCs during nerve 
outgrowth (299). We hypothesized that DFT1 may be a result of malignant transformation of the 
BSC and that facial injury, rich in whiskers and peripheral nerves, may provide the ‘niche’ 
microenvironment for successful transmission of DFT1. Comprehensively, our results show 
expression of specific markers upregulated in repair signalling; JUN, SHH, SOX2, STAT3, early SC 
lineage markers; TFAP2A, NGFR and autocrine survival factors such as BDNF, VEGF, IGFR2 and 
PDGFB. This scenario is true also for the inclusion of melanocyte markers because pigmentation 
can also occur at the site of nerve injury. 
4.5.5 Neural Crest Stem Cells, Multipotency and Self-renewal 
 
Recent publications have shown that nerve derived SCPs retain the ability to differentiate into 
pigment cells of the skin (144), endoneurial fibroblasts (143), parasympathetic neurons and 
ganglia (300, 301), enteric (302) and oesophageal neurons (303), mesenchymal stem cells 
producing dental pulp cells and odontoblasts (304) and chromaffin cells of the adrenal medulla 
(305), in addition to MSC and NMSC (109). Therefore, the SCP may represent multipotent NCSCs 
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capable of differentiation into a variety of cell types once considered to be only attributed to the 
embryonic NC (92). One property of all NC progenitors, from pluripotent to bipotent state, is the 
ability to yield glia illustrating their plasticity in response to various developmental signals (306) 
and the capacity of NCSC to self-renew has been recognised for some time. Stemple and Anderson 
et al. (307) isolated rat multipotent NCCs by their expression of NGFR and NES (both of which are 
expressed by DFT1) in culture these cells gave rise to not only G, N and others but also multipotent 
progeny, indicating the ability to self-renew. DFT1 also expresses NGFR and NES. Also evident was 
that self-renewal of the multipotent cells occurred by both symmetric and asymmetric cell 
divisions (307). Isolated NGFR+ MPZ- SCPs from rat foetal peripheral nerve, indistinguishable from 
NCSC invitro, generated both G and N when transplanted into chick embryos, indicating they self-
renew in vivo and persist at least a week after NC migration (308). In NGFR+ rat postmigratory DRG 
and differentiated NCSC cultures, multipotent progenitors expressing both MPZ and PMP22 gave 
rise to G, N and F. In this progenitor cell, MPZ and PMP22 mark glial cells long before myelination 
and PMP22 expression precedes neuronal differentiation (294), an important characteristic 
highlighted earlier because DFT1 expresses these proteins in an unmyelinated state. NCSCs 
isolated from rat sciatic nerve grafted into embryonic chick were able to differentiate into all types 
of peripheral glia and primarily parasympathetic neurons but in culture were able to differentiate 
into sympathetic neurons thus maintained multipotency and self-renewal (309). NGFR+ isolated 
from adult rat gut were also multipotent containing G, N and F in cultures that self-renewed and 
were confirmed as NCSCs (310). Rat NCSCs from both sciatic nerve and gut, although both 
multipotent and give rise to G and N, displayed cell-intrinsic factors biasing sciatic nerve NCSC to 
form neuronal and gut NCSCs can acquire glial fates despite the presence of both lineage 
determination factors (311). Multipotent rat sciatic and gut NCSC colonies exposed to NRG1, 
BMP4 and Delta-Fc gave rise to different progeny either F and G (sciatic) or N and F (gut) indicates 
the complexity in peripheral nerve development (143). The reprogramming of cultured chick SCs 
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isolated from sciatic nerve to F in additional to G and GM, normally seen only in cephalic NCSC in 
vivo, highlights the potential of TNCs to recapitulate mesenchymal fate (312). CNC and TNC 
cultures showed that bipotent GM and GF progenitors behave like stem cells by self-renewal and 
production of restricted progeny (249). Melanocytes of embryonic quail skin were dedifferentiated 
in culture giving rise to multipotent cells (GMF, GM, MF) that were able to self-renew but this 
capability was enhanced when cultured in the presence of ET3 (313). Murine embryonic cells 
expressing KIT+/CD45- were shown to be multipotent giving rise to N, G and F in addition to M with 
self-renewal capability including GM type colonies (251, 314). The same researchers also found 
that SOX10+/KIT+ and SOX10+/KIT- are both multipotent, differentiating into G, M, N, including GM 
type colonies irrespective of KIT expression (315), suggesting that previously described 
dorsolateral migrating KIT+ and dorsoventral KIT- migrating NCs is not strictly defined. Additionally, 
they also found that SOX10+/KIT+ present in the developing DRG and ear were also multipotent 
containing M colonies in addition to NG (316). Interestingly, KIT positivity occurred in about 10% of 
DRG cells identified as neurons (317). In vivo mouse experiments reveal that pre-migratory and 
migratory NCs are multipotent and the possibility of asymmetrical stem cell retention in the dorsal 
neural tube provides evidence of NCSCs in vivo (318). Cultured melanocyte spheres can be 
reprogrammed by NOTCH1 signalling to form functional induced NCSC, losing TYRP1 and PMEL, 
capable of self-renewal and differentiating into both mesenchymal and neural cell types 
expressing SMA, NEF and GFAP. These cells could also re-express melanocyte phenotype markers 
TYRP1 and PMEL including home to the basement membrane in a reconstructed skin context 
(319). As well as the upregulation if SHH in nerve injury, SHH is also required for survival of CNC 
and craniofacial development. SHH acts mainly on highly multipotent NC progenitors capable of 
differentiating into both neural and mesenchymal potential (G, M, F, N, chondrocytes C and 
osteocytes O), while positively influencing mesenchymal differentiation potential, SHH largely 
unaffected neural and melanocytic progenitors (320-322). Although crucial to embryonic 
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development or postnatal injury, the SHH pathway appears just as important in the progression of 
some cancers aberrantly expressing SHH. SHH can maintain stemness driving expression of genes 
such as SOX2, POU5F1, proliferation such as IGF2R, VEGF and TP53 and cross talk with other 
pathways such as WNT, TGFβ, NOTCH and IGF shows the complexity of the SHH pathway 
(reviewed in (323-327), all of which are expressed by DFT1. Whether DFT1s signalling is canonical 
or non-canonical, autocrine or paracrine, is yet to be determined but key genes such as receptor 
patched (PTCH1), smoothened (SMO) and suppressor of fused (SUFU) appear activated (4). 
Interestingly SHH can regulate WNT signalling through SUFU which can supress nuclear levels of 
CTNNB1, perhaps another possible explanation for CTNNB1 absence in DFT1 (327). As part of our 
immunohistochemical profile, we included the common epithelial markers epithelial cell adhesion 
molecule (EPCAM) together with cytokeratin markers (pan) AE1/AE3 and high molecular weight 
34Βe12 (DH, data not presented, figure 36F and 36G). While AE1/AE3 and 34Βe12 were negative, 
EPCAM/CD326 was expressed in all strains, a result quite unexpected as DFT1 is non-epithelial in 
origin. EPCAM is commonly used as a circulating tumour cell (CTC)/tumour initiating cell (TIC) 
marker of simple epithelia and a variety of epithelial carcinomas. EPCAM is not usually seen in 
tumours of mesodermal and ectodermal origin but it is also expressed by progenitor cells, normal 
and malignant stem cells, embryonic stem cells (328, 329), and neuroendocrine tumours (330). 
EPCAM is also expressed in early formation and assembly of the gonads (329) therefore we 
examined for the expression of a germ cell lineage using two commonly used antibodies; DEAD-
box helicase 4 (DDX4) and Y-Box binding protein 2 (YBX2) both of which were negative (DH, data 
not presented, see figure 36J-M) demonstrating that DFT1 is not a germ cell neoplasm. Elevated 
EPCAM is experienced in human foetal tissues during morphogenesis and is co-expressed with 
pluripotency stem cell markers such as SOX2 and POU5F1 thus associated with self-renewal and 
maintenance of the undifferentiated state (331, 332). In mouse ESCs it was shown that EPCAM IS 
downregulated in early differentiation along with SOX2, POU5F1 and STAT3 however, in the 
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undifferentiated state the converse applies and while EPCAM is essential it is not sufficient to 
maintain pluripotency on its own (333). Expression of EPCAM by DFT1 would indicate that the 
tumour is in a relatively undifferentiated state. Further to this relationship reprogramming of 
fibroblasts using EPCAM, a potent stem cell marker, and its cleaved extracellular domain (EpEX) to 
activate the STAT3 – hypoxia inducible factor 2α (HIF2A/EPAS1) pathway for the production of 
induced pluripotent stem cells (iPSC) demonstrates a reprogramming trigger (334). IGF2 is 
instrumental in two SC programs; in embryonic development as SCP transition to immature SC and 
in repair following axonal loss and IGF2R is certainly expressed by DFT1. Increasing evidence shows 
that IGF2, as well as IGF1 is required by embryonic stem cells for self-renewal, pluripotency and 
cell survival and the same factors also help maintain the stem cell phenotype in cancer (335). 
Because EPCAM, SOX2, POU5F1 and STAT3 are expressed by DFT1, this would suggest that the 
self-renewal program is activated despite the tumour not being completely undifferentiated or an 
embryonic state. STAT3 has been identified as a key transcription factor that enables embryonic 
stem cells to self-renew and maintains their undifferentiated pluripotent state (336, 337). As well 
as normal stem cells STAT3 has also been reported to have an essential role in maintaining gene 
expression important to the CSC phenotype such as CD44 and PROM1/CD133 (338), SOX2 and NES 
(339). As STAT3 is a key transcription factor for self-renewal in stem cells and is crucial to 
activating the repair SC program, I surmise that SC trans-differentiation and stem cells share a 
similar function and perhaps should not be considered mutually exclusive. Interestingly, 
independent DFT1 researchers have also found STAT3 to be active in DFT1 (6). CD44 and PROM1 
are often associated with CSCs so these markers were included on that premise. CD44 was 
expressed weakly by DFT1 in most of cells, primarily its role is bind hyaluronic acid and functions 
appear to be cell migration and adhesion. CD44 is expressed on haematopoietic, mesenchymal 
and adipose stem cells (340). CD44 co-localises with ERBB2-ERBB3 on the SC membrane during 
perinatal proliferation, crucial to heterodimerisation during NRG1 signalling (129). Although CD44-
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EREBB co-localisation occurs in normal development, it is possible that a relationship still exists in 
malignancy. CD44 has also been detected in NMSCs of the neuromuscular junction (NMJ) (341) 
and in vestibular Schwannoma (NF2) (342). In cancer cells, CD44 can activate various pathways 
such as MAPK, Hippo [active in DFT (8)], CTNNB, TGFβ, PDGF and STAT3 (all demonstrated in this 
research) among others (343). CD44s is the smallest and standard isoform however, alternative 
splicing encodes larger isoforms referred to as CD44v and often these isoforms are expressed in 
cancer cells (344). Our CD44 antibody was N-terminal polyclonal rabbit and therefore it is not 
possible to determine any splice variants. We have shown that DFT1 expresses SC and melanocyte 
linage markers so we explored the possibility that DFT1 may be multipotent and utilised neuronal 
markers NSE, UCHL1, neurofilament, and CALB2. Strong ENO2 staining was consistent across all 
DFT1 strains, interesting because normally ENO2 stains central and peripheral neurons and 
neuroendocrine cells but not SCs (345, 346). This result appears contraindicative and erroneous. 
We previously identified ENO2, chromogranin A (CHGA) and Synaptophysin (SYN) positivity in 
DFT1 (2) supporting neuroendocrine differentiation. Neurosecretory granules were identified on 
electron microscopy (1) and even though CHGA and SYN monoclonal antibodies were negative in 
subsequent testing (DH, personal observation), together demonstrate neuroendocrine epitopes 
are present on DFT1. Recently, Furlan et al. provides conclusive evidence that chromaffin cells of 
the adrenal medulla originate from SCPs migrating along preganglionic nerves innervating the 
adrenal medulla (305). Chromaffin cells typically contain secretory granules, stain positive for 
CHGA, SYN and ENO2 however the general distinctive histomorphology ‘Zellballen’ and S100 
positive sustentacular cells differs from DFT1 expression (347). Although pigmented 
paragangliomas and pheochromocytomas generally contain neuromelanin, they do not contain 
premelanosomes/melanosomes and are HMB45 negative (348-350), although others have 
reported that these features can be present (351-353). If we consider that the SCP can be the 
origin of melanocytes from dorsoventral migration, then melanocytic features are theoretically 
112 
 
possible. Instead of the neuroendocrine markers being aberrant in DFT1, it is conceivable that 
since SCPs are responsible for adrenal medulla chromaffin cells and melanocytes, the expression 
of ENO2 is not erroneous but appropriate for DFT1, and indeed possibly more specific than first 
thought (354). UCHL1 was also expressed by all strains and typically expressed by normal neural, 
neuroendocrine, melanocytes but not by SCs, however UCHL1 has been documented in a wide 
variety of tumours including neuroectodermal and mesenchymal (355), therefore its role is more 
complex that first thought. A study on mouse neural progenitor cells revealed that UCHL1 affected 
cell morphology of NES expressing neural precursors, however progenitors undergoing gliogenesis 
had little UCHL1 indicating UCHL1 supports neurogenesis (356). Normally SCs do not express 
UCHL1 but if a nerve is transected the denervated SC does have the ability to upregulate this 
protein and it has also been reported in nerve sheath tumours (357). In the developing enteric 
nervous system, UCHL1 can co-stain with NGFR glial precursors showing that UCHL1 is not 
necessarily specific for neural differentiation (358). These would indicate that neural 
differentiation cannot be categorically assured however, UCHL1 certainly has a role within 
progenitor cells during the early phases of neural/glial/melanocyte differentiation. In malignancy 
there is much to unravel as UCHL1 has been associated with CTNNB1, TP53 and JUN, all of which 
are expressed by DFT1, therefore UCHL1 may also be driven by other unknown factors (359). 
Neurofilament protein was essentially negative apart from a very occasional cytoplasmic 
expression perhaps suggestive of neural programming although this was not consistent feature. As 
previously mentioned it has been noted that loss of axonal contact can upregulate neurofilament 
in SCs. Because some SCPs undergo neurogenesis in the postnatal period, to provide CALB2 
expressing neurons to the enteric nervous system (302) we tested DFT1s ability to express CALB2. 
All strains were negative for CALB2 but interestingly, apart from peripheral nerve staining this 
marker has found use in differentiating a Schwannoma from neurofibroma with positive staining 
being associated with Schwannomas (360, 361). As a general aside, I noticed that DFT1 had 
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nuclear expression of markers MLANA, SMA (DH data not presented, SMA figure 36H, negative 
MSA 36I,) and Desert Hedgehog (DH, data not presented) when the expected result is cytoplasmic. 
Taken on their own the nuclear expression would appear anomalous, a possible result of cross-
reaction (human versus marsupial proteins) however, collectively it is conceivable that a 
progenitor cell, such as DFT1, may express these proteins aberrantly because the molecular 
machinery is intrinsic to the cell, but the expression is altered by malignant transformation. 
Signalling and maintenance of stem cells and self-renewal in normal as well as cancer cells involves 
a number of classic pathways such as WNT/β catenin, Hedgehog and Notch but in addition TGFβ, 
PI3K/ATK/mTOR, JAK/STAT and TP53 also contributes significantly to stemness (362-364). The 
intricacies of signalling are beyond our scope, but our current results have directly shown 
expression of CTNNB1, SHH, NOTCH1, TGFBR2, STAT3, TP53 (see below) and previously ERBB3 by 
DFT1, integral to the signalling pathways outlined above that maintain self-renewal in cancer or 
normal stem cells. Self-renewal and CSC markers were evident by DFT1s expression of markers 
SOX2, POU5F1, EPCAM, CD44 and CD133. 
 
4.5.6 Adult skin and Craniofacial Ectomesenchymal stem cells 
 
Craniofacial development requires embryonic CNC, the ectomesenchyme, to form both neural 
crest (neural, glial and melanocytes) and mesenchymal (skeletal, chondrocyte, connective tissues) 
derived tissues (322). Studies reveal that adult NCSCs reside in special craniofacial niches 
especially the oral region (365), including but not limited to stem cells of the palate (PNCSC), 
dental pulp (DPSC), skin (hair and whiskers) (366) fungiform papilla of the tongue (FPSC) (367) and 
oral mucosa stem cells (OMSC) (368) that are multipotent and have the ability to self-renew. The 
Tasmanian devil is notorious for challenging fellow devils while feeding or during mating, resulting 
in lacerations particularly around the facial region. Injuries to the lips and oral mucosa can also 
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occur as a result of feeding on large carcases, bone fragments and echidna spines and the number 
of injuries do not necessarily correlate to increased risk of acquiring DFT1 (64). Interestingly, 
tumours including the cheek, whisker pad, lip, gingiva, tongue, palate including loss of teeth 
(personal observations DH, GK,) involve the craniofacial niches mentioned above. Our research 
highlights that in addition to neural crest derived Schwann cells and melanocytes lineage markers, 
some are also expressed by several craniofacial stem cells. The discovery of rat PNCSCs as MSCs of 
possible lanceolate nerve endings that expressed NES, NGFR and S100 and pluripotency factors 
including SOX2 and POU5F1, are thought to arise because of their anatomical position and the 
injurious nature caused by mechanical stress, since sciatic nerve does not express these markers 
unless culture conditions mimic nerve injury (369). Subsequently, PNCSCs expressed GFAP (glia), 
neurofilament medium NEFM (neurons), SOX2, POU5F1 and PROM1 illustrating multipotency and 
self-renewal (370). The intermediate filament NES, recognised for its contribution to cellular 
structure has an additional role that is crucial to the survival and self-renewal of multipotent 
NCSCs (371). Mesenchymal DPSCs are self-renewing and retain the ability to be multipotent, 
including differentiation into glia and melanocytes, expressing NGFR, SOX10, NES, KIT, GFAP, 
MLANA, CD44 and PROM1 among others (372-374) and our research shows constant expression of 
these markers by DFT1 except for MLANA. The skin is home to several recognised stem cells; skin 
derived stem cells (SKPs) (375), epidermal neural crest stem cells (EPI-NCSC) (376) and hair follicle-
associated (HAP) stem cells (377) including the bulge area in particular has identified NES positive 
pluripotent stem cell (378, 379). SKPs that occupy the hair and whisker papillae, are NES+ NGFR- 
SOX10- multipotent cells differentiating into neurons expressing NEFM, Schwann cells expressing 
GFAP, MBP, MPZ, S100 and NGFR and smooth muscle expressing SMA, additionally expression of 
PAX3, VIM and NSE also (380, 381). Additional research by Toma et al. found SKPs had low levels 
of NGFR differentiating into neurons, glia and smooth muscle cells (382). Cultured rodent vibrissial 
follicle papilla cells formed spheres with a similar profile but also expressed SOX10 and PAX3 but 
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did not express POU5F1 (383). Beirnaskie et al. found SKPs expressed SOX2 in the dermal sheath in 
addition to the dermal papilla, expressed CD44 and were also able to culture neural and 
mesodermal differentiated cells (384). EPI-NCSC are pluripotent NCSC found in the outer root 
sheath from the bulge to the matrix. Clonal cultures of bulge area explants from mouse whisker 
contained neurons, smooth muscle cells (SMA), rare Schwann cells (GFAP, S100) and melanocytes 
(early melanocyte marker/MelEM) (385). Human EPI-NCSCs (hEPI-NCSCs) bulge explants were 
shown to differentiate into osteocytes and melanocytes (MITF+) and other cell types in secondary 
clones including self-renewal and pluripotency genes SOX2 and POU5F1 protein expression 
including SOX10, NGFR, NES, GFAP and SMA (386). Expansion of hEPI-NCSCs led to the expression 
of SOX10, EGR2, NGFR, MBP, GFAP, MPZ, 100B, VEGFA including JUN gene expression by 
manipulating SHH, WNT and TGFβ pathways in culture (387). Hair follicle-associated (HAP) stem 
cells, originally termed nestin-driven GFP (ND-GFP), are NES positive, cytokeratin 15 negative 
which can differentiate into neurons, glia, keratinocytes, smooth muscle cells and melanocytes 
(388, 389) isolated from the bulge area (390) but also migrate to the dermal papilla (391). These 
cells appear similar to EPI-NCSC. Identification of hair follicle stem cells (HFSC) in the bulge are of 
human scalp expressed NGFR, NES AND SOX10, spheres were multipotent differentiating into 
neural, melanocytes and smooth muscle cell types and able to self-renew expressing POU5F1 (392, 
393). Glabrous dermal stem cells (DSC) isolated from human foreskin expressed NGFR, NES and 
POU5F1, neural crest characteristics, and were able to be differentiated into neurons (NEFM), 
smooth muscle cells (SMA), chondrocytes, adipocytes and melanocytes (MITF, DCT, S100, PMEL). 
The markers NGFR, SOX10, S100, SOX2 and PROM1 in dermal papilla are expressed by 
guard/awl/auchene hairs illustrating the heterogeneity of the dermal papilla (394). FPSCs express 
NGFR and are multipotent, as NGFR+ NES+ spheres are able to be differentiated into neurons, glia, 
smooth muscle and keratinocytes (367). The isolation of NGFR and SOX10 positive human and 
mouse trunk skin was shown to be multipotent, giving rise to both neural (glia, melanocytes) and 
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non-neural lineages (smooth muscle, chondrocytes and adipocytes), are self-renewing and 
associated with the glial and melanocyte lineages, not from mesenchymal structures of the hair 
follicle (395). Finally, because oral tissue heals regeneratively, quickly and without scar tissue led 
to the discovery of OMSCs resident within the oral mucosa lamina propria (OMLP). Human buccal 
mucosal biopsies revealed a CD44+ CD45- progenitor cell population that was self-renewing (SOX2, 
POU5F1 -RNA), multipotent by differentiated into both mesenchymal and neuronal lineages (NES, 
NOTCH1, SOX10, GFAP, NEFM, S100 and MBP in culture) (368). Human gingival and alveolar 
biopsies expressed NGFR, SOX2, POU5F1 but not NES and cell cultures expressing NGFR, SOX2, 
POU5F1, NES, β-3 Tubulin (TUBB3) and GFAP showing stem cell factors and multipotency (396). Of 
note was the OLMPs also secreted VEGF among other growth factor, a marker also expressed by 
DFT1. Human alveolar, labial and palatal mucosal biopsies revealed CD44+NES+ OMSCs that were 
multipotent expressing SMA, NSE, TUBB3 and GFAP and under culture conditions differentiating 
into neurons, glia, myocytes, adipocytes, chondrocytes and osteoblasts (397). Our results illustrate 
that a great number of markers expressed by adult stem cells of PNCSC, DPSC, skin (SKP, EPI-NCSC, 
HAP) FPSC and OMSC are expressed by DFT1. Our hypothesis that the niche microenvironment 
provided by the injured facial tissues would most likely include adult stem cells residing in the 
various facial and oral environs comprehensively outlined above and that DFT1 could also have its 
origins from these cell types. 
4.5.7 DFT1: Clonal evolution, cancer stem cell and plasticity models 
 
We have shown that DFT1 expresses markers commonly associated with stem cells and self-
renewal, including, SOX2, POU5F1, NES, NGFR, CD44, PROM1 and EPCAM. The mere fact that the 
DFT1 is transmissible certainly poses a conceivable notion that DFT1 is CSC-like, a concept that 
other authors have also questioned (398, 399). Reliance on just cell markers alone is not sufficient 
to identify CSCs but if we consider additional evidence available from two separate research 
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findings, our results find corroboration. Firstly, a murine xenograft model for DFT1 showed 
conclusively that tumours grown in laboratory mice mimicked transmissible DFT1. Inoculation of 
DFT1 cell cultures into 17 non-obese diabetic/severe combined immunodeficiency (NOD/SCID) 
mice with all mice developing tumours (x-DFT1). In addition, 7 NOD/SCID mice were inoculated 
with viable cultures from x-DFT1, a second passage, with all mice once again producing tumours, 
suggesting self-renewal characteristics. All x-DFT1 tumours appeared histologically identical to the 
original DFT1 and the x-DFT1 karyotype was essentially similar to the pseudodiploid clone 
although an increase in the near triploid clone was observed. Neither immune competent BALB/c 
mice nor non-viable freeze/thaw tumour cells produced tumours. In this first study, because DFT1 
cancer cells did initiate tumours in xenotransplantation, this does imply the presence of tumour 
initiating cells/CSC. However, the inoculated cell culture was not flow cytometry/FACS sorted for 
self-renewal/stem cell markers prior to transplantation, commonly performed as the gold 
standard for CSC identification (400). Additionally, the xenograft is not subject to any innate 
immune response in the immunocompromised mouse host and therefor the tumour 
microenvironment does not fully replicate tumour transmission in Tasmanian devils. The second 
study employed experimental transmission of DFT1 tumour cells (both tumour and cell culture) 
from a diseased Tasmanian devil into non-diseased Tasmanian devils successfully producing 
subcutaneous tumours that developed into classic DFT1 (3). This allograft (tumour and cell culture) 
when compared to the xenograft above, demonstrates Tasmanian devil tumour transmission and 
development insitu, simulating as close as possible, the wound microenvironment permissive to 
DFT1 transplantation. Two common theories employed to explain cancer heterogeneity are the 
stochastic/clonal evolution (CE) or the hierarchical /CSC models. The CE model originates from any 
cell, instability accumulates genetic mutations over time resulting in a subclone of selected 
equivalent tumourigenic traits driving tumour progression and heterogeneity. In contrast to CE, 
the CSC model states that within the tumour only a very small subpopulation of stem cells are able 
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to self-renew and differentiate to form a hierarchical tumour consisting of stem cells, intermediate 
progenitors and differentiated progeny (401, 402). Now CE and CSC are not mutually exclusive and 
an alternative model or the reversible cellular plasticity (RCP) model could amalgamate aspects of 
both CE and CSC models.  This model considers intrinsic cell processes and microenvironmental 
stimuli that allow progenitor cancer cells to reacquire stem cell characteristics transforming 
between stem cell and differentiated state (401, 402).  The concept of plasticity would 
theoretically allow less symmetrical division (two daughter cancer stem cells or two daughter cells 
that differentiate) because resultant from CSC asymmetric division (one daughter cancer cell and 
one daughter cell that differentiates) are progenitor cells that would be able to convert back to 
CSC, thus increasing the CSC pool (403). Normal stem cells divide by asymmetric cell division (two 
daughter cells, one with self-renewal stem cell fate the other with differentiated characteristics) 
but this is inefficient during development or in response to injury. Dynamic control in such 
situations is achieved by stem cells having the potential to divide symmetrically producing a pool 
of daughter cells with the same fate (two daughter stem cells or two daughter differentiated cells), 
allowing stem cells to add more or less daughter stem cells or differentiated cells balanced by 
developmental and environmental conditions (404). DFT1 is a clonal transmissible tumour and our 
results show that the majority of tumour cells express self-renewal and stem cell markers, a rather 
shallow hierarchy, which is in contrast to the expected small population of stem cells according to 
the CSC model. How does DFT1 align with these models? Our results suggest that there is a blend 
of CE, RCP and CSC features. DFT1 is certainly clonally evolved, arising from a highly plastic SC 
lineage located in a repair microenvironment, that seemingly encompasses RCP, imparting a 
selective advantage for a progenitor cell expressing self-renewal and stem cell markers. The CSC 
model appears less likely because DFT1 has a lack of hierarchy and we observed that the majority 
of cells in DFT1 express proliferating cell nuclear antigen (PCNA) (DH, manuscript in preparation, 
figure 36R-S) indicating cells are proliferative and not quiescent. Ultimately the cell of origin, 
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genetic mutations and how self-renewal, proliferation and differentiation programs are regulated 
will determine the tumours path (405). CSCs may derive from normal progenitor cells that 
reacquire the ability to self-renew during mutation but are not necessarily the result of a stem cell 
that has undergone carcinogenesis (406). It is also possible, and we think that this is the case for 
DFT1, that CE may select for stem-like traits within a cancer such as a progenitor that re-acquires 
self-renewal capabilities, without committing to the CSC model (400). One possible explanation to 
the high numbers of cells expressing stem cell features is that they are dividing by symmetric cell 
division, a function enhanced by loss of tumour suppressor protein 53 (TP53), causing a tumour 
population with clonal progeny all lacking TP53 regulation and subsequent loss of tumour 
heterogeneity (400). Additionally, loss of TP53 appears to impart a stem cell transcriptional 
signature enhancing self-renewal in a mammosphere culture system (407). We found consistent 
nuclear expression of TP53 by DFT1 (DH, manuscript in preparation, data not presented, figure 
36P-Q) indicating dysfunction of the MDM2-TP53 autoregulatory feedback loop. Normally, TP53 
levels are low due to its short half-life but stabilisation and accumulation occurs in response to 
DNA damage, usually cytoplasmic ubiquitination and degradation or nuclear repression of TP53 
occurs mediated by MDM2 (408, 409). This correlates with recent chromosome mapping finding 
four copies of TP53, with two of those found on the marker chromosomes of DFT1, where function 
was likely to be affected (5). Interestingly we found no immunohistochemical expression of wild 
type TP53, however strong expression of TP53 antibody that contained both wild type and mutant 
TP53, indicating that TP53 has mutated in DFT1. CSC show downregulation of MHC molecules I, 
lacks MHC-II, and further downregulates antigen processing systems (410). Because DFT1 has been 
shown to lack expression of MHC-I and MHC-II molecules (43, 411), our results would reason that 
progenitor/self-renewal properties expressed by DFT1s would certainly contribute significantly to 
DFT1s MHC downregulation, immune evasion and therefore transmissibility. 
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A further note that offers a degree of complexity when comparing CE and CSC theories is the 
suggestion that DFT1 may have arisen from an extensive chromosomal rearrangement caused by a 
cataclysmic event known as chromothripsis, rather than an accumulation of genetic mutations 
(412). This occurs when chromosomes (single or several) or chromosomal segment shatters and 
re-joins by nonhomologous end-joining DNA repair mechanisms resulting in an extensive 
rearrangement of limited regions of the domain (413) and is postulated as a mechanism for clonal 
































Figure 36: Additional immunohistochemistry. 
 
DFT1 expressed moderate cytoplasmic staining of BDNF A, BDNF control peripheral nerve B, TRKB C. TRKB 
control peripheral nerve D. Very occasional isolated DFT1 cells did show cytoplasmic staining of 
Neurofilament protein (NEFL, NEFM, NEFH Pan) E. In ruling out epithelial origins of DFT1 we stained with 
pan cytokeratin AE1/AE3 which was not expressed, note internal positive control of hair shaft F. We also 
stained with high molecular weight cytokeratin 34Βe12 which was also not expressed, note internal 
positive control of hair shaft G. We stained for SMA and although there is clearly no cytoplasmic staining 
there is however DFT1 often demonstrated light nuclear staining was present, note blood vessel internal 
positive control H. There is no expression of MSA by DFT1, note internal positive control blood vessel and 
skeletal muscle I. We included two markers often used to define germ cell lineage DDX4 J, testis control 
DDX4 K and YBX2 L, testis control YBX2 M, both of which were not expressed by DFT1. In addition to RPSA, 
laminin (α, β, γ) stained moderate to strong cytoplasmic and membranous N, laminin control peripheral 
nerve O. Moderate nuclear expression of TP53 was evident P, control adenocarcinoma TP53 Q. DFT1 
expressed PCNA moderate to strong in the majority of cells R, control lung bronchial epithelium PCNA S. All 




4.6 Conclusion   
 
Our expressional results indicate six significant findings: 1. Histologically, strains 1-5 are very 
similar in appearance and difficult to differentiate on haematoxylin and eosin staining and for the 
most part share similar immunohistochemical expression. 2. The incredible SC plasticity is typified 
as many normal developmental stages of the Schwann cell lineage are represented including 
(TFAP2A) precursor, (PLP1) immature, (PRX) mature myelinating and (GFAP) non-myelinating 
Schwann cells however, no MBP is present. 3. The expression of growth factors IGFR2, BDNF, VEGF 
and PDGFRB indicates activated autocrine survival program from loss of axonal contact. 4. 
Expression of markers JUN, SHH and STAT3 that are specifically expressed by the Bungner 
Schwann cell suggests activation of the repair program. 5. Melanocyte markers were negative 
(MITF, MLANA, TYR), as predicted; however, unexpectedly, all DFT1 strains were positive for the 
melanocyte marker PNL2 suggesting a bipotent Schwann cell/melanocyte progenitor-like cell. 6. 
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The expression of SOX10, NGFR, NES, SOX2, POU5F1, EPCAM, CD44 and PROM1 indicates a 
NCSC/progenitor cell with self-renewal properties.  
 
The extensive literature presented above certainly advocates the remarkable plasticity of NCSCs 
and the Schwann cell and melanocyte lineages derived from them. Our results find that DFT1 is a 
progenitor-like cell, bipotent with both SC and melanocyte features, expressing repair 
transcription and growth factors with the acquisition of NCSC self-renewal properties. We theorise 
that the facial wound and resultant nerve injury would provide a perfect microenvironment, a 
niche, containing trophic signals necessary for migration, survival, proliferation and self-renewal of 
DFT1. The wound environment would be conducive to the genetic selection of a NC progenitor 
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Devil Facial Tumour 1 (DFT1) is one of two transmissible neoplasms of Tasmanian devils 
(Sarcophilus harrisii) predominantly affecting their facial regions. DFT1’s cellular origin is that of 
Schwann cell lineage where lesions are evident macroscopically late in the disease. Conversely, the 
pre-clinical timeframe from cellular transmission to appearance of DFT1 remains uncertain 
demonstrating the importance of an effective pre-clinical biomarker. We show that ERBB3, a 
marker expressed normally by the developing neural crest and Schwann cells, is 
immunohistohemically expressed by DFT1, therefore the potential of ERBB3 as a biomarker was 
explored. Under the hypothesis that serum ERBB3 levels may increase as DFT1 invades local and 
distant tissues our pilot study determined serum ERBB3 levels in normal Tasmanian devils and 
Tasmanian devils with DFT1. Compared to the baseline serum ERBB3 levels in unaffected 
Tasmanian devils, Tasmanian devils with DFT1 showed significant elevation of serum ERBB3 levels. 
Interestingly Tasmanian devils with cutaneous lymphoma (CL) also showed elevation of serum 
ERBB3 levels when compared to the baseline serum levels of Tasmanian devils without DFT1. 
Thus, elevated serum ERBB3 levels in otherwise healthy looking devils could predict possible DFT1 
or CL in captive or wild devil populations and would have implications on the management, 
welfare and survival of Tasmanian devils. ERBB3 is also a therapeutic target and therefore the 










5.2.1 Receptor tyrosine Kinases  
 
Receptor tyrosine kinases (RTK’s) are transmembrane cell surface receptors possessing protein 
tyrosine kinase activity. That are essential regulators of development, cell cycle, migration, 
survival, proliferation, differentiation and to date 58 human RTK’s have been identified, grouped 
into 20 subfamilies (414-416). Emerging is the concept that RTK’s are part of a complex signalling 
network rather than a vertical linear pathway where cross talk between RTK’s, plasma membrane 
and protein interaction domains, adaptor proteins, feed forward and feedback loops together 
synchronise a temperospatial signalling cascade allowing a dynamic cellular response to receptor 
activation. (Reviewed in (417-419).  
 
5.2.2 ERBB family of Receptor tyrosine Kinases 
 
The epidermal growth factor (EGF) family represents a complex group of type 1 transmembrane 
RTK’s with differing ligands that are capable of receptor cross talk and lateral signalling that 
activates various pathways regulated to execute diverse cellular functions (420, 421). This family 
consists of four members (HER1-4) belonging to the ERBB lineage of proteins (Erbb1-4) where HER 
is derived from human epidermal growth factor, and ERBB derived from avian erythroblastosis 
oncogene, v-erbB,  with each receptor numerically ascending 1-4. Collectively the human 
epidermal growth factor receptor gene family is designated EGFR/ERBB1/HER1, ERBB2/HER2, 
ERBB3/HER3 and ERBB4/HER4 (422). The extracellular domain (ECD) of the ERBB family members 
show high structural homology and consists of between 620-629 amino acids divided into four 
domains, I – IV. Domains I and III are leucine rich and interact with each other in an unstimulated 
state but also participate in ligand binding. Domains II and IV are cysteine rich and participate in 
127 
 
ERBB homo- and heterodimer complexes. Following the ECD is a single transmembrane segment 
of 19-25 amino acids and an  intracellular portion of approximately 550 amino acids consisting of 
the juxtamembrane segment (~40 amino acids), protein kinase domain (~260 amino acids) and 
carboxyterminal tail (~232amino acids) (422-425). The EGF consists of 11 peptide growth factor 
members including transforming growth factor-alpha (TGFα), amphiregulin (AR), beta- cellulin 
(BTC), heparin binding EGF-like growth factor (HB-EGF), epiregulin (EPR), epigen (EPG), and the 
neuregulins (NRG1-6). Binding of the EGF results in a conformational change responsible for homo 
and/or heterodimerisation combinations (422, 426-429). The ligand binding changes the 
conformation of the ECD for all ERBB’s except ERBB2 where the dimerization arm changes from a 
‘tethered’ to “extended’ to encourage dimer formation whereas ErbB2 remains in an extended 
conformation, reviewed in (430). Due to the presence of multiple p85 binding sites in its tyrosine 
kinase domain, ERBB3 efficiently activates the phoshatidylinositide 3-Kinase (PI3K) pathway (431) 
although the complex signalling network of ERBB receptors commonly activate the Ras- and Shc- 
mitogen activated protein kinase (MAPK) pathway and the phoshatidylinositide 3-Kinase (PI3K) 




The importance of lateral signalling among ERBB’s is no more apparent than with receptors Erbb2 
and ERBB3 that must heterodimerise with other ERBB members to signal (432) as ERBB3 has a 
ligand but impaired tyrosine kinase activity (436) whereas ErbB2 has no know ligand (orphan 
receptor) but a functional kinase region (437). Although ERBB3 has long been considered impaired 
or termed a pseudo-kinase, Shi et al. (438) has determined that ERBB3 does have sufficient kinase 
activity, although substantially reduced. Not long after ERBB3’s discovery and characterisation 
(439, 440), heregulin (neuregulin) was determined as its ligand (441) and the strong and preferred 
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dimer between ERBB2 and ERBB3 was soon recognised (442). Whilst the model of ‘inactive 
monomer-active dimer’ is long standing (443) researchers have provided new evidence of the 
intricacies of RTK signalling involving both extracellular and intracellular processes. How ERBB3 is 
able to activate other ERBB family members with its catalytically inactive domain has been elusive, 
Zhang (444) while studying the structure of EGFR described an allosteric mechanism termed an 
‘asymmetric dimer’ providing the process. Essentially, ERBB3 functions as a cyclin-like activator 
only (C-lobe face) for other EGFR family members because its kinase domain (N-lobe face) is 
divergent and this concept of ERBB3 behaving as an “activator” despite being catalytically inactive 
has been supported by readily activating ERBB2 (445) and EGFR (446, 447). Similar to the 
cytoplasmic complexities the plasma membrane also holds intricacies of receptor positioning 
where ligand binding inducing dimerization is generally accepted there is evidence that some 
RTK’s exist as oligomers (complexes of more than two receptors) or higher-order oligomerisation 
is required for activation (448). Unstimulated ERBB receptors have been shown to self-associate in 
oligomers that dissociate on NRG1 binding to allow heterodimers with ERBB2 (449) thus favouring 
ERBB2/ERBB3 heterodimerisation in the absence of homodimerisation (450). Although NRG1 
binding destabilises ERBB3 oligomers, dimers are neither stabilised nor disrupted upon ligand 
binding indicating that two interfaces exist and that oligomers, dimers and monomers are either 
extended or closed in their conformation (451). Higher order and proxy phosphorylation appear to 
be integral to ERBB2/ERBB3 signalling (452) and that the ERBB3 formations may act as a scaffold 
for the assembly of signalling complexes (453). Recently, Steinkanmp (454) has suggested a 
modified model for ERBB3 signalling in addition to heterodimerisation and transphosphorylation, 
ERBB3 activated homodimers should also be competent for both transphosphorylation and 
phosphorylation of cytoplasmic partners  leading to the development of a spatial stochastic model 
addressing the dynamics of ERBB3 homodimerisation and heterodimerisation with ERBB2 (455) by 
measures of diffusion, dimer-off rates, kinase activity and dephosphorylation. ERBB structure and 
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function has relied heavily on its crystallography (456), now new technologies such as fluorescence 
resonance energy transfer (FRET), single –particle tracking (SPT) and others are assisting 
researchers focusing on the dynamic regulation of signal transduction (448).  
 
5.2.4 ERBB3 Endocytosis 
 
Negative regulation and inactivation of ERBB receptors were thought to be similar to ERBB1, that 
is rapidly internalised in a clathrin mediated endocytosis (CME) destined for lysosomal 
degradation, although clathrin-independent endocytosis has been demonstrated (457, 458). 
However, in contrast it was found that ERBB2-4 appeared to be impaired and internalised very 
slowly (459-461) utilising pathways such as caveolin or micropinocytosis and clathrin-and caveolin 
independent pathways (462, 463). Unlike ERBB1, ERBB3 is degraded by proteasomes catalysed by 
the E3 ubiquitin ligase NRDP1 (Neuregulin Receptor Degradation Protein -1) (464) now known as 
RNF41 (Ring Finger 41, E3 Ubiquitin Protein Ligase) and that this protein acts as a regulator of 
steady-state ERBB3 receptor levels influencing NRG1 signalling (465-467). A recent study has 
shown that ERBB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner, 
independently of its tyrosine phosphorylation state (468). The ligand induced down regulation of 
ERBB3 is further enhanced by USP8 (Ubiquitin Specific Peptidase -8) which stabilises RNF41 (467). 
Yen et al. (469) suggests that RNF41 is pivotal in ERBB3 regulation as RNF41 mediated degradation 
supresses cellular growth and motility and that loss of RNF41 may promote tumour progression in 
breast cancer. RNF41 has also been shown to associate with nascent forms of ERBB3 to accelerate 
its degradation involving the endoplasmic reticulum – associated degradation (ERAD) pathway as a 
mechanism of controlling steady state levels of ERBB3 (470). Recently Huang et al. (471) 
demonstrated that NEDD4 (Neural Cell Precursor Expressed, Developmentally Down-regulated 4, 
E3 Ubiquitin Protein Ligase) an E3 ligase also regulates ERBB3 as NEDD4 knockdown resulted in 
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increased expression of ERBB3 and tumour proliferation suggesting both NEDD4 and RNF41 
interact with different domains to regulate ERBB3 levels. Mosesson et al. (472) suggests that 
defective internalisation, recycling and degradation of cell surface proteins and ligands is an 
emerging feature of cancer. Due to the oncogenic alterations of malignant cells aberrant function 
of E3 ubiquitin ligases such as NEDD4 enables degradation avoidance prolonging growth factor 
signalling and overexpression of receptors. Recently Shi et al. (473) suggested RNF41 mediated 
ERBB3 degradation could be beneficial in glioma therapy as overexpression of RNF41 decreased 
ERBB3 levels and suppressed glioma migration and invasion (A172 and U118 cell lines). 
 
5.2.5 Nuclear localisation of ERBB3 
 
Although the receptor ERBB3 is well known for its transmembrane exploits, nuclear detection of 
ERBB3 in certain cells suggests that nuclear- cytoplasmic shuttling can occur, although exactly how 
translocation occurs is yet to be defined. Nuclear expression has been observed in mammary 
epithelial cells and breast cancer (474), Schwann cells (475, 476), Prostate cancer (477-479), 
colorectal cancer , non-small cell lung cancer, head and neck Squamous cell carcinoma (480), 
colorectal cancer (481) and breast cancer (482). Recently an 80 kDa nuclear variant of ERBB3 
receptor (ERBB380kDa) in a human lung adenocarcinoma cell line corresponding to the intracellular 
domain has been identified whose translocation occurs independently of NRG1 and is associated 
with cell proliferation activating the Cyclin D1 promotor (483). In contrast, full length ERBB3 (185 
kDa) was found to translocate to the nucleus in a clathrin-independent pathway in breast cancer 
cell lines binding with STAT3 (signal transducer and activator of transcription 3) and STAT5, which 




5.2.6 Secreted ERBB3 
 
Shortly after ERBB3’s discovery and characterisation (439, 440), Katoh et al. (484) identified a 1.4 
kb transcript of ERBB3 (full length receptor is 6.2 kb) in gastric cancer cell lines due to alternative 
splicing of the ERBB3 gene which encodes a secreted form of the receptor. Funayama et al. (485) 
reported that mRNA levels of this secreted form (sERBB3) were expressed 5-15 times higher in 
Squamous cell carcinoma cell lines than normal cell lines. However, the ratio of secreted ERBB3 
type to the transmembrane ERBB3 type varied between cell lines suggesting that expression of 
secreted ERBB3 mRNA was regulated differently than transmembrane ERBB3 mRNA. Srinivasan et 
al. (486) found that the 1.4 kb transcript was also found intracellularly and predominantly as a 
glycosylated, disulphide-bonded dimer of 58kDa in breast and ovarian cancer cell lines as well as 
normal human tissues. Lee et al. (487) subsequently reported isolation of four novel alternative 
transcripts (1.6, 1.7, 2.1, and 2.3kb) from ovarian cancer cell lines all of which are truncated forms 
of the ligand binding domain and transfected fibroblast studies revealed three out of the four 
products are secreted proteins. Further studies by Lee et al. (488) found that the 2.1kb transcript 
also known as p85-SERB3, can bind to NRG1 with high affinity and can effectively block NRG1 
binding the cell surface receptors thus inhibiting activation of heterodimers. The secreted isoform 
of ERBB3 identified as a bone metastasis factor (MDA-BF-1), corresponding to the 1.7 kb /p45 
sERBB3 alternative transcript reported by Lee et al. (487, 488), was found by Vakar-Lopez et al. 
(489) to be highly expressed in the metastatic prostate carcinoma cells in both lymph node and 
bone. In addition MDA-BF-1 was also present in activated osteoblasts suggesting diverse functions 
in prostate cancer progression. Subsequently, the same secreted isoform (1.7 kb, p45-sERBB3, 
45kDa, MDA-BF-1) was found in a series of prostate carcinoma investigations where it promotes 
osteonectin (490), detection in serum of patients with castration resistant prostate cancer with 
bone metastasis (491), present in serum as well as activated osteoblasts and prostate cancer cells 
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and interestingly in men without clinical prostate cancer raising questions of sERBB3 involvement 
in other cellular functions (492). As well as prostate, secreted ERBB3 has been indicated as an 
early marker of hepatocellular carcinoma (HCC) in patients with chronic hepatitis and cirrhosis by 
Hsieh et al. (493) They found that sERBB3 was present in interstitial fluid and these levels also 
correlated with those in sera although not associated with expression levels of ERBB3 in tissues. 
Recently, Takahashi et al. (494) demonstrated that sERBB3 has strong suppressive effects on NRG1 
acting on cell surface molecules rather than the ligand and that the ERBB2/ERBB3 heterodimer is 
crucial for downstream signalling in MCF7 breast cancer cell lines. 
 
5.2.7 ERBB3 in Schwann cell development 
 
During development of the peripheral nervous system both myelinating and non-myelinating 
Schwann cells originate from the neural crest, initially migrating as multipotent cells that become 
fate restricted to Schwann cell lineage under trophic, mitogenic and axonal signalling influence. 
The sequential transition from Schwann cell precursor to immature Schwann cell and finally 
mature Schwann cell is under strict molecular signalling control resulting in two Schwann cell 
phenotypes emerging. Myelinating Schwann cells will form a 1:1 relationship with large calibre 
nerves whereupon a multilammelar myelin sheath or non-myelinating Schwann cells that envelop 
many small calibre nerves to form Remak bundles (reviewed in (109, 118, 119, 121, 264, 495-499). 
Meyer et al. (500) found that ERBB3 was expressed by developing Schwann cells and their 
precursors, was responsible for neuregulin-1 binding in the developing glial cells and that 
heterodimerisation occurs with a co-receptor ERBB2. Similar conclusions that ERBB3 was a 
receptor for neuregulin and that both ERBB3 and ERBB2 were able to be phosphorylated and that 
ERBB2 is able to mediate cellular transduction despite no known ligand (441, 501). The importance 
of neuregulin in early development became apparent when neuregulin mutant embryo mice 
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displayed multiple phenotypical changes in cells that express ERBB3 such as altered Schwann cell 
and ganglia development (500). Reithmacher et al. (502) found that mutant mice lacking ERBB3 
formed motor and sensory neurons of the dorsal root ganglia but the great majority undergo cell 
death. Grinspan et al. (503) found that the normal programmed cell death of ERBB3/ERBB2 
expressing pre-myelinating Schwann cells in neonatal rats was a consequence of competition for 
limited axonally derived neuregulin. This effectively limits the available pool of pre-myelinating 
Schwann cells to those with axonal contact and thus survival; however, apoptosis could be 
prevented if exogenous neuregulin was administered. Also noticed was that Schwann cell death 
was either reduced or absent in older animals following nerve transection compared to that of 
new born animals. Raabe etal. (504) found that neonatal rat cultured Schwann cells contain and 
secrete neuregulin which may act as a survival autocrine/paracrine or juxtacrine loop, while Cheng 
(505) also  that rat postnatal Schwann cells secreted autocrine factors that suggested that 
Schwann cells switch form axonal survival signals to autocrine signals at around the time of birth, 
as would be required for peripheral nerve regeneration after injury. Realising that transection in 
postnatal nerves results in loss of axonal contact for Schwann cells but not their death Meier et al. 
(197) demonstrated that postnatal Schwann cells do indeed have an autocrine loop consisting of a 
number of growth factors such as insulin growth factor, platelet derived growth factor – BB and 
neurotrophin-3 ensuring their survival. Interestingly their research also found that the Schwann 
cell precursors did not have the same autocrine loop and their survival seems to depend on axonal 
signals. Li et al. (435) found that cultured neonatal rat Schwann cells demonstrated that the PI3K 
was essential for transducing both autocrine and neuregulin mediated survival signals. Meyer et 
al. (506) concluded that of the 3 isoforms of neuregulin -1 in mouse development, type I is 
expressed by tissues including cranial ganglia and governs, among others, neural crest derived 
neurons whereas type III is expressed in differentiating sensory and motor neurons and acts on 
Schwann cell precursors driving their initial development. In addition, Michaelov et al. (507) found 
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that neuregulin-1 type III overexpression in transgenic mice resulted in thicker myelin therefore, 
neuregulin-1 type III is involved in regulation of myelin thickness. Over the next decade 
researchers consolidate the importance of ERBB2 (508) and the ERBB3/neuregulin -1 signalling 
being crucial for growth, development and proliferation of Schwann cells and their axonal 
regulated radial sorting, ensheathment and myelination (196, 509-515). The adult peripheral 
nervous system requires maintenance when it is injured and the NRG1/ERBB system is crucial to 
its degeneration, regeneration and remyelination following nerve injury. Fricker et al. (516) found 
that Schwann cell proliferation, dedifferentiation, mobilisation of macrophages and myelin clean-
up was not regulated by NRG1. However, NRG1 was required for target reinnervation, early phase 
of functional recovery and regulating remyelination but myelination fate was not absolutely 
dependent on NRG1. Ronchi et al. (279) demonstrated in rat median nerve one week after injury 
the expression of ERBB2/ERBB3 co-receptor is strongly upregulated and NRG type III was highly 
expressed and only switched off after axon regeneration illustrating the plasticity of the Schwann 
cell.  
 
5.2.8 ERBB3 as a potential biomarker 
 
ERBB2 and ERBB3 overexpression (439, 517, 518), cooperation in neoplastic transformation (431, 
519-521) and loss of ERBB3 preventing the progressive transformation of ERBB2-over expressing 
tumours (522) reinforces ERBB3’s pivotal role in ERBB signalling. Early studies revealed ERBB3 as a 
potential oncogene with overexpression due to possible increased transcription as no gene 
amplification was observed (523, 524) although recently oncogenic mutations have been reported 
(525) indicating either ERBB3 or its downstream components should represent a potential target 
for therapy (526). 
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ERBB3 is upregulated in a number of human cancers such breast, colon, gastric, ovarian and 
prostate (420, 527) but seldom reported in veterinary cancers (528-530) although it would appear 
the instrumental role that ERBB3 may play in some veterinary tumours is yet to be elucidated. 
DFT1’s immunohistochemical expression of ERBB3 led us to postulate that excess extracellular 
domain (ECD) may circulate in the host’s plasma and present itself as a possible candidate 
biomarker for DFT1. Literature reports five secreted alternative transcripts of ERBB3 present in 
serum or interstitial fluid (484, 487) which can be detected utilising ELISA methodology.  
 
Our pilot study assessed serum ERBB3 for the first time in Tasmanian devils revealing that serum 
ERBB3 was substantially elevated in the serum of Tasmanian devils with DFT1 compared to those 
Tasmanian devils without DFT1. Interestingly, the inclusion of some Tasmanian devils with CL in 
our pilot study revealed that ERBB3 may also be a biomarker for this disease, although CL is 
clinically distinct from DFT1. We identify ERBB3 as a potential biomarker of DFT1 and highlight 
current literature supporting the therapeutic possibilities that can be directed towards ERBB3 











5.3.1 Tasmanian devil ERBB3 pilot study 
 
A pilot study of thirty-five Tasmanian devils differing in age, sex and geographic location 
were selected and listed in table 5, to compare serum ERBB3 levels in clinically healthy Tasmanian 
devils (CHD), devils with DFT1 and those with CL. The Fifteen CHD’S included both adults (n=12) 
and clinically healthy juvenile Tasmanian devils (CHJD, n=3) 10 months of age. Adults included free 
range captive (n=5), captive (n=3) and wild devils (n=4). Clinically healthy adults either had no 
visible disease (ND, n=8) or had localised skin non-DFT1 dermatopathy (CHDD, n=4) consisting of 
two abscesses, a skin tag and localised dermatitis. Eight Tasmanian devils with clinical DFT1 and 
Twelve Tasmanian devils with CL. Tasmanian devils with CL were included in the study as a severe 
skin condition recognised clinically but very distinct from DFT1. All dermatopathies, DFT1 and CL 
were confirmed histologically by the Animal Health Laboratory, DPIPWE.   
 














1 982000190997443 13/3712 1 F Freycinet a CHD 
2 982000123211124 13/3683 3 F Freycinet a CHD 
3 982009104963600 13/3680 4 M Freycinet a CHD 
4 982009104860765 13/3713 4 M Freycinet a CHD 
5 982000123130282 13/3716 2 M Freycinet a CHD 
6 982009105111670 09/4200 3 F West Pencil Pine b CHD 
7 982009105849999 09/3957 2 M Tullah b CHD 
8 985154000001063 09/1051 1 M Cressy c CHD 
9 982009104269684 08/1805 2 M Narawntapu b CHDD 
10 982009106039877 10/0156 2 M Dunalley b CHDD 
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11 982009104236464 08/0798 1 F Taroona c CHDD 
12 982009104357109 09/2009 4 F Fern Tree c CHDD 
13 985154000001151 09/0451 <1 M Mt Pleasant d CHJD 
14 985154000001142 09/0449 <1 F Mt Pleasant d CHJD 
15 985154000001130 09/0448 <1 M Mt Pleasant d CHJD 
16 982009104841875 12/2065 6 F West Pencil Pine b DFT1 
17 982009106034139 11/0767 2 F Dunalley b DFT1 
18 982009104719592 12/0820 4 F West Pencil Pine b DFT1 
19 982000000122095 12/2095 2 F Upper Natone b DFT1 
20 982000123128645 11/3917 2 M Hamilton b DFT1 
21 982000123216973 11/3918 1 F Hamilton b DFT1 
22 982000123209814 11/4493 2 M Waratah b DFT1 
23 000000000130406 13/0406 2 F Mangalore b DFT1 
24 NC 11/0650 7 F Mole Creek c CL 
25 985120016024404 11/4290 8 F Mt Pleasant c CL 
26 982009106314654 10/4001 8 M Taranna c CL 
27 982009106585887 10/3765 5 F Calder b CL 
28 982009104789818 14/0034 6 F Cressy c CL 
29 NC 08/4048 4 F Circular Head b CL 
30 982009100786171 09/0402 6 F Mt Pleasant c CL 
31 982009101694833 10/1013 6 F Richmond c CL 
32 982009104910854 13/0518 6 F Cressy c CL 
33 NC 09/3035 5 F South Riana b CL 
34 NC 11/1615 6 F Mole Creek c CL 
35 982009104873582 13/3714 4 F Freycineta CL* 
NC not microchipped, CHD clinically healthy devil, CHDD clinically healthy devil with dermatopathy, CHJD clinically 
healthy juvenile devil, DFT1 devil facial tumour 1, CL cutaneous lymphoma, a Free range enclosure, b Wild devil, c 





5.3.2 Tasmanian devil serum sample and collection 
 
Bloods from Tasmanian devils (Table 5) were collected by wildlife veterinarians through 
jugular venepuncture, whilst the animals were restrained by a trained field officer. Ten millilitres 
of blood was collected in sterile serum separation tubes, stored on ice for transport to the 
laboratories, centrifuged and serum removed for archival storage at -20oC.  
Serum samples were retrieved from the frozen archive and thawed at room temperature 
immediately before analysis. 
 
 
5.3.3 ERBB3 ELISA assay 
 
Serum ERBB3 levels were measured using the RayBio anti-human ERBB3 ELISA Kit (Enzyme 
linked immunosorbent assay, ELH-ERBB3, RayBiotech Inc, GA, USA) according to manufacturer’s 
instructions. Briefly, serum samples were diluted 1/5 in Assay Diluent A and 100 uL of standard or 
diluted sample were added in duplicate to wells of a 96 well assay plate and incubated for 24 hrs 
at 4oC. The supernatant was removed and wells were washed 4 times with 300 uL of 1X wash 
solution using an Immunowash 1575 (BioRad Laboratories, CA, USA). One hundred microliters of 
prepared biotinylated anti-ERBB3 was added to each well and the assay plate incubated for 1 hour 
at room temperature. The assay plate was washed as described after which 100 uL of prepared 
HRP-streptavadin conjugate was added to each well and the assay plate incubated for 45 minutes 
at RT. The assay plate was again washed as described and 100 uL of TMP substrate was added and 
the plate incubated for 30 minutes at room temperature in the dark, after which 50 uL of stop 
reagent was added to each well. The absorbance of each well was measured at 450 nm using a 




5.3.4 Data analysis 
 
The ELISA standard curve was plotted using Prism v5 (GraphPad, CA, USA) and results for 
each serum interpolated and corrected for dilution. The significance of differences in serum ERBB3 
between groups was determined using a Kruskal-Wallis test with Dunn’s Multiple Comparison 
utilizing Prism v5 (GraphPad, CA, USA).  
5.3.5 ERBB3 immunohistochemistry 
 
Figure 37: Human and Tasmanian devil sequence alignment for ERBB3. 
Reference figure: Ensembl gene browser https://www.ensembl.org/ 
 
Monoclonal rabbit anti-human ERBB3 (Abcam, clone SP71, ab93739, internal region, depicted in 
figure 37 human Tasmanian devil ERBB3 sequence alignment below) was diluted 1:50 with 





5.4 Results  
 
5.4.1 Histology and Immunohistochemistry  
 
DFT1 histology (figure 38A) and Haematoxylin and Eosin demonstrates small round cells 
with indistinct cell membranes arranged in cords and packets. ERBB3 IHC on average revealed 
moderate to strong expression in 75% of cells in both primary and secondary DFT1 tumours in 
cytogenetically determined strains 1 to 5 of DFT1. Typical granular cytoplasmic expression (figure 
38B) demonstrated by DFT1 strain 3 cells with small and large aggregates noted. Higher 
magnification (figure 38C) shows accumulation in and around vacuolar structures within the 
cytoplasm. In sections of devil skin and subcutaneous (figure 38E), peripheral nerve was seldom 
positive for ERBB3 (red arrow) in keeping with downregulation of ERBB3 in the adult in contrast to 
DFT1 ERBB3 expression (black arrow). ERBB3 expression was noted in Tasmanian devil lymphoid 
follicle (figure 38F) where cytoplasmic expression of ERBB3 is present in both T (germinal centre) 
and B (mantle) cells. Devils with CL were not included in the ERBB3 immunohistochemical staining. 
Trigeminal nerve section (figure 38I) showed ERBB3 expression in nerve bodies (black arrow) and 
occasional ERBB3 expression in the adaxonal area (red arrows) but generally, small myelinated 
nerves were negative. Positive control included devil bowel (figure 38G) which exhibited a similar 
expression pattern to human ERBB3 and negative controls DFT1 (figure 38D), bowel (figure 38H) 
and Trigeminal nerve (figure 38J). The monoclonal rabbit anti-human ERBB3 clone SP71 is a synthetic 
peptide corresponding to an internal sequence of Human ERBB3. Although the exact sequence is a 
proprietary secret ERBB3 sequence alignment between human and Tasmanian devil in this region 






Figure 38: DFT1 staining and skin manifestation. 
A Haematoxylin and Eosin stained DFT1 x40, B ERBB3 Immunohistochemical expression in DFT1 strain 3 
x40, C ERBB3 immunohistochemical expression in DFT1 strain 3 x100, D DFT1 negative control, E Tasmanian 
devil skin and subcutis section with peripheral nerve (red arrow) and DFT1 (black arrow) x10, F Tasmanian 
devil lymph node ERBB3 expression lymphoid follicle x20, G Tasmanian devil bowel ERBB3 positive control 
x40, H ERBB3 IHC negative control bowel, I trigeminal nerve shows ERBB3 positive nerve body (black arrow) 
and occasional adaxonal ERBB3 positivity (red arrows) x40, J ERBB3 IHC negative control trigeminal nerve, K 
Tasmanian Devil gross appearance of DFT1. Photo credit: DPIPWE archive, L Tasmanian devil gross 








5.4.2 Serum ERBB3 in Tasmanian devils 
 
Serum ERBB3 levels are shown in Table 6 and graphically in figure 39. Serum ERBB3 in the Fifteen 
Tasmanian devils without neoplasia (devils 1-15 includes CHD, CHDD and CHJD) ranged from <30-
663 pg/ml with a median of 32 pg/mL (30 – 220; interquartile range). Serum ERBB3 levels in the 
eight Tasmanian devils (devils 16-23) with clinical DFT1 ranged from 766-18,254 pg/ml with 
median of 3051 pg/mL (1060 – 10879; interquartile range. In the twelve Tasmanian devils with 
cutaneous lymphoma (devils 24-35) serum ERBB3 levels ranged from <30-20,021 pg/ml with a 





Figure 39: Serum ERBB3 levels in Tasmanian devils.  
Serum ERBB3 levels were measured by ELISA in clinically healthy Tasmanian devils CHD (n=11), clinically healthy 
Tasmanian devils with dermatopathy CHDD (n=4), clinically diagnosed DFT1 (n=8) and those with cutaneous 
lymphoma CL (n=12). Horizontal dashed line indicates the limit of detection of the ELISA assay at 30 pg/mL. Results of 
individual devils are shown with the median and interquartile range identified by the whiskers. Significance testing 






5.6.1 ERBB3 in devils without DFT1  
 
Fifteen Tasmanian devils without neoplasia (twelve adults either wild caught, free range or 
from captive enclosures and three captive juveniles encompassing CHD, CHDD and CHJD) were 
studied with an average serum ERBB3 of 32 pg/ml. Collectively, CHD Tasmanian devils serum 
ERBB3 levels ranged from <30-663 pg/ml which could be considered representative of the 
reference range for Tasmanian devils. Wild caught devils 6 and 7 were unremarkable and had 
serum ERBB3 levels <30 pg/ml however devil 9 (220 pg/ml) and devil 10 (92 pg/ml) both recorded 
skin abscesses. The ERBB3 levels in the CHDD group (devils 9, 10, 11 and 12) ranged from <30-220 
pg/ml all had a small isolated dermatopathy such as abscess (devil 9), pyogranuloma (devil 10), 
skin tag with associated inflammation (devil 11) and small focus of dermatitis (devil 12) all 
recorded a low serum ERBB3 levels of <92 pg/ml. The CHJD (devils 13, 14 and 15) approximately 
10 months old had an unremarkable clinical history that indicated serum was collected for a health 
check only, reflected in the low serum ERBB3 level of <30 pg/ml. 
Further assessment of data and clinical history (Table 6) revealed that four out of five Tasmanian 
devils from the Freycinet free range enclosure (devils 1-5) had higher serum ERBB3 ranging from 
155-663 pg/ml compared to most other clinically healthy devils having serum ERBB3 levels <30 
pg/ml. The Freycinet free range enclosure (FRE) consists of a 22 Hectare natural reserve that 
creates living conditions that are more similar to the wild than traditional captive conditions. The 
structure is fenced completely enclosing an insurance population of healthy devils with density 
capped to approximately one devil per hectare. This type of enclosure allows devils the 
opportunity to compete at feeding and breeding times and bite wounds are therefore common 
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(David Schaap, personal communication). In contrast, captive devils are housed in small enclosures 














clinical history BCS, 0-5 DFT1 
strain 
DFT1 1o No 
range, cm 
Mets No 
1 155 N/A 1 CHD, NAD     
2 663 N/A 1 CHD, Localised alopecia      
3 207 OW 1 CHD, Multiple 
punctures  
    
4 313 N/A 1 CHD, Multiple 
punctures  
    
5 291 N/A 1 CHD, Multiple minor 
wounds  
    
6 <30 N/A 1 CHD, Few wounds, 
lactating 
    
7 <30 N/A 2 CHD, N/A     
8 <30 6 1 CHD, Great condition     
9 220 10.5 1 CHDD, Abscess/scab on 
face 
    
10 92 N/A 2 CHDD, Abscess left 
neck. 
    
11 <30 4.7 1 CHDD, Skin tag on left 
ear 
    
12 <30 N/A 1 CHDD, Dermatitis upper 
flank 
    
13 <30 4.2 1 CHJD, Health check     
14 32 3.4 1 CHJD, Health check     
15 <30 4.6 1 CHJD, Health check.     
16 18,254 N/A 1 DFT1, weak 2 2 2 (1.0-2.5)  3 
17 999 6.1 3 DFT1, Reared 4 young 2 3 4 (1.0-1.5) 5 
18 11,090 4.8 1 DFT1, Poor body 
condition 
1-2 1 4 (2.0-3.0) 1 
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19 1903 3.7 1 DFT1, Emaciated 
disorientated 
0 1 2 (1.6-5.2) 10 
20 10,247 10 3 DFT1, Multiple lesions 3 2 4 (1.0-2.0) 2 
21 1241 5 3 DFT1, Poor body 
condition 
2.5 2 3 (1.0-1.5) 1 
22 4198 9.3 4 DFT1, Advanced DFT1 2 4 7 (1.0-2.5) 0 
23 766 N/A 1 DFT1, Emaciated 2 1 7 (1.0-4.7) 1 
24 4383 6.7 1 CL, Generalised 
alopecia 
N/A    
25 <30 8.2 1 CL, cutaneous plaques 
chest 
N/A    
26 <30 8.0 1 CL, percutaneous 
plaque  
N/A    
27 2008 5.9 1 CL, Skin lesions N/A    
28 837 5.9 1 CL, Alopecia  Poor    
29 9703 5.3 1 CL, Generalised 
alopecia  
Poor    
30 2403 8.2 1 CL, Alopecia ventrally  N/A    
31 536 7.4 1 CL, Alopecia left neck, 
pouch 
N/A    
32 962 6.7 1 CL, Alopecia ventrally N/A    
33 11,837 5.4 1 CL, Widespread 
alopecia 
1-2    
34 207 5.7 1 CL, Multifocal 
dermatitis, cutaneous 
lump (acanthoma) 
Poor    
35 20,021 N/A 1 CL, Multifocal alopecia  N/A    
 
N/A not available, NAD no abnormality detected, OW over weight, BCS - body condition score, DFT1 strain 
–cytogenetically determined strain, DFT1 1o No – number and size of primary tumours recorded, Mets No - 
number of metastasis recorded, CHD clinically healthy devil, CHDD clinically healthy devil with 




We noted that skin injuries were commonly recorded although no abnormality was noted 
for devil 1, alopecia bilaterally around the hind limbs and flank was present on one mother due to 
her 3 pouch young (devil 2) and multiple puncture wounds were present on the remainder (devils 
3, 4 and 5). Given that these devils were otherwise clinically healthy it would suggest that skin 
wounds caused by biting may contribute to some elevation in the serum ERBB3 of Tasmanian 
devils. There is also the possibility that simply being a Tasmanian devil living in a free range 
enclosure as opposed to wild populations may in itself be contributory to elevation in serum 
ERBB3 due to more frequent devil-devil engagement. Our results indicate that Tasmanian devils 
without injuries or an isolated skin lesion have serum ERBB3 levels <30 pg/ml whereas Tasmanian 
devils with multiple injuries or large abscesses have serum ERBB3 levels ranging from 92-663 
pg/ml. Together, these results suggest that cancer-free Tasmanian devils have a serum ERBB3 
range of <30-663 pg/ml. 
 
5.6.2 ERBB3 in devils with DFT1 
 
All devils with DFT1 were wild caught and all subjected to field autopsy with most serum 
samples reaching the laboratory within one to three days. We assessed the available clinical 
history (Table 6) including animal weight, body condition score (BCS 1-5) where 1=emaciated, 
2=moderately thin, 3=average, 4= good and 5=obese (Sarah Peck, personal communication), as 
well as number of primary and metastatic DFT1’s and cytogenetic strain ensuring the 
consideration of any factors that may contribute to the ERBB3 range in DFT1 affected Tasmanian 
devils. No correlation was established between levels of ERBB3 and extent of DFT1 when 
comparing the number and size of primary DFT1 lesions and any metastatic disease (table 6). For 
example, the devil with the highest serum ERBB3 of 18,254 pg/ml (devil 16), had 2 primary lesions 
with 3 metastases whereas the lowest serum ERBB3 of 766 pg/ml (devil 23) had seven primary 
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DFT1 lesions and one metastasis. No correlation was established between serum ERBB3 levels and 
the BCS as most were low (BCS 1-2) with only one devil (devil 20) having a BCS of three out of five, 
indicating average body condition. Cytogenetic strain did not appear to correlate to serum ERBB3 
levels and reflects the immunohistochemical findings that ERBB3 expression was present in all 
cytogenetic strains of DFT1. Our results indicate that Tasmanian devils with DFT1 have elevated 
serum ERBB3 levels compared to clinically healthy Tasmanian devils ranging from 766-18,254 
pg/ml and that the extent of DFT1 does not readily correlate directly with the serum ERBB3 levels. 
Further investigations beyond the pilot study encompassing a larger study group of Tasmanian 
devils with advanced DFT1 and metastases would be necessary to establish any relationship with 
serum ERBB3 and the extent of DFT1. 
 
5.6.3 ERBB3 in devils with cutaneous lymphoma 
 
We included Tasmanian devils with cutaneous lymphoma (CL) in the study for two reasons.  
Firstly, they were non-DFT1 devils with a severe skin condition that can affect the facial regions 
and secondly, the disease presentation of alopecia, excoriation and thickened plaques is distinct 
from DFT1 (figs 38E and 38F). Our results revealed that some Tasmanian devils with CL had 
elevated serum ERBB3 levels, a result that was most unexpected. Although ERBB3 
immunohistochemistry on Tasmanian devils with CL was beyond the scope of this research, ERBB3 
Immunohistochemical staining of Tasmanian devil lymph node (fig. 38D) did reveal ERBB3 
expression in the lymphoid follicle where cytoplasmic expression of ERBB3 is present in both T 
(germinal centre) and B (mantle) cells. CL devils were in the older age bracket ranging from 4-8 
years where the maximum age of a wild devil would be considered 5-6 years (Sarah Peck, personal 
communication). Bodyweights ranging from 5.4-8.2 Kg compared to the mean weight of 6.6Kg for 
female and 8.3Kg for male (531) shows possible female underweight wild devils and overweight 
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captive devils.  Age or weight did not appear to correlate with the broad range of serum ERBB3 of 
30-20,021 pg/ml. interestingly, 11 of the 12 devils with CL were female. We noted that devils with 
widespread alopecia (devils 24, 29, 33 and 35), did exhibit increased serum ERBB3 levels ranging 
from 4383-20,021 pg/ml, suggesting that the severity of CL manifesting clinically as widespread 
alopecia may contribute to increased serum ERBB3 levels. Together, the elevated serum ERBB3 
results in devils with CL is unlikely to cause confusion with DFT1 as CL tends to affects devils in the 
older age group and the clinical signs of CL are also distinct from DFT1 in established disease. 
Additionally, if elevated serum ERBB3 levels in Tasmanian devils indicative of CL could be 
established (pre-clinical) this would improve the healthy captive breeding populations of 
Tasmanian devils to ensure survival of the species by excluding these devils from this program. 
 
5.6.4 Potential source of serum ERBB3 
 
The capture and detection of antibody in our ELISA assay is selective for the extracellular 
domain (ECD) of transmembrane ERBB3 in serum or plasma, thus that ERBB3’s ECD is cleaved and 
shed from the plasma membrane would be a natural assumption. In contrast the ERBB3 receptor 
is internalised, although very slowly, for negative regulation and inactivation (457-461) utilising 
pathways such as caveolin or micropinocytosis and clathrin-and caveolin independent pathways 
(462, 463). ERBB3 has also been shown to be endocytosed independent of phosphorylation and 
without ligand in clathrin-dependent manner (468). ERBB3 is degraded by proteasomes catalysed 
by two E3 ubiquitin ligases; NRDP1 (464), now known as RNF41 (465-467), and NEDD4 (471) that 
regulate steady-state ERBB3 levels influencing NRG1 signalling.  
Defective internalisation, recycling and degradation of cell surface proteins and ligands is 
an emerging feature of cancer (472). It is therefore conceivable that DFT1 is subjected to the same 
dysregulation and inefficient degradation and recycling resulting in over expression of ERBB3 
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receptor at the plasma membrane and subsequent detectable levels of serum ERBB3. While 
dysregulated endocytosis, deregulation and recycling may theoretically account for excess ERBB3 
ECD detectable in serum, secreted isoforms of ERBB3 must also be considered as an alternative 
explanation for the presence of excess ERBB3.  
As well as functional transmembrane forms, secreted soluble forms of Epidermal Growth 
Factor Receptors have been well documented for ERBB1 (532-535), ERBB2 (536-539) and ERBB4 
(540-542). Alternative transcripts for ERBB3 resulting in naturally occurring soluble truncated 
isoforms including a 1.4 kb transcript of ERBB3 in gastric cancer cell lines (484) and an additional 
four novel transcripts (1.6, 1.7, 2.1, and 2.3kb) from ovarian cancer cell lines (487) encouraged 
researchers to identify these secreted isoforms of ERBB3 in prostate (489-492), liver (493), breast 
(486, 494) and squamous cell carcinoma (485). ERBB3 isoforms have also been expressed 
intracellularly in breast cancer cell lines (486) as well as in the nucleus of Schwann cells (475, 476), 
prostate (477-479) and breast (474, 482). Secreted ERBB3 isoform p85 has been shown to inhibit 
the action of its ligand Neuregulin (488, 494), nuclear translocations act as co-transcriptional 
activators (480), possible post-translation modification and the tumour microenvironment are 
instructive to serum ERBB3 secretion from the cell (493) and functions yet to be determined.  
The antigenic peptide used for this assay is located within the N-terminal domain of the 
full-length ERBB3 protein. Full length ERBB3 translates into a 180 kDa protein whereas ERBB3 
transcripts, created by intron read through and alternative polyadenylation signals result in serum 
ERBB3 isoforms translating into various proteins ranging in size from 22-75 kDa (543). Secreted 
isoforms such as ERBB3-S (1.4kb, 140aa homologous to the N terminus and a 43aa unique carboxy 
terminal sequence) equates to approximately half of domain I, p50 (1.6kb, 351aa homologous to 
the N terminus and a 30aa unique carboxy terminal sequence) equates to domain I, II and some of 
domain III,  p45 (1.7kb, 310aa homologous to the N terminus and a 2aa unique carboxy terminal 
sequence) equates to domain I, II and some of domain III, p85 (2.1kb, 519aa homologous to the N 
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terminus and a 24aa unique carboxy terminal sequence) equates to domain I, II,III and some of 
domain IV,  p75 (2.3kb, 474aa homologous to the N terminus and a 41aa unique carboxy terminal 
sequence) equates to domain I, II and III (484, 487, 543) ERBB3 isoforms have been detected by a 
number of methods such as immunoprecipitation (486-488), immunohistochemistry (489) and 
ELISA (491-493). Isoforms that have been detected using ELISA assays include p45 sERBB3 utilising 
a capture antibody of sequence aa20-643 (detection antibody sequence was not recorded) (491, 
492) and 40-50kDa secreted isoforms (possible p45/p50) utilising  both capture and detection 
antibodies with a sequence aa20-643 (493). The Raybio ELISA kit utilised in our research uses a 
capture and detection antibody of sequence aa20-643 (personal communication Raybio) which 
accounts for most of the extracellular domain of ERBB3 and therefore would be able to capture 
and detect both truncated isoforms as well as the transmembrane ERBB3.  
The correlation of serum levels with disease severity and progression would be the 
foundation of a good biomarker (493) as well; the expected biomarker should be in excess when 
compared to clinically healthy individuals (532) or possess additional qualities such as theranostic 
and tertiary prevention (535). The use of serum ERBB’s as an indicator of human cancer appears 
useful however, its prognostic and theranostic value remains controversial and continued 
investigations will be required (485, 489-493, 532-542). The development of a diagnostic test for 
preclinical DFT1 would assist in the field operations if individuals could be identified before they 
become infectious (72), therefore application of serum ERBB3 as a diagnostic biomarker of DFT1 
has great potential. The simplicity of the ELISA Serum ERBB3 methodology is easily incorporated 
into routine batch testing or rapid turnaround of results for urgent cases if required. Our research 
suggests that serum ERBB3 can be used as a biomarker for DFT1 and CL irrespective of 
transmembrane or truncated forms being detected in the serum of affected animals and therefore 





5.6.5 ERBB3 and cancer 
 
Overexpression of ERBB2 and ERBB3 had been documented early (439, 517, 518) but cooperation 
of both ERBB2 and ERBB3 in neoplastic transformation was recognised by Alimandi et al. (519) in 
mammary carcinoma cell lines, supported by additional research from Seigel et al. (520) Olayioye 
et al. (431) and  Holbro et al. (521). As mentioned above ERBB3 was initially regarded as kinase 
deficient and that ERBB2, an orphan receptor, engage in heterodimerisation as a necessity for 
transactivation of the ERBB3 downstream signalling pathways PI3K and MAPK controlling gene 
expression, cell differentiation, proliferation, survival and apoptosis. Recently ERBB3 was 
confirmed as capable of allosterically activating other ERBB family members founding new interest 
in a receptor whose function was considered passive and clinical value greatly underestimated 
(reviewed in (544).  
 
The normal spatial arrangement of RTK’s is deregulated if both the cell polarity and cell-cell 
junctions are disturbed through loss of polarity and contact-dependent inhibition of proliferation 
due to gene amplification or overexpression in cancer. This deregulation can increases surface 
concentration and distribution, clustering and dimer formation and signalling (545). Yang et al. 
(546) found ERBB3 formed large clusters in breast cancer cell lines when treated with NRG. These 
complexes formed slowly and contained no visible clathrin structures consistent with slow 
internalisation. In addition, studies on Chinese hamster ovary cell line (CHO) revealed ERBB1-3 
cluster individually implicating that segregation is a possible mechanism by which ERBB family 
members limit heterodimerisation. A similar finding by park et al. (547) utilising Aptamers 
demonstrated receptor clustering of ERBB3 in MCF7 breast cancer cell line, that ERBB3 are 
apparently segregated from ERBB2 in their resting state and that both ligand activated ERBB3 and 
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ERBB2 do not share the same topography as inactive ERBB3. A decreased level of spatial 
sequestration of ERBB3 in MCF7 (excess ERBB2) cells may then encourage heterodimerisation. 
Recently Littlefield et al. (548) studied the heterodimeric structure of EGFR/ERBB3 revealing 
ERBB3 an allosteric activator of EGFR, and further, that the ERBB3 mutations associated with 
cancer where the protein-protein interface is altered actually enhanced the allosteric potential. 
 
Although ERBB3 is amplified or overexpressed in some cancers and oncogenic mutations had been 
reported, Jaiswal et al. (525) identified approximately 11% of colonic, 12% gastric, 1% of non-small 
cell lung cancer (NSCLC) adenocarcinoma and 1% of NSCLC (squamous) cancers had somatic 
mutations but their oncogenic activity was dependent on kinase active ERBB2. Most of the 
mutations identified clustered in the ECD region (eg V104) although some mapped to the kinase 
domain (EG Q809R) or intracellular domain of ERBB3. It was noted that most ECD mutations were 
oncogenic in the absence of ERBB3 ligand NRG1, but could be stimulated by addition of NRG1, in 
contrast G284R (ECD) and Q809R (KD) appeared to be less sensitive to ligand–mediated activation. 
Residues were mostly conserved across the orthologues indicating they may have a functional 
effect. Choi et al. (549) also found that the mutant V104 in exon 3 was also particularly related to 
gastric cancer and colorectal cancer and was not found in other cancers and an associated 
increased in the immunohistochemical expression of ERBB3 in the cancers with the mutation was 
observed. Gastric tumours that express ERBB2 and ERBB3 is a predictor of poor survival (550). 
Vaught et al. (522) showed that loss of ERBB3 prevents the progressive transformation of ERBB2 
over expressing mouse model breast carcinomas suggesting that ERBB3 promotes tumour 






5.6.6 Schwann cell neoplasms 
 
ERBB3 is crucial to the sequential transition from precursor to immature and finally mature 
Schwann cells where ERBB3 is down-regulated as myelination proceeds (495). The adult peripheral 
nervous system requires maintenance when injured and the NRG1/ERBB system is crucial to 
Schwann cell dedifferentiation, proliferation, and subsequent regeneration and remyelination 
where ERBB3 and NRG1 is upregulated and only switched off after axon regeneration illustrating 
the plasticity of the Schwann cell (279, 516, 551). Peripheral nerve sheath tumours [neurofibroma, 
malignant peripheral nerve sheath tumours (MPNST)] and schwannoma arise from the Schwann 
cell lineage and can be genetically characterised as Neurofibromas (either dermal or plexiform) 
and MPNST’s [Neurofibromatosis 1 (NF1)], or Schwannomas [Neurofibromatosis 2 (NF2)], 
Schwannomatosis and Carney complex type 1. Although distinct characterisation of these complex 
diseases is possible, frequent overlapping features make diagnosis difficult and must also include 
other tumours with a Schwannian component such as Neuroblastic and Granular Cell Tumours 
[reviewed in (552-556)]. Veterinary Schwann cell neoplasms have been recorded (557-561) 
although ERBB3 expression in Schwann cell neoplasia has not previously been reported in 
veterinary literature. ERBB3 receptor has been expressed in human Schwann cell neoplasms 
including neurofibroma, MPNST, Schwannoma, neuroblastic (281, 562) and ganglioneuroma (GN) 
tumours (563). Interestingly, the down regulation of MHC class 1 and 2 molecules in a MPNST cell 
line (564) contrasting normal expression (565, 566) may indeed be similar to the MHC class 1 
downregulation of DFT1 (43, 411, 567) resulting in defective antigen processing and presentation 






5.6.7 ERBB family targeting therapeutics 
 
The ERBB3 receptor has been identified in tumours in early studies. ERBB3 mRNA was detected in 
breast cancer cell lines (439) and overexpression of the receptor protein demonstrated by 
immunohistochemistry (518) was positively associated with node metastasis but not on patient 
survival. A subsequent study of NSCLC found that high ERBB3 expression was associated with 
shorter survival times in advanced NSCLC (stage III and IV) with squamous cell carcinoma most 
frequently observed followed by adenocarcinoma  and large cell carcinoma (568). Reschke et al. 
(524) showed that ERBB3 is upregulated in melanoma and its metastasis that correlated to 
decreased patient survival.  Early studies reveal ERBB3 as a potential oncogene with 
overexpression due to possible increased transcription as no gene amplification was observed 
(523, 524) indicating either ERBB3 or its downstream components should represent a potential 
target for therapy (526). ERBB3 has long been considered kinase impaired (436) and therefore, 
therapeutically, it has not been considered a primary target, particularly in breast cancer. Tanner 
et al. (569) reported that ERBB3 expression was associated with decreased survival in ovarian 
cancer despite only a fraction of tumours expressing ERBB2 indicating the importance of ERBB3.  
The use of tyrosine kinase inhibitors (TKI’s) such as gefitinib and erlotinib has been effective at 
inhibiting phosphorylation of ERBB1 and ERBB2 in breast tumours but not as effective in 
decreasing the advancement of the tumour due to communication with other ERBB family dimers, 
particularly transphosphorylation of ERBB3 and subsequent signalling through PI3K/AKT pathway 
(570). A multiscale modelling approach by Telesco et al. (571) to explore ERBB3 signalling and TKI 
resistance supported that ERBB3 was a weakly active kinase and this activity could be enough to 
induce AKT signalling and TKI resistance. to Liu et al. (572)  recognised potency of the 
ERBB2/ERBB3 heterodimer and showed that ERBB3 modulates ERBB2 and tomoxifen resistance 
and siRNA decreased levels of ERBB3 restored tomoxifen sensitivity, again illustrating the 
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importance of ERBB3 as a target for therapy.  The use of small interfering RNA (siRNA) proved 
successful by Sithanandam et al. (573) treating lung adenocarcinoma cells (H441, H1373 and A549) 
with siRNA directed at different regions of ERBB3 substantially suppressed expression of ERBB3. 
This raises the possibility of considering siRNA in a therapeutic approach. The central role that 
ERBB3 plays in ERBB2 amplified breast cancer was demonstrated by Lee-Hoeflich et al. (574) 
utilising siRNA/shRNA knockdown of ERBB3 in BT474M1 and MDA-MB-75 xenografts subjected to 
combined treatment of trastuzumab (humanised monoclonal antibody directed at a segment of 
the ECD of ERBB2 ) and pertuzumab (humanised monoclonal antibody directed at domain II 
dimerization arm of the ECD of ERBB2 blocking dimersiation of ERBB2/ERBB3) lead to sustained 
tumour growth inhibition. The evidence above reinforces the co-dependence of ERBB family 
members to compensate through lateral signalling allowing ERBB3 to escape drug therapy and 
persist signalling despite suppression of ERBB1 and ERBB2 beckons ERBB3 to be deemed a suitable 
biomarker(421) and certain candidate for therapeutic targeting. Sheng et al. (575) found in a 
subset of primary and ovarian cancer cell lines had an NRG1 activated ERBB3 autocrine loop 
although activation may be independent in some. Experimental procedures using RNA 
interference (RNAi) of multiple siRNA/shRNA of NRG1 or ERBB3 resulted in decrease in 
proliferation indicating that ERBB3 directed therapy must be further evaluated.  
 
5.6.8 Cancer resistance: ERBB and other RTK families.  
 
Recognition of other RTK families that may interact with the ERBB family supporting 
carcinogenesis and contributing to drug resistance must be considered in therapeutic approaches, 
particularly insulin-like growth factor 1 receptor (IGF1R) and hepatocyte growth factor receptor or 
c-MET (MET) (576). Protein-protein interactions have been observed between IGF1R and ERBB2 in 
trastuzumab resistant breast cancer sub cell line SKBR3 (577) and IGF1R, ERBB2 and ERBB3 
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heterodimerisation was found in trastuzumab resistant breast cancer subline pool2 (SKBR3 
trastuzumab resistant subline) and HR20 subline (BT74 trastuzumab resistant subline) cells (578). 
In exploring resistance gefitinib and erlotinib, TKI’s used to treat NSCLC, Engelman et al. (579) 
found firstly in CHO cells (normally do not express ERBB1/ERBB2/ERBB3) that coexpression of 
ERBB3 and MET resulted in increased phosphorylation of ERBB3 and secondly, in four of eight 
EGFR mutant NSCLC that showed amplification of MET. Yun et al. (580) also reported 
immunohistochemical staining and co-immunoprecipitation assays that dimers of ERBB3/MET and 
ERBB3/ERBB2 were present in human gastric cancers among other dimers illustrating crosstalk 
within RTK’s. These articles communicate the necessity of drug regimens to include a wider 
application than just ERBB family of therapeutics to include RTK’s such as IGF1R and MET in drug 
resistant tumours. 
 
5.6.9 ERBB3 Therapeutics 
 
Resistance to therapeutic agents such as TKI’s (gefitinib and erlotinib - ERBB1 targeted and 
lapatininb - ERBB2 targeted) and monoclonal antibodies (cetuximab - ERBB1 targeted and 
trastuzumab and pertuzumab - ERBB2 targeted) has revealed escape mechanisms such as ERBB 
family crosstalk, cross talk with other RTK family members as well as up regulation of ERBB3 that 
contribute to ERBB1/2 resistance (581, 582).  The large body of evidence illustrates the key role 
ERBB3 plays in various tumours prompting research into therapeutic options targeting ERBB3, 
particularly over the last decade [reviewed in (420, 527, 583-591)]. To date no FDA approved 
treatment has emerged specifically for ERBB3 although several agents are either in pre-clinical 
testing or clinical trials. Current therapeutic agents in pre-clinical stages or clinical trials have been 




Table 7: ERBB3 therapeutic agents cited in literature. 












chain FV antibody 
 
ERBB2/ERBB3 2008 Pre-clinical Robinson et al.  (593) 
105.5 and 
2D1D12 
antibody ERBB3  2008 Pre-clinical Reschke et al. (524) 











ERBB2/ERBB3 2009 Phase 2 Huang et al. (595) 
MM-121 Monoclonal 
antibody 
ERBB3 ECD 2009 Phase 2 Schoeberl et al.  (596, 
597), Liles et al. (598) 










EBRR1/ERBB3 2011 Phase 2 Schaefer et al. (600) 
A3 and A4 Monoclonal 
antibody 
ERBB3 2012 Pre-clinical Belleudi et al.  (601) 
MM-111 Bispecific  ERBB2/ERBB3 2012 Phase 2 McDonagh et al.  (602) 
SL-175 and  
SL176 
Surrobody ERBB3 2012 Pre-clinical Foreman et al.  (603) 
SGP1 Monoclonal 
antibody 
ERBB3 ECD 2012 Pre-clinical Blackburn et al.  (604) 
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at domain I and III 
ERBB3 ECD 2013 Pre-clinical Lazrek et al.  (605) 
LJM716 Monoclonal 
antibody directed at 
domain II and IV 
ERBB3 ECD 2013 Phase1/2 Garner et al.  (606) 
EV20 Monoclonal 
antibody 
ERBB3 ECD 2013 Pre-clinical Sala et al.  (607) 
RG7116 Monoclonal 
antibody 
ERBB3 ECD 2013 Phase 1 Mirschberger (608) 




ERBB3 RNA  2013  Wu et al. (609) 
D1 and DIII 
(F4 and A5) 
Antibodies directed 
at domain I and III 
ERBB3 ECD 2014 Pre-clinical D’Souza et al.  (610) 
D1,D2,D3 Peptide mimic and 
Vaccine 





2014 Phase 2 Fitzgerald (612) 




2014 Pre-clinical Francis et al. (613) 
REGN1400 Monoclonal 
antibody 
ERBB3 ECD 2014 Phase 1 Zhang et al. (614) 
GSK2849330 Monoclonal 
antibody 
ERBB3 ECD 2014 Phase 1 Clarke et al (615) 
NG33 Mouse monoclonal ERBB3 ECD 2015 Pre-clinical Gaborit et al.  (616) 
KTN3379 Monoclonal 
antibody 
ERBB3 ECD 2015 Phase 1  Lee et al. (617) 
AV-203 Monoclonal 
antibody 
ERBB3 ECD 2015 Phase 1 Meetze et al. (618) 
DVD Ig bispecific duel 
variable domain 
immunoglobulin 
ERBB1/ERBB3 2015 Pre-clinical Gu et al.(619) 




ECD= extracellular domain, Current clinical trial status= status at clinicaltrials.gov 
 
5.6.10     ERBB3 as a therapeutic target 
 
Despite evidence for multiple resistance mechanisms for existing therapeutic targeting of ERBB1/2 
(570, 572, 573, 576-582, 621) numerous researchers have over the last decade explored the 
potential of ERBB3 as a therapeutic target [reviewed in (420, 527, 583-591)] using monoclonal 
antibodies (524, 592-594, 596, 597, 600-602, 604-608, 610, 612-619, 622-625), histone inhibitors 
(595),  TKI (599), surrobodies (603), locked nucleic acid (LNA)-based ERBB3 antisense 
oligonucleotide (ASO) (609), peptide mimics and vaccine (611), anti-anginal drug (620) and 
disulphide disrupting agent (626), shown in table 7. 
 
However, managing wildlife disease is considerably more difficult than human disease 
because of limited data, the effect of the disease on the host and the transmission of disease 
within a dynamic population makes it difficult to model (76). Previous efforts to eradicate DFT1 
from wild populations by selective culling has proven unsuccessful because of the frequency-
dependent transmission of DFT1 and the latency period (71, 72, 76). TKI’s as a therapeutic 
approach may be limited due primarily to the early observation that kinase region of ERBB3 had 
substantialy reduced activity, however cancer immunotherapy broadly categorised as passive 
(including monoclonal antibodies, Cytokines, adoptive cell transfer) or active (including 
therapeutic cancer vaccine, immune checkpoint inhibitors) remains optimistic (627-632). Many of 
these successful human immunotherapeutics hold similar promise in veterinary medicine (633-
635) however, drug administration to wild Tasmanian devils is very different from the clinical 
setting of human and companion animals and therefore treatments such as adoptive cell transfer 
would be difficult to implement.  The fact that DFT1 expresses tumour associated antigens (TAA’s) 
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such as ERBB3 invites the application of monoclonal antibodies and therapeutic cancer vaccines as 
prospective treatments. The passive administration of monoclonal antibodies to ERBB3 primarily 
focused on blocking receptor epitopes is still experimental (524, 592-594, 596, 597, 600-602, 604-
608, 610, 612-619, 622-625) and any humanised anti-ERBB3 would certainly have to be become 
species specific (devil anti-ERBB3) to prevent adverse immunologic reactions (636). Very few 
monoclonal antibodies have been developed in veterinary oncology although two caninised 
antibodies anti-ERBB1 (637) and anti-CD20 (638) show promise. Therapeutic cancer vaccination 
modalities applicable to wildlife include antigen delivery vaccines that utilise inactivated cancer 
cells (autologous or allogenic) or peptide vaccines that mimic antigen sequences. Conclusive 
results using an inactivated cancer cell vaccine trial (allogenic DFT1 cell line) are eagerly awaited. 
Confidence that immunisation can be successful stems from research showing that Tasmanian 
devils have a competent immune system (26, 28, 411, 639) and can produce cytotoxic antibodies 
(31, 32). An alternative antigen presentation modality to cancer cell vaccine is a peptide vaccine, 
where single or multiple amino acid sequences (long or short) representing a defined antigen is 
combined with adjuvant to elicit an immune response (640). Development of just a single ERBB3 
peptide vaccine can be found in the literature (611) however, peptide vaccines targeting ERBB1 
(641, 642), ERBB2 (643-645) or both ERBB1/2 (646) including a monoclonal antibody against 
tyrosine related protein 1 (TRP-1) and altered peptide sequence to gp100 for mouse melanoma 
(647) all show promise. Overcoming self-tolerance is a major hurdle. One such strategy is the use 
of Xenoantigens, that is the exact same antigen but from a different species that has considerable 
sequence homology, differing only by several amino acids which appear to the host as altered 
epitopes or as “altered self” and therefore tolerance can be broken causing a T-cell response 
against the endogenous self-antigen (648). Veterinary xenogeneic vaccinations include a DNA 
plasmid vaccine encoding human Tyrosinase (TYR) (649) the only veterinary therapeutic tumour 
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vaccine licensed by the United States Department of Agriculture (USDA) for the use of oral and 
digital melanoma, now marketed as OnceptTM.  
 
Recent investigations reveal that the tumour microenvironment of metastatic DFT1 
expressed PDL1 (programmed cell death 1 ligand 1/CD274/B7-H1) and DFT1 cell lines could 
upregulate PDL1 (650). Immune-suppressive tumour microenvironment created by tumour cells 
that escape ‘immunoediting’ allowing tumour growth and proliferation (651) where certain 
checkpoint pathways will be used advantageously by tumour cells to confer immune resistance 
(652). Hence, checkpoint blockades (monoclonal antibodies) targeting PDL1 and Cytotoxic T 
Lymphocyte Antigen 4 (CTLA-4) are now attractive therapeutical targets (653). Recent views 
consider cancer immunotherapy invaluable although a single treatment mode may be suitable for 
some cases, more combinatorial approach will be needed for others (654, 655).  
 
Our research has highlighted ERBB3 as a potential therapeutic target although treatment 
of Tasmanian devils with DFT1 with therapeutic regimes such as chemotherapy and radiotherapy 
are impractical. However, a combinatorial approach using therapeutic cancer vaccines including 
inactivated allogenic DFT1 cancer vaccine, ERBB3 monoclonal antibody, ERBB3 Peptide or 
xenogeneic vaccine in combination with anti-immune checkpoint blockade therapy would be 











ERBB3 had previously avoided scrutiny due to its kinase inactivity; however, ERBB3 has 
been the subject of intense investigation over the past decade and is now recognised as a potent 
partner of the epidermal growth receptor family. ERBB3 upregulation during developmental, 
dedifferentiation and regenerative processes encapsulates the Schwann cell’s inherent plasticity 
and imparts certain characteristics of malignant transformation advantageous to transmission of 
DFT1. Our pilot study has shown for the first time that ERBB3 is consistently expressed 
immunohistochemically and that ERBB3 is also elevated in the serum of Tasmanian devils with 
advanced DFT1 and cutaneous lymphoma.  Therefore, our research indicates that serum ERBB3 
has the potential to be employed as a biomarker of DFT1 or CL in Tasmanian devils to assist 
conservationists in the management and welfare of Tasmanian devils and species survival. The 
simplicity of the ELISA Serum ERBB3 methodology is easily incorporated into routine laboratory 
batch testing and equally applied to include rapid turnaround of results for urgent cases. Extension 
of this research is necessary to include greater numbers of healthy Tasmanian devils both with and 
without visible injuries, devils with large and small DFT1 lesions as well as pre-clinical DFT1. This 
will firmly establish the normal reference range for serum ERBB3 from which potential pre-clinical 
DFT1 may be identified. In addition, ERBB3 is now recognised as a therapeutic target and 
therefore the potential exists to consider modes of administration in addition to existing whole 
cell vaccination such as ERBB3 monoclonal antibody, peptide or xenogeneic vaccines including 
checkpoint inhibitors. A combinatorial immunotherapeutic approach will enhance cytotoxic 
destruction, provide long term immunity from DFT1 and therefore eradicate this transmissible 









The emergence of a second transmissible tumour is a completely unforeseen development in 
Tasmanian devil facial tumour research requiring immediate investigations to expose similar or 
different relationships to the original facial tumour, DFT1. As a result, I have collaborated with 
fellow Tasmanian devil researchers Ruth Pye, Max Stammnitz and Elizabeth Murchison providing 
histological and immunohistochemical support for their research papers. While DFT2 was not 
originally included in my candidature, DFT2 research is crucial to understanding transmissibility of 
both DFT1 and DFT2 and therefore, I have summarized our research below. 
6.1.1 A second transmissible cancer in Tasmanian devils 
 
The Channel area is a peninsula of approximately 550 km2 south of Hobart, adjacent to the 
D’Entrecasteaux channel. DFTD was first detected in this area in 2012 and since that time, five 
cases out of twelve from that area have been identified as non-classical DFTD. Although the 
external appearance of facial tumours were indistinguishable to DFTD, the histomorphology was 
not consistent with typical pleomorphic small round cells forming distinct bundles, cords or 
packets of DFTD (1). Two interesting cases in 2014 were examined by our research team and 
reported by Pye et al. (7) and in contrast to DFTD, these cases had pleomorphic sheets containing 
amorphic, stellate and fusiform cell types with the distinct bundles, cords or packets characteristic 
of DFTD noticeably absent. Immunohistochemical staining was performed using Periaxin (figure 
40), a Schwann cell marker, which is expressed by DFTD but was negative on these two unusual 
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facial tumours. At this early stage, the possibility that these two tumours either spontaneously 
arose from the hosts or they were derived from DFTD was still considered a possibility. Therefore, 
cytogenetic and genetic analysis was performed on these two tumours, three additional unusual 
tumours, as well as DFTD tumours from the Channel area. 
As previously discussed, the distinctive DFTD karyotype has both chromosome two homologs 
absent, one of the chromosome 5 homologs absent, both X sex chromosomes absent and the 
presence of four abnormal marker chromosomes. In contrast to DFTDs karyotype, the unusual 
tumour’s karyotype included additional material from chromosomes one, two and four, a deletion 
involving chromosome 5 and monosomy for chromosome six (figure 41). Both X and Y sex 
chromosomes were present. Of greatest significance was that all five tumours had the identical 
complex karyotype and therefore it was conceivable that they were derived from a single clone 
and for this reason we named the tumour DFT2, a second transmissible devil facial tumour. 
Previous investigations using fluorescent insitu hybridization had identified two X chromosome 
copies in DFT1 (19, 45) and further examination by Pye et al. (7) of 10 X chromosome variants all 
mapping to the X chromosome only, confirms that DFT1 carries two homologous X chromosomes 
and the tumour probably arose from a female devil originally. Because the DFT2 karyotype is 
completely different to DFT1, it carries a Y chromosome indicating the origin of DFT2 was from a 
male devil, and the fact that DFT2 is negative for Periaxin, together supports the conclusion that a 
single clonal origin of DFT1 and DFT2 is discordant. When the genotype of DFT1 and DFT2 were 
compared at nine polymorphic microsatellite loci, it was found that DFT1 tumours shared an 
identical genotype and DFT2 tumours also shared a different identical genotype which were both 
genetically distinct from the host’s genotype. Additionally we identified that DFT2 has a different 
MHC class I genotype than DFT1 and that this genotype is also distinct from the hosts genotype, so 
like DFT1, DFT2 is not restricted to hosts with an identical genotype to the tumour. Together, our 
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study indicates that DFT2 is a transmissible tumour that is distinct from DFT1, however both are 
indistinguishable when observing facial tumours grossly. This discovery of DFT2 certainly provides 
some insight into the vulnerabilities of the Tasmanian devil given this is the second transmissible 
tumour in the species within twenty-two years, with DFT2 appearing as recently as 2014. No 
obvious shared DNA was identified between DFT2 and DFT1 leaving reduced genetic diversity 
contributing to the probability of these two transmissible tumours.  
6.1.2 The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian 
Devils 
 
We further investigated and reported (8) on the functional and genetic characteristics of DFT1 and 
DFT2 in an attempt to elucidate any commonalities between the two transmissible tumours. Our 
panel of IHC (figure 43) showed similar characteristics with both DFT1 and DFT2, both being 
positive for S100, ENO2 and VIM and negative for SMA and CK. As previously reported, DFT1 is 
strongly positive for PRX (20) such that it is routinely used for a diagnostic marker; however, in 
contrast to DFT1, DFT2 is negative for PRX, providing an expressional distinction. Although the 
macroscopic appearance of the tumours might suggest that the cancer is from a comparable cell 
type, no expression of PRX and dissimilar histomorphology would suggest the tumours may be 
unrelated. Genotyping DFT1 and DFT2 at 320 nuclear polymorphic loci, and compared to previous 
data (84) found that DFT1 arose geographically in the North East of Tasmania Mt William area 
however, DFT2 arose in the south east Channel Peninsula area. Essentially, DFT1 and DFT2 appear 
to have emerged independently at separate locations. Investigation of exogenous pathogens such 
as viruses, mutational signatures and UV light in the genomes of DFT1, DFT2 and healthy devils did 
not provide any evidence of viral DNA, mutational signatures or UV light exposure (perhaps not 
surprising for a nocturnal marsupial). Identifying and annotating DFT1 and DFT2 founder 
individuals’ inherited germline single-nucleotide variant (SNV) and small insertion and deletion 
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(indel) alleles to characterise any somatic mutations. SNVs and indels were detected in both DFT1 
and DFT2 but none were confirmed in genes causative of cancer, however a DFT1 mutation in 
WWC family member 3 (WWC3) and a DFT2 mutation in multiple PDZ crumbs cell complex polarity 
complex component (MPDZ) genes may be early somatic mutations prior to clonal changes. 
Interestingly, both MPZD and WWC3 are purported to be negative regulators of YES associated 
protein 1 (YAP1) and WW domain containing transcription regulator 1 (TAZ) which are core 
effectors of the Hippo pathway. We performed immunohistochemistry for YAP1 and TAZ on DFT1 
and DFT2 finding both cytoplasmic and nuclear expression illustrating these transcriptional co-
activators are active shuttling between the cytoplasm and nucleus (Figure 43). This would suggest 
that the mutation in WWC3 and MPDZ genes may lead to ineffective regulation of YAP1 and TAZ. 
The insertion of the chromosome six homologue into the pericentric region of chromosome two, 
characteristic of DFT2, was shown by chromosome painting and FISH that chromosome six had a 
short telomere. Tasmanian devils have unusual telomeres characterized by extreme length 
dimorphism, a feature that is lost in DFT1 (52) and therefore, the possibility of unusual telomere 
length may predispose Tasmanian devils to the risk of chromosomal rearrangement (8). We tested 
copy number variants (CNVs) in DFT1 and DFT2, the majority of tumors being diploid. Among a 
number of findings was a gain in copy number of platelet derived growth factor α and β (PDGFA, 
PDGFB) in DFT2 and in some DFT1s extra-chromosomal DMs, correlated with strong 
immunohistochemical expression of both PDGFA and PDGFB in DFT1 and DFT2 (Figure 42). We 
also noted an increased copy number for Neuregulin-2 (NRG2) which is one ligand of ERBB3, which 
we have previously reported as expressing ERBB3 (47) with increased copy number (5). 
Interestingly, because DFT2 contains a Y chromosome it was noticed that of the now nine DFT2 
tumours identified  (85), seven were grafted into male hosts, one a female host and in the other 
female host the Y chromosome was not detected. It remains to be seen if female devil hosts 
provide DFT2 with some sort of immunological resistance. In wrapping up our research a number 
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of drugs were screened for the possibility of therapeutic agents. It was found that both DFT1 and 
DFT2 were sensitive to RTKs, particular DFT1 is sensitive to ERBB2 mediated Afatinib which is 
reassuring as our ERBB3 studies suggested a number of regimes that included the dimer 
ERBB2/ERBB3. DFT2 also showed sensitivity to Axitinib which is active against PDGFR and KIT 
which were both identified in this research, as described in chapter two of my thesis. In a recent 
publication Caldwell et al. (86) has found DFT2 expresses B2M and classical and non-classical MHC 
class I molecules which is contrary to DFT1 which has lost expression of MHC class I molecules. 
Results showed that expression of MHC class I alleles varied on DFT2 tumours with the highest 
expression of classic MHC-I allele also found present within host devils. This research by Caldwell 
et al. (86) suggests that loss of MHC is not necessary for tumour transmission because of varied 
expression; however, subclones may be selected upon transmission if they have downregulated 
MHC as the tumour encounters different devil’s immune systems. It is predicted that DFT2 is likely 
to be losing MHC antigens already and this could lead to widespread transmission throughout the 




6.2.1 Histology and immunohistochemistry 
 
Standard histologic, immunohistochemical and photographic methods were used as outlined in 
chapter 3.0 
 
6.2.2 Primary antibodies utilized for Immunohistochemistry 
 
Primary antibodies PRX, PDGFRB, VIM, NSE, S100, SMA and CK have been outlined in table 2 
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Additionally, Polyclonal rabbit anti-human PDGFRA 1:800 (Cat#ab124392, Abcam, Cambridge, UK), 
Monoclonal mouse anti-human YAP1 1:100 (Cat#WH0010413M1, Sigma-Aldrich) and Polyclonal 







Figure 40: DFT2 tumours are histologically distinct from DFT1.  
Representative images of H&E stained histological sections of DFT1 and DFT2 tumours (Upper and Middle). 
(Lower) Histological sections stained with DFT1 marker, PRX. Scale bars represent 200 μm (Upper) or 100 
μm (Middle and Lower). Arrows indicate peripheral nerve bundles, which are positive for PRX. Figure 







Figure 41: DFT2 tumours are cytogenetically distinct from DFT1.  
Representative karyotypes of a normal male devil, a DFT1 tumour, and four DFT2 tumours. Red arrows 
indicate chromosomes carrying cytogenetic abnormalities. Four marker chromosomes found in DFT1 (9) are 








Figure 42: (C) Copy number and immunohistochemistry for PDGFRA and PDGFRB.  
Reads mapping within 500 base pair genomic bins were counted and normalized; each dot represents log2R 
for a single bin, where R = (read count tumour)/(read count 203H). CN, copy number. Structural variants 
are represented by dashed gray lines connected by black lines. Genes are represented as black bars, and 
locations and orientations of PDGFRA and PDGFRB are shown. Brown stain reports expression, 
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counterstained with blue hematoxylin. Scale bar, 30 mm. Figure reference: Figure 4 Stammnitz et al. 2018 
(8) (appendix 6) 
 
 
Figure 43: Immunohistological comparisons of DFT1 and DFT2 
DFT1 (left), DFT2 (centre) and control (right) tissues stained with tissue lineage markers (Loh et al. 2006). 
PRX is included as a control (Pye et al., 2016 appendix 5). Scale bar, 30 μm. PRX, periaxin; VIM, vimentin; 
NSE, neural specific enolase; SMA, smooth muscle actin; YAP1 (bottom left panels), yes-associated protein 
1; TAZ/WWTR1 (bottom right panels), transcriptional coactivator with PDZ-binding motif/WW domain-
containing transcription regulator 1. Nuclear localization of YAP1 and TAZ/WWTR1 indicates 
dephosphorylated, active states of the proteins. Figure reference: Figure S1, related to Figure 1: 






6.4 Discussion  
 
The results and discussion are described in detail in the DFT2 Introduction 6.1, 6.1.1 and 6.1.2. 
 
7.0 Final comments and future directions. 
 
My research has comprehensively redefined the Immunophenotype of DFTD documenting the 
expression of 37 new and novel proteins not available in the current literature. My research 
expands on Schwann cell markers documented in current literature demonstrating the 
developmental stages of the Schwann cell lineage including precursor, immature, mature 
myelinating and non-myelinating Schwann cells. The expression of certain Schwann cell growth 
and transcription factors normally not expressed, suggests the activation of an autocrine repair 
program. Unexpectedly, my research demonstrated DFT1 expresses a melanocyte marker 
suggesting that DFT1 has divergent origins, a progenitor like cell with Schwann cell and 
melanocyte lineages with self-renewal characteristics. My research indicates that a progenitor-like 
state contributes to MHC down regulation, known in DFT1 cells, contributing to transmissibility of 
DFT1. I describe for the first time the histomorphology of the five strains of DFTD and extensively 
immunohistochemically stain these strains. I have described the expressional differences between 
strains and compared immunohistochemical expression with gene abundance data. The extensive 
literature presented above certainly advocates the remarkable plasticity of NCSCs and the 
Schwann cell and melanocyte lineages derived from them. Our results find that DFT1 is a 
progenitor-like cell, bipotent with both SC and melanocyte features, expressing repair 
transcription and growth factors with the acquisition of NCSC self-renewal properties. We theorise 
that the facial wound and resultant nerve injury would provide a perfect microenvironment, a 
niche, containing trophic signals necessary for migration, survival, proliferation and self-renewal of 
DFT1. The wound environment would be conducive to the genetic selection of a NC progenitor 
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with the molecular plasticity and MHC downregulation, causal to DFT1s clonal nature and 
transmissibility. I have prepared a manuscript ready for imminent submission of these research 
findings.  
 
My research published the first description of the expression of ERBB3 by DFTD and measurement 
of ERBB3 as a possible early detection and therapeutic approach to tumour treatment. ERBB3 
upregulation during developmental, dedifferentiation and regenerative processes encapsulates 
the Schwann cell’s inherent plasticity and imparts certain characteristics of malignant 
transformation advantageous to transmission of DFT1. My pilot study has shown for the first time 
that ERBB3 is consistently expressed immunohistochemically and that ERBB3 is also elevated in 
the serum of Tasmanian devils with advanced DFT1. I also first reported that cutaneous lymphoma 
expresses ERBB3 in cutaneous lymphoma in Tasmanian devils, useful to the scientific community, 
both animal and human. Therefore, my research indicates that serum ERBB3 has the potential to 
be employed as a biomarker of DFT1 or CL in Tasmanian devils to assist conservationists in the 
management and welfare of Tasmanian devils and species survival. My research has devised a 
simple ELISA Serum ERBB3 methodology that is easily incorporated into routine laboratory batch 
testing, equally applied to include rapid turnaround of results for urgent cases. 
My future directions include further studies on ERBB3, if determined by the STDP, extending this 
research is necessary to include greater numbers of healthy Tasmanian devils both with and 
without visible injuries, devils with large and small DFT1 lesions as well as pre-clinical DFT1. This 
will firmly establish the normal reference range for serum ERBB3 from which potential pre-clinical 
DFT1 may be identified. My research has specifically explored ERBB3, now recognised as a 
therapeutic target; therefore the potential exists to consider modes of administration. 
Additionally, quite a number of the unique proteins identified in my research can be targeted by 
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therapeutic monoclonal antibodies, another research project on its own. There will be ongoing 
research on DFT2 as directed by STDP, but monitoring any diffusion from the Channel Peninsula 
area as well as the pathobiology of both DFT1 and DFT2 will be a priority. From my current 
extensive research, I have a number of manuscripts in preparation including; DFT1 and the 
extracellular matrix, the latent period of DFT1 from exhaustive mining of the DPIPWE database 
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Abstract
Devil Facial Tumour 1 (DFT1) is one of two transmissible neoplasms of Tasmanian devils
(Sarcophilus harrisii) predominantly affecting their facial regions. DFT1’s cellular origin is
that of Schwann cell lineage where lesions are evident macroscopically late in the disease.
Conversely, the pre-clinical timeframe from cellular transmission to appearance of DFT1
remains uncertain demonstrating the importance of an effective pre-clinical biomarker.
We show that ERBB3, a marker expressed normally by the developing neural crest and
Schwann cells, is immunohistohemically expressed by DFT1, therefore the potential of
ERBB3 as a biomarker was explored. Under the hypothesis that serum ERBB3 levels may
increase as DFT1 invades local and distant tissues our pilot study determined serum
ERBB3 levels in normal Tasmanian devils and Tasmanian devils with DFT1. Compared to
the baseline serum ERBB3 levels in unaffected Tasmanian devils, Tasmanian devils with
DFT1 showed significant elevation of serum ERBB3 levels. Interestingly Tasmanian devils
with cutaneous lymphoma (CL) also showed elevation of serum ERBB3 levels when com-
pared to the baseline serum levels of Tasmanian devils without DFT1. Thus, elevated
serum ERBB3 levels in otherwise healthy looking devils could predict possible DFT1 or CL
in captive or wild devil populations and would have implications on the management, welfare
and survival of Tasmanian devils. ERBB3 is also a therapeutic target and therefore the
potential exists to consider modes of administration that may eradicate DFT1 from the wild.
Introduction
The Tasmanian devil (Sarcophilus harrisii) belongs to the Dasyuridae family, it is a carnivorous
marsupial that is extinct on mainland Australia and now found only on the island of Tasmania.
Superficial dermal cutaneous lesions of wild Tasmanian devils can be found commonly in the
form of skin sores [1] and neoplasia [2]. Spontaneous neoplasms in captive Tasmanian devils
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including squamous cell carcinoma of the lip and gingiva, dermal lymphosarcoma [3], trichoe-
pithelioma, papilloma and keratoacanthoma [4] and a single devil with multiple unrelated
tumours involving internal organs in combination with skin [5] have been recorded, sugges-
tive of potential metastasis. Similar observations were made while reviewing Dasyurid archival
material at the Australian Registry of Wildlife Health [6] and recently, two captive female dev-
ils with pruritus and dermatitis were diagnosed with cutaneous T-cell lymphoma [7]. None of
the recorded neoplastic superficial lesions found in captive or wild Tasmanian devils appeared
to mimic the firm, flattened centrally ulcerated soft tissue lesions of DFT1 affected Tasmanian
devils [8].
Although the first evidence of DFT1 in wild populations occurred in 1996 when several
Tasmanian devils were photographed by Christo Baars in the north east of the state with facial
lesions. However, a tissue diagnosis was not obtained until 2001 [9]. Review of Tasmanian
devil archival slides submitted to the Animal Health Laboratory, DPIPWE, revealed a single
case in 1997 that was consistent with DFT1 [8, 10]. An emerging disease was finally recognised
in 2003 [10] and subsequent investigations revealed the tumour to be a transmissible allograft
being transferred from devil to devil via biting [11] with tumours tending to be located on the
face, lips and oral mucosa [8].The timeframe of the pre-clinical stage of DFTD1 remains
largely undetermined with observations ranging from 2–13 months [9, 12–15] but as little as 1
month has been recorded (Author unpublished observation, laboratory records, DPIPWE).
Immunohistochemical examination of DFT1 suggested a possible undifferentiated neuroen-
docrine tumour [16, 17] although subsequent molecular testing lead to the conclusion that
DFT1 is of Schwann cell origin [18]. Down-regulation mechanisms causing absence of major
histocompatibility complex (MHC) class 1 cell surface antigens is a major contributing factor
allowing the DFT1 allograft to evade the host devil’s immune system without rejection [19–
21]. Further cytogenetic and molecular techniques have identified four karyotypic strains that
are differentiated by a small number of identifiable rearrangements [22, 23]. As a consequence
of this cancer, wild populations of the Tasmanian devil have been significantly reduced in
Tasmania where the possibility of extinction either locally within 10–15 years [24, 25] or com-
pletely within 25–35 years [25] has been predicted. The impedance of this 2007 dire prediction
includes the adaption of wild Tasmanian devils to their life history change by precocial sexual
maturity [26] and through a strong collaborative scientific research and conservation manage-
ment framework devised by the Save the Tasmanian Devil Program (STDP) [27]. A second
transmissible tumour in Tasmanian devils, devil facial tumour 2 (DFT2), distinct from DFT1
has recently been reported [28] suggesting that the species may well be prone to transmissible
cancers, increasing the urgency of biomarker identification and therapeutic intervention.
ERBB3 is expressed in early embryonal development and plays an integral role in the devel-
opment of the neural crest and Schwann cells [29] regulating pathways that execute diverse cel-
lular functions including development, cell cycle, migration, survival, proliferation and
differentiation [30–34]. ERBB3 is a member of the Epidermal Growth Factor (EGF) family
representing a complex group of type 1 transmembrane receptor tyrosine kinase (RTK) with
differing ligands. The EGF family consists of four members and collectively the human epider-
mal growth factor receptor gene family members are designated EGFR/ERBB1/HER1, ERBB2/
HER2, ERBB3/HER3 and ERBB4/HER4 [35]. The extracellular domain (ECD) of ERBB recep-
tors has high structural homology although they bind selectively within a group of 11 peptide
growth factor members that includes Neuregulin 1 and 2 (NRG1/NRG2) both ERBB3 ligands.
[35–39]. Although the complex signalling network of ERBB receptors commonly activate the
mitogen activated protein kinase (MAPK) pathway and the phosphatidylinositide 3-Kinase
(PI3K) pathway [40–43], ERBB3 efficiently activates the PI3K pathway [44] due to the presence
of multiple p85 binding sites in its tyrosine kinase domain.
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Lateral signalling among ERBB’s is no more apparent than with receptors ERBB2 and
ERBB3 that must heterodimerise with other ERBB members to signal [40] as ERBB3 has a
ligand but impaired tyrosine kinase activity [45] and ERBB2 has no known ligand (orphan
receptor) but a functional kinase region [46]. Although ERBB3 has long been considered
impaired or termed a pseudo-kinase, it does have sufficient, although substantially reduced
[47], kinase activity. How ERBB3 is able to activate other ERBB family members with its weak
catalytic domain remained elusive until an allosteric mechanism termed an ‘asymmetric
dimer’ enabling trans-autophosphorylation was discovered [48].
ERBB2 and ERBB3 overexpression [49–51], cooperation in neoplastic transformation [44,
52–54] and loss of ERBB3 preventing the progressive transformation of ERBB2-over express-
ing tumours [55] reinforces ERBB3’s pivotal role in ERBB signalling. Early studies revealed
ERBB3 as a potential oncogene with overexpression due to possible increased transcription as
no gene amplification was observed [56, 57] although recently oncogenic mutations have been
reported [58] indicating either ERBB3 or its downstream components should represent a
potential target for therapy [59].
ERBB3 is upregulated in a number of human cancers such breast, colon, gastric, ovarian
and prostate [33, 60] but seldom reported in veterinary cancers [61–63] although it would
appear the instrumental role that ERBB3 may play in some veterinary tumours is yet to be elu-
cidated. DFT1’s immunohistochemical expression of ERBB3 led us to postulate that excess
extracellular domain (ECD) may circulate in the host’s plasma and present itself as a possible
candidate biomarker for DFT1. Literature reports five secreted alternative transcripts of
ERBB3 present in serum or interstitial fluid [64, 65] which can be detected utilising ELISA
methodology.
Our pilot study assessed serum ERBB3 for the for the first time in Tasmanian devils reveal-
ing that serum ERBB3 was substantially elevated in the serum of Tasmanian devils with DFT1
compared to those Tasmanian devils without DFT1. Interestingly, the inclusion of some Tas-
manian devils with CL in our pilot study revealed that ERBB3 may also be a biomarker for this
DFT1, although CL is clinically distinct from DFT1. We identify ERBB3 as a potential bio-
marker of DFT1 and highlight current literature supporting the therapeutic possibilities that
can be directed towards ERBB3 overexpressing tumours that may be helpful in the elimination
of DFT1 from the wild.
Materials and methods
Animal ethics statement
Serum and paraffin embedded tissue samples were collected by veterinary staff for the Save the
Tasmanian Devil Program (STDP) http://www.tassiedevil.com.au/tasdevil.nsf encompassing
health checks, field trapping trips, or autopsy due to animal welfare reasons. All samples were
accessed from the Animal Health Laboratory archive and did not require ethics approval.
Tasmanian devil ERBB3 pilot study
A pilot study of thirty-five Tasmanian devils differing in age, sex and geographic location were
selected (Table 1) to compare serum ERBB3 levels in clinically healthy Tasmanian devils
(CHD), devils with DFT1 and those with CL. The Fifteen CHD’S included both adults (n = 12)
and clinically healthy juvenile Tasmanian devils (CHJD, n = 3) 10 months of age. Adults
included free range captive (n = 5), captive (n = 3) and wild devils (n = 4). Clinically healthy
adults either had no visible disease (ND, n = 8) or had localised skin non-DFT1 dermatopathy
(CHDD, n = 4) consisting of two abscesses, a skin tag and localised dermatitis. Eight Tasma-
nian devils with clinical DFT1 and Twelve Tasmanian devils with CL. Tasmanian devils with
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CL were included in the study as a severe skin condition recognised clinically but very distinct
from DFT1. All dermatopathies, DFT1 and CL were confirmed histologically by the Animal
Health Laboratory.
Table 1. Tasmanian devil pilot study individuals.
Devil Microchip Identification Laboratory accession Age (years) Sex (M/F) Geographic location Clinical status
1 982000190997443 13/3712 1 F Freycinet a CHD
2 982000123211124 13/3683 3 F Freycinet a CHD
3 982009104963600 13/3680 4 M Freycinet a CHD
4 982009104860765 13/3713 4 M Freycinet a CHD
5 982000123130282 13/3716 2 M Freycinet a CHD
6 982009105111670 09/4200 3 F West Pencil Pine b CHD
7 982009105849999 09/3957 2 M Tullah b CHD
8 985154000001063 09/1051 1 M Cressy c CHD
9 982009104269684 08/1805 2 M Narawntapu b CHDD
10 982009106039877 10/0156 2 M Dunalley b CHDD
11 982009104236464 08/0798 1 F Taroona c CHDD
12 982009104357109 09/2009 4 F Fern Tree c CHDD
13 985154000001151 09/0451 <1 M Mt Pleasant d CHJD
14 985154000001142 09/0449 <1 F Mt Pleasant d CHJD
15 985154000001130 09/0448 <1 M Mt Pleasant d CHJD
16 982009104841875 12/2065 6 F West Pencil Pine b DFT1
17 982009106034139 11/0767 2 F Dunalley b DFT1
18 982009104719592 12/0820 4 F West Pencil Pine b DFT1
19 982000000122095 12/2095 2 F Upper Natone b DFT1
20 982000123128645 11/3917 2 M Hamilton b DFT1
21 982000123216973 11/3918 1 F Hamilton b DFT1
22 982000123209814 11/4493 2 M Waratah b DFT1
23 000000000130406 13/0406 2 F Mangalore b DFT1
24 NC 11/0650 7 F Mole Creek c CL
25 985120016024404 11/4290 8 F Mt Pleasant c CL
26 982009106314654 10/4001 8 M Taranna c CL
27 982009106585887 10/3765 5 F Calder b CL
28 982009104789818 14/0034 6 F Cressy c CL
29 NC 08/4048 4 F Circular Head b CL
30 982009100786171 09/0402 6 F Mt Pleasant c CL
31 982009101694833 10/1013 6 F Richmond c CL
32 982009104910854 13/0518 6 F Cressy c CL
33 NC 09/3035 5 F South Riana b CL
34 NC 11/1615 6 F Mole Creek c CL
35 982009104873582 13/3714 4 F Freycineta CL*
NC not microchipped, CHD clinically healthy devil, CHDD clinically healthy devil with dermatopathy, CHJD clinically healthy juvenile devil, DFT1 devil facial
tumour 1, CL cutaneous lymphoma




* no tissue diagnosis.
https://doi.org/10.1371/journal.pone.0177919.t001
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Tasmanian devil serum sample and collection
Blood samples from Tasmanian devils (Table 1) were collected by wildlife veterinarians
through jugular venepuncture, whilst the animals were restrained by a trained field officer.
Ten millilitres of blood was collected in sterile serum separation tubes, stored on ice for trans-
port to the laboratories, centrifuged and serum removed for archival storage at -20˚C. Serum
samples were retrieved from the frozen archive and thawed at room temperature immediately
before analysis.
Histology
Tasmanian Devil tissues were fixed in 10% Neutral Buffered Formaldehyde (Confix, ACFC,
Australian Biostain, Traralgon, Victoria, Australia) for 24 hours and selected tissues were cas-
setted and processed overnight using a standard 15 hour overnight procedure in the TP1050
tissue processor (Leica Microsystems, Wetzlar, Germany). Tissues were orientated on the
EG1160 (Leica), embedded in paraffin wax (Surgipath Paraplast, 39601006, Leica) and sec-
tioned at 3 microns using Leica RM2245 microtome and adhered to microscope slides (Menzel
Glaser, Braunschweig, Germany) for 20 minutes at 60˚C. Sections were deparaffinised, rehy-
drated and stained using Jung autostainer XL (Leica) for Haematoxylin (Harris’ Haematoxylin,
AHHNA, Australian Biostain) and Eosin, dehydrated cleared and mounted in CV Mount
(Leica, 046430011).
Immunohistochemistry
Archival Tasmanian devil tissues and tumours were sectioned at 3 microns, floated onto
Superfrost plus slides (Menzel Glaser) and subjected to standard deparaffinisation and rehy-
dration techniques using an automated stainer (Leica). Antigen retrieval in tissue sections was
conducted in citrate buffer at pH 6.0 (Reveal Decloaker, Biocare Medical, California, USA) at
120˚C for 8 minutes using a Pascal pressure chamber (Dako, Glostrup, Denmark) then cooled
to 20˚C. Endogenous peroxidase activity was quenched using 3% hydrogen peroxide (Ajax
Finechem, Sydney, Australia, 260) in methanol (Ajax, 723) for 30 minutes. Detection of pri-
mary antibodies was achieved using Mach1 Universal HRP-Polymer detection kit (Biocare
Medical, California, USA, M1U539GL10). Protein block (Background Sniper BS966L10) was
applied for 20 minutes prior to application of primary antibodies. Monoclonal rabbit anti-
human ERBB3 (Abcam, clone SP71, ab93739, internal region) was diluted 1:50 with antibody
diluent (Dako, S0809) and applied to both devil tumour and normal devil control tissues at
room temperature for 30 minutes. Negative control was omission of primary antibody with
buffer substitution. Universal HRP-polymer was applied for 30 minutes (MRH538L10) fol-
lowed by 1 drop of Betazoid DAB Chromogen 3,3 Diaminobenzidine (BDB900G) in 1ml
of substrate buffer (DB900) applied for 4 minutes. Tris buffered saline (Biocare Medical,
TWB945) was used to rinse between all steps. Slides were rinsed, stained with Carazzi’s Hae-
matoxylin for 5 minutes, washed for 3 minute in tap water, dehydrated, cleared and mounted
in CV mount. Sections were viewed under light microscopy using Olympus BX41 (Olympus
corporation, Tokyo, Japan) and selected areas were photographed using an Olympus digital
camera (DP20).
ERBB3 ELISA assay
Serum ERBB3 levels were measured using the RayBio anti-human ERBB3 ELISA Kit
(ELH-ERBB3, RayBiotech Inc, GA, USA) according to manufacturer’s instructions. Briefly,
serum samples were diluted 1/5 in Assay Diluent A and 100 uL of standard or diluted sample
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were added in duplicate to wells of a 96 well assay plate and incubated for 24 hrs at 4˚C. The
supernatant was removed and wells were washed 4 times with 300 uL of 1X wash solution
using an Immunowash 1575 (BioRad Laboratories, CA, USA). One hundred microliters of
prepared biotinylated anti-ERBB3 was added to each well and the assay plate incubated for 1
hour at room temperature. The assay plate was washed as described after which 100 uL of pre-
pared HRP-streptavadin conjugate was added to each well and the assay plate incubated for 45
minutes at RT. The assay plate was again washed as described and 100 uL of TMP substrate
was added and the plate incubated for 30 minutes at room temperature in the dark, after
which 50 uL of stop reagent was added to each well. The absorbance of each well was measured
at 450 nm using a Tecan Infinite M200 microplate reader (Tecan, Salzburg, AUT).
Data analysis
The ELISA standard curve was plotted using Prism v5 (GraphPad, CA, USA) and results for
each serum interpolated and corrected for dilution. The significance of differences in serum
ERBB3 between groups was determined using a Kruskal-Wallis test with Dunn’s Multiple
Comparison utilizing Prism v5 (GraphPad, CA, USA).
Results
Histology and Immunohistochemstry
DFT1 histology (Fig 1A) and Haematoxylin and Eosin demonstrates small round cells with
indistinct cell membranes arranged in cords and packets. ERBB3 IHC on average revealed mod-
erate to strong expression in 75% of cells in both primary and secondary DFT1 tumours in cyto-
genetically determined strains 1 to 5 of DFT1. Typical granular cytoplasmic expression (Fig 1B)
demonstrated by DFT1 strain 3 cells with small and large aggregates noted. Higher magnifica-
tion (Fig 1C) shows accumulation in and around vacuolar structures within the cytoplasm. In
sections of devil skin and subcutous (Fig 1E), peripheral nerve was seldom positive for ERBB3
(red arrow) in keeping with downregulation of ERBB3 in the adult in contrast to DFT1 ERBB3
expression (black arrow). ERBB3 expression was noted in Tasmanian devil lymphoid follicle
(Fig 1F) where cytoplasmic expression of ERBB3 is present in both T (germinal centre) and B
(mantle) cells. Devils with CL were not included in the ERBB3 immunohistochemical staining.
Trigeminal nerve section (Fig 1I) showed ERBB3 expression in nerve bodies (black arrow) and
occasional ERBB3 expression in the adaxonal area (red arrows) but generally small myelinated
nerves were negative. Positive control included devil bowel (Fig 1G) which exhibited a similar
expression pattern to human ERBB3 and negative controls DFT1 (Fig 1D), bowel (Fig 1H) and
Trigeminal nerve (Fig 1J). The monoclonal rabbit anti-human ERBB3 clone SP71 is a synthetic
peptide corresponding to an internal sequence of Human ERBB3. Although the exact sequence
is a proprietary secret ERBB3 sequence alignment between Human and Tasmanian devil in this
region has high homology (S1 Fig. ERBB3 Orthologue protein alignment).
Serum ERBB3 in Tasmanian devils
Serum ERBB3 levels are shown in Table 2 and graphically in Fig 2. Serum ERBB3 in the Fifteen
Tasmanian devils without neoplasia (devils 1–15 includes CHD,CHDD and CHJD) ranged
from <30–663 pg/ml with a median of 32 pg/mL (30–220; interquartile range). Serum ERBB3
levels in the eight Tasmanian devils (devils 16–23) with clinical DFT1 ranged from 766–18,254
pg/ml with median of 3051 pg/mL (1060–10879; interquartile range. In the twelve Tasmanian
devils with cutaneous lymphoma (devils 24–35) serum ERBB3 levels ranged from <30–20,021
pg/ml with a median of 1485 pg/mL (289–7901; interquartile range).
Devil facial tumour disease (DFTD)
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Discussion
ERBB3 in devils without DFT1
Fifteen Tasmanian devils without neoplasia (twelve adults either wild caught, free range or
captive enclosures and three captive juveniles encompassing CHD, CHDD and CHJD) were
studied with an average serum ERBB3 of 32 pg/ml. Collectively, CHD Tasmanian devils serum
ERBB3 levels ranged from<30–663 pg/ml which could be considered representative of the ref-
erence range for Tasmanian devils. Wild caught devils 6 and 7 were unremarkable and had
serum ERBB3 levels <30 pg/ml however devil 9 (220 pg/ml) and devil 10 (92 pg/ml) both
recorded skin abscesses. The ERBB3 levels in the CHDD group (devils 9, 10, 11 and 12) ranged
from<30–220 pg/ml all had a small isolated dermatopathy such as abscess (devil 9), pyogranu-
loma (devil 10), skin tag with associated inflammation (devil 11) and small focus of dermatitis
(devil 12) all recorded a low serum ERBB3 levels of<92 pg/ml. The CHJD (devils 13, 14 and
15) approximately 10 months old had an unremarkable clinical history that indicated serum
was collected for a health check only, reflected in the low serum ERBB3 level of<30 pg/ml.
Fig 1. DFT1 staining and skin manifestation. (A) Haematoxylin and Eosin stained DFT1 x40, (B) ERBB3
Immunohistochemical expression in DFT1 strain 3 x40, (C) ERBB3 immunohistochemical expression in DFT1
strain 3 x100, (D) DFT1 negative control, (E) Tasmanian devil skin and subcutis section with peripheral nerve
(red arrow) and DFT1 (black arrow) x10, (F) Tasmanian devil lymph node ERBB3 expression lymphoid follicle
x20, (G) Tasmanian devil bowel ERBB3 positive control x40, (H) ERBB3 IHC negative control bowel, (I)
trigeminal nerve shows ERBB3 positive nerve body (black arrow) and occasional adaxonal ERBB3 positivity
(red arrows) x40, (J) ERBB3 IHC negative control trigeminal nerve, (K) Tasmanian Devil gross appearance of
DFT1. Photo credit: DPIPWE archive, (L) Tasmanian devil gross appearance cutaneous lymphoma. Photo
credit DPIPWE archive.
https://doi.org/10.1371/journal.pone.0177919.g001
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Further assessment of data and clinical history (Table 2) revealed that four out of five Tas-
manian devils from the Freycinet free range enclosure (devils 1–5) had higher serum ERBB3
ranging from 155–663 pg/ml compared to most other clinically healthy devils having serum
ERBB3 levels <30 pg/ml. The Freycinet free range enclosure (FRE) consists of a 22 Hectare
natural reserve that creates living conditions that are more similar to the wild than traditional
captive conditions. The structure is fenced completely enclosing an insurance population of















1 155 N/A 1 CHD, NAD
2 663 N/A 1 CHD, Localised alopecia
3 207 OW 1 CHD, Multiple punctures
4 313 N/A 1 CHD, Multiple punctures
5 291 N/A 1 CHD, Multiple minor wounds
6 <30 N/A 1 CHD, Few wounds, lactating
7 <30 N/A 2 CHD, N/A
8 <30 6 1 CHD, Great condition
9 220 10.5 1 CHDD, Abscess/scab on face
10 92 N/A 2 CHDD, Abscess left neck.
11 <30 4.7 1 CHDD, Skin tag on left ear
12 <30 N/A 1 CHDD, Dermatitis upper flank
13 <30 4.2 1 CHJD, Health check
14 32 3.4 1 CHJD, Health check
15 <30 4.6 1 CHJD, Health check.
16 18,254 N/A 1 DFT1, weak 2 2 2 (1.0–2.5) 3
17 999 6.1 3 DFT1, Reared 4 young 2 3 4 (1.0–1.5) 5
18 11,090 4.8 1 DFT1, Poor body condition 1–2 1 4 (2.0–3.0) 1
19 1903 3.7 1 DFT1, Emaciated disorientated 0 1 2 (1.6–5.2) 10
20 10,247 10 3 DFT1, Multiple lesions 3 2 4 (1.0–2.0) 2
21 1241 5 3 DFT1, Poor body condition 2.5 2 3 (1.0–1.5) 1
22 4198 9.3 4 DFT1, Advanced DFT1 2 4 7 (1.0–2.5) 0
23 766 N/A 1 DFT1, Emaciated 2 1 7 (1.0–4.7) 1
24 4383 6.7 1 CL, Generalised alopecia N/A
25 <30 8.2 1 CL, cutaneous plaques chest N/A
26 <30 8.0 1 CL, percutaneous plaque N/A
27 2008 5.9 1 CL, Skin lesions N/A
28 837 5.9 1 CL, Alopecia Poor
29 9703 5.3 1 CL, Generalised alopecia Poor
30 2403 8.2 1 CL, Alopecia ventrally N/A
31 536 7.4 1 CL, Alopecia left neck, pouch N/A
32 962 6.7 1 CL, Alopecia ventrally N/A
33 11,837 5.4 1 CL, Widespread alopecia 1–2
34 207 5.7 1 CL, Multifocal dermatitis, cutaneous lump
(acanthoma)
Poor
35 20,021 N/A 1 CL, Multifocal alopecia N/A
N/A not available, NAD no abnormality detected, OW over weight, BCS—body condition score, DFT1 strain–cytogenetically determined strain, DFT1 1o
No–number and size of primary tumours recorded, Mets No—number of metastasis recorded, CHD clinically healthy devil, CHDD clinically healthy devil
with dermatopathy, CHJD clinically healthy juvenile devil, DFT1 devil facial tumour 1, CL cutaneous lymphoma
https://doi.org/10.1371/journal.pone.0177919.t002
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healthy devils with density caped to approximately one devil per hectare. This type of enclo-
sure allows devils the opportunity to compete at feeding and breeding times and bite wounds
are therefore common (David Schaap, personal communication). In contrast, captive devils
are housed in small enclosures that measure approximately 100 m2 containing capped at one
devil per 100 m2.
We noted that skin injuries were commonly recorded although no abnormality was noted
for devil 1, alopecia bilaterally around the hind limbs and flank was present on one mother
due to her 3 pouch young (devil 2) and multiple puncture wounds were present on the remain-
der (devils 3, 4 and 5). Given that these devils were otherwise clinically healthy it would suggest
that skin wounds caused by biting may contribute to some elevation in the serum ERBB3 of
Tasmanian devils. There is also the possibility that simply being a Tasmanian devil living in a
free range enclosure as opposed to wild populations may in itself be contributory to elevation
in serum ERBB3 due to more frequent devil-devil engagement. Our results indicate that Tas-
manian devils without injuries or an isolated skin lesion have serum ERBB3 levels <30 pg/ml
whereas Tasmanian devils with multiple injuries or large abscesses have serum ERBB3 levels
ranging from 92–663 pg/ml. Together, these results suggest that cancer-free Tasmanian devils
have a serum ERBB3 range of<30–663 pg/ml.
ERBB3 in devils with DFT1
All devils with DFT1 were wild caught and all subjected to field autopsy with most serum sam-
ples reaching the laboratory within one to three days. We assessed the available clinical history
(Table 2) including animal weight, body condition score (BCS 1–5) where 1 = emaciated,
2 = moderately thin, 3 = average, 4 = good and 5 = obese (Sarah Peck, personal communica-
tion), number of primary and metastatic DFT1’s and cytogenetic strain ensuring the consider-
ation of any factors that may contribute to the ERBB3 range in DFT1 affected Tasmanian
Fig 2. Serum ERBB3 levels in Tasmanian devils. Serum ERBB3 levels were measured by ELISA in
clinically healthy Tasmanian devils CHD (n = 11), clinically healthy Tasmanian devils with dermatopathy
CHDD (n = 4), clinically diagnosed DFT1 (n = 8) and those with cutaneous lymphoma CL (n = 12). Horizontal
dashed line indicates the limit of detection of the ELISA assay at 30 pg/mL. Results of individual devils are
shown with the median and interquartile range identified by the whiskers. Significance testing using a Kruskal-
Wallis test with Dunn’s Multiple Comparison Testing shown with * representing p < 0.05.
https://doi.org/10.1371/journal.pone.0177919.g002
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devils. No correlation was established between levels of ERBB3 and extent of DFT1 when com-
paring the number and size of primary DFT1 lesions and any metastatic disease (see Table 2).
For example, the devil with the highest serum ERBB3 of 18,254 pg/ml (devil 16), had 2 primary
lesions with 3 metastases whereas the lowest serum ERBB3 of 766 pg/ml (devil 23) had seven
primary DFT1 lesions and one metastasis. No correlation was established between serum
ERBB3 levels and the BCS as most were low (BCS 1–2) with only one devil (devil 20) having a
BCS of three out of five, indicating average body condition. Cytogenetic strain did not appear
to correlate to serum ERBB3 levels and reflects the immunohistochemical findings that ERBB3
expression was present in all cytogenetic strains of DFT1. Our results indicate that Tasmanian
devils with DFT1 have elevated serum ERBB3 levels compared to clinically healthy Tasmanian
devils ranging from 766–18,254 pg/ml and that the extent of DFT1 does not readily correlate
directly with the serum ERBB3 levels. Further investigations beyond the pilot study encom-
passing a larger study group of Tasmanian devils with advanced DFT1 and metastases would
be necessary to establish any relationship with serum ERBB3 and the extent of DFT1.
ERBB3 in devils with cutaneous lymphoma
We included Tasmanian devils with cutaneous lymphoma (CL) in the study for two reasons.
Firstly, they were non-DFT1 devils with a severe skin condition that can affect the facial
regions and secondly, the disease presentation of alopecia, excoriation and thickened plaques
is distinct from DFT1 (Fig 1E and 1F). Our results revealed that some Tasmanian devils with
CL had elevated serum ERBB3 levels, a result that was most unexpected. Although ERBB3
immunohistochemistry on Tasmanian devils with CL was beyond the scope of this research,
ERBB3 Immunohistochemical staining of Tasmanian devil lymph node (Fig 1D) did reveal
ERBB3 expression in the lymphoid follicle where cytoplasmic expression of ERBB3 is present
in both T (germinal centre) and B (mantle) cells. CL devils were in the older age bracket rang-
ing from 4–8 years where the maximum age of a wild devil would be considered 5–6 years
(Sarah Peck, personal communication). Bodyweights ranging from 5.4–8.2 Kg compared to
the mean weight of 6.6Kg for female and 8.3Kg for male [66] shows possible female under-
weight wild devils and overweight captive devils. Age or weight did not appear to correlate to
the broad range of serum ERBB3 of 30–20,021 pg/ml. Interestingly, 11 of the 12 devils with CL
were female. We noted that devils with widespread alopecia (devils 24, 29, 33 and 35), did
exhibit increased serum ERBB3 levels ranging from 4383–20,021 pg/ml, suggesting that the
severity of CL manifesting clinically as widespread alopecia may contribute to increased serum
ERBB3 levels. Together, the elevated serum ERBB3 results in devils with CL is unlikely to
cause confusion with DFT1 as CL tends to affects devils in the older age group and the clinical
signs of CL are also distinct from DFT1 in established disease. Additionally, if elevated serum
ERBB3 levels in Tasmanian devils indicative of CL could be established (pre-clinical) this
would improve the healthy captive breeding populations of Tasmanian devils to ensure sur-
vival of the species by excluding these devils from this program.
Potential source of serum ERBB3
The capture and detection of antibody in our ELISA assay is selective for the extracellular
domain (ECD) of transmembrane ERBB3 in serum or plasma, thus ERBB3’s ECD is cleaved
and shed from the plasma membrane would be a natural assumption. In contrast the ERBB3
receptor is internalised, although very slowly, for negative regulation and inactivation [67–71]
utilising pathways such as caveolin or micropinocytosis and clathrin-and caveolin indepen-
dent pathways [72, 73]. ERBB3 has also been shown to be endocytosed independent of phos-
phorylation and without ligand in clathrin-dependent manner [74]. ERBB3 is degraded by
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proteasomes catalysed by two E3 ubiquitin ligases; NRDP1 (Neuregulin Receptor Degradation
Protein -1) [75], now known as RNF41 (Ring Finger 41, E3 Ubiquitin Protein Ligase) [76–78],
and NEDD4 (Neural Cell Precursor Expressed, Developmentally Down-regulated 4, E3 Ubiqui-
tin Protein Ligase) [79] that regulate steady-state ERBB3 levels influencing NRG1 signalling.
Defective internalisation, recycling and degradation of cell surface proteins and ligands is
an emerging feature of cancer [80]. It is therefore conceivable that DFT1 is subjected to the
same dysregulation and inefficient degradation and recycling resulting in over expression of
ERBB3 receptor at the plasma membrane and subsequent detectable levels of serum ERBB3.
While dysregulated endocytosis, deregulation and recycling may theoretically account for
excess ERBB3 ECD detectable in serum, secreted isoforms of ERBB3 must also be considered
as an alternative explanation for the presence of excess ERBB3.
As well as functional transmembrane forms, secreted soluble forms of Epidermal Growth
Factor Receptors have been well documented for ERBB1 [81–84], ERBB2 [85–88] and ERBB4
[89–91]. Alternative transcripts for ERBB3 resulting in naturally occurring soluble truncated
isoforms including a 1.4 kb transcript of ERBB3 in gastric cancer cell lines [64] and an addi-
tional four novel transcripts (1.6, 1.7, 2.1, and 2.3kb) from ovarian cancer cell lines [65] en-
couraged researchers to identify these secreted isoforms of ERBB3 in Prostate [92–95], liver
[96], breast [97, 98] and squamous cell carcinoma [99]. ERBB3 isoforms have also been ex-
pressed intracellularly in breast cancer cell lines [97] as well as in the nucleus of Schwann cells
[100, 101], prostate [102–104] and breast [105, 106]. Secreted ERBB3 isoform p85 has been
shown to inhibit the action of its ligand Neuregulin [98, 107], nuclear translocations act as co-
transcriptional activators [108], possible post-translation modification and the tumour micro-
environment are instructive to serum ERBB3 secretion from the cell [96] and functions yet to
be determined.
The antigenic peptide used for this assay is located within the N-terminal domain of the full
length ERBB3 protein. Full length ERBB3 translates into a 180 kDa protein whereas ERBB3
transcripts, created by intron read through and alternative polyadenylation signals result in
serum ERBB3 isoforms translating into various proteins ranging in size from 22–75 kDa [109].
Secreted isoforms such as ERBB3-S (1.4kb, 140aa homologous to the N terminus and a 43aa
unique carboxy terminal sequence) equates to approximately half of domain I, p50 (1.6kb,
351aa homologous to the N terminus and a 30aa unique carboxy terminal sequence) equates
to domain I, II and some of domain III, p45 (1.7kb, 310aa homologous to the N terminus and
a 2aa unique carboxy terminal sequence) equates to domain I, II and some of domain III, p85
(2.1kb, 519aa homologous to the N terminus and a 24aa unique carboxy terminal sequence)
equates to domain I, II,III and some of domain IV, p75 (2.3kb, 474aa homologous to the N ter-
minus and a 41aa unique carboxy terminal sequence) equates to domain I, II and III [64, 65,
109] ERBB3 isoforms have been detected by a number of methods such as immunoprecipita-
tion [65, 97, 107], immunohistochemistry [92] and ELISA [94–96]. Isoforms that have been
detected using ELISA assays include p45 sERBB3 utilising a capture antibody of sequence
aa20-643 (detection antibody sequence was not recorded) [94, 95] and 40-50kDa secreted iso-
forms (possible p45/p50) utilising both capture and detection antibodies with a sequence aa20-
643 [96]. The Raybio ELISA kit utilised in our research uses a capture and detection antibody
of sequence aa20-643 (personal communication Raybio) which accounts for most of the extra-
cellular domain of ERBB3 and therefore would be able to capture and detect both truncated
isoforms as well as the transmembrane ERBB3.
The correlation of serum levels with disease severity and progression would be the founda-
tion of a good biomarker [96] as well; the expected biomarker should be in excess when com-
pared to clinically healthy individuals [81] or possess additional qualities such as theranostic
and tertiary prevention [84]. The use of serum ERBB’s as an indicator of human cancer
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appears useful however, its prognostic and theranostic value remains controversial and contin-
ued investigations will be required [81–96, 99]. The development of a diagnostic test for pre-
clinical DFT1 would assist in the field operations if individuals could be identified before they
become infectious[110], therefore application of serum ERBB3 as a diagnostic biomarker of
DFT1 has great potential. The simplicity of the ELISA Serum ERBB3 methodology is easily
incorporated into routine batch testing or rapid turnaround of results for urgent cases if
required. Our research suggests that serum ERBB3 can be used as a biomarker for DFT1 and
CL irrespective of transmembrane or truncated forms being detected in the serum of affected
animals and therefore the potential of serum ERBB3 as a biomarker of early DFT1 detection
should be explored.
Schwann cell neoplasms
ERBB3 is crucial to the sequential transition from precursor to immature and finally mature
Schwann cells where ERBB3 is down-regulated as myelination proceeds [111]. The adult
peripheral nervous system requires maintenance when injured and the NRG1/ERBB system is
crucial to Schwann cell dedifferentiation, proliferation, and subsequent regeneration and
remyelination where ERBB3 and NRG1 is upregulated and only switched off after axon re-
generation illustrating the plasticity of the Schwann cell [112–114]. Peripheral nerve sheath
tumours [neurofibroma, malignant peripheral nerve sheath tumours (MPNST)] and schwan-
noma arise from the Schwann cell lineage and can be genetically characterised as Neurofibro-
mas (either dermal or plexiform) and MPNST’s [Neurofibromatosis 1 (NF1)], or Schwannomas
[Neurofibromatosis 2 (NF2)], Schwannomatosis and Carney complex type 1. Although distinct
characterisation of these complex diseases is possible, frequent overlapping features make diag-
nosis difficult and must also include other tumours with a Schwannian component such as
Neuroblastic and Granular Cell Tumours [reviewed in [115–119]]. Veterinary Schwann cell
neoplasms have been recorded [120–124] although ERBB3 expression in Schwann cell neoplasia
has not previously been reported in veterinary literature. ERBB3 receptor has been expressed in
human Schwann cell neoplasms including neurofibroma, MPNST, Schwannoma, neuroblastic
[125, 126] and ganglioneuroma (GN) tumours [127]. Interestingly, the down regulation of
MHC class 1 and 2 molecules in a MPNST cell line [128] contrasting normal expression [129,
130] may indeed be similar to the MHC class 1 downregulation of DFT1 [19–21] resulting in
defective antigen processing and presentation of the malignant Schwann cell neoplasm.
ERBB3 as a therapeutic target
Despite evidence for multiple resistance mechanisms for existing therapeutic targeting of
ERBB1/2 [131–141] numerous researchers have over the last decade explored the potential of
ERBB3 as a therapeutic target [reviewed in [33, 60, 142–150]] using monoclonal antibodies
[57, 151–176], histone inhibitors [177], TKI [178], surrobodies [179], locked nucleic acid
(LNA)-based ERBB3 antisense oligonucleotide (ASO) [180], peptide mimics and vaccine
[181], anti-anginal drug [182] and disulphide disrupting agent [183].
However, managing wildlife disease is considerably more difficult than human disease
because of limited data, the effect of the disease on the host and the transmission of disease
within a dynamic population makes it difficult to model [184]. Previous efforts to eradicate
DFT1 from wild populations by selective culling has proven unsuccessful because of the fre-
quency-dependent transmission of DFT1 and the latency period [110, 184, 185]. TKI’s as a
therapeutic approach may be limited due primarlily to the early observation that kinase region
of ERBB3 had substantialy reduced activity, however cancer immunotherapy broadly catego-
rised as passive (including monoclonal antibodies, Cytokines, adoptive cell transfer) or active
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(including therapeutic cancer vaccine, immune checkpoint inhibitors) remains optimistic
[186–191]. Many of these successful human immunotherapeutics do hold similar promise in
veterinary medicine [192–194] however, drug administration to wild Tasmanian devils is very
different from the clinical setting of human and companion animals and therefore treatments
such as adoptive cell transfer would be difficult to implement. The fact that DFT1 expresses
tumour associated antigens (TAA’s) such as ERBB3 invites the application of monoclonal anti-
bodies and therapeutic cancer vaccines as prospective treatments. The passive administration
of monoclonal antibodies to ERBB3 primarily focused on blocking receptor epitopes are still
experimental [57, 151–176] and any humanised anti-ERBB3 would certainly have to be become
species specific (devil anti-ERBB3) to prevent adverse immunologic reactions [195]. Very few
monoclonal antibodies have been developed in veterinary oncology although two caninised anti-
bodies anti-ERBB1 [196] and anti-CD20 [197] show promise. Therapeutic cancer vaccination
modalities applicable to wildlife include antigen delivery vaccines that utilise inactivated cancer
cells (autologous or allogenic) or peptide vaccines that mimic antigen sequences. Results using
an inactivated cancer cell vaccine trial (allogenic DFT1 cell line) are eagerly awaited (http://
www.utas.edu.au/news/2015/10/16/19-world-first-trial-of-tasmanian-devil-vaccine-begins-in-
the-wild/). Confidence that immunisation can be successful stems from research showing that
Tasmanian devils have a competent immune system [21, 198–200] and can produce cytotoxic
antibodies [14, 201]. An alternative antigen presentation modality to cancer cell vaccine is a
peptide vaccine, where single or multiple amino acid sequences (long or short) representing a
defined antigen is combined with adjuvant to elicit an immune response [202]. Development of
just a single ERBB3 peptide vaccine can be found in the literature [181] however, peptide vac-
cines targeting ERBB1 [203, 204], ERBB2 [205–207] or both ERBB1/2 [208] including monoclo-
nal antibody against tyrosine related protein 1 (TRP-1) and altered peptide sequence to gp100
for mouse melanoma [209] all show promise. Overcoming self-tolerance is a major hurdle,
one such strategy is the use of Xenoantigens, that is the exact same antigen but from a different
species that has considerable sequence homology, differing only by several amino acids which
appear to the host as altered epitopes or as “altered self” and therefore tolerance can be broken
causing a T-cell response against the endogenous self-antigen [210]. Veterinary xenogeneic vac-
cinations include a DNA plasmid vaccine encoding human Tyrosinase (TYR) [211] the only vet-
erinary therapeutic tumour vaccine licensed by the United States department of Agriculture
(USDA) for the use of oral and digital melanoma, now marketed as OnceptTM.
Recent investigations reveal that the tumour microenvironment of metastatic DFT1
expressed B7-H1 and DFT1 cell lines could upregulate B7-H1[212]. Immune-suppressive
tumour microenvironment created by tumour cells that escape ‘immunoediting’ allowing
tumour growth and proliferation [213] where certain checkpoint pathways will be used advan-
tageously by tumour cells to confer immune resistance [214]. Hence, checkpoint blockades
(monoclonal antibodies) targeting Programmed Cell Death 1 (PD1 or PDCD1) and its ligand
PD-L1 (B7-H1) and Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) are now attractive thera-
peutical targets [215]. Recent views consider cancer immunotherapy invaluable although a sin-
gle treatment mode may be suitable for some cases, more combinatorial approach will be
needed for others [216, 217].
Our research has highlighted ERBB3 as a potential therapeutic target however treatment of
Tasmanian devils with DFT1 with therapeutic regimes such as chemotherapy and radiother-
apy are impractical. However, a combinatorial approach using therapeutic cancer vaccines
including inactivated allogenic DFT1 cancer vaccine, ERBB3 monoclonal antibody, ERBB3
Peptide or xenogeneic vaccine in combination with anti-immune checkpoint blockade therapy
would be easier to implement in the field as well as providing a sustained immunological
response against DFT1.
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Conclusion
ERBB3 had previously avoided scrutiny due to its kinase inactivity; however, ERBB3 has now
been the subject of intense investigation over the past decade and is now recognised as a potent
partner of the epidermal growth receptor family. ERBB3 upregulation during developmental,
dedifferentiation and regenerative processes encapsulates the Schwann cell’s inherent plasticity
and imparts certain characteristics of malignant transformation advantageous to transmission
of DFT1. Our pilot study has shown for the first time that ERBB3 is consistently expressed
immunohistochemically and that ERBB3 is also elevated in the serum of Tasmanian devils
with advanced DFT1 and cutaneous lymphoma. Therefore, our research indicates that serum
ERBB3 has the potential to be employed as a biomarker of DFT1 or CL in Tasmanian devils to
assist conservationists in the management and welfare of Tasmanian devils and species sur-
vival. The simplicity of the ELISA Serum ERBB3 methodology is easily incorporated into rou-
tine laboratory batch testing and equally applied to include rapid turnaround of results for
urgent cases. Extension of this research is necessary to include greater numbers of healthy Tas-
manian devils both with and without visible injuries, devils with large and small DFT1 lesions
as well as pre-clinical DFT1. This will firmly establish the normal reference range for serum
ERBB3 from which potential pre-clinical DFT1 may be identified. In addition, ERBB3 is now
recognised as a therapeutic target and therefore the potential exists to consider modes of
administration in addition to existing whole cell vaccination such as ERBB3 monoclonal anti-
body, peptide or xenogeneic vaccines including checkpoint inhibitors. A combinatorial immu-
notherapeutic approach will enhance cytotoxic destruction, provide long term immunity from
DFT1 and therefore eradicate this transmissible tumour from the wild.
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Stammnitz et al. show that the two
transmissible cancer clones that affect
Tasmanian devils are very similar in their
tissues-of-origin, mutational patterns and
driver gene candidates. Importantly,
these cancers are both highly sensitive to
inhibitors of some receptor tyrosine
kinases as well as to inhibitors of DNA
repair.
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https://doi.org/10.1016/j.ccell.2018.03.013SUMMARYTransmissible cancers are clonal lineages that spread through populations via contagious cancer cells.
Although rare in nature, two facial tumor clones affect Tasmanian devils. Here we perform comparative ge-
netic and functional characterization of these lineages. The two cancers have similar patterns ofmutation and
show no evidence of exposure to exogenous mutagens or viruses. Genes encoding PDGF receptors have
copy number gains and are present on extrachromosomal double minutes. Drug screening indicates caus-
ative roles for receptor tyrosine kinases and sensitivity to inhibitors of DNA repair. Y chromosome loss
from amale clone infecting a female host suggests immunoediting. These results imply that Tasmanian devils
may have inherent susceptibility to transmissible cancers and present a suite of therapeutic compounds for
use in conservation.INTRODUCTION
Tasmanian devils (Sarcophilus harrisii) are marsupial carnivores
endemic to the Australian island of Tasmania. This species is
considered endangered due to the emergence of a clonally
transmissible cancer known as devil facial tumor 1 (DFT1)
(Pearse and Swift, 2006). DFT1 presents as facial and oral tu-
mors, and the disease is contagious between animals by the
transfer of living cancer cells by biting (Hamede et al., 2013;Significance
Transmissible cancers are malignant clones that ‘‘metastasize
cers emerge, spread, and escape the allogeneic immune syst
known transmissible cancers in nature, Tasmanian devils har
investigate the underlying mechanisms of devil transmissible
analyses of the two clones. The cancers show striking similar
tional patterns, driver gene candidates, and drug vulnerabilities
cers carry deletions at loci relevant for immunogenicity. Importa
DNA repair pathways provides opportunities for targeted ther
Cancer Cell 33, 607–619
This is an open access article undPearse and Swift, 2006). First observed in north-east Tasmania
in 1996, DFT1 is a somatic clone that originally arose from the
cells of an individual female devil (Deakin et al., 2012; Hawkins
et al., 2006; Murchison et al., 2012). The lineage spawned by
this animal has subsequently spread widely throughout Tasma-
nia, causing significant declines in devil populations (Hawkins
et al., 2006; Lazenby et al., 2018).
In 2014, routine diagnostic screening revealed a second trans-
missible cancer in Tasmanian devils (Pye et al., 2016b). This’’ between individuals. The mechanisms whereby such can-
em are poorly understood. Remarkably, despite the rarity of
bor two distinct transmissible facial tumor clones. Here, we
cancers by performing comparative genetic and functional
ities in their tissues-of-origin, genome architectures, muta-
, suggesting that they arose via similar processes. Both can-
ntly, common dependence on receptor tyrosine kinases and
apy and Tasmanian devil conservation.
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cancer, DFT2, causes oral and facial tumors that are grossly
indistinguishable from those caused by DFT1 (Pye et al.,
2016b). However, DFT2 tumors are histologically, cytogeneti-
cally, and genetically distinct from DFT1. Indeed, karyotype evi-
dence suggests that DFT2 arose from the somatic cells of a male
animal, in contrast to the female origin of DFT1 (Pye et al.,
2016b). To date, DFT2 has been confirmed in only 11 devils, all
located on the Channel Peninsula in Tasmania’s south-east
(Kwon et al., 2018).
The discovery of a second transmissible cancer in Tasmanian
devils was entirely unexpected and remains unexplained. Other
than DFT1 and DFT2 in devils, only one other naturally occurring
transmissible cancer is known in mammals, which is the
11,000-year-old canine transmissible venereal tumor in dogs
(Murchison et al., 2014). Outside of mammals, only five transmis-
sible cancers have been observed, all of which cause leukemia-
like diseases in marine bivalves (Metzger et al., 2015, 2016). The
scarcity of known transmissible cancers in nature suggests that
such diseases emerge rarely. Furthermore, in Tasmanian devils,
there were no reports of animals with facial tumors comparable
with those caused by DFT1 and DFT2 prior to 1996 (Hawkins
et al., 2006; Loh et al., 2006a). Thus, the recent identification of
two transmissible cancers in Tasmanian devils, detected within
an interval of 18 years, is very surprising, and suggests that
exogenous or anthropogenic factors may contribute to risk of
transmissible cancer development specifically in this species.
Despite an urgent need to further understand the molecular
basis of transmissible cancers in Tasmanian devils, little is
known of the underlying genetic changes that initially caused
these cancers and that promote their colonization of allogeneic
hosts. The genome of DFT1 indicates that this lineage has ac-
quired several thousand mutations during its evolution (Murchi-
son et al., 2012). Although some genes have been somatically
altered (Miller et al., 2011; Murchison et al., 2012; Taylor et al.,
2017), no ‘‘driver’’ mutations with a clear causative role in
DFT1 emergence or evolution have been identified. Major histo-
compatibility complex (MHC) molecules are undetectable on the
surface of most DFT1 cells, likely explaining the low immunoge-
nicity of these cells in allogeneic hosts (Siddle et al., 2013). How-
ever, no mutations in genes involved in antigen presentation
have been defined. DFT2 has not yet been characterized beyond
a preliminary assessment of its histology, karyotype, and genetic
profiles at microsatellite and MHC loci (Pye et al., 2016b).
Given the similar phenotypes of DFT1 and DFT2, the emer-
gence of DFT2 provides an opportunity to understand the com-
mon factors that underlie transmissible cancers in Tasmanian
devils. Here, we provide a comparative genetic and functional




DFT2 tumors are histologically distinct from those of DFT1 (Pye
et al., 2016b). DFT2 is characterized by sheets of pleomorphic
cells (amorphic to stellate and fusiform), whereas DFT1 is
composed of pleomorphic round cells often arranged in bundles,
cords, or packets (Loh et al., 2006a; Pye et al., 2016b). DFT1 ex-
presses neuroectodermal markers, and is proposed to be of608 Cancer Cell 33, 607–619, April 9, 2018Schwann cell origin; indeed, a Schwann cell marker, PRX, is
used to confirm DFT1 diagnosis (Loh et al., 2006b; Murchison
et al., 2010; Tovar et al., 2011). DFT2 does not express PRX
(Pye et al., 2016b) and its histogenesis remains unknown.
We used a panel of antibodies to broadly characterize the
DFT2 tissue-of-origin by immunohistochemistry. Similar to
DFT1, DFT2 is negative for cytokeratin and smooth muscle actin,
and positive for vimentin, neural-specific enolase, and S100 (Fig-
ure S1). The similarity in tissue markers and gross phenotype be-
tween DFT1 and DFT2 suggests that these cancers arose from a
similar cell type.
Germline Genotypes and Populations-of-Origin
To further understand the identities, locations and relationship
between the DFT1 and DFT2 founder individuals, whose cells
spawned the two lineages, we compared the germline alleles
present in DFT1 and DFT2 with those in the devil population.
Tasmanian devil genetic analysis has revealed population sub-
structure between eastern devil populations and those in the
more isolated north-west (Br€uniche-Olsen et al., 2014; Jones
et al., 2004; Miller et al., 2011). Genotyping of DFT1 and DFT2
(Table S1) at 320 nuclear polymorphic loci, and comparison
with 401 devils sampled from seven locations between 1999
and 2014 (Br€uniche-Olsen et al., 2016), confirmed that both
DFT1 and DFT2 arose from individuals with ‘‘eastern’’ genotypes
(Figure 1). Further analysis indicated that DFT1 clustered most
strongly with individuals sampled in north-east Tasmania (Mount
William) in 2004, whereas DFT2 bore closest identity with individ-
uals collected in 2014 from the Channel Peninsula (Figure 1).
Overall, these findings are consistent with the notion that DFT1
and DFT2 arose within the areas in which they were first
observed (Figure 1B), implying that both lineages may have
been discovered relatively soon after their emergence.
The independent emergence of transmissible cancers from
two Tasmanian devils both belonging to the eastern subpopula-
tion suggests the possibility of inherited germline predisposition
alleles that increase risk of transmissible cancer development.
We investigated this hypothesis by sequencing the genomes of
DFT1 and DFT2 (Table S1) and identifying and annotating their
founder individuals’ inherited germline single-nucleotide variant
(SNV) and small insertion and deletion (indel) alleles (variants
were considered likely to be germline if they were shared
with R1 normal devil or if they were found in both DFT1 and
DFT2, see the STAR Methods). Although a subset of these
caused putative non-synonymous gene alterations in 908 genes
(Table S1), none bore homology to known inherited cancer risk
loci in humans (Forbes et al., 2015). Overall, although this
approach revealed a number of candidate loci, we cannot
confirm their involvement in DFT risk.
Virus Screen
We next investigated the possibility that exposure to exogenous
pathogens, such as viruses, may increase the risk of DFT dis-
eases developing in Tasmanian devils.We produced de novo as-
semblies of two DFT1 and two DFT2 genomes, and used whole
genome and short read alignments to identify contigs that were
exclusive to tumors and absent from four normal devils (see
STAR Methods). This approach did not provide evidence for
exogenous viral DNA in DFT1 or DFT2 (Table S1), consistent
Figure 1. Origins of DFT1 and DFT2
(A) Map of Tasmania illustrating sampling locations of 400 devil individuals represented in (B). Number of individuals sampled from each location is labeled
(Br€uniche-Olsen et al., 2016). ‘‘East’’ and ‘‘West’’ denote the populations that cluster separately in (B), separated by dotted line. One individual was sampled from
a captive population and is not shown on map. Devil silhouettes depict locations and year of first observations of DFT1 and DFT2.
(B) Hierarchical clustering of 320 SNP genotypes across a panel of 401 devils, DFT1 (blue) and DFT2 (red); individuals are represented as rows and loci as
columns. Genotypes are coded as white (homozygous 1/1), black (homozygous 2/2), and gray (heterozygous 1/2). East and West populations, as defined in (A),
are labeled. Right, detail of Euclidian distance dendrogram with sampling years and locations of devils neighboring DFT1 and DFT2 genotypes.
See also Table S1 and Figure S1.with the results of previous screens for viruses in DFT1 using
sequence alignments and transmission electron microscopy
(Murchison et al., 2012; Pyecroft et al., 2007). However, we
cannot exclude the potential involvement of DNA viruses that
have not been maintained, small circular unintegrated DNA vi-
ruses not captured by our DNA extraction method, RNA viruses,
or other pathogens in triggering DFT emergence.
Mutational Signatures
Further evidence for the involvement of exogenous agents in
DFT1 and DFT2 pathogenesis might be gained from examination
of mutational signatures (Alexandrov et al., 2013, 2015a; Baez-
Ortega and Gori, 2017). The similarity in mutational spectra, a
representation of the six SNV mutation types together with their
immediate 50 and 30 contexts found in DFT1 and DFT2 tumors,
suggests that similar mutational processes have operated in
these two cancers (Figure 2A). We applied Markov Chain Monte
Carlo sampling with a Bayesian statistical model to refit the
30mutational signatures cataloged in human cancers (COSMIC,
2017) to pools of mutations in DFT1 and DFT2. This analysis re-
vealed that refitting with human mutational signatures 1 and 5,
both of which are ‘‘clock-like’’ age-associated signatures, which
are almost universally active in human cancer and normal cells
and are not indicative of exogenous mutational exposures (Alex-
androv et al., 2013, 2015a; Blokzijl et al., 2016; Ju et al., 2017;
Rahbari et al., 2016), adequately reconstructed the mutational
spectra observed in both DFT1 and DFT2 (cosine similarity
0.93 and 0.95, respectively) (Figure 2B; Table S2).
Interestingly, neither DFT1 nor DFT2 genomes analyzed here
bear imprints of exposure to UV light, a mutagen that leaves a
readily recognizable mutational signature (Table S2). This con-
trasts with the transmissible venereal tumor in dogs, in which
40% of mutations have been caused by UV (Murchison et al.,
2014). Given that both DFT1 and DFT2 tumors are frequently
located on external regions of the face, this observation sug-
gests that either the nocturnal Tasmanian devil is rarely exposed
to UV or, alternatively, that the cells that propagate DFT1 andDFT2 are not those on the surface of cutaneous tumors, but
rather derive from non-exposed regions, such as the oral cavity
or deep within the tumor mass.
Early Somatic Mutations
Our analysis has not provided evidence that exogenous expo-
sures or germline risk contributed to DFT emergence. Next, we
further characterized the functional consequences of putative
somatic mutations in the two cancers. We identified 2,884
SNVs and 410 indels (DFT1), and 3,591 SNVs and 572 indels
(DFT2), which were present in the genomes of two sequenced
DFT1 tumors (86T and 88T, collected from Central Tasmania
in 2005 and Eastern Tasmania in 2007, respectively) or two
sequenced DFT2 tumors (202T2 and 203T3, both collected
from the Channel Peninsula in 2014), but were not detected in
the genomes of 46 normal devils (Figure 2C; Table S2). As we
do not have germline DNA from the DFT1 or DFT2 founder devils,
we cannot ascertain the provenance of these variants; however,
a subset will be early somatic variants that occurred after emer-
gence of each lineage and prior to divergence of the tumor iso-
lates analyzed here (Figure 2C). Only 18 (18 SNVs, 0 indels) of
these variants in DFT1 and 19 (16 SNVs, 3 indels) in DFT2 were
predicted to be non-synonymous, with no intersection between
the genes harboring non-synonymous variants in DFT1 and
DFT2 (Figure 2C; Table S2). None of these putative early somatic
non-synonymous SNV or indel mutations occurred in a set of
genes with confirmed causative involvement in human cancer
(http://cancer.sanger.ac.uk/cosmic/census/) (Tables S2 and
S3). Themajority of thesemutationswere predicted to be hetero-
zygous (Table S2). However, we observed that DFT1 harbored a
hemizygous nonsense mutation inWWC3 (R945* in exon 21/24),
and DFT2 carried a hemizygous truncating indel inMPDZ (S496X
in exon 9/47); in both cases, the second copy was deleted, likely
leading to complete loss-of-function (Tables S2 and S4). We
genotyped these variants across eight additional geographically
dispersed DFT1 tumors (WWC3) and two additional DFT2 tu-
mors (MPDZ) (Table S2); in both cases, the relevant variantCancer Cell 33, 607–619, April 9, 2018 609
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Figure 2. Single-Nucleotide Variants and In-
dels in DFT1 and DFT2
(A) Mutational spectra of single-nucleotide variants
(SNVs). Only SNVs that are unique to one tumor
within a lineage, and therefore likely to be somatic,
are displayed (n = 6,812 [DFT1], n = 626 [DFT2]).
Each bar represents a mutation category defined by
themutation type shown in upper gray panel, and its
immediate 50 and 30 base context; mutation classes
are presented in the order shown in (COSMIC,
2017), and prominent mutation types are labeled (N,
any base). Mutation counts are normalized to cor-
responding nucleotide triplet frequencies in the devil
genome.
(B) Best fit of two mutational signatures. Signatures
1 and 5, extracted from human cancers (Alexandrov
et al., 2013), were fitted to SNVs derived from DFT1
and DFT2. DFT1 and DFT2 SNVs were represented
by a pool of those that are unique to one tumor
within each lineage. Error bars display 95%
Bayesian credible intervals of the posterior proba-
bility after 105 Markov Chain Monte Carlo samples.
(C) Analysis of early somatic variants. Left, simplified
phylogenetic trees represent origins of DFT1 and
DFT2 from their respective founder devils, and their
respective divergence after the most recent com-
mon ancestor (MRCA) of the tumor isolates analyzed here (86T and 88T, DFT1) and (202T2 and 203T3, DFT2). Plausible range of somatic SNV and indel counts
within the trunk of each tree is indicated, with the upper bound defined by those variants shared between both tumor isolates in each lineage but not detected in
46 normal devil genomes. The upper bounds of early somatic non-synonymous mutations in each lineage is shown and, right, annotation of these variants is
represented. * indicates the truncating mutations in WWC3 and MPDZ are hemizygous as in both cases the second allele has been deleted.
See also Tables S2, S3, and S4.was present in all tumors analyzed, suggesting that these vari-
ants may be somatic mutations acquired early, prior to clonal
diversification. Interestingly, both WWC3 and MPDZ are pro-
posed to encode negative regulators of YAP1 and WWTR1/
TAZ, core effectors of the Hippo signaling pathway, which has
conserved roles in development, regeneration, and cancer
(Han et al., 2017; Juan and Hong, 2016; Moroishi et al., 2015;
Varelas et al., 2010; Zanconato et al., 2016). YAP1 and
WWTR1/TAZ are transcriptional co-activators that shuttle be-
tween cytoplasm and nucleus; in both DFT1 and DFT2 cells,
YAP1 and WWTR1/TAZ are expressed and show nuclear locali-
zation, indicating activity (Figure S1). The Hippo pathway has
been implicated in several human cancer histotypes, and is of
particular importance in Schwann cell cancers (Wu et al., 2018;
Zanconato et al., 2016).
Cytogenetics and Structural Variants
Structural variants (SVs) are another source of somatic variation
that may have contributed to DFT oncogenesis. Chromosome
painting revealed that the DFT2 karyotype (Pye et al., 2016b)
appears to have arisen via insertion of chromosome 6 into the
pericentric region of chromosome 2, forming a large derived
chromosome (Figure 3A). We used discordantly mapped
paired-end sequence reads and PCR screens to identify putative
somatic SVs in DFT1 and DFT2. The pattern of SVs in DFT1 re-
vealed a cluster of rearrangements on chromosome 2 that was
acquired prior to divergence of the tumors sequenced in this
study (Figure 3B; Table S5). We also identified a focus of SVs
on chromosome 1 in one DFT1 tumor, which marks the region
from which the extrachromosomal double minutes (DMs) in
this tumor derive (Taylor et al., 2017) (Figures 3A and 3B;610 Cancer Cell 33, 607–619, April 9, 2018Table S5). We identified 64 and 23 rearrangements involving
genes in one or both DFT1 genomes or in one or both DFT2 ge-
nomes analyzed here, respectively, but not in 34 normal devil ge-
nomes (Table S5). These predicted three DFT1-specific in-frame
fusion genes, PDZD11-RFX2, CAMK2A-NEURL1B, and EZH2-
ETNK2; the latter two potential fusion genes were found in only
one of two analyzed DFT1 tumors, and are thus unlikely to
have arisen early in DFT1 tumor evolution (Tables S3 and S5).
Genotyping of PDZD11-RFX2, however, confirmed its presence
in eight additional geographically dispersed DFT1 tumors (Table
S2), suggesting that it may be a somatic rearrangement that
occurred early in the DFT1 lineage. EZH2, encoding a histone
methyltransferase, is dysregulated in many cancers (Kim and
Roberts, 2016), but it is unclear if the disruption of this gene in
a subset of DFT1s has provided a selective advantage to this
lineage (Table S3). Overall, the DFT2 genomes analyzed here
have simpler structures and fewer rearrangements than those
of the DFT1 genomes analyzed here. However, similar microho-
mology-mediated repair processes operated during clonal evo-
lution of both DFT1 and DFT2 (Figure 3B; Table S5).
Telomeres
Rearrangements in cancer are frequently triggered by telomere
crisis (Maciejowski and de Lange, 2017). Tasmanian devils have
unusual telomeres characterized by extreme length dimorphism
between homologs (Bender et al., 2012). This feature has been
lost in DFT1, which carries uniformly short telomeres (Bender
et al., 2012). We used fluorescence in situ hybridization (FISH) to
examine telomere length in DFT2. Our analysis revealed that cells
derived from DFT2 exhibited telomere length dimorphism be-
tween homologs similar to normal cells (Figure 3C), and indicated
Figure 3. Structural Variation and Telo-
meres in DFT1 and DFT2
(A) Chromosome painting. Normal devil female,
DFT1 (tumor 88T) and DFT2 (tumor 203T3) meta-
phases hybridized with devil chromosome-spe-
cific fluorescent probes. DM, double minutes; the
Y chromosome lacks a specific probe and is
indicated with ‘‘Y’’; * indicates locations of overlap
between chromosome arms that were present in
images used to generate karyotypes.
(B) Structural variant (SV) mutations. Larger upper
circos plots represent likely somatic SVs shared
between 86T and 88T (DFT1) or 202T2 and 203T3
(DFT2), respectively, but that are not found in 34
normal devils. Lower circos plots represent SVs
that are uniquely found in one of the sequenced
tumors of the two lineages. DM, SVs involved in
double minutes. Blue or red lines connect chro-
mosomal coordinates involved in SV. Stacked bar
plots indicate percentage of breakpoints display-
ing short regions of microhomology, non-tem-
plated sequence insertions or blunt ends. n.s.,
Pearson’s chi square test, p > 0.05.
(C) Telomeres. Normal devil female, DFT1 (tumor
88T) and DFT2 (tumor 202T2) metaphases hy-
bridized with telomere-specific fluorescent probes
(green). Chromosomes are labeled red. DMs and Y
chromosome are indicated, as well as site of
integration of chromosome 6 into the derivative
chromosome 2 in DFT2.
See also Tables S3 and S5.that it was the chromosome 6 homolog with short telomeres that
was incorporated into chromosome 2 to generate the large deriv-
ative chromosome in DFT2 (Figure 3C). Thus, although loss of
telomere length dimorphism is not essential for the emergence
of transmissible cancers in Tasmanian devils, this species’ un-
usual telomere organization may contribute to risk of chromo-
somal rearrangement, which may predispose to DFT cancer.
Copy Number Variants
We next characterized copy number variants (CNVs) in the two
cancers. A comparison of CNVs in DFT1 and DFT2 confirmed
that all of the tumor isolates analyzed here are largely diploid
(Figure 4A; Table S4). Most CNVs in DFT1 and DFT2 involved
different genomic regions; however, an 18.4 megabase hemi-
zygous deletion on chromosome 3 was found in both lineages
(Figure 4A; Table S4). This CNV, which was not detected in 46
normal devil genomes suggesting that it is possibly somatic (Fig-
ure S2), reduces dosage of 74 genes in both DFT1 and DFT2
(Figure 4B and Table S4). One gene in DFT1 (MAST3) (Murchison
et al., 2012) and four genes in DFT2, including HGF and TP73,
have undergone homozygous deletion (Figure 4B; Table S4);
the other two homozygously deleted genes in DFT2,CACNA2D1
and ENSSHAG0000005243, are linked to HGF and TP73,
respectively. Interestingly, TP73 acts downstream of Hippo
pathway effectors to activate apoptosis (Moroishi et al., 2015).
Copy number gains have increased the dosage of 1,129 genes
in DFT1 and 501 genes in DFT2. Strikingly, we observed that
genes encoding the two platelet-derived growth factor
receptors (PDGFRs), PDGFRA and PDGFRB, were respectively
gained in copy number in DFT2 (copy number 4, focal amplifica-
tion) and some DFT1s (as part of extrachromosomal DMs)(Figure 4C;TablesS3andS4). This correlatedwith strongexpres-
sion of both PDGFRs inDFT1 andDFT2 (Figure 4C). Interestingly,
both PDGFA and PDGFB, encoding ligands for PDGFRs, have
undergone copy number gains in DFT1 (and PDGFA is addition-
ally involved in a SV in DFT1 [Murchison et al., 2012; Tables S4
and S5]). Furthermore, ERBB3 showed copy number gains in
DFT1 and is expressed in DFT1 (Hayes et al., 2017; Taylor
et al., 2017), and a subset of DFT1s carried gains of NRG2, en-
coding an ERBB ligand (Figure 4B; Tables S3 and S4).
Immune Genes and Loss of Y Chromosome
DFT clones must escape the host immune system despite their
statusasallogeneicgrafts. Interestingly,B2M, encodingacompo-
nent of MHC class I, has undergone hemizygous deletion in DFT1
(Figure 4D). This copy number loss may have contributed to the
downregulation of MHC observed in DFT1, resulting in this line-
age’s low immunogenicity (Siddle et al., 2013). We also observed
thatDFT1carriedaheterozygous truncatingmutation inCD40, en-
coding an immune co-stimulatory molecule that may be ex-
pressed together with MHC class II by Schwann cells (Figures 2C
and 4B) (Duan et al., 2007; Meyer zu Hörste et al., 2010).
DFT2 faces a further potential immunological challenge due to
its possession of the Y chromosome. This lineage arose in amale
devil and has, to date, usually been observed in males (of the 11
reported cases of DFT2, 9 involve a male host [Kwon et al.,
2018]). This apparent bias toward male hosts raises the possibil-
ity that females may be less susceptible to DFT2 due to immuno-
genicity of antigens derived from the Y chromosome. We inves-
tigated the stability of the Y chromosome in DFT2 by PCR
amplifying the Y-linked SRY locus in a panel of DFT tumors
and their male and female hosts (Figure 4E; Table S6). AsCancer Cell 33, 607–619, April 9, 2018 611
Figure 4. Copy Number Variation and Functional Annotation in DFT1 and DFT2
(A) DFT1 (tumor 88T) and DFT2 (tumor 202T2) autosomal copy number generated using read counts at 735,281 SNP loci. Each dot represents log2R, where
R = (read depth in tumor)/(read depth in 203H), at a single SNP. CN, copy number. Arrow, chromosomal origin of DMs; arrowheads, hemizygous deletion
identified in both DFT1 and DFT2.
(B) Illustration of gene alterations. In each Venn diagram, number of genes altered inR1 DFT1 tumors are shown in blue on the left, and number of genes altered in
R1 DFT2 tumors are shown in red on the right; numbers of genes that are similarly altered inR1 DFT1 andR1 DFT2 tumor are shown in pink in the center of each
diagram. Only autosomal genes are considered and ‘disrupted’ alleles include only predicted loss-of-function alterations. Genes-of-interest are written in text
beside diagrams. * indicates these genes are amplified on extrachromosomal DMs.
(legend continued on next page)
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expected, Y chromosome DNAwas not detected in DFT1, which
is derived from a female founder devil, regardless of the gender
of the host (Figure 4E). In DFT2, Y chromosome DNA was pre-
sent in DFT2 tumors in male hosts, as well as in one DFT2 tumor
in a female host, Devil 812 (Devil 812 also carried two DFT1 tu-
mors [Kwon et al., 2018]). However, the Y chromosome locus
could not be detected in the DFT2 tumor derived from the sec-
ond female host, Devil 637 (Figure 4E).
DFT1 and DFT2 Drug Screen
To gain further insight into the signaling pathwayswhich promote
DFT1 and DFT2 growth and survival, and to uncover potential
therapeutic vulnerabilities, we performed a high-throughput
in vitro drug sensitivity screen. Four DFT1 cell lines and two
DFT2 cell lines (Table S7) were treated with a 7-point titration
(1,000-fold concentration range) of 104 pre-clinical and clinical
compounds with activity against a wide range of molecular
targets (Figure 5A; Table S7) prior to cell viability quantification.
Hierarchical clustering based on half maximal inhibitory concen-
tration (IC50) values indicated that DFT1 and DFT2 are distin-
guishable from each other based on their drug sensitivity
(Figure 5B); however, the two cancers share a striking overall
similarity in drug response profile compared with several hun-
dred human cancer cell lines (Figures 5C–5F; Table S7 [Yang
et al., 2013]).
Both DFT1 and DFT2 are sensitive to a suite of inhibitors of re-
ceptor tyrosine kinases (RTKs) (Figure 5C). In particular, DFT1
cell lines are remarkably responsive to Afatinib, an inhibitor of
ERBB2 and EGFR (DFT1 cell lines top 0.4%–1.1% most sensi-
tive of 959 cell lines, geometric mean DFT1 IC50: 9.8 nM) (Fig-
ure 5C). This sensitivity is likely mediated by ERBB2 inhibition,
as DFT1 is resistant to Gefitinib and Erlotinib, agents that specif-
ically target EGFR (Table S7). Remarkably, DFT1 cell lines show
significantly greater sensitivity to Afatinib than a panel of ERBB2-
amplified human breast cancer cell lines (Figure 5E; geometric
mean DFT1 IC50: 9.8 nM, geometric mean ERBB2
+ Breast can-
cer cell lines IC50: 314.9 nM; p = 0.000516, Wilcoxon rank-sum
test). DFT2, on the other hand, is highly sensitive to Axitinib, a
compound with activity against PDGFR, KIT, and vascular endo-
thelial growth factor receptor (VEGFR) (DFT2 cell lines top 0.2%–
0.4%most sensitive of 854 cell lines, geometric meanDFT2 IC50:
5.0 nM) (Figure 5C). In addition, both DFT1 and DFT2 show
sensitivity to Dasatinib, a tyrosine kinase inhibitor whose targets
include PDGFR, ABL, SRC, ephrins, and KIT (geometric mean
DFT1 IC50: 7.5 nM; geometric mean DFT2 IC50: 6.4 nM) (Fig-
ure 5C). Both DFT1 and DFT2 are markedly sensitive to
CHEK1/CHEK2 inhibitor AZD7762, and poly-ADP ribose poly-
merase (PARP) inhibitors Talazoparib and Olaparib, suggesting
that DFT cancers are intolerant of DNA damage (Figure 5D;(C) Copy number and immunohistochemistry for PDGFRA and PDGFRB. Reads m
cn.MOPS (Klambauer et al., 2012); each dot represents log2R for a single bin, w
variants are represented by dashed gray lines connected by black lines. Genes a
PDGFRB are shown. Brown stain reports expression, counterstained with blue h
(D) Copy number at B2M locus. Copy number was determined and displayed as
(E) PCR amplification of the Y chromosome-linked SRY locus. DFT1 tumors (95T, 8
labeled in blue and red, respectively, and DFT1 hosts (95H, 88H, 812H, and 813H
upper panel shows SRY product and the lower panel shows positive control (RP
(Kwon et al., 2018). Red arrows highlight presence (812T1) or absence (637T1) o
See also Tables S3, S4, S5, S6, and Figure S2.Table S7), perhaps explaining the remarkable genomic stability
observed in DFT1 (Deakin et al., 2012; Murchison et al., 2012).
The response of DFT cell lines to Talazoparib was particularly
notable and is comparable with that of highly sensitive
human Ewing’s sarcoma cell lines (geometric mean DFT1 IC50:
33.1 nM, top 0.2%–2.0% of 922 cell lines, geometric mean
DFT2 IC50: 74.2 nM, top 0.7%–5.2% of 922 cell lines, geometric
mean Ewing’s IC50: 330.2 nM, top 0.3%–72.1% of 922 cell lines)
(Brenner et al., 2012; Garnett et al., 2012) (Figure 5F). This sensi-
tivity likely does not reflect defects in homologous recombina-
tion, aswe do not detect evidence for COSMICmutational signa-
ture 3 (Figure 2A; Table S2) (Alexandrov et al., 2015b; Alexandrov
et al., 2013; COSMIC, 2017; Nik-Zainal et al., 2012; Nik-Zainal
et al., 2016). Altogether, this screen highlights key vulnerabilities
inherent to DFT cells and strongly implicates RTK signaling in
driving oncogenesis of both DFT1 and DFT2.
DISCUSSION
DFT2 has changed our perception of the nature of transmissible
cancers. Previously, transmissible cancers were believed to
arise very rarely in nature, with the existing examples represent-
ing exceptional cases that had overcome strong natural barriers.
Indeed, the observation that all sampled transmissible venereal
tumors in dogs belong to a single clone which originated several
thousand years ago (Murgia et al., 2006; Rebbeck et al., 2009;
Strakova et al., 2016) suggests that such canine cancers appear
and disperse infrequently. However, the emergence of DFT2,
together with the discovery of several transmissible cancers in
marine bivalves (Metzger et al., 2015, 2016), suggests that
some speciesmay have a particular vulnerability for the develop-
ment of this type of disease and that, at least in these species,
transmissible cancers may be spawned relatively frequently.
The reason for Tasmanian devils’ apparent susceptibility to
transmissible cancers is not clear. The striking similarities in tis-
sues-of-origin, genome architectures, mutational processes,
driver gene candidates, and drug vulnerabilities, strongly sug-
gest that DFT1 and DFT2 belong to the same cancer type and
arose via similar oncogenic mechanisms. DFTs are likely of neu-
roectodermal origin, and may show differentiation toward the
neural crest-derived Schwann cell lineage (Murchison et al.,
2010). The closest human cancer histotype to DFT is not clear
(Loh et al., 2006b), and comparative studies with human and vet-
erinary cancers are further hampered by lack of knowledge of the
body site from which DFT cancers first arise. It is notable that,
although Tasmanian devils are reported to have high frequencies
of host-derived neoplasia (Griner, 1979), no lesions have been
described that are consistent with pre-transmissible DFT; given
that hundreds of wild and captive devils are routinely monitoredapping within 500 base pair genomic bins were counted and normalized using
here R = (read count tumor)/(read count 203H). CN, copy number. Structural
re represented as black bars, and locations and orientations of PDGFRA and
ematoxylin. Scale bar, 30 mm.
in (C). Bins within B2M are colored in black. CN, copy number.
8T, 812T2, and 813T1) and DFT2 tumors (202T2, 203T3, 812T1, and 637T1) are
) and DFT2 hosts (202H1, 203H, 812H, and 637H) are displayed in black. The
L13A) and diagnostic amplification product for confirmation of DFT1 or DFT2
f an SRY band in DFT2 tumors infecting female Tasmanian devils.




Figure 5. DFT1 and DFT2 Drug Screen
(A) Four DFT1 (85T, 86T, 87T, and 88T) and two DFT2 (203T3 and 809T) cell lines were screened against a panel of 104 drugs under clinical and pre-clinical
investigation in human oncology. Cell viability was measured after 144 hr.
(B) Hierarchical clustering of loge (IC50) values for 6 DFT cell lines (columns) screened with 104 compounds (rows).
(C and D) IC50 for DFT1 (blue) and DFT2 (red) cell lines for four receptor tyrosine kinase (RTK) inhibitors (C) or two DNA repair inhibitors (D). Gray dots represent
human cancer cell lines (GDSC set). Drug molecular targets are indicated. Horizontal bars represent geometric mean IC50. *p < 0.05, **p < 0.001; n.s., not
significant, Wilcoxon rank-sum test for DFT1 and DFT2 compared with human cell lines.
(E) Afatinib IC50 for 953 human cancer cell lines (All), 15 ERBB2-amplified human breast cancer cell lines (ERBB2
+ breast), and DFT1 and DFT2 cell lines.
Horizontal bars represent geometric mean IC50. **p < 0.001; n.s., not significant, Wilcoxon rank-sum test.
(F) Talazoparib IC50 for 922 human cancer cell lines (All), 21 Ewing’s sarcoma cell lines (Ewing’s), and DFT1 and DFT2 cell lines. Horizontal bars represent
geometric mean IC50. *p < 0.05, **p < 0.001; Wilcoxon rank-sum test.
See also Table S7.
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each year, this suggests that either such lesions are difficult to
detect or recognize or that DFT cancers arise rarely but carry a
high risk of becoming transmissible. Importantly, we cannot
completely negate the possibility that DFT1 and/or DFT2 arose
via a horizontal DNA transfer event involving an ancestral DFT
cell and a normal cell (Pye et al., 2016b); however, the lack of
germline and somatic genetic similarity between DFT1 and
DFT2 suggests that this scenario is unlikely.
We investigated genetic and phenotypic features of DFT1 and
DFT2, and compared the two lineages with each other and with
catalogs of known human cancer genes and drug sensitivity pro-
files. These data suggest an important role for RTK signaling,
most likely involving ERBB2 (DFT1 only) and PDGFRs (DFT1
and DFT2), in sustaining growth and survival of DFT cancers. In
this context, it is likely that copy number gains involving PDGFR
genes may have provided selective advantage in these cancers.
Furthermore, we noted thatPDGFRB has been amplified onDMs
in some DFT1s, and may be the positively selected driver
required to maintain this extrachromosomal DNA. We did not
identify anymutations in ERBB2 in DFT1. However, we observed
copy number gains involving ERBB3, encoding an ERBB2 heter-
odimerization partner, and NRG2, encoding an ERBB3 ligand
(Hynes and Lane, 2005; Taylor et al., 2017), suggesting a possible
mechanism for ERBB2 activation. Both DFTs show remarkably
few perturbations in known cancer genes, and only two genes
in DFT1 and five genes in DFT2 are predicted to have undergone
biallelic loss-of-function. Thus, the observation that DFT1 and
DFT2 both harbor predicted two-hit loss-of-function mutations
in genes encoding proposed regulators and effectors of Hippo
signaling (WWC3,MPDZ, TP73), togetherwith evidence for activ-
ity of Hippo effectors YAP1 and WWTR1/TAZ in DFT1 and DFT2
cells, raises the possibility that this pathway is involved in
DFT cancers in Tasmanian devils. The Hippo pathway plays
conserved roles in differentiation, proliferation, and regeneration
in several tissues (Moroishi et al., 2015;Yuet al., 2015; Zanconato
et al., 2016), and in the Schwann cell context drives transcrip-
tional upregulation of PDGF and ERBB signaling components
(Deng et al., 2017; Wu et al., 2018).
DFT clones must escape the host immune system despite
their status as allogeneic grafts. Although low Tasmanian devil
population genetic diversity may reduce capacity for foreign tis-
sue detection (Miller et al., 2011; Siddle et al., 2007), this species’
rejection of skin allografts (Kreiss et al., 2011) suggests that
DFT1 and DFT2 clones have specific adaptations favoring im-
mune escape. Our analysis did not identify any genomic aberra-
tions common to both cancers that might underlie such adapta-
tions, raising the possibilities that they may be epigenetically
controlled (Siddle et al., 2013), or that DFT cancers arise from
cell types that already harbor low immunogenicity. Nevertheless,
it is possible that hemizygous deletion of B2Mmay have contrib-
uted to downregulation of MHC class I in DFT1, although the re-
maining intact copy can be robustly expressed in response to the
inflammatory cytokine, interferon gamma (Siddle et al., 2013). In
DFT2, both copies of B2M remain intact, and B2M expression
has been detected in at least a subset of tumor cells (H. Siddle,
unpublished data). This suggests that DFT1 and DFT2 may have
adopted different strategies for immune evasion, although the
significance of these findings is not yet confirmed. Loss of Y
chromosome DNA in DFT2 may have rendered this cancer lessimmunogenic in female hosts, although we cannot exclude the
possibility that this loss is selectively neutral. If Y chromosome
loss is indeed a selective advantage to the lineage, we may
expect in future to observe Y-null DFT2 strains, perhaps derived
from several independent Y chromosome loss events, becoming
dominant in the population. Despite limited understanding of the
mechanisms of DFT immune evasion, recent observations of
natural immune responses against DFT1 (Pye et al., 2016a), as
well as allele frequency shifts indicative of selection in DFT1-
affected populations (Epstein et al., 2016), suggest that some
devils may be capable of mounting immune responses against
DFT cancers.
Altogether, our findings present the possibility that transmis-
sible cancersmay be a part of Tasmanian devils’ natural ecology.
Indeed, we did not find evidence for the involvement of exoge-
nous exposures or pathogens in DFT carcinogenesis, nor did
we identify any known cancer predisposition alleles in the in-
herited genomes of the DFT1 or DFT2 founder devils. Thus, it
seems plausible that additional DFTs occurred in the past but
escaped detection, perhaps because they remained in localized
populations or because they existed prior to the nineteenth-cen-
tury arrival of European documenters.
It is worth speculating about biological features specific to
devils that may spur DFT cancer development. Devils bite each
other frequently around the facial area, often causing significant
tissue injury (Hamede et al., 2013). Given the important roles for
Hippo and RTK signaling in wound-healing responses (Zanco-
nato et al., 2016), particularly in Schwann cells (Mindos et al.,
2017; Fex Svennigsen and Dahlin, 2013), it is tempting to spec-
ulate that DFT cancers may arise from aberrant maintenance of
proliferative cells involved in tissue repair after injury. Under this
model, the facial biting behavior of Tasmanian devils may predis-
pose these animals to emergence of cancers via tissue injury,
simultaneously providing a route of cell transmission. Further-
more, it is possible that anthropogenic factors may have indi-
rectly increased the risk of DFT emergence or spread in recent
years. For instance, it is possible that some modern land use
practices, such as pastoralism, may have provided favorable
conditions for devils, leading to elevations in local devil densities
(Guiler, 1970, 1982; Jones et al., 2004); this might have led to
increased intra-specific competition, perhaps increasing inter-
actions and fights, which may in turn have raised probabilities
of DFTs arising or spreading. Road construction may have
caused increased connectivity between devil populations,
providing more opportunities for DFTs to spread. Finally, perse-
cution of devils by European colonists (Hawkins et al., 2006) may
have contributed to this species’ low genetic diversity (Jones
et al., 2004), a possible risk factor for DFT immune escape and
disease spread (Siddle et al., 2007). In future, it will be important
to continue to monitor Tasmanian devils for evidence of addi-
tional DFT clones and to track the evolution and spread of
DFT1 and DFT2.
At present, there are few options for DFT treatment, and most
animals succumb to disease. Given the failure of conventional
chemotherapy agents against DFT1 (Phalen et al., 2013), the po-
tential for orally delivered, targeted therapies offer considerable
promise. We have shown that DFT1 and DFT2 are exquisitely
sensitive to a suite of RTK inhibitors, including those targeting
PDGFRs (DFT1 and DFT2) and ERBB2 (DFT1 only), as well asCancer Cell 33, 607–619, April 9, 2018 615
to inhibitors of DNA repair. The recent success of experimental
immunotherapy regimens against DFT1 (Tovar et al., 2017) opens
the possibility that therapies which combine RTK or PARP inhibi-
tion with immune activation may present new opportunities for
combatting DFT clones and saving the Tasmanian devil.
DFT1 and DFT2 arose from two unremarkable individuals,
which gave rise to cancers with strikingly similar, but subtly
different, histologic, genomic, and drug sensitivity phenotypes.
We have shown that, at least in Tasmanian devils, relatively sim-
ple genomic changes coupled with incessant growth factor
signaling spur the transition from somatic cell to parasitic clonal
lineage. Transmissible cancers in Tasmanian devils exploit a per-
verse niche created by their host species and illustrate one
context in which runaway selfish evolution can thrive.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Tissue Sampling and Ethics
Tissues were sampled from wild Tasmanian devils that were subsequently released, or from animals euthanized for welfare reasons.
All animal procedures were performed under a Standard Operating Procedure approved by the General Manager, Natural and
Cultural Heritage Division, Tasmanian Government Department of Primary Industries, Parks, Water and the Environment (DPIPWE),
in agreement with the DPIPWE Animal Ethics Committee, or under University of Tasmania Animal Ethics Committee Permit
A0014976. The project was approved by the University of Cambridge Department of Veterinary Medicine Ethics and Welfare
Committee, reference CR191.
Cell Lines and Cell Culture
DFT1 cell lines 86T and 88T have been previously described with the names 1426 and 4906 respectively (Siddle et al., 2013). DFT2
cell lines 202T2 and 203T3 cell lines were established as follows. Micro-biopsies of approximately 2 mm in diameter were collected
into RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) with 2% vol./vol. antibiotic-antimycotic (Thermo Fisher Scientific).
Biopsies were flushed through a tea-strainer sized metal mesh with amniomax (Thermo Fisher Scientific). Subsequently, cells
were plated in 6 well flat-bottomed plates (Corning Inc., Corning, NY, USA) with 3 ml amniomax and 2% vol./vol. antibiotic-antimy-
cotic, and placed at 35C with 5% atm. CO2. After 24 hr, medium was replaced and plates were incubated with the same conditions
for an additional 48 hr. Cells were then transferred into T25 flasks with the same medium, and after reaching confluence approxi-
mately 48 hr later, flasks were split and media changed to RPMI 1640; 1% vol./vol. GlutaMAX (Thermo Fisher Scientific); 10%
vol./vol. FCS (Bovogen Biologicals, Melbourne, VIC, Australia), 20% vol./vol. amniomax and 1% vol./vol. antibiotic-antimycotic.
We used MycoAlert (Lonza, Basel, Switzerland) and EZ-Mycoplasma Test (Biological Industries, Kibbutz Beit-Haemek, Israel) kits
to screen cell lines for Mycoplasma according to manufacturers’ instructions. Details about dates of sampling and Mycoplasma
status for cell lines sequenced in this study are indicated below.Name Year of Establishment Year of DNA Extraction Estimated Tumor Purity* Mycoplasma
86T 2005 2009 100% negative
88T 2007 2009 100% negative
202T2 2014 2015 100% positive
203T3 2014 2015 90-95% negative
*See SNV-based Tumor Purity Estimation for methods.Tables S1, S2, S6, and S7 and the Key Resources Table list information on all Tasmanian devil and DFT cell lines, as well as other
samples used in this study.
METHOD DETAILS
Cytogenetics
Chromosome-specific probes were derived from flow sorted chromosomes and hybridized with metaphases as described (Murch-
ison et al., 2012). For fluorescence in situ hybridization with telomeric probes, we used the Telomere PNA (Peptide Nucleic Acids)/Cy3Cancer Cell 33, 607–619.e1–e15, April 9, 2018 e4
kit (Dako, Glostrup, Denmark). There are two nomenclature systems in use for Tasmanian devil chromosomes (Deakin et al., 2012;
Pearse and Swift, 2006). These two systems differ in their designations of the two largest devil chromosomes, chromosomes 1 and 2.
The chromosome named chromosome 1 in the first system is named chromosome 2 in the second system, and vice versa. In this
study, we used the nomenclature adopted by Pearse and Swift (Pearse and Swift, 2006); this system is also used in the Tasmanian
devil reference genome (Murchison et al., 2012).
Histology
Tasmanian devil tissues were fixed in 10% Neutral Buffered Formaldehyde (Australian Biostain, Traralgon, VIC, Australia) for 24 hr
and selected tissues were cassetted (Techno Plas, St. Marys, SA, Australia) and processed overnight using a standard 15-hr
overnight procedure in the TP 1050 tissue processor (Leica Microsystems, Wetzlar, Germany). Tissues were orientated on the
EG1160 (Leica Microsystems), embedded in paraffin wax (Leica Microsystems) and sectioned at 3 microns using a Leica
RM2245 microtome and adhered to microscope slides (Menzel Gl€aser, Thermo Fisher Scientific) for 20 min at 60C. Sections
were deparaffinized, rehydrated and stained using Jung autostainer XL (Leica Microsystems) for Hematoxylin (Australian Biostain)
and Eosin, dehydrated, cleared, cover slipped (Leica Microsystems) and mounted in CV Mount (Leica Microsystems) (Hayes
et al., 2017).
Immunohistochemistry
Tasmanian devil tissues and tumors were sectioned at 3 microns, floated onto Superfrost plus slides (Menzel Gl€aser) and subjected
to standard deparaffinization and rehydration techniques using an automated stainer (Leica Microsystems). Antigen retrieval in tis-
sue sections was conducted in citrate buffer at pH 6.0 (Reveal Decloaker, Biocare Medical, Pacheco, CA, USA) at 120C for 8 min
using a Pascal pressure chamber (Dako) then cooled to 20C. Endogenous peroxidase activity was quenched using 3% hydrogen
peroxide (Ajax Finechem, Thermo Fisher Scientific) in methanol (Ajax Finechem) for 30 min. Detection of primary antibodies was
achieved using Mach1 Universal HRP-Polymer detection kit (Biocare Medical). Protein block (Background Sniper, Biocare Medical)
was applied for 20 min prior to application of primary antibodies. Polyclonal rabbit anti-human PDGFRA 1:800 (Cat#ab124392,
Abcam, Cambridge, UK), Monoclonal rabbit anti-human PDGFRB 1:50 (Cat#ab32570, Abcam), Polyclonal Rabbit anti-human
S100 1:1500 (Cat#Z0311, Dako), Monoclonal Mouse anti-human Neuron Specific Enolase 1:200 (Cat#M0873, Dako), Monoclonal
Mouse anti-human Cytokeratin 1:100 (Cat#M3515, Dako), Monoclonal Mouse anti-human Vimentin 1:800 (Cat#M0725, Dako),
Monoclonal Mouse anti-human Smooth Muscle Antigen 1:200 (Cat#M0851, Dako), Monoclonal Mouse anti-human Muscle Specific
Actin 1:50 (Cat#NCL-MSA, Leica Microsystems), Polyclonal Rabbit anti-human Periaxin 1:400 (Cat#HPA001868, Sigma-Aldrich,
St. Louis, MO, USA), Monoclonal mouse anti-human YAP1 1:100 (Cat#WH0010413M1, Sigma-Aldrich) and Polyclonal rabbit
anti-human WWTR1/TAZ 1:100 (Cat#T4077, Sigma-Aldrich) were diluted as indicated with antibody diluent (Dako) and applied
to both devil tumor and normal devil control tissues at room temperature for 30 min. Negative control was omission of primary anti-
body with buffer substitution. Universal HRP-polymer was applied for 30 min (MRH538L10, Biocare Medical) followed by 1 drop of
Betazoid DAB Chromogen 3,3 Diaminobenzidine (BDB900G, Biocare Medical) in 1 ml of substrate buffer (DB900, Biocare Medical)
applied for 4 min. Tris-buffered saline (Biocare Medical) was used to rinse between all steps. Slides were rinsed, stained with
Carazzi’s Hematoxylin for 5 min, washed for 3 min in tap water, dehydrated, cleared, cover slipped (CV5030, Leica Microsystems)
and mounted in CV mount (Leica Microsystems) (Hayes et al., 2017). Sections were viewed under light microscopy using Olympus
BX41 (Olympus Corporation, Shinjuko, Tokyo, Japan) and selected areas were photographed using a digital camera (DP20,
Olympus Corporation).
Sample Processing and Sequencing
DNA Extraction
DNA from all samples except for 86T and 88T was extracted using the DNeasy Blood and Tissue extraction kit (Qiagen, Hilden,
Germany). DNA from 86T and 88T was extracted using the Genomic-Tip kit (Qiagen).
Library Preparation
500 ng of genomic DNA was fragmented (average size distribution 425 base pair (BP), LE220, Covaris, Woburn, MA, USA), purified,
libraries prepared (Agilent SureSelect XT, HSQ, Agilent Technologies, Santa Clara, CA, USA), and index tags applied (Sanger 168 tag
set). Index tagged samples were amplified (6 cycles of PCR, KAPA HiFi kit, KAPA Biosystems, Wilmington, MA, USA), quantified
(1k assay, LabChip GX, PerkinElmer, Waltham, MA, USA), then pooled together in an equimolar fashion.
High-Coverage DNA Sequencing
Pooled samples were quantified (1K assay, Bioanalyzer, Agilent Technologies), normalized (6 nM), and submitted to cluster
formation for HiSeq V4 sequencing (125 BP paired-end (PE) reads, Illumina, San Diego, CA, USA). We sequenced the equivalent
of two lanes per tumor, and one lane per host; however, sequencing was multiplexed across several lanes. The table below
indicates average insert size, read length and average read depth for samples sequenced at high coverage in this study (see
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ID Average Sequencing Depth Average Insert Size Read Length
202H1 49 X 417 BP 125 PE
202T2 67 X 418 BP 125 PE
203H 45 X 428 BP 125 PE
203T3 70 X 429 BP 125 PE
86T 86 X 430 BP 125 PE
88T 67 X 428 BP 125 PESequence reads were aligned to the Tasmanian devil reference genome Devil7.1, an in-house assembly which is identical to the
publicly available Devil7.0 (http://www.ensembl.org/Sarcophilus_harrisii/Info/Index), except Devil7.1 excludes the mitochondrial
contig. Throughout the study, we used custom scaffold identifiers. Correspondence between our scaffold identifiers and those
used in Devil7.0 can be found at Mendeley Data (https://doi.org/10.17632/znfphvhmbv.1). Alignment was performed using BWA-
backtrack (Li and Durbin, 2009) and duplicate flagging and removal was conducted using PICARD (DePristo et al., 2011).
Low-Coverage DNA Sequencing
Thirty normal genomes were additionally sequenced at low coverage (1 X) (Table S2). Library preparation and sequencing were
performed as described for high-coverage genomes. Reads were aligned to Devil7.1+MT with BWA-MEM.
Published Normal Devil Genomes
We included data from two previously sequenced normal Tasmanian devil genomes, 31H and 91H, in this study ((Murchison
et al., 2012); 31H and 91H are the ‘‘male’’ and ‘‘female’’ normal genomes respectively). However, only a subset of 31H
data (lanes 999#1, 999#2, 999#3, 999#4, 999#6, 1000#1, 1000#2, 1000#4, 1000#6, 1000#7, 1000#8, 1002#1, 1002#7, 1003#1,
1003#2, 1003#3, 1003#7) were included, as some lanes fell below sequencing quality thresholds (average sequencing coverage
for this sample was 17 X). Two previously sequenced DFT1 tumors from this study, 53T and 87T (Murchison et al., 2012), were
not included in the current study, as they fell below sequencing quality thresholds. Twelve previously sequenced devil normal
genomes were also used in this study (Wright et al., 2017) (Table S2). These were aligned to Devil7.1+MT with BWA-MEM.
Whole Genome Amplification
Whole genome amplification was performed to create DNA stocks for PCR screening. Depending on the concentration, 1-2 ml of
DNA (concentration range 20 to 50 ng/ml) from each sample was used as input for whole genome amplification using the illustra
GenomiPhi V2 DNA Amplification kit (GE Healthcare, Chicago, IL, USA).
SNV Validation
We performed experimental validation on a set of 96 single-nucleotide variants (SNVs) obtained through our computational filtering
pipelines. The SNVs selected for validation were derived from computation sets found in both DFT1s (86T and 88T), both DFT2s
(202T2 and 203T3) or in all four tumors (86T, 88T, 202T2, 203T3). Primers were designed around each SNV (Table S2) and used
to amplify a 500 BP region around the SNV site with conditions as follows. Template DNA was an equal volume pool of whole
genome amplified DNA from 86T, 88T, 202T2 and 203T3.Ingredient Company Volume (ml)
Water - 6.2
Phusion HF buffer (5x) Thermo Fisher Scientific 4.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 3.0
Primer reverse (10 mM) Sigma-Aldrich 3.0
Template DNA - 2.0
Phusion HF Polymerase Thermo Fisher Scientific 0.2
Total - 20.0
Step Duration (s) Cycles




Final elongation (72C) 300 1
Final cooling (4C) - 1
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Amplification products were purified with the QIAquick PCR purification kit (Qiagen), and pooled in roughly equimolar quantities.
Pooled amplicon DNA was quantified (dsDNA BR assay, Thermo Fisher Scientific), purified, libraries prepared (NEBNext Sanger
Sequencing Kit, New England Biolabs, Ipswich, MA, USA), and index tags applied (Sanger 168 tag set). Index tagged samples
were amplified (8 cycles of PCR, KAPA HiFi kit, KAPA Biosystems), quantified by qPCR (KAPA Library Quant Kit, KAPA Biosystems)
and submitted to cluster formation for MiSeq sequencing (300 BP PE read length, Illumina).
12,831,254 sequence readswere obtained and aligned to 2000BPwindows around each of the 96SNV loci in theDevil7.1 reference
usingBWA-MEM (Li, 2013); the95 loci (onePCR failed) hadamedian readcoverageof 70,941X (range1,730X to481,111X).Wemanu-
ally inspected each of the 95 loci using the Integrative Genomics Viewer (IGV) (Thorvaldsdóttir et al., 2013) to ensure alignment accu-
racy. As the template DNA used in this experiment was a pool of DNA from four tumors, and each SNVwas predicted to be present, at
least in the heterozygous state, in at least two of the four tumors, theminimum variant allele fraction (VAF), for the predicted alternative
allelewasexpected tobe0.25. In order to distinguish truealleles frombackground sequencing errors,wefirst usedalleleCount (https://
github.com/cancerit/alleleCount) to calculate VAF for the two nucleotide bases that were neither the reference allele nor predicted
alternative allele. We fitted a gamma distribution to these ‘‘background VAFs’’ and used this distribution to test if our predicted alter-
native allele VAF was significantly different to background. Predicted alternative alleles with VAF values that fell above 95% of the cu-
mulative probability under the gammacurvewere defined as validatedSNVs.Overall, 93/95 SNVswere validated, detailed in TableS2.
SNV Genotyping across Normal Panel
We PCR screened each of the 93 validated SNVs across a panel of 30 normal devils to confirm genotyping accuracy. Whole genome
amplified DNA from 30 devils was distributed with equal volume into three pools of 10 devils (Table S2). PCRs were performed, am-
plicons were pooled, libraries prepared and MiSeq sequencing performed (see section SNV Validation) with 300 BP PE reads.
12,116,462 sequence reads were generated, and mapped to 2000 BP windows around each of the 95 SNV loci in Devil7.1 using
BWA-MEM (Li, 2013) with a median read depth of 80,778 X (range 1,594 X to 328,569 X). Using the same approach outlined above
(see section SNV Validation), we obtained the classification results summarized in Table S2.
SNV Genotyping of WWC3 and MPDZ Mutations
To assess the somatic pervasiveness of hemizygous WWC3 SNV (DFT1) and MPDZ indel (DFT2) predicted loss-of-function muta-
tions, we used the following sequencing approach. We PCR amplified (primers WWC3 forward and WWC3 reverse, see Key Re-
sources Table) a 200 BP region around the affected WWC3 locus on exon 21 in ten tumors 36T2, 85T, 86T, 87T, 88T, 95T, 96T,
221T, 331T and 333Ta which cover a wide spatiotemporal range (Table S2). Similarly, a region around the frameshift MPDZ indel
on exon 9 was amplified (primers MPDZ forward and MPDZ reverse, see Key Resources Table) in the four DFT2 tumors 202T2,
203T3, 338T and 339T (Table S2). PCR products were cleaned up with the QIAquick PCR Purification kit (Qiagen). Products were
then capillary sequenced with the corresponding PCR primers WWC3 forward and MPDZ forward (Key Resources Table).Ingredient Company Volume (ml)
Water - 5.5
PCR buffer (10x) Qiagen 5.0
dNTP-mix (2.5 mM each) Qiagen 4.0
Primer forward (10 mM) Sigma-Aldrich 7.5
Primer reverse (10 mM) Sigma-Aldrich 7.5
Template DNA - 20.0
Taq Polymerase Qiagen 0.5
Total - 50.0
Step Duration (s) Cycles




Final elongation (72C) 300 1
Final cooling (4C) - 1SV Validation
Candidate Structural Variants (SVs) were validated with PCRs spanning breakpoints. PCR primers are listed in Table S5, and PCR
conditions are listed below. Of the 345 candidate SVs, 345 (100%) were validated (Table S5). Candidate somatic SV amplicons
were sequenced on the Illumina MiSeq platform. Amplicons were purified and libraries generated as described above in SNV Vali-
dation and were sequenced with 300 BP PE reads.e7 Cancer Cell 33, 607–619.e1–e15, April 9, 2018
Ingredient Company Volume (ml)
Water - 8.3
CoralLoad buffer (10x) Qiagen 2.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 3.0
Primer reverse (10 mM) Sigma-Aldrich 3.0
Template DNA - 2.0
Taq Polymerase Qiagen 0.1
Total - 20.0
Step Duration (s) Cycles




Final elongation (72C) 300 1
Final cooling (4C) - 1SV Genotyping across Normal Panel
We screened all PCR validated SVs across a panel of 34 normal devil genomes. Briefly, whole genome amplified DNA from 34 devils
was pooled in equal volume into four pools (3 pools of 10 devils, and 1 pool of 4 devils that comprised DNA from 202H1, 203H, 31H
and 91H; Table S2) and PCRs were conducted with the reagents and conditions as described above (see section SV Validation). SVs
that amplified in any one of the normal pools were classed as germline, and those which were not amplified in any of the normal pools
were retained as candidate somatic. The SVs predicted to be unique to a single tumor were validated by confirming their absence by
PCR in other tumors (Table S5).
SV Genotyping of PDZD11-RFX2
In order to establish the somatic pervasiveness of a detected intron-to-intron structural variant interlinking genes PDZD11
and RFX2 across the DFT1 tumor phylogeny, we used a similar PCR strategy as described above for the WWC3 and MPDZ
mutation screening. Briefly, a 231 BP amplicon involving breakpoints on chromosomes 2 and X, was obtained in eight additional
DFT1 tumors 36T2, 85T, 87T, 95T, 96T, 221T, 331T and 333Ta (Table S2). Primers used were PDZD11-RFX2 forward and
PDZD11-RFX2 reverse (Key Resources Table), and PCR conditions are listed below.Ingredient Company Volume (ml)
Water - 5.3
CoralLoad buffer (10x) Qiagen 2.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 3.0
Primer reverse (10 mM) Sigma-Aldrich 3.0
Template DNA - 5.0
Taq Polymerase Qiagen 0.1
Total - 20.0
Step Duration (s) Cycles




Final elongation (72C) 300 1
Final cooling (4C) - 1
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DFT Diagnostic PCRs
A multiplex DFT diagnostic PCR has been developed to confirm DFT1 or DFT2 diagnosis (Kwon et al., 2018). Briefly, the PCR incor-
porates three primer sets, respectively targeting a DFT1-specific structural variant, a DFT2-specific structural variant, and the
RPL13A locus, which acts as an internal positive control. The PCR was performed as described (Kwon et al., 2018).
Y Chromosome PCRs
Samples included in this analysis are listed in Table S6. Whole genome amplified DNA was used as a template for amplification of
SRY or a set of DFT1/DFT2 diagnostic markers as follows with primers SRY forward and SRY reverse (Key Resource Table).Ingredient Company Volume (ml)
Water - 11.3
PCR buffer (10x) Qiagen 2.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 1.5
Primer reverse (10 mM) Sigma-Aldrich 1.5
Template DNA - 2.0
Taq Polymerase Qiagen 0.1
Total - 20.0
Step Duration (s) Cycles




Final elongation (72C) 300 1
Final cooling (4C) - 1Drug Screen
Automated High-throughput Screen
Details of cell lines used in drug screen are presented in Table S7. Cells were seeded into 384-well plates using a XRD-384 (FluidX,
Brooks Automation, Chelmsford, MA, USA) reagent dispenser. The number of cells seeded was individually optimized for each cell
line to maximize the dynamic range of the assay: 85T = 600, 86T = 1200, 87T = 2000, 88T = 1600, 203T3 = 3200, 809T = 1600. Com-
pounds were stored in Storage Pods (Roylan Developments, Fetcham, UK) providing a moisture-free, low oxygen environment, and
protection from UV damage. Compounds were screened using a 7-point dose response curve and a linear half-log dilution series
covering a 1000-fold concentration range. The dosing of the compounds was carried out using an Echo 555 (Labcyte, San Jose,
CA, USA) acoustic dispenser and the duration of drug treatment was 144 hr (6 days). Cell number at the end of 6 days was measured
using CellTitre-Glo 2.0 (Promega, Madison, WI, USA) reagent. 85T, 86T, 87T and 88T cell lines were screened as a single technical
replicate in each of two separate screening runs. 203T3 cell line was screened in duplicate in each of two separate screening runs.
809T was screened in duplicate in each of two separate screening runs for a proportion of compounds, and was screened as a single
replicate on the remaining proportion of compounds. Fluorescence intensity data from screening plates for each dose response
curve was fitted using a multi-level fixed effect model (Vis et al., 2016).
Manual Follow-up Screen
We performed a follow-up drug screen to further elucidate the drug sensitivity of DFT1 cell lines to dual EGFR and ERBB2 inhibitors.
Specifically, DFT1 showed particular sensitivity to Afatinib, an inhibitor of both ERBB2 and EGFR (Table S7). The observation that
DFT1 cell lines were resistant to Gefitinib, an inhibitor of EGFR, suggests that the sensitivity to Afatinib is mediated by ERBB2.
We further tested this hypothesis bymanually screening DFT1 cell lines (85T, 86T, 87T, 88T) and three human cancer cell line controls
(A549, AU565 and PC-9) with Erlotinib and Gefitinib (EGFR inhibitors), and Lapatinib and Afatinib (EGFR and ERBB2 inhibitors), as
displayed in Table S7.
The control human cancer cell lines have the following known sensitivities. PC-9 has a drug sensitive deletion in EGFR (E746-A750
in exon 19) and is thus susceptible to EGFR inhibitors (Bean et al., 2007; Li et al., 2008). PC-9 cells are known to be highly sensitive
to Gefitinib, Afatinib, and Erlotinib while exhibiting only a very modest sensitivity to Lapatinib (Bean et al., 2007). AU565 is an ERBB2-
dependent breast cancer cell line and as such is sensitive to the ERBB2 inhibitors Afatinib and Lapatinib, but is insensitive to drugs
targeting only EGFR. A549 is a human lung adenocarcinoma cell line with an oncogenic KRAS G12S point mutation, displaying
resistance to both EGFR and ERBB2 inhibitors (Li et al., 2008). DFT1 cell lines and A549 were grown in DMEM/F-12 media,
AU565 and PC-9 were grown in RPMI-1640 media. All cells were maintained at 37C and 5% CO2.e9 Cancer Cell 33, 607–619.e1–e15, April 9, 2018
Dose-response curves were obtained by setting up 96-well cell culture plates for each drug. DFT1 cells in each well were dosed
with drugs at exponentially decreasing concentration. The maximum drug concentration was 1 mM. The cells were cultured in the
presence of drugs for 48 hr. A fluorescence-based live-cell assay (Thermo Fisher Scientific) was used to detect cell viability. After
live-cell detection, the cells were fixed overnight. On the next day, the cells were prepared for fixed cell detection. Cells were washed
two times with 200 ml/well of water and stained with Syto60 1:5000 (Thermo Fisher Scientific). After 1 hr of incubation at room tem-
perature, plates were washed two times with 200 ml/well of water. Lastly, 100 ml of water was added to each well and the plate was
detected. The experiment was repeated in triplicates for each cell line and drug. IC50 values from this experiment are shown below as
loge(mM) concentrations, indicate that DFT1 is resistant to Erlotinib, and that 3 of 4 DFT1 cell lines here tested show sensitivity to
Lapatinib under these conditions (Table S7).
QUANTIFICATION AND STATISTICAL ANALYSES
Bioinformatics downstream analyses of ancestral data, mutational calls and drug screen results were performed in the R language for
statistical computing (R Core Team, 2015), using existing Bioconductor libraries (Huber et al., 2015) and customized scripts.
Devil Population Analysis
Wegenotyped tumors 86T and 88T (DFT1), tumors 202T2 and 203T3 (DFT2), and normal devils 202H1, 203H and 91H against a panel
of previously ascertained variants (Br€uniche-Olsen et al., 2016). Of the 2,281 variants described by Br€uniche-Olsen et al., we
excluded (i) indels, (ii) single nucleotide polymorphisms (SNPs) falling into RADseq-fragments ambiguously mapping to the reference
genome (i.e. >2 mismatching bases or one or more alignment gaps of total length >2 BP), (iii) SNPs mapping in windows of 5 BP
around simple repeats, 500 BP around contig ends or 1,000 BP around scaffold ends, (iv) SNPs mapping to the X chromosome
and (v) SNPs falling into regions which are non-diploid in any of the tumor samples (Table S4). In addition, using the genotypes pro-
vided by Br€uniche-Olsen et al., we excluded those SNPs which showed limited variation across the population. Specifically, for each
SNP we computed the proportion of individuals that shared identical genotypes. SNPs were ranked by the proportion of individuals
sharing identical genotypes, and those SNPs which were within the group of 60% least varying across the population were excluded.
Finally, if >1 SNPmapped to the same RADseq fragment, only the SNPmapping closest to the 5’ end of the fragment (with respect to
the reference) was selected for further analysis. These steps provided a final set of 320 SNPs.
Of the 527 individuals genotyped in (Br€uniche-Olsen et al., 2016), we excluded any individual with missing genotype data at more
than 20%of loci. For the remaining 398 individuals, we extracted the genotypes assigned in (Br€uniche-Olsen et al., 2016). Genotypes
across DFT1 tumors 86T and 88T, DFT2 tumors 202T2 and 203T3, as well as normal devils 91H, 202H1 and 203H were genotyped
at the 320 SNP loci using alleleCount (https://github.com/cancerit/alleleCount). Sites with <7 read coverage were marked asmissing
data, and remaining sites were coded as follows:
(i) homozygous 1/1: >70% reads support allele 1
(ii) heterozygous 1/2: >30% and <70% reads support alleles 1 and 2
(iii) homozygous 2/2: >70% reads support allele 2
Our 1 and 2 allele definitions were used as per Br€uniche-Olsen et al. (2016). Missing genotypes across all 405 individuals were
imputed by adopting the genotypes of the closest related SNP, as measured by Euclidian distance across the sample set.
Hierarchical clustering was then performed by applying the default R hclust() function (method: ’complete’), defining each geno-
type value as follows:
(i) homozygous 1/1: 0
(ii) heterozygous 1/2: 0.5
(iii) homozygous 2/2: 1SNV and Indel Analysis
SNV and Indel Calling
We used Platypus version 0.8.1 for detecting and genotyping single nucleotide variants (SNVs) and small insertions and deletions
(indels) (Rimmer et al., 2014). Variants were ascertained from the high-coverage genomes sequenced in this study (86T, 88T,
202T2, 203T3, 202H1, 203H) as well as from two previously sequenced devil genomes (31H, 91H) (Tables S1 and S2). Platypus
was run twice on each BAM file with two different settings: (i) default mode with additional flags –minReads=3 and –minPosterior=0,
(ii) default mode with –minReads=3, –minPosterior=0, –minFlank=0 and –trimReadFlank=10. Variants flagged with badReads, MQ,
strandBias, SC and QD were removed, and remaining variants were merged into a single file and genotyped across each sample.
Genotyped variants flagged with badReads, MQ, strandBias, SC and QD were removed for both SNVs and indels. The final variant
list contained 1,882,666 SNVs and 356,570 indels genotyped across the set of tumors (86T, 88T, 202T2, 203T3) and hosts (202H1,
203H, 91H, 31H). The following post-processing steps were applied to our set of genotyped SNVs and indels.Cancer Cell 33, 607–619.e1–e15, April 9, 2018 e10
(i) Homozygous-variant-in-reference filter. Sample 91Hwas used to assemble the Tasmanian devil reference genome (Murchison
et al., 2012). This implies that variants called with a high variant allele fraction (VAF, proportion of reads at a base position
supporting the variant allele) in this sample are likely to represent reference assembly errors. Thus, SNVs and indels called
with VAF >0.9 in sample 91H were discarded from our variant list.
(ii) Strand bias filter. In regions with total coverage R11 across all eight samples, we rejected variant calls with less than 20%
support on either forward or reverse sequencing strands. In regions with total coverage <11 reads across all samples, we
removed variants that had less than two supporting reads in either forward or reverse direction.
(iii) Sequencing noise filter. Low-VAF SNVs and indels were found across all samples, including hosts, and therefore likely reflect
consistent sequencing noise or alignment artefacts in these positions. A variant with VAF <0.2 in all samples withR1 support-
ing reads was discarded if at least one of the host samples had R1 supporting reads.
(iv) Simple repeats regions filter. SNVs and indels lying within a 5 BP window around simple repeat regions, as annotated by Tan-
dem Repeat Finder (Benson, 1999), were discarded.
(v) Regions filter. The Tasmanian devil reference genome (Devil7.1) is a scaffold-level assembly, consisting of 237,291 contigs
assembled into 35,974 scaffolds. We rejected any variant mapping within 500 BP from the start or end of a contig, or within
1000 BP from the start of end of a scaffold. In addition, variant calls mapping to scaffolds not assigned to a chromosome were
discarded.
Combined, these filtering steps left 988,972 SNVs and 194,250 indels. We further genotyped these across our panel of 30 low-
coverage normal devil genomes and 12 previously published normal devil genomes (Wright et al., 2017) using Platypus with settings
–minPosterior=0 and –minReads=0.
SNV and Indel Subsetting
We classified our variants into different categories, outlined below. Number of variants in each set is indicated in table below.
(i) Germline variants, which are present in the Tasmanian devil population, were defined as variants which had R5 supporting
sequence reads in high-coverage normal genomes 91H, 202H1 or 203H, or R1 supporting sequence read in genome 31H
and 42 low-coverage normal genomes (samples listed in Table S2).
(ii) Potentially somatic variants are shared between both tumors of the same lineage, or all four tumors, with R5 reads in each
tumor, but have <5 reads in each of the three high-coverage normal devil genomes 91H, 202H1 and 203H, and 0 reads in
genome 31H and 42 low-coverage normal devil genomes (Table S2). This set includes the following three subsets:
DFT1 Potentially Somatic Variants. Present withR5 reads in 86T and 88T, but%5 reads in DFT2 tumors and 202H1, 203H and 91H
normal devil genomes, and 0 reads in genome 31H and 42 low-coverage normal devil genomes (Table S2). These represent both
germline variation that was inherited by the DFT1 founder devil, but that is not captured in the DFT2 founder devil, nor in the normal
genomes examined here; and somatic variants that were acquired before divergence of 86T and 88T.
DFT2 Potentially Somatic Variants. Present with R5 reads in 202T2 and 203T3, but %5 reads in DFT1 tumors and normal devil
genomes 202H1, 203H and 91H, and 0 reads in genome 31H and 42 low-coverage normal devil genomes (Table S2). These represent
both germline variation that was inherited by the DFT2 founder devil, but that is not captured in the DFT1 founder devil, nor the normal
genomes examined here; and somatic variants that were acquired before divergence of 202T2 and 203T3.
DFT1 and DFT2 Potentially Somatic Variants. Present with R5 reads in 86T, 88T, 202T2 and 203T3, but %5 reads in normal devil
genomes 202H1, 203H and 91H, and 0 reads in genome 31H and 42 low-coverage normal devil genomes (Table S2). These poten-
tially represent both germline variation that was inherited by both the DFT1 and DFT2 founder devil, but that is not captured in the
normal genomes examined here; and somatic variants that were acquired by DFT1 before the divergence of 86T and 88T, and
were also independently acquired by DFT2 before the divergence of 202T2 and 203T3.
(iii) Tumor-unique variants are those variants that are present withR5 reads in only one tumor, and are supported by <5 reads in
every other tumor and normal genomes 91H, 202H1 and 203H, as well as 0 reads in genome 31H and 42 additional normal
genomes (Table S2). These variants could be newly arising somatic mutations that occurred after divergence of 86T-88T or
202T2-203T3 from their most recent common ancestor (MRCA) tumors; or germline variants inherited by the DFT1 or DFT2
founder devils but not shared with the normal panel, or somatic mutations that arose before the MRCA of 86T-88T or 202T2-
203T3, that were subsequently lost in one tumor due to back mutation or copy number loss.
(iv) Remainder variants comprise SNVs or indels which are either (i) represented by support from R5 reads in at least one DFT1
and one DFT2 tumor, but not found with R5 reads in all four tumors, not found with R5 reads in any high-coverage normal
genomes (202H1, 203H, 91H) or with >0 reads in 31H and 42 low-coverage hosts (Table S2); or (ii) supported by <5 reads in
ascertainment panel samples (86T, 88T, 202T2, 203T3, 202H1, 203H, 91H).
The table below indicates number of variants belonging to each category outlined above. Panels on right indicate with ‘‘x’’ the
presence and "-" the absence of variants belonging to each category within each sample.e11 Cancer Cell 33, 607–619.e1–e15, April 9, 2018
Set SNVs Indels 86T 88T 202T2 203T3 Normal Devils
Total 988,972 194,250

























































Remainder 1,104 1,162 x x x x xGenome browser visual assessments of 75 individual variant calls yielded false positive call rates of <5% for SNVs (2/75) and <15%
for indels (9/75).
SNV and Indel Annotation
Of the 602 genes in the COSMIC Cancer Gene Census (http://cancer.sanger.ac.uk/census/; downloaded on 17/05/2016), 490 were
annotated in the Ensembl Devil7.0 genebuild (http://www.ensembl.org/Sarcophilus_harrisii/Info/Index). An additional 69 genes were
annotated only in the NCBI 101 annotation gene set (https://www.ncbi.nlm.nih.gov/genome/annotation_euk/Sarcophilus_harrisii/
101/; downloaded on 17/05/2016), but were not in the Ensembl gene set; thus, 43 cancer geneswere not detectable in the Tasmanian
devil reference genome (Table S3). SNV and indel subsets were annotated with the Ensembl variant effect predictor (VEP) using
default settings (McLaren et al., 2010) (Tables S2, S3, and S4). We also ran an alternative variant caller, SAMtools mpileup, specif-
ically on the COSMIC Cancer Gene Census gene set (Table S3) and searched manually for additional protein-altering variants, how-
ever, this did not detect additional variants.
SNV-Based Tumor Purity Estimation
Tumor DNA sequenced in this study was derived from cell lines, and thus is likely to be relatively pure. However, it is possible, partic-
ularly for early passage cell lines, that host cells remain in culture. We assessed the purity of 86T, 88T, 202T2 and 203T3 by examining
VAF of germline SNVs. This analysis revealed that 86T, 88T and 202T2 contain only tumor DNA, whereas 203T3 had approximately
5-10% host DNA at the time when DNA was collected for sequencing.
Copy Number Analysis
Scaffold Exclusion
The Tasmanian devil genome Devil7.1 has 35,974 scaffolds, most of which are assigned to chromosomes (Murchison et al., 2012),
with scaffolds ordered along chromosomes using synteny with the opossum genome (Mikkelsen et al., 2007; Murchison et al., 2012).
Short scaffolds, for which synteny with the opossum genome could not be determined, are placed at the end of each chromosome.
We excluded these latter scaffolds from copy number analysis, together with the entire X chromosome. Coordinates of excluded
scaffolds are listed below.Chromosome Excluded Scaffolds
1 Chr1_supercontig_000000399 to Chr1_supercontig_000006728
2 Chr2_supercontig_000000501 to Chr2_supercontig_000008380
3 Chr3_supercontig_000000417 to Chr3_supercontig_000007196
4 Chr4_supercontig_000000317 to Chr4_supercontig_000006728
5 Chr5_supercontig_000000218 to Chr5_supercontig_000003187
6 Chr6_supercontig_000000194 to Chr6_supercontig_000002843
X Chrx_supercontig_000000000 to Chrx_supercontig_000002377
Un ChrU_supercontig_000000000 to ChrU_supercontig_000000439Copy Number Calling
We used the read-depth based algorithm cn.MOPS to assign copy numbers to genomic segments of our four high-coverage tumor
genomes (Klambauer et al., 2012). Samples 91H, 202H1 and 203H served as normal controls. Briefly, read-depths were counted in
500 BP bins across selected scaffolds using cn.MOPS getReadCountsFromBAM(), and coverage was normalized to the mode. After
modelling copy number posterior likelihoods between copy number (CN) 0 and CN6 for each 500 BP bin in each sample, the
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Copy Number Filtering
Each candidate copy number variant (CNV) (defined as a segment with CNs2) was filtered through a number of steps. First, the min-
imum size of copy number changes specific to a unique tumor within either the DFT1 or DFT2 lineage (tumor-unique CNVs) was set to
5000 BP, i.e. at least 10 neighboring bins of 500 BP. To further validate tumor-unique CNV segments, we conducted quantitative,
lineage-specific sequence read count comparisons. CNVs were only retained when their dispersions significantly differed
(p<0.01) between 86T-88T or 202T2-203T3, as measured by a paired two-sided Student’s t-test. For segments with insignificantly
differing read count distributions, copy number posterior likelihoods from cn.MOPS were pooled between both tumors. The highest
scoring median value was then chosen for assigning the same segmental copy number to both 86T and 88T or 202T2 and 203T3.
Table S4 lists copy number segments and assignments.
Copy Number Annotation
Non-diploid copy number segments were intersected with the set of Ensembl genes (Devil7.0) (Tables S3 and S4). Genes that were
completely or partially represented on non-diploid segments, such that loss of one copy or gain of one ormore copies was predicted,
were considered to be involved in a CNV (Figure 4A, Tables S3 and S4).
To validate gene copy number annotations in COSMIC Cancer Gene Census genes (http://cancer.sanger.ac.uk/census/; down-
loaded on 17/05/2016), and to obtain calls of those COSMIC genes falling into previously excluded scaffolds (seeScaffold Exclusion),
and which are not annotated by Ensembl, we conducted an independent, parallel copy number assessment (Table S3). 559/602
COSMIC Cancer Gene Census genes are annotated in the devil reference genome in the Ensembl and/or NCBI gene sets (see
SNV and Indel Annotation). To search for the remaining 43 genes, which were annotated neither by Ensembl nor NCBI, we obtained
transcript sequences for each gene’s opossum – or if this was not available – human orthologue. We used BLAT (Kent, 2002) to align
the gene transcript to the devil genome; this approach allowed us to preliminary annotate an additional 4 genes. Next, each gene’s
footprint was defined as the genomic interval between the start of the first exon and the end of the last exon of each gene. Gene
footprints were divided into bins of 500 BP, or – in the case when the gene region would be partitioned into fewer than 10 bins –
into bins of 50 BP. For each bin in each sample, the average coverage was collected from the aligned reads using the SAMtools
bedcov function (Li et al., 2009). Samples were divided into the following groups: DFT1 (86T, 88T), DFT2 (202T2, 203T3) and host
(31H, 91H, 202H1, 203H). An ANOVA test was used to identify gene loci with a heterogeneous distribution of coverage, where the
mean of one group differed significantly from the other two with a confidence level of 0.0001. Tukey’s range test was then performed
to establish which samples had a different mean. A threshold difference of 0.25 was used in order to call a copy number gain or loss
after a significant difference was determined. This threshold was also used to assign individual copy number variants to specific
samples.
CNV Genotyping across Normal Panel
We analyzed copy number changes on chromosome 3 in our panel of 46 normal devil genomes as follows. Sequencing reads falling
into 10,000BPwindows tiled along the chromosomewere counted by cn.MOPS getReadCountsFromBAM() (Klambauer et al., 2012).
Bin counts were normalized by the average sequencing depth across the whole respective sample, as listed in Table S2.
Structural Variant Analysis
Structural Variant Calling
We used Breakpoints via Assembly (BRASS), a tool that uses discordantly mapped read pairs, for detecting structural variants (SVs).
Aminimumof two discordant reads detecting a breakpoint in any one sample was required tomake a call. SVs were ascertained from
tumors 86T, 88T, 202T2 and 203T3, and normal genomes 91H, 31H, 202H1 and 203H.
Structural Variant Filtering
We rejected SV calls for which at least one end fell within a scaffold not assigned to a chromosome. Only calls with a total of >10
supporting reads across all eight samples (86T, 88T, 202T2, 203T3, 31H, 91H, 202H1, 203H) were retained. Moreover, any SV pre-
diction with >2 combined supporting reads across any of the four normals 31H, 91H, 202H1, and 203H was discarded as a likely
germline polymorphism. Somatic and potentially somatic SVs were defined as having >10 supporting reads in individual tumors
or both tumors of a lineage respectively, together with <3 supporting reads in all other samples combined.
Structural Variant Display
Circos plots of the set of SVs that were not detected in the normal panel are displayed in Figure 3B using the R circlize package (Gu
et al., 2014).
Structural Variant Breakpoint Assembly
Exact breakpoint types and corresponding single-base resolution were reconstructed through an in-house analysis pipeline centered
around the TIGRA assembler (Chen et al., 2014). Briefly, the structural variant breakpoint predictions identified by BRASS were given
as input to TIGRA. TIGRA was used to select structural variant-supporting reads from tumors (86T, 88T, 202T2 and 203T3), and from
them assemble contigs spanning the structural variant breakpoints. These contigs were realigned to the devil reference sequence
using BWA-MEM (Li, 2013). We selected those contigs that mapped to both scaffold locations predicted by BRASS. We analyzed
these alignments to determine the precise location of the breakpoint, to base pair resolution, and to categorize each as either
non-templated sequence insertions, microhomologies, or blunt-end breakpoints (Table S5). Of these selected contigs, those with
the highest scoring alignments were aligned against the MiSeq amplicon reads. The resulting contig-amplicon read alignmentse13 Cancer Cell 33, 607–619.e1–e15, April 9, 2018
were manually inspected using IGV to further validate the breakpoint junction sequences (Thorvaldsdóttir et al., 2013). As an addi-
tional check, the results obtained through our TIGRApipeline were also reproduced using the assembly based structural variant caller
SvABA (Wala et al., 2018).
Structural Variant Annotation
SV breakpoints were intersected with Ensembl gene predictions. SVs that were predicted within a gene footprint are annotated in
Table S5. Strand and frame information was used to predict the potential for SVs to create in-frame fusion genes (Tables S3 and S5).
Mutational Signature Analysis
SNV Spectra for Somatic Mutational Signatures
The set of tumor-unique SNVs for each tumor (see SNV and Indel Subsetting) were extracted, together with their immediate 5’ and 3’
contexts (96 mutation types). 86T and 88T tumor-unique variants were pooled, and 202T2 and 203T3 tumor-unique variants were
pooled, generating DFT1 and DFT2 somatic mutation sets, respectively. Triplet frequency normalization was done as follows. We
counted frequencies of the 32 pyrimidine-context nucleotide triplet combinations in the variant-calling accessible (see SNV and Indel
Calling) Devil7.1 reference. Each of the 96 observedmutation counts were then divided by its corresponding triplet frequency, prior to
rescaling the sum of mutational proportions to 100%.
Normalization of COSMIC Mutational Signatures
The thirty consensus mutational signatures derived from human cancers which are available in the COSMIC database (http://cancer.
sanger.ac.uk/cosmic/signatures; downloaded on 01/06/2017) and are relative to the human genome were normalized as follows: we
counted frequencies of the 32 pyrimidine-context nucleotide triplet combinations in the human reference genome GRCh37 (hg19).
Each of the 96 mutation proportions of each COSMIC signature were then divided by its corresponding triplet frequency, yielding a
species-agnostic mutational signature, prior to rescaling the sum of mutational proportions to 100%.
Fitting COSMIC Mutational Signatures DFT1 and DFT2 Spectra
We developed a Bayesian multinomial mixture model to refit known COSMIC mutational signatures to devil DFT1 and DFT2 somatic
spectra. The fitting is done using Markov Chain Monte Carlo sampling (MCMC), using the No-U-Turn sampler implemented in the
Stan programming language (Carpenter et al., 2017). In the model, the mutational signatures are interpreted as the probability pa-
rameters of independent multinomial distributions, and the observed mutation counts in the 96 mutational categories are treated
as draws from a mixture of these multinomials. The MCMC process samples mixture weights that specify the degree to which
each signature contributes to the observedmutations.We use a symmetrical, uniformDirichlet distribution as our prior on themixture
weights.
Model specification:W  Dirichlet (1) Prior on mixture weights
q = WS Multinomial mixture probabilities
M  Multinomial (q) LikelihoodM: 1396 vector of mutation counts by category;
1: 13K vector, each entry is 1;
W: 13K vector of mixture weights;
S: K396 matrix of mutational signatures;
K: number of mutational signatures;
q: 1396 vector of multinomial probabilities resulting from the mixture of mutational signatures, S, according to weights, W.
Given that human signatures 1 and 5 are almost universal in human cancer and normal tissues (Alexandrov et al., 2013, 2015a;
Blokzijl et al., 2016; Ju et al., 2017; Rahbari et al., 2016), we first fitted human signatures 1 and 5 to pooled DFT1 (6,812 variants)
and DFT2 (629 variants) variants.
Next, we assessed the improvement of fit when introducing the remaining 28 known human signatures. We assessed
cosine similarities between the DFT-unique spectra and double-fits of signatures 1, 5, as well as of any triple-fits of signatures
1, 5, N ˛ [2-4,6-30] (Table S2). In order to avoid overfitting, we set a minimum threshold of 0.02 cosine similarity increase between
1, 5 and any 1, 5, N signature combinations for significance, as previously described (Schulze et al., 2015). However, only signature
combinations 1, 5, 6 and 1, 5, 14 and 1, 5, 15 withstood this criterion in case of the fitting to the DFT1-unique spectrum (D0.0479 for
signature combination 1, 5, 6; D0.0492 for signature combination 1, 5, 14; D0.0669 for signature combination 1, 5, 15), whereas
no combinations surpassed D0.02 in the case of DFT2-unique variants (Table S2). As we did not detect the additional hallmarks
of signature 6 and 15 (large numbers of small (<3BP) indels atmono/polynucleotide repeats) or signature 14 (high numbers of somatic
mutations (>200 per megabase), see http://cancer.sanger.ac.uk/cosmic/signatures; last access on 05/10/2017), we believe that it is
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Virus Screen and PAV Analysis
De Novo Genome Assembly
De novo assemblies were produced from four tumor genomes (86T and 88T (DFT1) and 202T2 and 203T3 (DFT2)) and two host ge-
nomes (202H1 and 203H).We used Fermi (Li, 2012) to perform base error corrections for raw reads, to remove erroneous sequencing
data and to generate a contig-wise assembly. We also ran Phusion2 (Mullikin and Ning, 2003) to obtain a second assembly with the
base error corrected short reads. SOAPdenovo (Li et al., 2010) was used to process the cleaned reads in a third assembly run, which
was improved using SSPACE (Boetzer et al., 2011). Next, Fermi/Phusion2 contigs were aligned to the SOAP scaffolds and assembly
gaps closed when a piece of Fermi/Phusion2 sequence bridged two neighboring SOAP scaffolds.
Presence/Absence Variation (PAV) Analysis
Presence/absence variations (PAVs) are the sequences that are present in one genome assembly, but which are undetectable in
another. We focused on identifying PAV contigs that were present one or more of the four tumor de novo assemblies, but which
were absent from the reference genome. We first built an alignment index for absence in the reference assembly Devil7.1 using
SMALT (https://sourceforge.net/projects/smalt/). In order to reduce CPU time, we shredded each tumor assembly into 1 kilobase
fragments while removing ‘N’ bases, prior to alignment against the indexed absence (Devil7.1) assembly. Last, we filtered out small
repetitive elements placed at ambiguous locations. We have integrated this software into a pipeline, scanPAV, which can be down-
loaded from https://github.com/wtsi-hpag/scanPAV/ (Giordano et al., 2018). This method produced a set of PAV candidate contigs
which had evidence for presence in one or more tumor genome assembly, but which appeared to be absent from the devil reference
genome. We further filtered these candidate tumor-specific PAV contigs by aligning sequence reads derived from the reference
genome (91H) to them. Contigs with 91H sequence coverage >10 X were removed.
To further filter candidate PAV contigs for absence across a panel of normal devil genomes, the set of candidate tumor-unique PAV
contigs were concatenated with Devil7.1 to create four Devil7.1+PAV assemblies, with each assembly carrying the set of PAVs
unique to one of the four tumors. Next, we extracted the set of sequence reads from tumors 86T, 88T, 202T2 and 203T3 and normal
devils 31H, 91H, 202H1 and 203H which previously did not map to Devil7.1, and aligned these to Devil7.1+PAV using BWA-MEM (Li,
2013). Wemeasured the read depth of each candidate PAV contig in each sample, and retained those contigs that had read depth of
at least 40% mean whole genome read depth in at least one tumor (thresholds were as follows, 86T – 34.4 X, 88T – 26.8 X, 202T2 –
26.8 X, 203T3 – 28.0 X), but that did not reach 20% whole genome read depth in any host (thus plausibly representing a single copy
integration event in tumors but not in normal genomes); the thresholds for hosts were as follows: 31H – 3.4 X, 91H – 13.0 X, 202H1 –
9.8 X, 203H – 9.0 X. After this filtering, a total of 139 candidate tumor-specific PAV contigs remained (Table S1). The tumor-specificity
of these contigs was assessed by aligning reads from the other three tumors to each individual tumor’s set of candidate PAVs. The
contigs were further evaluated by comparing against the NCBI ’nt’ sequence database with the default ’dc-megablast’ option in
BLAST+ 2.6.0 (Camacho et al., 2009). The top hit was annotated, including target species name, ID, BLAST identity, hit length, E-
value and bitscore (Table S1).
Y Chromosome Contig Identification
We used genome assemblies of a male host, 202H1, as well as DFT2 tumors 202T2 and 203T3 to identify Y chromosome contigs that
were present in these assemblies but whichwere absent in the female Tasmanian devil reference genomeDevil7.1. Contigs identified
in 202H1, 202T2 and 203T3 which were absent in the reference genome were screened using BLAT (Kent, 2002) for the presence
of a  825 BP dasyurid-specific intron located within the SRY gene (O’Neill et al., 1998). As an input query, we used the intronic
SRY sequence of the stripe-faced dunnart (Sminthopsis macroura). Identified sequences were used as seeds for alignments of
the neighboring exons with SRY cDNA sequences identified in rock wallabies (O’Neill et al., 1997).
Contigs devil-202H_4481 (202H1, length: 84,660 BP), devil-202T_3709 (202T2, length: 84,684 BP) and devil-203T_28242 (203T3,
length: 70,068 BP) were identified as Y chromosomal sequences harboring SRY.
Drug Screen IC50 Analysis
IC50 drug sensitivity values for different cell lines, as derived from our high-throughput screen, were used as an input for loge(IC50)
hierarchical clustering. This was performed by applying the default R hclust() function (method: ’complete’) on the Euclidian distance
matrix derived from each pairwise drug and cell line combination. Figure 5B shows data for 6 DFT cell lines clustered with 104 com-
pounds. IC50 data from human cell lineswas obtained from theGenomics of Drug Sensitivity in Cancer (GDSC) database (http://www.
cancerrxgene.org/, downloaded on 07/05/2017, Yang et al. (2013)).
DATA AND SOFTWARE AVAILABILITY
The accession number for genomic data reported in this paper is ENA: PRJEB21902. Additional materials such as IHC and
FISH images, mutational calls, Devil7.0 to Devil7.1 translations, genome assembly contigs and PAVs can be found on Mendeley
Data (https://doi.org/10.17632/znfphvhmbv.1). Code used in this study is made available on Github (https://github.com/
MaximilianStammnitz).e15 Cancer Cell 33, 607–619.e1–e15, April 9, 2018
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Figure S1, related to Figure 1: Immunohistochemistry. 
DFT1 (left), DFT2 (center) and control (right) tissues stained with tissue lineage markers (Loh et al., 
2006). PRX is included as a control (Pye et al., 2016b). Scale bar, 30 µm. PRX, periaxin; VIM, vimentin; 
NSE, neural specific enolase; SMA, smooth muscle actin; YAP1 (bottom left panels), yes-associated 
protein 1; TAZ/WWTR1 (bottom right panels), transcriptional coactivator with PDZ-binding motif/WW 
domain-containing transcription regulator 1. Nuclear localization of YAP1 and TAZ/WWTR1 indicates 
































Figure S2, related to Figure 4: Genomic copy number at chromosome 3 locus in DFT1, DFT2 and 
46 normal Tasmanian devil genomes. 
Copy numbers of DFT1, DFT2 and 46 normal Tasmanian devil genomes at the chromosome 3 locus 
that has undergone hemizygous deletion in both DFT1 and DFT2 (Chr3_SC_000000273 position 
360,001 to Chr3_SC_000000312 position 30,000). Dots represent number of sequence reads mapping 
in 10,000 base pair non-overlapping bins normalized to average sequencing depth. The region that has 
undergone hemizygous deletion in DFT1 and DFT2 is marked with a blue and red star, respectively. 
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Discussion
ERBB3 had previously avoided scrutiny due to its kinase inactivity; however, ERBB3 has now 
been the subject of intense investigation over the past decade and recognised now as a potent 
partner of the epidermal growth receptor family. ERBB3 upregulation during developmental, 
dedifferentiation and regenerative processes encapsulates the Schwann cell’s inherent plasticity 
and imparts certain characteristics of malignant transformation advantageous to transmission of 
DFT1. Our pilot study has shown for the first time that ERBB3 is consistently expressed 
immunohistochemically and that ERBB3 is also elevated in the serum of Tasmanian devils with 
advanced DFT1 and cutaneous lymphoma. Therefore, our research indicates that serum ERBB3 
has the potential to be utilised as a biomarker of DFT1 or CL in Tasmanian devils to assist 
conservationists in the management and welfare of Tasmanian devils and species survival. The 
simplicity of the ELISA Serum ERBB3 methodology is easily incorporated into routine laboratory 
batch testing, equally it can be applied to include rapid turnaround of results for urgent cases. 
Extension of this research is necessary to include greater numbers of healthy Tasmanian devils 
both with and without visible injuries, devils with large and small DFT1 lesions as well as pre-
clinical DFT1. This will firmly establish the normal reference range for serum ERBB3 from which 
potential pre-clinical DFT1 devils may be identified. In addition, because ERBB3 is now 
recognised as a therapeutic target, potential exists to consider modes of administration in 
addition to existing whole cell vaccination such as ERBB3 monoclonal antibody, peptide or 
xenogeneic vaccines including checkpoint inhibitors. A combinatorial immunotherapeutic 
approach will enhance cytotoxic destruction, provide long-term immunity from DFT1 and 
therefore eradicate this transmissible tumour from the wild
Figure 1. DFT1 staining and skin manifestation.
(A) Haematoxylin and Eosin stained DFT1 x40, (B) ERBB3 Immunohistochemical expression in DFT1 strain
3 x40, (C) ERBB3 immunohistochemical expression in DFT1 strain 3 x100, (D) DFT1 negative control, (E)
Tasmanian devil skin and subcutis section with peripheral nerve (red arrow) and DFT1 (black arrow) x10,
(F) Tasmanian devil lymph node ERBB3 expression lymphoid follicle x20, (G) Tasmanian devil bowel
ERBB3 positive control x40, (H) ERBB3 IHC negative control bowel, (I) trigeminal nerve shows ERBB3
positive nerve body (black arrow) and occasional adaxonal ERBB3 positivity (red arrows) x40, (J) ERBB3
IHC negative control trigeminal nerve, (K) Tasmanian Devil gross appearance of DFT1. Photo credit:
DPIPWE archive, (L) Tasmanian devil gross appearance cutaneous lymphoma. Photo credit DPIPWE
archive.
Figure 2. Serum ERBB3 levels in Tasmanian devils. 
Serum ERBB3 levels were measured by ELISA in clinically healthy Tasmanian devils CHD (n=11), clinically 
healthy Tasmanian devils with dermatopathy CHDD (n=4), clinically diagnosed DFT1 (n=8) and those 
with cutaneous lymphoma CL (n=12). Horizontal dashed line indicates the limit of detection of the 
ELISA assay at 30 pg/mL. Results of individual devils are shown with the median and interquartile range 
identified by the whiskers. Significance testing using a Kruskal-Wallis test with Dunn’s Multiple 
Comparison Testing shown with * representing p < 0.05. 
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Introduction
Devil Facial Tumour 1 (DFT1) is one of two transmissible neoplasms of Tasmanian devils 
(Sarcophilus harrisii) predominantly affecting their facial regions. DFT1’s cellular origin is that of 
Schwann cell lineage where lesions are evident macroscopically late in the disease. Conversely, 
the pre-clinical timeframe from cellular transmission to appearance of DFT1 remains uncertain 
demonstrating the importance of an effective pre-clinical biomarker.
ERBB3 is expressed in early embryonal development and plays an integral role in the 
development of the neural crest and Schwann cells. ERBB3 is one of four members of the 
Epidermal Growth Factor (EGF) family representing a complex group of type 1 transmembrane 
receptor tyrosine kinase (RTK) designated EGFR/ERBB1/HER1, ERBB2/HER2, ERBB3/HER3 and 
ERBB4/HER4. ERBB3 is upregulated in a number of human cancers such as breast, colon, gastric, 
ovarian and prostate but seldom reported in animal cancers. 
DFT1’s expression of ERBB3 immunohistochemically expression led us to postulate that excess 
extracellular domain (ECD) may circulate in the host’s plasma and present itself as a possible 
candidate biomarker for DFT1.
Methods
A pilot study of thirty-five Tasmanian devils including clinically healthy Tasmanian devils (CHD, 
n=15), clinically healthy devils with dermatopathy (CHDD, n=4), Tasmanian devils with clinical 
DFT1 (DFT1, n=8) and Tasmanian devils with cutaneous lymphoma (CL, n=12) 
Briefly, paraffin embedded tissues were processed using standard Histological and 
Immunohistochemical methods using citrate buffer antigen retrieval, Biocare Medical universal 
HRP detection kit and monoclonal rabbit anti-human ERBB3 (Abcam, clone SP71, ab93739, 
1:50). Serum ERBB3 levels were measured using the RayBio anti-human ERBB3 ELISA Kit 
according to the manufacturer’s instructions. The ELISA standard curve was plotted using Prism 
v5 and results for each serum interpolated and corrected for dilution. The significance of 
differences in serum ERBB3 between groups was determined using a Kruskal-Wallis test with 
Dunn’s Multiple Comparison utilizing Prism v5.
Abstract
Devil Facial Tumour 1 (DFT1) is one of two transmissible neoplasms of Tasmanian devils (Sarcophilus harrisii) predominantly affecting their facial regions. DFT1’s cellular origin is that of Schwann 
cell lineage where lesions are evident macroscopically late in the disease. Conversely, the pre-clinical timeframe from cellular transmission to appearance of DFT1 remains uncertain 
demonstrating the importance of an effective pre-clinical biomarker. We show that ERBB3, a marker expressed normally by the developing neural crest and Schwann cells, is 
immunohistohemically expressed by DFT1, therefore the potential of ERBB3 as a biomarker was explored. Under the hypothesis that serum ERBB3 levels may increase as DFT1 invades local and 
distant tissues our pilot study determined serum ERBB3 levels in normal Tasmanian devils and Tasmanian devils with DFT1. Compared to the baseline serum ERBB3 levels in unaffected 
Tasmanian devils, Tasmanian devils with DFT1 showed significant elevation of serum ERBB3 levels. Interestingly Tasmanian devils with cutaneous lymphoma (CL) also showed elevation of serum 
ERBB3 levels when compared to the baseline serum levels of Tasmanian devils without DFT1. Thus, elevated serum ERBB3 levels in otherwise healthy looking devils could predict possible DFT1 
or CL in captive or wild devil populations and would have implications on the management, welfare and survival of Tasmanian devils. ERBB3 is also a therapeutic target and therefore the 
potential exists to consider modes of administration that may eradicate DFT1 from the wild.
Results
DFT1 histology (Fig 1A) Haematoxylin and Eosin. ERBB3 IHC revealed moderate to strong 
expression in 75% of cells in all strains of DFT1 (Fig 1B). Higher magnification (Fig 1C). Devil skin 
and subcutis (Fig 1E), peripheral nerve was seldom positive for ERBB3 (red arrow) in keeping 
with downregulation of ERBB3 in the adult in contrast to DFT1 ERBB3 expression (black arrow). 
ERBB3 in Tasmanian devil lymphoid follicle (Fig 1F). Trigeminal nerve section (Fig 1I) showed 
ERBB3 expression in nerve bodies (black arrow) and occasional ERBB3 expression in the adaxonal
area (red arrows). Positive control devil bowel (Fig 1G) and negative controls DFT1 (Fig 1D), 
bowel (Fig 1H) and Trigeminal nerve (Fig 1J).
Serum ERBB3 levels are shown in figure 2. Serum ERBB3 in the Fifteen Tasmanian devils without 
neoplasia ranged from <30-663 pg/ml with a median of 32 pg/mL (30 – 220; interquartile range). 
Serum ERBB3 levels in the eight Tasmanian devils (devils 16-23) with clinical DFT1 ranged from 
766-18,254 pg/ml with median of 3051 pg/mL (1060 – 10879; interquartile range. In the twelve
Tasmanian devils with cutaneous lymphoma (devils 24-35) serum ERBB3 levels ranged from <30-
20,021 pg/ml with a median of 1485 pg/mL (289 – 7901; interquartile range). In summary,
serum ERBB3 levels are elevated in devils with DFT1 and CL when compared to clinically healthy
devils.
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